Eigene Vorlage

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Mepolizumab (Nucala) – CRSwNP

GlaxoSmithKline GmbH & Co. KG

Separater Anhang 4-G
zu Modul 4A

Tabellen und Abbildungen

Stand: 24.11.2021

Inhaltsverzeichnis

14 Ergebnisse für Veränderung der VAS Verlust des Geruchsinns aus RCT mit dem zu bewertenden Arzneimittel – Woche 73-76

15 Ergebnisse für Veränderung des UPSIT aus RCT mit dem zu bewertenden Arzneimittel

16 Ergebnisse für Veränderung des SNOT-22 aus RCT mit dem zu bewertenden Arzneimittel – Woche 52

17 Ergebnisse für Veränderung des SNOT-22 aus RCT mit dem zu bewertenden Arzneimittel – Woche 76

18 Ergebnisse für Veränderung der Domänen des SNOT-22 aus RCT mit dem zu bewertenden Arzneimittel

19 Ergebnisse für Zeit bis zur ersten Nasenpolypenoperation oder Therapie mit SCS aus RCT mit dem zu bewertenden Arzneimittel

20 Ergebnisse für Zeit bis zur ersten Nasenpolypenoperation aus RCT mit dem zu bewertenden Arzneimittel – Woche 52

21 Ergebnisse für Zeit bis zur ersten Nasenpolypenoperation aus RCT mit dem zu bewertenden Arzneimittel – Woche 76

22 Ergebnisse für Zeit bis zur ersten Therapie mit SCS aus RCT mit dem zu bewertenden Arzneimittel

23 Ergebnisse für Veränderung des ACQ-5 aus RCT mit dem zu bewertenden Arzneimittel

24 Ergebnisse für Veränderung des SF-36 PCS aus RCT mit dem zu bewertenden Arzneimittel

25 Ergebnisse für Veränderung des SF-36 MCS aus RCT mit dem zu bewertenden Arzneimittel

26 Ergebnisse für Veränderung der Gesundheitsdomänen des SF-36 aus RCT mit dem zu bewertenden Arzneimittel

27 Ergebnisse für Veränderung des WPAI aus RCT mit dem zu bewertenden Arzneimittel

28 Subgruppenanalysen zu Nasenpolypenscore aus RCT mit dem zu bewertenden Arzneimittel

29 Subgruppenanalysen zu Nasenpolypenscore Responder aus RCT mit dem zu bewertenden Arzneimittel

30 Subgruppenanalysen zu VAS Symptom Gesamtscore aus RCT mit dem zu bewertenden Arzneimittel

31 Subgruppenanalysen zu VAS Nasale Obstruktion aus RCT mit dem zu bewertenden Arzneimittel

32 Subgruppenanalysen zu VAS Nasaler Ausfluss aus RCT mit dem zu bewertenden Arzneimittel

33 Subgruppenanalysen zu VAS Schleim im Rachenraum aus RCT mit dem zu bewertenden Arzneimittel

34 Subgruppenanalysen zu VAS Schmerzen/Druckgefühl im Gesichtsbereich aus RCT mit dem zu bewertenden Arzneimittel

35 Subgruppenanalysen zu VAS Verlust des Geruchssinns aus RCT mit dem zu bewertenden Arzneimittel

36 Subgruppenanalysen zu UPSIT aus RCT mit dem zu bewertenden Arzneimittel

37 Subgruppenanalysen zu SNOT-22 aus RCT mit dem zu bewertenden Arzneimittel

38 Subgruppenanalysen zu SNOT-22 Responder (≥ 8.9 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

39 Subgruppenanalysen zu Zeit bis zur ersten Nasenpolypenoperation mit dem zu bewertenden Arzneimittel

40 Subgruppenanalysen zu Zeit bis zur ersten Nasenpolypenoperation aus RCT mit dem zu bewertenden Arzneimittel

41 Subgruppenanalysen zu Nasenpolypenoperation – Jahresrate aus RCT mit dem zu bewertendem Arzneimittel

42 Subgruppenanalysen zu Reduktion von Antibiotika aus RCT mit dem zu bewertenden Arzneimittel

43 Subgruppenanalysen zu Asthma Exazerbationen aus RCT mit dem zu bewertenden Arzneimittel

44 Subgruppenanalysen zu ACQ-5 Responder (≥0.5 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

45 Subgruppenanalysen zu SF-36 Responder (PCS ≥5 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

46 Subgruppenanalysen zu SF-36 Responder (MCS ≥5 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

47 Subgruppenanalysen zu WPAI (Versäumte Arbeitszeit aufgrund von Krankheit) aus RCT mit dem zu bewertenden Arzneimittel

48 Subgruppenanalysen zu WPAI (Beeinträchtigung im Berufsleben aufgrund von Krankheit) aus RCT mit dem zu bewertenden Arzneimittel

49 Subgruppenanalysen zu WPAI (Beeinträchtigung der Arbeitsleistung insgesamt aufgrund von Krankheit) aus RCT mit dem zu bewertenden Arzneimittel

50 Subgruppenanalysen zu WPAI (Beeinträchtigung der Aktivität aufgrund von Krankheit) aus RCT mit dem zu bewertenden Arzneimittel

51 Subgruppenanalysen zu Unerwünschte Ereignisse aus RCT mit dem zu bewertenden Arzneimittel

52 Subgruppenanalysen zu Unerwünschte Ereignisse nach SOC und PT aus RCT mit dem zu bewertenden Arzneimittel

53 Subgruppenanalysen zu Schwerwiegende Unerwünschte Ereignisse aus RCT mit dem zu bewertenden Arzneimittel

54 Subgruppenanalysen zu Studienabbruch wegen unerwünschter Ereignisse aus RCT mit dem zu bewertenden Arzneimittel

55 Subgruppenanalyse zu Unerwünschte Ereignisse von besonderem Interesse aus RCT mit dem zu bewertenden Arzneimittel

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Screening	Total Endoscopic Score	n	200	206
		Median	6.0	6.0
		Min.	4	4
		Max.	8	8
		Mean	5.9	5.9
		SD	0.94	0.86
Baseline	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	2
		Max.	8	8
		Mean	5.6	5.4
		SD	1.41	1.17

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 4	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	1
		Max.	8	8
		Mean	5.5	5.2
		SD	1.46	1.27
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-4	-4
		Q1	-1.0	-1.0
		Q3	1.0	1.0
		Max.	4	4
		Mean	-0.1	-0.2
		SD	1.22	1.27

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 8	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.6	5.2
		SD	1.41	1.36
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-4	-4
		Q1	-1.0	-1.0
		Q3	1.0	1.0
		Max.	4	4
		Mean	0.0	-0.2
		SD	1.26	1.41

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.5	5.0
		SD	1.60	1.37
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-5	-5
		Q1	-1.0	-1.0
		Q3	1.0	1.0
		Max.	3	4
		Mean	0.0	-0.3
		SD	1.21	1.42

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 16	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.5	5.1
		SD	1.55	1.41
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-4	-5
		Q1	-1.0	-1.0
		Q3	1.0	1.0
		Max.	3	2
		Mean	-0.1	-0.3
		SD	1.38	1.46

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.5	4.9
		SD	1.53	1.51
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-5	-5
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	4	3
		Mean	0.0	-0.5
		SD	1.39	1.55

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 24	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.6	4.9
		SD	1.55	1.55
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-6	-5
		Q1	-1.0	-2.0
		Q3	1.0	1.0
		Max.	4	3
		Mean	0.0	-0.5
		SD	1.40	1.63

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 32	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.5	4.9
		SD	1.58	1.65
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-5	-6
		Q1	-1.0	-1.0
		Q3	1.0	1.0
		Max.	3	4
		Mean	0.0	-0.5
		SD	1.37	1.77

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 40	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.6	4.7
		SD	1.56	1.71
	Change from Baseline	n	201	206
		Median	0.0	0.0
		Min.	-4	-6
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	6	4
		Mean	0.0	-0.7
		SD	1.44	1.78

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 48	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.5	4.6
		SD	1.66	1.72
	Change from Baseline	n	201	206
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	3	4
		Mean	0.0	-0.8
		SD	1.46	1.90

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.1
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	Total Endoscopic Score	n	201	206
		Median	6.0	5.0
		Min.	0	0
		Max.	8	8
		Mean	5.4	4.5
		SD	1.85	1.85
	Change from Baseline	n	201	206
		Median	0.0	-1.0
		Min.	-5	-6
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	3	3
		Mean	-0.1	-0.9
		SD	1.46	1.90

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
ssing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.5 (0.08)	5.3 (0.08)
LS Mean Change (SE)	0.0 (0.08)	-0.2 (0.08)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-0.43, 0.03)
p-value		0.091
Corrected Hedges g [3]		-0.17
95% CI		(-0.36, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.6 (0.09)	5.3 (0.09)
LS Mean Change (SE)	0.1 (0.09)	-0.2 (0.09)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.33
95% CI		(-0.58, -0.08)
p-value		0.009
Corrected Hedges g [3]		-0.26
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.5 (0.09)	5.2 (0.09)
LS Mean Change (SE)	0.1 (0.09)	-0.3 (0.09)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.36
95% CI		(-0.62, -0.10)
p-value		0.006
Corrected Hedges g [3]		-0.27
95% CI		(-0.47, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.5 (0.10)	5.2 (0.10)
LS Mean Change (SE)	0.1 (0.10)	-0.2 (0.10)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.30
95% CI		(-0.59, -0.02)
p-value		0.036
Corrected Hedges g [3]		-0.21
95% CI		(-0.40, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.6 (0.11)	5.1 (0.11)
LS Mean Change (SE)	0.2 (0.11)	-0.4 (0.11)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.55
95% CI		(-0.86, -0.25)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.55, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.7 (0.11)	5.1 (0.11)
LS Mean Change (SE)	0.2 (0.11)	-0.4 (0.11)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.63
95% CI		(-0.94, -0.31)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.58, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.8 (0.12)	5.2 (0.12)
LS Mean Change (SE)	0.3 (0.12)	-0.3 (0.12)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.60
95% CI		(-0.94, -0.25)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.9 (0.13)	5.0 (0.13)
LS Mean Change (SE)	0.4 (0.13)	-0.5 (0.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.88
95% CI		(-1.24, -0.53)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.9 (0.14)	4.9 (0.13)
LS Mean Change (SE)	0.4 (0.14)	-0.6 (0.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.99
95% CI		(-1.37, -0.62)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.71, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.1
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 52
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.8 (0.14)	4.9 (0.14)
LS Mean Change (SE)	0.3 (0.14)	-0.6 (0.14)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.90
95% CI		(-1.30, -0.51)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Screening	Total Endoscopic Score	n	64	69
		Median	6.0	6.0
		Min.	4	5
		Max.	8	8
		Mean	5.8	6.0
		SD	0.88	0.75
Baseline	Total Endoscopic Score	n	65	69
		Median	6.0	6.0
		Min.	2	2
		Max.	8	8
		Mean	5.6	5.6
		SD	1.38	1.12

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 4	Total Endoscopic Score	n	65	69
		Median	6.0	6.0
		Min.	2	2
		Max.	8	7
		Mean	5.4	5.3
		SD	1.55	1.12
	Change from Baseline	n	65	69
		Median	0.0	0.0
		Min.	-3	-4
		Q1	-1.0	-1.0
		Q3	1.0	0.0
		Max.	2	4
		Mean	-0.2	-0.3
		SD	1.14	1.30

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 8	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	2	2
		Max.	8	8
		Mean	5.6	5.0
		SD	1.33	1.19
	Change from Baseline	n	65	69
		Median	0.0	0.0
		Min.	-3	-4
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	4	4
		Mean	0.0	-0.6
		SD	1.22	1.38

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 12	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	0	2
		Max.	8	7
		Mean	5.5	5.1
		SD	1.76	1.05
	Change from Baseline	n	65	69
		Median	0.0	0.0
		Min.	-5	-4
		Q1	-1.0	-1.0
		Q3	1.0	0.0
		Max.	2	4
		Mean	-0.1	-0.5
		SD	1.13	1.47

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 16	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	0	2
		Max.	8	7
		Mean	5.5	5.0
		SD	1.62	1.18
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-4
		Q1	-1.0	-1.0
		Q3	1.0	0.0
		Max.	3	2
		Mean	-0.1	-0.6
		SD	1.37	1.43

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 20	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	2	1
		Max.	8	7
		Mean	5.5	4.7
		SD	1.47	1.36
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-3	-4
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	2	3
		Mean	-0.1	-0.8
		SD	1.18	1.57

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 24	Total Endoscopic Score	n	65	69
		Median	5.0	5.0
		Min.	2	0
		Max.	8	6
		Mean	5.5	4.6
		SD	1.43	1.39
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-5
		Q1	-1.0	-2.0
		Q3	0.0	0.0
		Max.	4	2
		Mean	-0.1	-1.0
		SD	1.24	1.58

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 32	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	0	0
		Max.	8	7
		Mean	5.6	4.5
		SD	1.63	1.65
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-5	-6
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	3	4
		Mean	-0.1	-1.0
		SD	1.31	1.83

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 40	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	1	0
		Max.	8	7
		Mean	5.5	4.4
		SD	1.68	1.73
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	-1.0	-2.0
		Q3	0.0	0.0
		Max.	3	4
		Mean	-0.2	-1.2
		SD	1.31	1.94

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 48	Total Endoscopic Score	n	65	69
		Median	5.0	5.0
		Min.	2	0
		Max.	8	7
		Mean	5.6	4.4
		SD	1.60	1.57
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	-1.0	-3.0
		Q3	1.0	0.0
		Max.	3	4
		Mean	-0.1	-1.2
		SD	1.42	1.99

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 52	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	1	0
		Max.	8	7
		Mean	5.3	4.3
		SD	1.97	1.76
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	-1.0	-2.0
		Q3	0.0	0.0
		Max.	2	3
		Mean	-0.3	-1.3
		SD	1.42	1.89

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 60	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.6	4.7
		SD	1.78	1.85
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	0.0	-2.0
		Q3	1.0	0.0
		Max.	2	4
		Mean	0.0	-0.9
		SD	1.33	1.89

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 68	Total Endoscopic Score	n	65	69
		Median	5.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.4	4.5
		SD	1.87	1.90
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-5
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	4	3
		Mean	-0.3	-1.1
		SD	1.50	1.94

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Table 2.63
Summary of Total Endoscopic Nasal Polyps Score (Centrally Read) for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 76	Total Endoscopic Score	n	65	69
		Median	6.0	5.0
		Min.	1	0
		Max.	8	8
		Mean	5.5	4.4
		SD	1.88	1.90
	Change from Baseline	n	65	69
		Median	0.0	-1.0
		Min.	-4	-6
		Q1	-1.0	-2.0
		Q3	1.0	0.0
		Max.	4	3
		Mean	-0.1	-1.2
		SD	1.59	1.80

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ng visit.

PPD

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.5 (0.14)	5.3 (0.14)
LS Mean Change (SE)	-0.1 (0.14)	-0.3 (0.14)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-0.55, 0.23)
p-value		0.422
Corrected Hedges g [3]		-0.14
95% CI		(-0.48, 0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.7 (0.15)	5.0 (0.14)
LS Mean Change (SE)	0.1 (0.15)	-0.6 (0.14)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.63
95% CI		(-1.03, -0.23)
p-value		0.002
Corrected Hedges g [3]		-0.53
95% CI		(-0.88, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.5 (0.16)	5.2 (0.15)
LS Mean Change (SE)	-0.1 (0.16)	-0.4 (0.15)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.35
95% CI		(-0.78, 0.08)
p-value		0.108
Corrected Hedges g [3]		-0.28
95% CI		(-0.62, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.5 (0.17)	5.0 (0.16)
LS Mean Change (SE)	0.0 (0.17)	-0.5 (0.16)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-0.96, -0.04)
p-value		0.032
Corrected Hedges g [3]		-0.37
95% CI		(-0.71, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.6 (0.17)	4.9 (0.16)
LS Mean Change (SE)	0.0 (0.17)	-0.7 (0.16)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.71
95% CI		(-1.17, -0.25)
p-value		0.003
Corrected Hedges g [3]		-0.52
95% CI		(-0.87, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.6 (0.17)	4.7 (0.17)
LS Mean Change (SE)	0.0 (0.17)	-0.9 (0.17)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.94
95% CI		(-1.42, -0.47)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.02, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.9 (0.21)	4.6 (0.20)
LS Mean Change (SE)	0.3 (0.21)	-1.0 (0.20)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.83, -0.69)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.10, -0.40)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.7 (0.22)	4.5 (0.21)
LS Mean Change (SE)	0.1 (0.22)	-1.0 (0.21)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.12
95% CI		(-1.72, -0.51)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.97, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.8 (0.21)	4.5 (0.21)
LS Mean Change (SE)	0.2 (0.21)	-1.1 (0.21)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.85, -0.68)
p-value		<0.001
Corrected Hedges g [3]		-0.73
95% CI		(-1.08, -0.38)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.5 (0.23)	4.4 (0.22)
LS Mean Change (SE)	-0.1 (0.23)	-1.2 (0.22)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.17
95% CI		(-1.79, -0.55)
p-value		<0.001
Corrected Hedges g [3]		-0.64
95% CI		(-0.99, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.8 (0.22)	4.9 (0.22)
LS Mean Change (SE)	0.2 (0.22)	-0.7 (0.22)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.93
95% CI		(-1.55, -0.31)
p-value		0.004
Corrected Hedges g [3]		-0.51
95% CI		(-0.85, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 76
Mixed Model Repeated Measures

Visit: Week 68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.6 (0.24)	4.7 (0.24)
LS Mean Change (SE)	0.0 (0.24)	-0.9 (0.24)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.88
95% CI		(-1.55, -0.20)
p-value		0.011
Corrected Hedges g [3]		-0.44
95% CI		(-0.79, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.9
Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read)
at Week 76
Mixed Model Repeated Measures

Visit: Week 76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.8 (0.24)	4.6 (0.23)
LS Mean Change (SE)	0.2 (0.24)	-1.0 (0.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.19
95% CI		(-1.86, -0.53)
p-value		<0.001
Corrected Hedges g [3]		-0.61
95% CI		(-0.96, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	9.20	9.12
		Min.	7.21	7.17
		Max.	10.00	10.00
		Mean	9.10	9.04
		SD	0.721	0.766
Weeks 1-4	VAS Score	n	201	206
		Median	8.91	8.62
		Min.	1.33	0.15
		Max.	10.00	10.00
		Mean	8.54	8.34
		SD	1.416	1.453
	Change from Baseline	n	201	206
		Median	-0.16	-0.33
		Min.	-8.07	-9.64
		Q1	-0.61	-0.76
		Q3	0.00	-0.04
		Max.	1.51	0.74
		Mean	-0.56	-0.70
		SD	1.257	1.315

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	8.54	7.99
		Min.	0.27	0.09
		Max.	10.00	10.00
		Mean	7.98	7.41
		SD	1.995	2.143
	Change from Baseline	n	201	206
		Median	-0.40	-0.96
		Min.	-9.70	-9.70
		Q1	-1.39	-2.17
		Q3	-0.05	-0.23
		Max.	1.85	0.83
		Mean	-1.12	-1.63
		SD	1.886	2.037

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	8.22	7.19
		Min.	0.17	0.09
		Max.	10.00	10.00
		Mean	7.60	6.67
		SD	2.284	2.503
	Change from Baseline	n	201	206
		Median	-0.79	-1.60
		Min.	-9.80	-9.91
		Q1	-1.98	-3.46
		Q3	-0.03	-0.44
		Max.	1.46	0.82
		Mean	-1.50	-2.37
		SD	2.192	2.428

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	7.76	6.48
		Min.	0.03	0.00
		Max.	10.00	10.00
		Mean	7.28	6.13
		SD	2.492	2.744
	Change from Baseline	n	201	206
		Median	-0.90	-2.29
		Min.	-9.94	-10.00
		Q1	-2.79	-4.34
		Q3	-0.08	-0.68
		Max.	1.19	1.26
		Mean	-1.82	-2.91
		SD	2.391	2.687

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	7.73	6.02
		Min.	0.15	0.00
		Max.	10.00	10.00
		Mean	7.05	5.76
		SD	2.708	2.926
	Change from Baseline	n	201	206
		Median	-1.01	-2.68
		Min.	-9.54	-10.00
		Q1	-3.27	-5.46
		Q3	-0.13	-0.80
		Max.	1.49	1.55
		Mean	-2.06	-3.28
		SD	2.595	2.879

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	7.56	5.77
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.90	5.52
		SD	2.784	3.063
	Change from Baseline	n	201	206
		Median	-1.20	-3.02
		Min.	-9.67	-10.00
		Q1	-3.49	-5.94
		Q3	-0.04	-0.70
		Max.	1.18	1.38
		Mean	-2.21	-3.52
		SD	2.671	3.028

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	7.30	5.62
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.69	5.37
		SD	2.835	3.111
	Change from Baseline	n	201	206
		Median	-1.70	-3.13
		Min.	-9.74	-10.00
		Q1	-3.91	-6.12
		Q3	-0.06	-0.83
		Max.	1.19	1.42
		Mean	-2.41	-3.67
		SD	2.715	3.087

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	7.54	5.13
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.67	5.15
		SD	2.937	3.180
	Change from Baseline	n	201	206
		Median	-1.48	-3.72
		Min.	-9.67	-10.00
		Q1	-4.18	-6.56
		Q3	0.00	-0.94
		Max.	1.19	1.14
		Mean	-2.43	-3.88
		SD	2.814	3.156

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	7.54	4.73
		Min.	0.06	0.00
		Max.	10.00	10.00
		Mean	6.66	5.03
		SD	3.015	3.237
	Change from Baseline	n	201	206
		Median	-1.21	-4.02
		Min.	-9.60	-10.00
		Q1	-4.34	-6.72
		Q3	0.00	-0.87
		Max.	1.19	1.45
		Mean	-2.44	-4.00
		SD	2.884	3.208

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	7.65	4.61
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	6.70	4.99
		SD	3.035	3.327
	Change from Baseline	n	201	206
		Median	-1.21	-4.08
		Min.	-9.68	-10.00
		Q1	-4.28	-7.06
		Q3	0.00	-0.47
		Max.	1.19	1.72
		Mean	-2.40	-4.05
		SD	2.922	3.305

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	7.87	4.36
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.69	4.84
		SD	3.101	3.382
	Change from Baseline	n	201	206
		Median	-1.16	-4.65
		Min.	-9.22	-10.00
		Q1	-4.57	-7.18
		Q3	0.00	-0.51
		Max.	1.22	1.49
		Mean	-2.41	-4.20
		SD	2.995	3.355

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	7.72	4.45
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.68	4.77
		SD	3.157	3.413
	Change from Baseline	n	201	206
		Median	-1.12	-4.47
		Min.	-9.25	-10.00
		Q1	-4.87	-7.15
		Q3	0.00	-0.62
		Max.	1.19	1.48
		Mean	-2.43	-4.26
		SD	3.013	3.393

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.29
Summary of Overall VAS score

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	7.96	4.18
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.65	4.76
		SD	3.226	3.464
	Change from Baseline	n	201	206
		Median	-0.90	-4.48
		Min.	-9.11	-10.00
		Q1	-4.76	-7.04
		Q3	0.00	-0.40
		Max.	1.19	1.62
		Mean	-2.45	-4.27
		SD	3.082	3.434

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.51 (0.090)	8.37 (0.089)
LS Mean Change (SE)	-0.56 (0.090)	-0.70 (0.089)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.14
95% CI		(-0.39, 0.11)
p-value		0.269
Corrected Hedges g [3]		-0.11
95% CI		(-0.30, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.95 (0.138)	7.45 (0.136)
LS Mean Change (SE)	-1.12 (0.138)	-1.62 (0.136)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-0.88, -0.12)
p-value		0.010
Corrected Hedges g [3]		-0.26
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.58 (0.162)	6.70 (0.160)
LS Mean Change (SE)	-1.49 (0.162)	-2.37 (0.160)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.88
95% CI		(-1.32, -0.43)
p-value		<0.001
Corrected Hedges g [3]		-0.38
95% CI		(-0.58, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.26 (0.180)	6.18 (0.177)
LS Mean Change (SE)	-1.81 (0.180)	-2.89 (0.177)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.08
95% CI		(-1.57, -0.58)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.62, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.04 (0.194)	5.83 (0.192)
LS Mean Change (SE)	-2.03 (0.194)	-3.24 (0.192)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.21
95% CI		(-1.75, -0.67)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.63, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.91 (0.205)	5.61 (0.202)
LS Mean Change (SE)	-2.15 (0.205)	-3.46 (0.202)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.31
95% CI		(-1.87, -0.74)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.65, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.73 (0.210)	5.47 (0.207)
LS Mean Change (SE)	-2.34 (0.210)	-3.60 (0.207)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.84, -0.68)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.62, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.74 (0.217)	5.26 (0.214)
LS Mean Change (SE)	-2.33 (0.217)	-3.81 (0.214)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.48
95% CI		(-2.08, -0.88)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.74 (0.222)	5.15 (0.220)
LS Mean Change (SE)	-2.33 (0.222)	-3.92 (0.220)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.59
95% CI		(-2.21, -0.98)
p-value		<0.001
Corrected Hedges g [3]		-0.50
95% CI		(-0.70, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.79 (0.228)	5.14 (0.226)
LS Mean Change (SE)	-2.28 (0.228)	-3.93 (0.226)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.65
95% CI		(-2.28, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.71, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.80 (0.233)	4.99 (0.231)
LS Mean Change (SE)	-2.27 (0.233)	-4.08 (0.231)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.81
95% CI		(-2.45, -1.16)
p-value		<0.001
Corrected Hedges g [3]		-0.55
95% CI		(-0.74, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.80 (0.237)	4.94 (0.234)
LS Mean Change (SE)	-2.27 (0.237)	-4.13 (0.234)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.86
95% CI		(-2.51, -1.20)
p-value		<0.001
Corrected Hedges g [3]		-0.55
95% CI		(-0.75, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.27
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.79 (0.242)	4.94 (0.239)
LS Mean Change (SE)	-2.28 (0.242)	-4.13 (0.239)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.85
95% CI		(-2.52, -1.18)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.74, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	9.06	9.09
		Min.	7.33	7.23
		Max.	10.00	10.00
		Mean	9.03	9.07
		SD	0.680	0.783
Weeks 1-4	VAS Score	n	65	69
		Median	8.98	8.72
		Min.	6.92	4.43
		Max.	10.00	10.00
		Mean	8.81	8.53
		SD	0.824	1.190
	Change from Baseline	n	65	69
		Median	-0.12	-0.22
		Min.	-1.49	-4.58
		Q1	-0.39	-0.81
		Q3	0.03	0.02
		Max.	1.08	0.69
		Mean	-0.22	-0.54
		SD	0.464	0.907

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	8.72	7.95
		Min.	4.71	1.93
		Max.	10.00	10.00
		Mean	8.46	7.34
		SD	1.134	2.223
	Change from Baseline	n	65	69
		Median	-0.31	-0.95
		Min.	-4.35	-7.61
		Q1	-1.06	-2.49
		Q3	-0.06	-0.17
		Max.	1.21	0.74
		Mean	-0.57	-1.73
		SD	0.906	2.129

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	8.32	6.86
		Min.	3.56	0.09
		Max.	10.00	10.00
		Mean	8.10	6.37
		SD	1.463	2.738
	Change from Baseline	n	65	69
		Median	-0.44	-1.63
		Min.	-5.32	-9.91
		Q1	-1.55	-3.89
		Q3	-0.06	-0.50
		Max.	1.29	0.21
		Mean	-0.93	-2.70
		SD	1.305	2.717

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	8.02	6.18
		Min.	2.38	0.00
		Max.	10.00	10.00
		Mean	7.64	5.80
		SD	1.973	2.964
	Change from Baseline	n	65	69
		Median	-0.74	-2.23
		Min.	-6.68	-10.00
		Q1	-2.40	-5.70
		Q3	-0.12	-0.87
		Max.	1.19	0.09
		Mean	-1.40	-3.27
		SD	1.855	2.898

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	7.98	5.45
		Min.	0.15	0.00
		Max.	10.00	10.00
		Mean	7.23	5.33
		SD	2.453	3.069
	Change from Baseline	n	65	69
		Median	-1.01	-2.79
		Min.	-8.92	-10.00
		Q1	-2.97	-6.59
		Q3	-0.19	-1.31
		Max.	1.49	0.05
		Mean	-1.80	-3.74
		SD	2.352	3.028

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	7.76	5.17
		Min.	0.11	0.00
		Max.	10.00	9.99
		Mean	6.98	5.07
		SD	2.608	3.069
	Change from Baseline	n	65	69
		Median	-1.15	-3.70
		Min.	-8.96	-10.00
		Q1	-3.43	-6.29
		Q3	-0.11	-1.30
		Max.	0.87	0.08
		Mean	-2.05	-4.00
		SD	2.508	3.022

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	7.11	4.71
		Min.	0.18	0.00
		Max.	10.00	9.98
		Mean	6.62	4.75
		SD	2.817	3.112
	Change from Baseline	n	65	69
		Median	-1.81	-3.68
		Min.	-8.89	-10.00
		Q1	-3.74	-6.97
		Q3	-0.11	-1.60
		Max.	1.19	0.09
		Mean	-2.41	-4.32
		SD	2.673	3.082

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	7.48	4.31
		Min.	0.14	0.00
		Max.	10.00	9.99
		Mean	6.62	4.32
		SD	2.929	3.161
	Change from Baseline	n	65	69
		Median	-1.48	-4.17
		Min.	-8.93	-10.00
		Q1	-4.01	-7.82
		Q3	0.00	-1.93
		Max.	1.19	0.10
		Mean	-2.41	-4.75
		SD	2.808	3.127

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	7.86	4.13
		Min.	0.06	0.00
		Max.	10.00	9.98
		Mean	6.71	4.15
		SD	3.010	3.222
	Change from Baseline	n	65	69
		Median	-1.11	-4.63
		Min.	-9.00	-10.00
		Q1	-4.18	-7.98
		Q3	0.00	-2.25
		Max.	1.19	0.30
		Mean	-2.32	-4.92
		SD	2.898	3.186

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	7.56	4.03
		Min.	0.06	0.00
		Max.	10.00	9.99
		Mean	6.59	3.99
		SD	3.044	3.189
	Change from Baseline	n	65	69
		Median	-1.01	-5.13
		Min.	-8.99	-10.00
		Q1	-4.42	-8.07
		Q3	0.00	-2.40
		Max.	1.19	0.55
		Mean	-2.45	-5.07
		SD	2.945	3.177

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	7.65	2.85
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.47	3.74
		SD	3.197	3.212
	Change from Baseline	n	65	69
		Median	-1.11	-5.27
		Min.	-8.97	-10.00
		Q1	-4.78	-8.34
		Q3	0.00	-2.69
		Max.	1.19	0.55
		Mean	-2.57	-5.33
		SD	3.089	3.196

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	7.12	3.62
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	6.37	3.79
		SD	3.098	3.203
	Change from Baseline	n	65	69
		Median	-1.57	-5.53
		Min.	-8.96	-10.00
		Q1	-4.93	-7.98
		Q3	0.00	-3.19
		Max.	1.19	0.55
		Mean	-2.66	-5.28
		SD	2.971	3.164

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	6.91	3.37
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	6.29	3.70
		SD	3.237	3.202
	Change from Baseline	n	65	69
		Median	-1.56	-5.76
		Min.	-8.97	-10.00
		Q1	-4.90	-8.11
		Q3	0.00	-3.21
		Max.	1.19	0.55
		Mean	-2.74	-5.37
		SD	3.085	3.158

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	7.34	3.26
		Min.	0.01	0.00
		Max.	10.00	9.99
		Mean	6.31	3.82
		SD	3.340	3.343
	Change from Baseline	n	65	69
		Median	-1.56	-6.04
		Min.	-8.97	-10.00
		Q1	-5.03	-7.82
		Q3	0.00	-3.35
		Max.	1.25	0.55
		Mean	-2.72	-5.25
		SD	3.180	3.267

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	7.56	3.42
		Min.	0.01	0.00
		Max.	10.00	9.99
		Mean	6.47	4.02
		SD	3.325	3.331
	Change from Baseline	n	65	69
		Median	-0.61	-5.55
		Min.	-8.96	-10.00
		Q1	-5.05	-8.07
		Q3	0.00	-2.30
		Max.	1.25	0.55
		Mean	-2.57	-5.05
		SD	3.151	3.315

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	7.88	3.90
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	6.41	4.15
		SD	3.402	3.337
	Change from Baseline	n	65	69
		Median	-0.71	-5.09
		Min.	-8.96	-10.00
		Q1	-5.20	-8.02
		Q3	0.00	-1.88
		Max.	1.30	0.55
		Mean	-2.63	-4.91
		SD	3.245	3.338

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	7.83	4.10
		Min.	0.03	0.00
		Max.	10.00	9.99
		Mean	6.51	4.41
		SD	3.417	3.407
	Change from Baseline	n	65	69
		Median	-0.60	-4.76
		Min.	-8.97	-10.00
		Q1	-5.36	-7.68
		Q3	0.00	-1.62
		Max.	1.32	0.55
		Mean	-2.52	-4.66
		SD	3.262	3.410

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	7.49	4.51
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	6.35	4.60
		SD	3.444	3.474
	Change from Baseline	n	65	69
		Median	-0.69	-4.67
		Min.	-8.97	-10.00
		Q1	-5.35	-7.41
		Q3	0.00	-1.40
		Max.	1.28	0.61
		Mean	-2.68	-4.47
		SD	3.274	3.477

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Overall Nasal Polyp Symptoms

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	8.20	4.89
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.43	4.80
		SD	3.446	3.516
	Change from Baseline	n	65	69
		Median	-0.83	-4.39
		Min.	-9.03	-10.00
		Q1	-5.39	-7.59
		Q3	0.00	-0.92
		Max.	1.39	0.65
		Mean	-2.60	-4.27
		SD	3.271	3.495

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.82 (0.091)	8.52 (0.089)
LS Mean Change (SE)	-0.23 (0.091)	-0.54 (0.089)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.31
95% CI		(-0.56, -0.05)
p-value		0.018
Corrected Hedges g [3]		-0.41
95% CI		(-0.76, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.48 (0.207)	7.33 (0.201)
LS Mean Change (SE)	-0.57 (0.207)	-1.73 (0.201)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.15
95% CI		(-1.72, -0.58)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.03, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.11 (0.267)	6.36 (0.259)
LS Mean Change (SE)	-0.94 (0.267)	-2.69 (0.259)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.75
95% CI		(-2.49, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.81
95% CI		(-1.16, -0.46)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.65 (0.307)	5.81 (0.298)
LS Mean Change (SE)	-1.40 (0.307)	-3.24 (0.298)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.84
95% CI		(-2.68, -0.99)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.26 (0.342)	5.35 (0.332)
LS Mean Change (SE)	-1.79 (0.342)	-3.71 (0.332)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.92
95% CI		(-2.86, -0.98)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.04, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.02 (0.349)	5.09 (0.339)
LS Mean Change (SE)	-2.04 (0.349)	-3.97 (0.339)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.93
95% CI		(-2.89, -0.97)
p-value		<0.001
Corrected Hedges g [3]		-0.68
95% CI		(-1.03, -0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.69 (0.364)	4.76 (0.353)
LS Mean Change (SE)	-2.36 (0.364)	-4.29 (0.353)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.93
95% CI		(-2.93, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-1.00, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.74 (0.378)	4.34 (0.366)
LS Mean Change (SE)	-2.31 (0.378)	-4.71 (0.366)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.40
95% CI		(-3.45, -1.36)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.14, -0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.84 (0.387)	4.16 (0.376)
LS Mean Change (SE)	-2.21 (0.387)	-4.89 (0.376)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.67
95% CI		(-3.74, -1.61)
p-value		<0.001
Corrected Hedges g [3]		-0.85
95% CI		(-1.21, -0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.71 (0.392)	4.03 (0.380)
LS Mean Change (SE)	-2.34 (0.392)	-5.02 (0.380)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.68
95% CI		(-3.76, -1.60)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.20, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.59 (0.402)	3.78 (0.390)
LS Mean Change (SE)	-2.46 (0.402)	-5.27 (0.390)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.81
95% CI		(-3.92, -1.70)
p-value		<0.001
Corrected Hedges g [3]		-0.86
95% CI		(-1.22, -0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.50 (0.393)	3.83 (0.382)
LS Mean Change (SE)	-2.55 (0.393)	-5.22 (0.382)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.67
95% CI		(-3.76, -1.59)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.19, -0.48)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.42 (0.400)	3.73 (0.388)
LS Mean Change (SE)	-2.63 (0.400)	-5.32 (0.388)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.69
95% CI		(-3.79, -1.59)
p-value		<0.001
Corrected Hedges g [3]		-0.83
95% CI		(-1.18, -0.48)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.45 (0.413)	3.86 (0.401)
LS Mean Change (SE)	-2.60 (0.413)	-5.19 (0.401)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.59
95% CI		(-3.73, -1.45)
p-value		<0.001
Corrected Hedges g [3]		-0.77
95% CI		(-1.12, -0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.62 (0.418)	4.10 (0.406)
LS Mean Change (SE)	-2.43 (0.418)	-4.95 (0.406)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.52
95% CI		(-3.67, -1.36)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.55 (0.425)	4.24 (0.412)
LS Mean Change (SE)	-2.50 (0.425)	-4.81 (0.412)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.31
95% CI		(-3.48, -1.14)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.02, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.68 (0.433)	4.53 (0.420)
LS Mean Change (SE)	-2.37 (0.433)	-4.52 (0.420)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.15
95% CI		(-3.34, -0.96)
p-value		<0.001
Corrected Hedges g [3]		-0.61
95% CI		(-0.96, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.50 (0.437)	4.72 (0.424)
LS Mean Change (SE)	-2.55 (0.437)	-4.33 (0.424)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.78
95% CI		(-2.99, -0.58)
p-value		0.004
Corrected Hedges g [3]		-0.50
95% CI		(-0.85, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.35
Analysis of Mean Change from Baseline Overall VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.59 (0.438)	4.92 (0.425)
LS Mean Change (SE)	-2.47 (0.438)	-4.13 (0.425)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.66
95% CI		(-2.87, -0.45)
p-value		0.007
Corrected Hedges g [3]		-0.47
95% CI		(-0.81, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	9.14	9.01
		Min.	5.31	6.54
		Max.	10.00	10.00
		Mean	9.02	8.92
		SD	0.828	0.832
Weeks 1-4	VAS Score	n	201	206
		Median	8.78	8.50
		Min.	1.51	0.12
		Max.	10.00	10.00
		Mean	8.47	8.19
		SD	1.408	1.504
	Change from Baseline	n	201	206
		Median	-0.16	-0.31
		Min.	-7.86	-9.65
		Q1	-0.62	-0.89
		Q3	0.00	-0.02
		Max.	1.52	0.89
		Mean	-0.55	-0.73
		SD	1.277	1.354

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	8.50	7.80
		Min.	0.30	0.00
		Max.	10.00	10.00
		Mean	7.91	7.24
		SD	2.024	2.196
	Change from Baseline	n	201	206
		Median	-0.37	-1.03
		Min.	-9.69	-9.77
		Q1	-1.37	-2.50
		Q3	-0.02	-0.18
		Max.	2.58	1.22
		Mean	-1.11	-1.68
		SD	1.950	2.063

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	8.21	6.98
		Min.	0.13	0.08
		Max.	10.00	10.00
		Mean	7.53	6.50
		SD	2.304	2.556
	Change from Baseline	n	201	206
		Median	-0.69	-1.75
		Min.	-9.86	-9.88
		Q1	-2.01	-3.73
		Q3	-0.06	-0.46
		Max.	2.58	1.49
		Mean	-1.49	-2.42
		SD	2.248	2.461

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	7.80	6.14
		Min.	0.04	0.00
		Max.	10.00	10.00
		Mean	7.20	5.90
		SD	2.527	2.792
	Change from Baseline	n	201	206
		Median	-0.84	-2.45
		Min.	-9.95	-9.98
		Q1	-2.69	-4.83
		Q3	-0.07	-0.74
		Max.	2.58	1.54
		Mean	-1.82	-3.03
		SD	2.480	2.711

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	7.74	5.74
		Min.	0.06	0.00
		Max.	10.00	10.00
		Mean	6.93	5.55
		SD	2.768	2.969
	Change from Baseline	n	201	206
		Median	-0.88	-2.78
		Min.	-9.63	-9.93
		Q1	-3.46	-5.86
		Q3	-0.09	-0.83
		Max.	2.58	1.54
		Mean	-2.09	-3.38
		SD	2.714	2.898

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	7.47	5.55
		Min.	0.03	0.00
		Max.	10.00	10.00
		Mean	6.80	5.31
		SD	2.855	3.121
	Change from Baseline	n	201	206
		Median	-1.04	-3.23
		Min.	-9.68	-9.96
		Q1	-3.58	-6.16
		Q3	-0.01	-0.80
		Max.	2.58	1.54
		Mean	-2.22	-3.61
		SD	2.799	3.072

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	7.16	5.47
		Min.	0.04	0.00
		Max.	10.00	10.00
		Mean	6.62	5.20
		SD	2.847	3.156
	Change from Baseline	n	201	206
		Median	-1.62	-3.28
		Min.	-9.70	-9.97
		Q1	-3.94	-6.32
		Q3	0.00	-1.01
		Max.	2.58	1.54
		Mean	-2.40	-3.73
		SD	2.788	3.105

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	7.33	5.05
		Min.	0.03	0.00
		Max.	10.00	10.00
		Mean	6.59	5.01
		SD	2.931	3.232
	Change from Baseline	n	201	206
		Median	-1.36	-3.62
		Min.	-9.67	-9.97
		Q1	-4.29	-6.91
		Q3	0.00	-1.04
		Max.	2.58	1.54
		Mean	-2.43	-3.91
		SD	2.866	3.181

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	7.33	4.69
		Min.	0.04	0.00
		Max.	10.00	10.00
		Mean	6.56	4.90
		SD	3.013	3.288
	Change from Baseline	n	201	206
		Median	-1.04	-3.66
		Min.	-9.55	-9.93
		Q1	-4.36	-7.02
		Q3	0.00	-0.92
		Max.	2.58	1.54
		Mean	-2.46	-4.02
		SD	2.938	3.247

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	7.54	4.63
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	6.60	4.86
		SD	3.040	3.367
	Change from Baseline	n	201	206
		Median	-1.23	-4.21
		Min.	-9.69	-9.93
		Q1	-4.49	-7.13
		Q3	0.00	-0.42
		Max.	2.58	1.54
		Mean	-2.42	-4.06
		SD	2.980	3.330

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	7.61	4.33
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.59	4.73
		SD	3.129	3.407
	Change from Baseline	n	201	206
		Median	-1.18	-4.35
		Min.	-9.19	-9.90
		Q1	-4.66	-7.22
		Q3	0.00	-0.69
		Max.	2.58	1.54
		Mean	-2.43	-4.19
		SD	3.081	3.357

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	7.74	4.31
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.57	4.70
		SD	3.197	3.415
	Change from Baseline	n	201	206
		Median	-1.09	-4.19
		Min.	-9.24	-9.90
		Q1	-5.04	-7.20
		Q3	0.00	-0.62
		Max.	3.45	1.54
		Mean	-2.45	-4.22
		SD	3.113	3.374

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	8.00	4.31
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.57	4.68
		SD	3.261	3.486
	Change from Baseline	n	201	206
		Median	-0.82	-4.41
		Min.	-9.23	-9.90
		Q1	-4.84	-7.27
		Q3	0.00	-0.36
		Max.	2.58	1.54
		Mean	-2.45	-4.24
		SD	3.147	3.423

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.43 (0.092)	8.24 (0.091)
LS Mean Change (SE)	-0.54 (0.092)	-0.73 (0.091)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.19
95% CI		(-0.44, 0.06)
p-value		0.142
Corrected Hedges g [3]		-0.15
95% CI		(-0.34, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.86 (0.141)	7.29 (0.139)
LS Mean Change (SE)	-1.11 (0.141)	-1.68 (0.139)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.58
95% CI		(-0.97, -0.18)
p-value		0.004
Corrected Hedges g [3]		-0.29
95% CI		(-0.48, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.50 (0.166)	6.55 (0.164)
LS Mean Change (SE)	-1.47 (0.166)	-2.43 (0.164)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.96
95% CI		(-1.42, -0.50)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.60, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.17 (0.184)	5.96 (0.182)
LS Mean Change (SE)	-1.80 (0.184)	-3.01 (0.182)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.21
95% CI		(-1.72, -0.70)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.66, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.92 (0.200)	5.62 (0.197)
LS Mean Change (SE)	-2.05 (0.200)	-3.35 (0.197)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.30
95% CI		(-1.85, -0.75)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.65, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.82 (0.211)	5.42 (0.209)
LS Mean Change (SE)	-2.15 (0.211)	-3.55 (0.209)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.40
95% CI		(-1.98, -0.81)
p-value		<0.001
Corrected Hedges g [3]		-0.47
95% CI		(-0.66, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.66 (0.214)	5.32 (0.211)
LS Mean Change (SE)	-2.31 (0.214)	-3.66 (0.211)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-1.93, -0.75)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.67 (0.221)	5.14 (0.218)
LS Mean Change (SE)	-2.30 (0.221)	-3.83 (0.218)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.53
95% CI		(-2.15, -0.92)
p-value		<0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.69, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.65 (0.226)	5.03 (0.224)
LS Mean Change (SE)	-2.32 (0.226)	-3.94 (0.224)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.62
95% CI		(-2.25, -0.99)
p-value		<0.001
Corrected Hedges g [3]		-0.50
95% CI		(-0.70, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.69 (0.232)	5.03 (0.230)
LS Mean Change (SE)	-2.28 (0.232)	-3.94 (0.230)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-2.31, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.50
95% CI		(-0.70, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.69 (0.237)	4.90 (0.234)
LS Mean Change (SE)	-2.28 (0.237)	-4.07 (0.234)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.80
95% CI		(-2.45, -1.14)
p-value		<0.001
Corrected Hedges g [3]		-0.53
95% CI		(-0.73, -0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.70 (0.241)	4.89 (0.238)
LS Mean Change (SE)	-2.27 (0.241)	-4.08 (0.238)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.81
95% CI		(-2.48, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.53
95% CI		(-0.73, -0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.18
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.70 (0.245)	4.88 (0.242)
LS Mean Change (SE)	-2.27 (0.245)	-4.09 (0.242)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.82
95% CI		(-2.50, -1.14)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.72, -0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	8.96	9.03
		Min.	6.90	6.77
		Max.	10.00	10.00
		Mean	8.88	8.97
		SD	0.817	0.844
Weeks 1-4	VAS Score	n	65	69
		Median	8.72	8.53
		Min.	6.70	4.33
		Max.	10.00	10.00
		Mean	8.69	8.27
		SD	0.894	1.321
	Change from Baseline	n	65	69
		Median	-0.09	-0.31
		Min.	-1.24	-4.61
		Q1	-0.36	-0.96
		Q3	0.01	0.00
		Max.	1.49	0.79
		Mean	-0.19	-0.70
		SD	0.456	1.079

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	8.52	7.68
		Min.	5.04	1.16
		Max.	10.00	10.00
		Mean	8.36	7.03
		SD	1.176	2.309
	Change from Baseline	n	65	69
		Median	-0.26	-1.10
		Min.	-3.32	-8.31
		Q1	-0.92	-3.16
		Q3	-0.02	-0.20
		Max.	2.58	0.59
		Mean	-0.53	-1.94
		SD	0.946	2.217

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	8.29	6.48
		Min.	2.36	0.12
		Max.	10.00	10.00
		Mean	8.02	6.07
		SD	1.538	2.778
	Change from Baseline	n	65	69
		Median	-0.47	-2.06
		Min.	-6.60	-9.88
		Q1	-1.43	-4.58
		Q3	-0.04	-0.70
		Max.	2.58	0.37
		Mean	-0.87	-2.90
		SD	1.371	2.741

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	7.86	5.91
		Min.	1.84	0.00
		Max.	10.00	10.00
		Mean	7.57	5.48
		SD	2.015	3.001
	Change from Baseline	n	65	69
		Median	-0.63	-2.85
		Min.	-7.12	-9.98
		Q1	-2.26	-6.09
		Q3	-0.03	-0.85
		Max.	2.58	0.08
		Mean	-1.32	-3.49
		SD	1.903	2.928

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	7.74	5.31
		Min.	0.06	0.00
		Max.	10.00	10.00
		Mean	7.12	5.08
		SD	2.505	3.117
	Change from Baseline	n	65	69
		Median	-0.88	-3.21
		Min.	-8.98	-9.93
		Q1	-2.95	-6.81
		Q3	-0.12	-1.25
		Max.	2.58	0.28
		Mean	-1.77	-3.89
		SD	2.423	3.064

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	7.52	5.10
		Min.	0.04	0.00
		Max.	10.00	9.98
		Mean	6.86	4.84
		SD	2.718	3.123
	Change from Baseline	n	65	69
		Median	-1.09	-3.66
		Min.	-9.00	-9.96
		Q1	-3.37	-7.06
		Q3	-0.04	-1.43
		Max.	2.58	0.26
		Mean	-2.02	-4.13
		SD	2.660	3.051

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	6.86	4.65
		Min.	0.07	0.00
		Max.	10.00	9.99
		Mean	6.57	4.51
		SD	2.798	3.087
	Change from Baseline	n	65	69
		Median	-1.91	-4.53
		Min.	-8.97	-9.97
		Q1	-3.88	-7.13
		Q3	0.00	-1.98
		Max.	2.58	0.20
		Mean	-2.32	-4.46
		SD	2.685	3.041

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	6.50	3.88
		Min.	0.09	0.00
		Max.	10.00	9.98
		Mean	6.51	4.14
		SD	2.914	3.138
	Change from Baseline	n	65	69
		Median	-1.63	-4.40
		Min.	-8.95	-9.97
		Q1	-4.07	-7.76
		Q3	0.00	-2.32
		Max.	2.58	0.09
		Mean	-2.38	-4.83
		SD	2.818	3.091

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	7.74	3.86
		Min.	0.04	0.00
		Max.	10.00	9.99
		Mean	6.58	4.03
		SD	2.992	3.152
	Change from Baseline	n	65	69
		Median	-0.80	-5.22
		Min.	-9.00	-9.93
		Q1	-4.36	-7.68
		Q3	0.00	-2.46
		Max.	2.58	0.71
		Mean	-2.30	-4.94
		SD	2.908	3.136

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	7.08	3.71
		Min.	0.05	0.00
		Max.	10.00	9.99
		Mean	6.42	3.91
		SD	3.063	3.162
	Change from Baseline	n	65	69
		Median	-1.39	-5.07
		Min.	-8.99	-9.93
		Q1	-4.49	-8.07
		Q3	0.00	-2.59
		Max.	2.58	0.43
		Mean	-2.46	-5.06
		SD	2.987	3.177

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	7.18	3.08
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.33	3.72
		SD	3.218	3.193
	Change from Baseline	n	65	69
		Median	-1.06	-5.30
		Min.	-9.01	-9.90
		Q1	-4.86	-8.09
		Q3	0.00	-2.48
		Max.	2.58	0.43
		Mean	-2.55	-5.25
		SD	3.138	3.176

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	6.95	3.91
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	6.25	3.82
		SD	3.153	3.148
	Change from Baseline	n	65	69
		Median	-1.63	-5.46
		Min.	-9.00	-9.90
		Q1	-4.86	-7.72
		Q3	0.00	-2.99
		Max.	2.58	0.43
		Mean	-2.63	-5.15
		SD	3.049	3.104

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	6.77	3.48
		Min.	0.00	0.00
		Max.	10.00	9.95
		Mean	6.19	3.74
		SD	3.299	3.170
	Change from Baseline	n	65	69
		Median	-1.70	-5.54
		Min.	-9.02	-9.90
		Q1	-4.93	-7.60
		Q3	0.00	-3.48
		Max.	2.58	0.43
		Mean	-2.70	-5.23
		SD	3.152	3.100

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	7.22	3.30
		Min.	0.01	0.00
		Max.	10.00	9.96
		Mean	6.20	3.96
		SD	3.445	3.292
	Change from Baseline	n	65	69
		Median	-1.15	-5.49
		Min.	-8.99	-9.90
		Q1	-5.00	-7.71
		Q3	0.00	-3.32
		Max.	2.58	0.43
		Mean	-2.68	-5.01
		SD	3.299	3.168

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	7.97	3.51
		Min.	0.00	0.00
		Max.	10.00	9.97
		Mean	6.35	4.13
		SD	3.431	3.263
	Change from Baseline	n	65	69
		Median	-0.60	-5.19
		Min.	-8.96	-9.90
		Q1	-5.06	-7.15
		Q3	0.00	-2.28
		Max.	2.58	0.43
		Mean	-2.53	-4.84
		SD	3.271	3.190

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	7.90	4.06
		Min.	0.00	0.00
		Max.	10.00	9.97
		Mean	6.25	4.21
		SD	3.498	3.238
	Change from Baseline	n	65	69
		Median	-0.63	-4.72
		Min.	-9.02	-9.90
		Q1	-5.50	-7.58
		Q3	0.00	-2.51
		Max.	2.58	0.43
		Mean	-2.63	-4.76
		SD	3.365	3.194

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	8.19	4.70
		Min.	0.02	0.00
		Max.	10.00	9.99
		Mean	6.39	4.51
		SD	3.482	3.309
	Change from Baseline	n	65	69
		Median	-0.62	-4.40
		Min.	-9.01	-9.89
		Q1	-5.29	-7.25
		Q3	0.00	-1.42
		Max.	2.58	0.43
		Mean	-2.49	-4.46
		SD	3.328	3.255

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	7.53	4.86
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.24	4.73
		SD	3.506	3.299
	Change from Baseline	n	65	69
		Median	-0.83	-4.34
		Min.	-9.02	-9.87
		Q1	-5.18	-7.16
		Q3	0.00	-1.28
		Max.	2.58	0.60
		Mean	-2.64	-4.24
		SD	3.347	3.273

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Obstruction

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	7.98	5.09
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.31	4.99
		SD	3.500	3.382
	Change from Baseline	n	65	69
		Median	-0.80	-3.89
		Min.	-9.03	-9.87
		Q1	-5.25	-6.46
		Q3	0.00	-0.72
		Max.	2.58	0.86
		Mean	-2.57	-3.98
		SD	3.345	3.291

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.73 (0.106)	8.24 (0.103)
LS Mean Change (SE)	-0.20 (0.106)	-0.69 (0.103)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.49
95% CI		(-0.78, -0.20)
p-value		0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.92, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.39 (0.216)	7.00 (0.210)
LS Mean Change (SE)	-0.54 (0.216)	-1.93 (0.210)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.39
95% CI		(-1.99, -0.79)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.15, -0.44)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.05 (0.273)	6.05 (0.265)
LS Mean Change (SE)	-0.88 (0.273)	-2.88 (0.265)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.00
95% CI		(-2.76, -1.25)
p-value		<0.001
Corrected Hedges g [3]		-0.91
95% CI		(-1.26, -0.55)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.60 (0.313)	5.48 (0.304)
LS Mean Change (SE)	-1.32 (0.313)	-3.45 (0.304)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.12
95% CI		(-2.99, -1.26)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.19, -0.48)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.17 (0.349)	5.08 (0.339)
LS Mean Change (SE)	-1.76 (0.349)	-3.85 (0.339)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.09
95% CI		(-3.05, -1.13)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.91 (0.361)	4.84 (0.350)
LS Mean Change (SE)	-2.01 (0.361)	-4.09 (0.350)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.07
95% CI		(-3.07, -1.08)
p-value		<0.001
Corrected Hedges g [3]		-0.71
95% CI		(-1.06, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.66 (0.363)	4.51 (0.353)
LS Mean Change (SE)	-2.27 (0.363)	-4.42 (0.353)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.15
95% CI		(-3.15, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.73
95% CI		(-1.08, -0.38)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.65 (0.378)	4.13 (0.367)
LS Mean Change (SE)	-2.27 (0.378)	-4.79 (0.367)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.52
95% CI		(-3.56, -1.48)
p-value		<0.001
Corrected Hedges g [3]		-0.82
95% CI		(-1.17, -0.47)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.73 (0.386)	4.04 (0.375)
LS Mean Change (SE)	-2.20 (0.386)	-4.89 (0.375)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.70
95% CI		(-3.76, -1.63)
p-value		<0.001
Corrected Hedges g [3]		-0.86
95% CI		(-1.22, -0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.58 (0.396)	3.94 (0.384)
LS Mean Change (SE)	-2.35 (0.396)	-4.98 (0.384)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.63
95% CI		(-3.73, -1.54)
p-value		<0.001
Corrected Hedges g [3]		-0.82
95% CI		(-1.17, -0.47)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.49 (0.406)	3.75 (0.394)
LS Mean Change (SE)	-2.44 (0.406)	-5.18 (0.394)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.74
95% CI		(-3.86, -1.62)
p-value		<0.001
Corrected Hedges g [3]		-0.83
95% CI		(-1.19, -0.48)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.41 (0.397)	3.84 (0.385)
LS Mean Change (SE)	-2.51 (0.397)	-5.08 (0.385)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.57
95% CI		(-3.67, -1.47)
p-value		<0.001
Corrected Hedges g [3]		-0.80
95% CI		(-1.15, -0.45)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.36 (0.404)	3.76 (0.392)
LS Mean Change (SE)	-2.57 (0.404)	-5.17 (0.392)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.60
95% CI		(-3.71, -1.48)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.15, -0.44)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.38 (0.417)	3.98 (0.405)
LS Mean Change (SE)	-2.55 (0.417)	-4.95 (0.405)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.40
95% CI		(-3.55, -1.25)
p-value		<0.001
Corrected Hedges g [3]		-0.71
95% CI		(-1.06, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.54 (0.421)	4.19 (0.409)
LS Mean Change (SE)	-2.39 (0.421)	-4.73 (0.409)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.35
95% CI		(-3.51, -1.19)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.04, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.43 (0.427)	4.28 (0.414)
LS Mean Change (SE)	-2.49 (0.427)	-4.64 (0.414)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.15
95% CI		(-3.33, -0.97)
p-value		<0.001
Corrected Hedges g [3]		-0.62
95% CI		(-0.97, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.60 (0.432)	4.62 (0.419)
LS Mean Change (SE)	-2.33 (0.432)	-4.31 (0.419)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.99
95% CI		(-3.18, -0.79)
p-value		0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.91, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.43 (0.434)	4.84 (0.421)
LS Mean Change (SE)	-2.50 (0.434)	-4.09 (0.421)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.59
95% CI		(-2.79, -0.39)
p-value		0.010
Corrected Hedges g [3]		-0.45
95% CI		(-0.80, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.26
Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.50 (0.434)	5.11 (0.421)
LS Mean Change (SE)	-2.42 (0.434)	-3.82 (0.421)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.40
95% CI		(-2.59, -0.20)
p-value		0.023
Corrected Hedges g [3]		-0.40
95% CI		(-0.74, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	9.04	8.93
		Min.	1.39	1.03
		Max.	10.00	10.00
		Mean	8.78	8.78
		SD	1.251	1.066
Weeks 1-4	VAS Score	n	201	206
		Median	8.70	8.36
		Min.	0.98	0.13
		Max.	10.00	10.00
		Mean	8.24	8.12
		SD	1.660	1.585
	Change from Baseline	n	201	206
		Median	-0.14	-0.30
		Min.	-8.08	-9.63
		Q1	-0.65	-0.81
		Q3	0.01	-0.06
		Max.	1.87	2.77
		Mean	-0.54	-0.66
		SD	1.314	1.326

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	8.31	7.72
		Min.	0.33	0.01
		Max.	10.00	10.00
		Mean	7.67	7.15
		SD	2.200	2.224
	Change from Baseline	n	201	206
		Median	-0.40	-1.02
		Min.	-9.67	-9.75
		Q1	-1.37	-2.13
		Q3	0.00	-0.24
		Max.	1.93	2.86
		Mean	-1.12	-1.63
		SD	1.995	2.063

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	8.00	6.93
		Min.	0.05	0.01
		Max.	10.00	10.00
		Mean	7.26	6.39
		SD	2.448	2.579
	Change from Baseline	n	201	206
		Median	-0.69	-1.82
		Min.	-9.92	-9.85
		Q1	-2.09	-3.62
		Q3	-0.04	-0.50
		Max.	1.87	2.88
		Mean	-1.52	-2.39
		SD	2.304	2.465

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	7.59	6.02
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.91	5.79
		SD	2.668	2.821
	Change from Baseline	n	201	206
		Median	-0.89	-2.43
		Min.	-9.96	-9.94
		Q1	-2.68	-4.70
		Q3	-0.07	-0.73
		Max.	1.87	2.93
		Mean	-1.87	-2.98
		SD	2.550	2.721

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	7.46	5.53
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.67	5.41
		SD	2.880	2.992
	Change from Baseline	n	201	206
		Median	-0.95	-2.67
		Min.	-9.97	-9.89
		Q1	-3.34	-6.08
		Q3	-0.09	-0.86
		Max.	1.87	2.96
		Mean	-2.11	-3.37
		SD	2.751	2.926

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	7.38	5.37
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.55	5.19
		SD	2.921	3.127
	Change from Baseline	n	201	206
		Median	-1.10	-3.15
		Min.	-9.97	-9.92
		Q1	-3.80	-6.31
		Q3	0.00	-0.86
		Max.	1.87	2.97
		Mean	-2.23	-3.59
		SD	2.833	3.117

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	6.99	5.19
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	6.30	5.03
		SD	2.962	3.130
	Change from Baseline	n	201	206
		Median	-1.69	-3.17
		Min.	-9.96	-9.92
		Q1	-4.23	-6.30
		Q3	-0.03	-1.14
		Max.	1.87	2.96
		Mean	-2.48	-3.75
		SD	2.877	3.125

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	7.13	5.02
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.31	4.84
		SD	3.006	3.234
	Change from Baseline	n	201	206
		Median	-1.44	-3.70
		Min.	-9.97	-9.89
		Q1	-4.66	-6.90
		Q3	0.00	-1.16
		Max.	5.47	2.96
		Mean	-2.47	-3.93
		SD	2.968	3.234

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	7.18	4.53
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.28	4.73
		SD	3.079	3.269
	Change from Baseline	n	201	206
		Median	-1.48	-3.78
		Min.	-9.97	-9.88
		Q1	-4.66	-7.10
		Q3	0.00	-0.94
		Max.	5.75	2.07
		Mean	-2.50	-4.05
		SD	3.041	3.271

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	7.13	4.53
		Min.	0.02	0.00
		Max.	10.00	10.00
		Mean	6.35	4.69
		SD	3.112	3.350
	Change from Baseline	n	201	206
		Median	-1.19	-4.02
		Min.	-9.95	-9.87
		Q1	-4.47	-7.28
		Q3	0.00	-0.54
		Max.	5.74	1.92
		Mean	-2.43	-4.09
		SD	3.070	3.356

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	7.33	4.17
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.35	4.57
		SD	3.181	3.376
	Change from Baseline	n	201	206
		Median	-0.94	-4.59
		Min.	-9.95	-9.87
		Q1	-4.84	-7.32
		Q3	0.00	-0.35
		Max.	6.04	1.80
		Mean	-2.43	-4.21
		SD	3.145	3.384

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	7.24	4.23
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.36	4.53
		SD	3.232	3.401
	Change from Baseline	n	201	206
		Median	-1.12	-4.51
		Min.	-9.96	-9.87
		Q1	-5.02	-7.24
		Q3	0.00	-0.46
		Max.	6.26	1.90
		Mean	-2.42	-4.25
		SD	3.151	3.408

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	7.48	4.13
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.33	4.55
		SD	3.313	3.465
	Change from Baseline	n	201	206
		Median	-0.85	-4.51
		Min.	-9.94	-9.87
		Q1	-4.80	-7.19
		Q3	0.00	-0.27
		Max.	6.48	2.09
		Mean	-2.45	-4.23
		SD	3.234	3.457

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.23 (0.092)	8.12 (0.091)
LS Mean Change (SE)	-0.55 (0.092)	-0.66 (0.091)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.11
95% CI		(-0.36, 0.14)
p-value		0.391
Corrected Hedges g [3]		-0.09
95% CI		(-0.28, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.66 (0.142)	7.16 (0.140)
LS Mean Change (SE)	-1.12 (0.142)	-1.62 (0.140)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-0.89, -0.11)
p-value		0.012
Corrected Hedges g [3]		-0.25
95% CI		(-0.44, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.27 (0.167)	6.40 (0.165)
LS Mean Change (SE)	-1.50 (0.167)	-2.38 (0.165)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.87
95% CI		(-1.33, -0.41)
p-value		<0.001
Corrected Hedges g [3]		-0.37
95% CI		(-0.56, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.94 (0.186)	5.83 (0.184)
LS Mean Change (SE)	-1.84 (0.186)	-2.95 (0.184)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.11
95% CI		(-1.62, -0.59)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.70 (0.201)	5.45 (0.199)
LS Mean Change (SE)	-2.07 (0.201)	-3.33 (0.199)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.25
95% CI		(-1.81, -0.70)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.63, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.62 (0.214)	5.28 (0.211)
LS Mean Change (SE)	-2.16 (0.214)	-3.50 (0.211)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-1.93, -0.75)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.41 (0.218)	5.13 (0.215)
LS Mean Change (SE)	-2.37 (0.218)	-3.65 (0.215)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.28
95% CI		(-1.88, -0.67)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.45 (0.226)	4.95 (0.223)
LS Mean Change (SE)	-2.33 (0.226)	-3.82 (0.223)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.50
95% CI		(-2.12, -0.88)
p-value		<0.001
Corrected Hedges g [3]		-0.47
95% CI		(-0.66, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.46 (0.231)	4.85 (0.228)
LS Mean Change (SE)	-2.32 (0.231)	-3.93 (0.228)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.60
95% CI		(-2.24, -0.97)
p-value		<0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.69, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.54 (0.237)	4.85 (0.234)
LS Mean Change (SE)	-2.24 (0.237)	-3.93 (0.234)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.69
95% CI		(-2.34, -1.03)
p-value		<0.001
Corrected Hedges g [3]		-0.50
95% CI		(-0.70, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.57 (0.241)	4.73 (0.238)
LS Mean Change (SE)	-2.21 (0.241)	-4.05 (0.238)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.84
95% CI		(-2.50, -1.17)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.73, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.59 (0.244)	4.71 (0.241)
LS Mean Change (SE)	-2.19 (0.244)	-4.07 (0.241)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.88
95% CI		(-2.55, -1.20)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.74, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.45
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.57 (0.250)	4.73 (0.247)
LS Mean Change (SE)	-2.21 (0.250)	-4.05 (0.247)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.84
95% CI		(-2.53, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.72, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	8.97	8.91
		Min.	1.39	7.11
		Max.	10.00	10.00
		Mean	8.59	8.91
		SD	1.508	0.856
Weeks 1-4	VAS Score	n	65	69
		Median	8.73	8.32
		Min.	0.98	4.27
		Max.	10.00	10.00
		Mean	8.41	8.25
		SD	1.528	1.249
	Change from Baseline	n	65	69
		Median	-0.11	-0.27
		Min.	-1.22	-4.64
		Q1	-0.37	-1.05
		Q3	0.01	-0.04
		Max.	1.87	0.92
		Mean	-0.18	-0.66
		SD	0.474	1.054

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	8.45	7.70
		Min.	0.46	1.46
		Max.	9.99	10.00
		Mean	8.09	7.01
		SD	1.670	2.305
	Change from Baseline	n	65	69
		Median	-0.28	-1.18
		Min.	-2.71	-8.05
		Q1	-0.88	-2.67
		Q3	0.00	-0.19
		Max.	1.60	1.19
		Mean	-0.50	-1.90
		SD	0.836	2.244

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	8.01	6.51
		Min.	0.91	0.01
		Max.	9.98	10.00
		Mean	7.74	6.09
		SD	1.843	2.753
	Change from Baseline	n	65	69
		Median	-0.36	-1.87
		Min.	-5.86	-9.85
		Q1	-1.49	-4.45
		Q3	0.00	-0.81
		Max.	1.87	0.50
		Mean	-0.85	-2.82
		SD	1.272	2.701

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	7.76	6.00
		Min.	1.05	0.00
		Max.	10.00	9.99
		Mean	7.30	5.54
		SD	2.187	2.954
	Change from Baseline	n	65	69
		Median	-0.77	-2.50
		Min.	-6.42	-9.94
		Q1	-2.18	-5.78
		Q3	0.00	-0.99
		Max.	1.87	0.26
		Mean	-1.29	-3.37
		SD	1.845	2.873

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	7.46	5.40
		Min.	0.08	0.00
		Max.	10.00	10.00
		Mean	6.88	5.10
		SD	2.605	3.065
	Change from Baseline	n	65	69
		Median	-0.92	-3.01
		Min.	-8.95	-9.89
		Q1	-2.89	-6.41
		Q3	-0.15	-1.34
		Max.	1.87	0.07
		Mean	-1.71	-3.81
		SD	2.330	2.983

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	7.38	5.06
		Min.	0.05	0.00
		Max.	10.00	9.97
		Mean	6.67	4.85
		SD	2.671	3.075
	Change from Baseline	n	65	69
		Median	-0.98	-3.63
		Min.	-8.98	-9.92
		Q1	-3.17	-6.76
		Q3	-0.08	-1.54
		Max.	1.87	0.07
		Mean	-1.92	-4.06
		SD	2.546	2.972

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	6.61	4.50
		Min.	0.09	0.00
		Max.	10.00	9.97
		Mean	6.17	4.44
		SD	2.889	3.034
	Change from Baseline	n	65	69
		Median	-1.69	-4.45
		Min.	-8.94	-9.92
		Q1	-4.23	-6.84
		Q3	-0.06	-1.76
		Max.	1.87	0.07
		Mean	-2.42	-4.47
		SD	2.725	2.960

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	6.23	3.86
		Min.	0.11	0.00
		Max.	10.00	9.98
		Mean	6.23	4.07
		SD	2.924	3.134
	Change from Baseline	n	65	69
		Median	-1.44	-4.93
		Min.	-8.92	-9.89
		Q1	-4.08	-7.70
		Q3	0.00	-2.03
		Max.	1.87	0.08
		Mean	-2.36	-4.84
		SD	2.745	3.065

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	7.13	3.76
		Min.	0.05	0.00
		Max.	10.00	9.99
		Mean	6.35	3.95
		SD	2.977	3.131
	Change from Baseline	n	65	69
		Median	-1.11	-5.38
		Min.	-8.98	-9.88
		Q1	-4.27	-7.71
		Q3	0.01	-2.45
		Max.	1.87	0.09
		Mean	-2.24	-4.96
		SD	2.829	3.083

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	6.49	3.53
		Min.	0.06	0.00
		Max.	10.00	9.97
		Mean	6.20	3.78
		SD	3.060	3.110
	Change from Baseline	n	65	69
		Median	-1.25	-5.49
		Min.	-8.96	-9.87
		Q1	-4.34	-8.11
		Q3	0.00	-2.71
		Max.	1.87	0.42
		Mean	-2.38	-5.13
		SD	2.917	3.095

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	7.13	2.95
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	6.11	3.66
		SD	3.197	3.157
	Change from Baseline	n	65	69
		Median	-0.90	-5.39
		Min.	-9.00	-9.87
		Q1	-4.61	-8.00
		Q3	0.00	-2.84
		Max.	1.87	0.42
		Mean	-2.48	-5.25
		SD	3.092	3.135

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	6.52	3.14
		Min.	0.00	0.01
		Max.	10.00	9.99
		Mean	6.05	3.72
		SD	3.103	3.122
	Change from Baseline	n	65	69
		Median	-1.75	-5.58
		Min.	-8.99	-9.87
		Q1	-4.89	-7.51
		Q3	0.02	-2.93
		Max.	1.87	0.42
		Mean	-2.54	-5.19
		SD	2.978	3.058

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	6.30	3.25
		Min.	0.00	0.00
		Max.	10.00	9.97
		Mean	6.01	3.67
		SD	3.265	3.167
	Change from Baseline	n	65	69
		Median	-1.60	-5.91
		Min.	-9.01	-9.87
		Q1	-4.80	-7.67
		Q3	0.00	-3.05
		Max.	1.87	0.42
		Mean	-2.58	-5.24
		SD	3.127	3.096

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	7.00	3.32
		Min.	0.01	0.00
		Max.	10.00	9.99
		Mean	6.03	3.84
		SD	3.372	3.287
	Change from Baseline	n	65	69
		Median	-0.94	-5.83
		Min.	-9.01	-9.87
		Q1	-4.77	-7.79
		Q3	0.00	-3.10
		Max.	1.87	0.42
		Mean	-2.55	-5.06
		SD	3.255	3.152

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	7.13	3.34
		Min.	0.01	0.00
		Max.	10.00	9.98
		Mean	6.16	4.00
		SD	3.340	3.258
	Change from Baseline	n	65	69
		Median	-0.60	-5.62
		Min.	-8.95	-9.87
		Q1	-4.80	-7.81
		Q3	0.03	-2.50
		Max.	1.87	0.42
		Mean	-2.43	-4.91
		SD	3.199	3.181

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	7.26	3.69
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.06	4.04
		SD	3.396	3.255
	Change from Baseline	n	65	69
		Median	-0.62	-5.25
		Min.	-9.02	-9.87
		Q1	-5.20	-7.78
		Q3	0.03	-2.23
		Max.	1.87	0.42
		Mean	-2.53	-4.87
		SD	3.290	3.189

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	7.50	3.95
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	6.20	4.35
		SD	3.389	3.285
	Change from Baseline	n	65	69
		Median	-0.62	-4.82
		Min.	-9.00	-9.87
		Q1	-4.80	-7.45
		Q3	0.03	-2.20
		Max.	1.87	0.51
		Mean	-2.39	-4.56
		SD	3.236	3.206

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	6.73	4.54
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	6.07	4.55
		SD	3.408	3.357
	Change from Baseline	n	65	69
		Median	-0.73	-4.50
		Min.	-9.01	-9.87
		Q1	-4.96	-7.07
		Q3	0.00	-1.52
		Max.	1.87	0.88
		Mean	-2.52	-4.35
		SD	3.254	3.299

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Nasal Discharge

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	6.99	4.41
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.14	4.80
		SD	3.396	3.446
	Change from Baseline	n	65	69
		Median	-0.79	-4.12
		Min.	-9.02	-9.86
		Q1	-4.77	-6.99
		Q3	0.03	-0.98
		Max.	1.87	1.16
		Mean	-2.45	-4.11
		SD	3.255	3.327

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.56 (0.104)	8.11 (0.101)
LS Mean Change (SE)	-0.19 (0.104)	-0.65 (0.101)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.45
95% CI		(-0.74, -0.17)
p-value		0.002
Corrected Hedges g [3]		-0.54
95% CI		(-0.89, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.23 (0.214)	6.87 (0.208)
LS Mean Change (SE)	-0.52 (0.214)	-1.88 (0.208)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.37
95% CI		(-1.96, -0.77)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.14, -0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.89 (0.267)	5.96 (0.259)
LS Mean Change (SE)	-0.86 (0.267)	-2.79 (0.259)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.93
95% CI		(-2.67, -1.19)
p-value		<0.001
Corrected Hedges g [3]		-0.89
95% CI		(-1.24, -0.53)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.44 (0.307)	5.44 (0.298)
LS Mean Change (SE)	-1.31 (0.307)	-3.31 (0.298)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.00
95% CI		(-2.85, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.80
95% CI		(-1.15, -0.45)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.05 (0.340)	5.00 (0.330)
LS Mean Change (SE)	-1.71 (0.340)	-3.75 (0.330)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.04
95% CI		(-2.98, -1.10)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.82 (0.350)	4.77 (0.339)
LS Mean Change (SE)	-1.94 (0.350)	-3.99 (0.339)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.05
95% CI		(-3.02, -1.08)
p-value		<0.001
Corrected Hedges g [3]		-0.72
95% CI		(-1.07, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.40 (0.366)	4.36 (0.355)
LS Mean Change (SE)	-2.36 (0.366)	-4.39 (0.355)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.03
95% CI		(-3.05, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.03, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.52 (0.377)	3.99 (0.366)
LS Mean Change (SE)	-2.24 (0.377)	-4.77 (0.366)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.53
95% CI		(-3.57, -1.48)
p-value		<0.001
Corrected Hedges g [3]		-0.83
95% CI		(-1.18, -0.47)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.70 (0.388)	3.90 (0.376)
LS Mean Change (SE)	-2.06 (0.388)	-4.86 (0.376)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.80
95% CI		(-3.87, -1.73)
p-value		<0.001
Corrected Hedges g [3]		-0.89
95% CI		(-1.25, -0.54)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.54 (0.396)	3.75 (0.384)
LS Mean Change (SE)	-2.21 (0.396)	-5.00 (0.384)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.79
95% CI		(-3.89, -1.70)
p-value		<0.001
Corrected Hedges g [3]		-0.87
95% CI		(-1.22, -0.52)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.45 (0.408)	3.63 (0.396)
LS Mean Change (SE)	-2.31 (0.408)	-5.12 (0.396)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.81
95% CI		(-3.94, -1.68)
p-value		<0.001
Corrected Hedges g [3]		-0.85
95% CI		(-1.20, -0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.40 (0.399)	3.69 (0.387)
LS Mean Change (SE)	-2.36 (0.399)	-5.07 (0.387)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.71
95% CI		(-3.81, -1.61)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.19, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.36 (0.411)	3.63 (0.398)
LS Mean Change (SE)	-2.40 (0.411)	-5.12 (0.398)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.73
95% CI		(-3.86, -1.59)
p-value		<0.001
Corrected Hedges g [3]		-0.82
95% CI		(-1.17, -0.47)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.40 (0.423)	3.81 (0.411)
LS Mean Change (SE)	-2.36 (0.423)	-4.95 (0.411)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.59
95% CI		(-3.76, -1.42)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.11, -0.40)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.57 (0.431)	4.05 (0.418)
LS Mean Change (SE)	-2.18 (0.431)	-4.70 (0.418)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.52
95% CI		(-3.71, -1.33)
p-value		<0.001
Corrected Hedges g [3]		-0.72
95% CI		(-1.07, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.46 (0.435)	4.10 (0.422)
LS Mean Change (SE)	-2.29 (0.435)	-4.65 (0.422)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.36
95% CI		(-3.56, -1.16)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.02, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.64 (0.438)	4.44 (0.425)
LS Mean Change (SE)	-2.12 (0.438)	-4.32 (0.425)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.20
95% CI		(-3.41, -0.99)
p-value		<0.001
Corrected Hedges g [3]		-0.62
95% CI		(-0.97, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.48 (0.443)	4.65 (0.430)
LS Mean Change (SE)	-2.27 (0.443)	-4.10 (0.430)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.83
95% CI		(-3.06, -0.61)
p-value		0.004
Corrected Hedges g [3]		-0.51
95% CI		(-0.85, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.53
Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.56 (0.446)	4.89 (0.433)
LS Mean Change (SE)	-2.19 (0.446)	-3.86 (0.433)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-2.91, -0.44)
p-value		0.008
Corrected Hedges g [3]		-0.46
95% CI		(-0.81, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	9.07	8.88
		Min.	0.47	0.18
		Max.	10.00	10.00
		Mean	8.58	8.51
		SD	1.625	1.608
Weeks 1-4	VAS Score	n	201	206
		Median	8.62	8.35
		Min.	0.31	0.08
		Max.	10.00	10.00
		Mean	8.06	7.89
		SD	1.908	1.883
	Change from Baseline	n	201	206
		Median	-0.18	-0.28
		Min.	-8.15	-7.25
		Q1	-0.62	-0.86
		Q3	0.00	0.00
		Max.	1.57	2.62
		Mean	-0.52	-0.62
		SD	1.251	1.241

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	8.33	7.66
		Min.	0.14	0.02
		Max.	10.00	10.00
		Mean	7.50	6.96
		SD	2.407	2.440
	Change from Baseline	n	201	206
		Median	-0.37	-0.97
		Min.	-9.86	-9.08
		Q1	-1.36	-2.17
		Q3	0.00	-0.16
		Max.	1.42	2.70
		Mean	-1.09	-1.55
		SD	2.015	2.020

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	7.95	6.89
		Min.	0.09	0.01
		Max.	10.00	10.00
		Mean	7.12	6.25
		SD	2.611	2.723
	Change from Baseline	n	201	206
		Median	-0.62	-1.61
		Min.	-9.91	-9.91
		Q1	-2.09	-3.29
		Q3	-0.01	-0.43
		Max.	2.12	4.46
		Mean	-1.46	-2.26
		SD	2.286	2.511

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	7.46	6.01
		Min.	0.07	0.00
		Max.	10.00	10.00
		Mean	6.78	5.68
		SD	2.794	2.906
	Change from Baseline	n	201	206
		Median	-0.99	-2.20
		Min.	-9.93	-9.96
		Q1	-2.69	-4.90
		Q3	-0.03	-0.68
		Max.	4.24	3.42
		Mean	-1.80	-2.83
		SD	2.508	2.783

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	7.33	5.53
		Min.	0.04	0.00
		Max.	10.00	10.00
		Mean	6.57	5.36
		SD	2.932	3.074
	Change from Baseline	n	201	206
		Median	-0.97	-2.33
		Min.	-9.69	-9.96
		Q1	-3.25	-5.38
		Q3	-0.04	-0.78
		Max.	5.49	3.42
		Mean	-2.01	-3.16
		SD	2.682	2.990

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	7.24	5.27
		Min.	0.03	0.00
		Max.	10.00	9.99
		Mean	6.48	5.09
		SD	2.958	3.153
	Change from Baseline	n	201	206
		Median	-1.05	-3.10
		Min.	-9.71	-9.97
		Q1	-3.63	-6.43
		Q3	0.00	-0.70
		Max.	4.84	2.82
		Mean	-2.11	-3.43
		SD	2.754	3.134

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	6.86	5.16
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.25	4.96
		SD	3.013	3.195
	Change from Baseline	n	201	206
		Median	-1.66	-2.99
		Min.	-9.71	-9.97
		Q1	-3.75	-6.36
		Q3	0.00	-0.76
		Max.	1.57	2.83
		Mean	-2.33	-3.55
		SD	2.809	3.151

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	6.73	4.93
		Min.	0.04	0.00
		Max.	10.00	10.00
		Mean	6.23	4.79
		SD	3.058	3.278
	Change from Baseline	n	201	206
		Median	-1.54	-3.41
		Min.	-9.82	-9.97
		Q1	-4.28	-6.72
		Q3	0.00	-0.72
		Max.	5.63	2.84
		Mean	-2.36	-3.72
		SD	2.958	3.247

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	7.11	4.52
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.22	4.70
		SD	3.122	3.300
	Change from Baseline	n	201	206
		Median	-1.46	-3.63
		Min.	-9.55	-9.97
		Q1	-4.38	-6.84
		Q3	0.00	-0.64
		Max.	5.85	1.88
		Mean	-2.37	-3.81
		SD	3.015	3.283

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	6.64	4.59
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.19	4.71
		SD	3.175	3.389
	Change from Baseline	n	201	206
		Median	-1.54	-3.75
		Min.	-9.69	-9.97
		Q1	-4.43	-6.89
		Q3	0.00	-0.18
		Max.	5.80	1.81
		Mean	-2.39	-3.81
		SD	3.047	3.373

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	6.94	4.15
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.17	4.60
		SD	3.258	3.403
	Change from Baseline	n	201	206
		Median	-1.13	-4.14
		Min.	-9.84	-9.97
		Q1	-4.75	-6.96
		Q3	0.00	-0.10
		Max.	6.04	1.83
		Mean	-2.41	-3.92
		SD	3.153	3.410

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	6.95	4.26
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.15	4.56
		SD	3.313	3.436
	Change from Baseline	n	201	206
		Median	-1.20	-4.27
		Min.	-9.75	-9.96
		Q1	-5.04	-6.95
		Q3	0.00	-0.06
		Max.	6.41	1.87
		Mean	-2.44	-3.95
		SD	3.192	3.438

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	7.22	4.16
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.15	4.59
		SD	3.400	3.509
	Change from Baseline	n	201	206
		Median	-0.97	-4.21
		Min.	-9.64	-9.97
		Q1	-4.83	-6.80
		Q3	0.00	-0.06
		Max.	6.58	2.07
		Mean	-2.43	-3.93
		SD	3.271	3.502

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.03 (0.087)	7.92 (0.086)
LS Mean Change (SE)	-0.52 (0.087)	-0.63 (0.086)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.11
95% CI		(-0.35, 0.13)
p-value		0.380
Corrected Hedges g [3]		-0.09
95% CI		(-0.28, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.47 (0.141)	7.00 (0.139)
LS Mean Change (SE)	-1.08 (0.141)	-1.55 (0.139)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.47
95% CI		(-0.86, -0.08)
p-value		0.019
Corrected Hedges g [3]		-0.23
95% CI		(-0.43, -0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.13 (0.169)	6.28 (0.167)
LS Mean Change (SE)	-1.42 (0.169)	-2.27 (0.167)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.85
95% CI		(-1.31, -0.38)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.55, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.81 (0.187)	5.74 (0.185)
LS Mean Change (SE)	-1.74 (0.187)	-2.81 (0.185)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-1.59, -0.56)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.60, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.61 (0.201)	5.42 (0.198)
LS Mean Change (SE)	-1.93 (0.201)	-3.13 (0.198)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.19
95% CI		(-1.75, -0.64)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.58 (0.214)	5.24 (0.212)
LS Mean Change (SE)	-1.97 (0.214)	-3.31 (0.212)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.33
95% CI		(-1.93, -0.74)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.63, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.40 (0.221)	5.14 (0.219)
LS Mean Change (SE)	-2.14 (0.221)	-3.41 (0.219)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.88, -0.65)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.60, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.44 (0.230)	4.98 (0.227)
LS Mean Change (SE)	-2.11 (0.230)	-3.57 (0.227)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.46
95% CI		(-2.10, -0.83)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.65, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.48 (0.235)	4.90 (0.232)
LS Mean Change (SE)	-2.07 (0.235)	-3.65 (0.232)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-2.23, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.47
95% CI		(-0.67, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.46 (0.240)	4.93 (0.238)
LS Mean Change (SE)	-2.09 (0.240)	-3.62 (0.238)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.53
95% CI		(-2.19, -0.86)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.48 (0.245)	4.82 (0.242)
LS Mean Change (SE)	-2.07 (0.245)	-3.73 (0.242)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.66
95% CI		(-2.34, -0.98)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.67, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.51 (0.250)	4.80 (0.247)
LS Mean Change (SE)	-2.04 (0.250)	-3.75 (0.247)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.71
95% CI		(-2.40, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.54
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.53 (0.256)	4.83 (0.253)
LS Mean Change (SE)	-2.02 (0.256)	-3.72 (0.253)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.70
95% CI		(-2.41, -0.99)
p-value		<0.001
Corrected Hedges g [3]		-0.47
95% CI		(-0.66, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	8.79	8.86
		Min.	1.09	0.30
		Max.	10.00	10.00
		Mean	8.28	8.52
		SD	1.896	1.603
Weeks 1-4	VAS Score	n	65	69
		Median	8.63	8.27
		Min.	1.45	0.33
		Max.	10.00	10.00
		Mean	8.13	7.96
		SD	1.760	1.671
	Change from Baseline	n	65	69
		Median	-0.10	-0.26
		Min.	-1.64	-4.66
		Q1	-0.32	-0.90
		Q3	0.03	0.01
		Max.	1.57	1.64
		Mean	-0.15	-0.56
		SD	0.505	1.055

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	8.30	7.50
		Min.	2.51	0.36
		Max.	10.00	10.00
		Mean	7.84	6.76
		SD	1.814	2.448
	Change from Baseline	n	65	69
		Median	-0.33	-1.01
		Min.	-2.67	-7.96
		Q1	-0.80	-2.91
		Q3	0.00	0.00
		Max.	1.42	2.55
		Mean	-0.44	-1.76
		SD	0.834	2.248

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	7.88	6.47
		Min.	2.16	0.01
		Max.	9.99	10.00
		Mean	7.49	5.80
		SD	1.892	2.893
	Change from Baseline	n	65	69
		Median	-0.53	-1.71
		Min.	-3.61	-9.91
		Q1	-1.34	-5.01
		Q3	0.00	-0.61
		Max.	2.12	4.46
		Mean	-0.79	-2.72
		SD	1.164	2.934

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	7.46	5.70
		Min.	2.25	0.00
		Max.	10.00	9.99
		Mean	7.03	5.30
		SD	2.228	3.090
	Change from Baseline	n	65	69
		Median	-0.87	-2.26
		Min.	-6.49	-9.96
		Q1	-2.35	-5.94
		Q3	0.00	-0.68
		Max.	4.24	3.42
		Mean	-1.25	-3.22
		SD	1.875	3.102

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	7.33	5.37
		Min.	0.07	0.00
		Max.	10.00	9.99
		Mean	6.68	4.84
		SD	2.672	3.193
	Change from Baseline	n	65	69
		Median	-0.94	-2.75
		Min.	-9.04	-9.96
		Q1	-2.81	-6.49
		Q3	-0.04	-1.10
		Max.	5.49	3.42
		Mean	-1.60	-3.68
		SD	2.448	3.236

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	7.24	4.75
		Min.	0.05	0.00
		Max.	10.00	9.98
		Mean	6.52	4.49
		SD	2.680	3.174
	Change from Baseline	n	65	69
		Median	-0.99	-3.19
		Min.	-9.06	-9.97
		Q1	-3.28	-7.16
		Q3	0.00	-1.12
		Max.	4.84	1.60
		Mean	-1.76	-4.03
		SD	2.569	3.196

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	6.44	3.89
		Min.	0.08	0.00
		Max.	10.00	9.99
		Mean	6.03	4.19
		SD	2.827	3.235
	Change from Baseline	n	65	69
		Median	-1.96	-3.81
		Min.	-9.03	-9.97
		Q1	-3.84	-7.24
		Q3	0.00	-1.52
		Max.	1.57	1.57
		Mean	-2.25	-4.33
		SD	2.680	3.233

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	6.14	3.27
		Min.	0.04	0.00
		Max.	10.00	9.97
		Mean	6.04	3.89
		SD	2.880	3.262
	Change from Baseline	n	65	69
		Median	-1.57	-4.73
		Min.	-8.99	-9.97
		Q1	-4.11	-7.50
		Q3	0.00	-1.76
		Max.	2.21	1.71
		Mean	-2.24	-4.63
		SD	2.782	3.242

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	6.19	2.76
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	6.12	3.77
		SD	2.902	3.275
	Change from Baseline	n	65	69
		Median	-2.05	-5.33
		Min.	-9.05	-9.97
		Q1	-4.21	-7.65
		Q3	0.06	-1.91
		Max.	5.12	1.88
		Mean	-2.17	-4.75
		SD	2.896	3.311

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	5.69	2.60
		Min.	0.00	0.00
		Max.	10.00	9.97
		Mean	6.00	3.73
		SD	2.975	3.273
	Change from Baseline	n	65	69
		Median	-2.23	-5.21
		Min.	-9.03	-9.97
		Q1	-4.43	-8.11
		Q3	0.06	-2.05
		Max.	4.46	1.80
		Mean	-2.28	-4.79
		SD	2.950	3.337

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	5.82	2.44
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.90	3.60
		SD	3.137	3.298
	Change from Baseline	n	65	69
		Median	-1.17	-5.25
		Min.	-9.08	-9.97
		Q1	-4.75	-8.27
		Q3	0.02	-1.94
		Max.	4.70	1.79
		Mean	-2.39	-4.92
		SD	3.142	3.389

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	5.19	2.65
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	5.79	3.68
		SD	3.046	3.264
	Change from Baseline	n	65	69
		Median	-1.95	-5.75
		Min.	-9.07	-9.96
		Q1	-4.81	-7.47
		Q3	0.00	-1.94
		Max.	3.36	1.71
		Mean	-2.49	-4.84
		SD	3.006	3.313

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	5.42	2.42
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	5.83	3.64
		SD	3.204	3.339
	Change from Baseline	n	65	69
		Median	-1.31	-5.71
		Min.	-9.08	-9.97
		Q1	-4.73	-7.55
		Q3	0.02	-2.20
		Max.	3.13	1.93
		Mean	-2.46	-4.88
		SD	3.108	3.376

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	4.99	2.25
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	5.82	3.66
		SD	3.268	3.382
	Change from Baseline	n	65	69
		Median	-1.03	-5.73
		Min.	-9.09	-9.97
		Q1	-4.81	-7.82
		Q3	0.01	-1.77
		Max.	5.20	1.95
		Mean	-2.46	-4.86
		SD	3.244	3.420

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	6.46	2.40
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	5.96	3.77
		SD	3.249	3.302
	Change from Baseline	n	65	69
		Median	-1.06	-5.40
		Min.	-9.02	-9.97
		Q1	-4.80	-7.69
		Q3	0.02	-1.96
		Max.	5.52	1.42
		Mean	-2.32	-4.75
		SD	3.206	3.370

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	6.72	3.23
		Min.	0.00	0.00
		Max.	10.00	9.97
		Mean	5.85	3.97
		SD	3.329	3.427
	Change from Baseline	n	65	69
		Median	-0.71	-5.11
		Min.	-9.07	-9.97
		Q1	-5.26	-7.57
		Q3	0.02	-0.86
		Max.	6.03	1.97
		Mean	-2.44	-4.55
		SD	3.353	3.451

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	7.29	3.85
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	6.01	4.17
		SD	3.358	3.316
	Change from Baseline	n	65	69
		Median	-0.66	-4.72
		Min.	-9.08	-9.96
		Q1	-5.22	-7.06
		Q3	0.02	-1.57
		Max.	6.65	2.07
		Mean	-2.27	-4.35
		SD	3.347	3.382

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	6.62	4.39
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.81	4.49
		SD	3.436	3.478
	Change from Baseline	n	65	69
		Median	-0.71	-4.54
		Min.	-9.09	-9.97
		Q1	-5.49	-6.84
		Q3	0.02	-0.37
		Max.	6.86	7.30
		Mean	-2.47	-4.03
		SD	3.415	3.722

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Mucus in Throat

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	6.93	4.38
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.85	4.64
		SD	3.433	3.537
	Change from Baseline	n	65	69
		Median	-0.83	-4.11
		Min.	-9.10	-9.96
		Q1	-4.83	-6.86
		Q3	0.02	-0.44
		Max.	6.92	7.30
		Mean	-2.43	-3.88
		SD	3.413	3.744

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.24 (0.101)	7.86 (0.098)
LS Mean Change (SE)	-0.17 (0.101)	-0.54 (0.098)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.37
95% CI		(-0.65, -0.09)
p-value		0.010
Corrected Hedges g [3]		-0.45
95% CI		(-0.80, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.93 (0.210)	6.67 (0.204)
LS Mean Change (SE)	-0.47 (0.210)	-1.73 (0.204)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.84, -0.68)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.66 (0.280)	5.74 (0.271)
LS Mean Change (SE)	-0.75 (0.280)	-2.67 (0.271)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.92
95% CI		(-2.69, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.85
95% CI		(-1.20, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.20 (0.321)	5.27 (0.312)
LS Mean Change (SE)	-1.21 (0.321)	-3.13 (0.312)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.92
95% CI		(-2.81, -1.04)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.85 (0.358)	4.81 (0.347)
LS Mean Change (SE)	-1.55 (0.358)	-3.59 (0.347)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.04
95% CI		(-3.03, -1.05)
p-value		<0.001
Corrected Hedges g [3]		-0.70
95% CI		(-1.05, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.69 (0.358)	4.47 (0.348)
LS Mean Change (SE)	-1.72 (0.358)	-3.94 (0.348)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.22
95% CI		(-3.21, -1.23)
p-value		<0.001
Corrected Hedges g [3]		-0.76
95% CI		(-1.11, -0.41)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.33 (0.378)	4.18 (0.367)
LS Mean Change (SE)	-2.08 (0.378)	-4.22 (0.367)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.15
95% CI		(-3.19, -1.10)
p-value		<0.001
Corrected Hedges g [3]		-0.70
95% CI		(-1.05, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.44 (0.390)	3.88 (0.378)
LS Mean Change (SE)	-1.96 (0.390)	-4.52 (0.378)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.56
95% CI		(-3.63, -1.48)
p-value		<0.001
Corrected Hedges g [3]		-0.81
95% CI		(-1.16, -0.46)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.62 (0.399)	3.78 (0.387)
LS Mean Change (SE)	-1.79 (0.399)	-4.62 (0.387)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.84
95% CI		(-3.94, -1.74)
p-value		<0.001
Corrected Hedges g [3]		-0.88
95% CI		(-1.23, -0.52)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.50 (0.406)	3.76 (0.394)
LS Mean Change (SE)	-1.90 (0.406)	-4.64 (0.394)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.74
95% CI		(-3.86, -1.62)
p-value		<0.001
Corrected Hedges g [3]		-0.83
95% CI		(-1.18, -0.48)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.40 (0.419)	3.64 (0.406)
LS Mean Change (SE)	-2.01 (0.419)	-4.77 (0.406)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.76
95% CI		(-3.91, -1.60)
p-value		<0.001
Corrected Hedges g [3]		-0.81
95% CI		(-1.16, -0.46)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.30 (0.411)	3.72 (0.399)
LS Mean Change (SE)	-2.11 (0.411)	-4.69 (0.399)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.58
95% CI		(-3.71, -1.44)
p-value		<0.001
Corrected Hedges g [3]		-0.77
95% CI		(-1.12, -0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.34 (0.423)	3.67 (0.411)
LS Mean Change (SE)	-2.06 (0.423)	-4.74 (0.411)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.67
95% CI		(-3.84, -1.50)
p-value		<0.001
Corrected Hedges g [3]		-0.78
95% CI		(-1.13, -0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.31 (0.439)	3.84 (0.426)
LS Mean Change (SE)	-2.09 (0.439)	-4.56 (0.426)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.47
95% CI		(-3.68, -1.26)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.04, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.48 (0.434)	3.99 (0.422)
LS Mean Change (SE)	-1.92 (0.434)	-4.41 (0.422)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.49
95% CI		(-3.69, -1.29)
p-value		<0.001
Corrected Hedges g [3]		-0.71
95% CI		(-1.06, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.38 (0.442)	4.06 (0.429)
LS Mean Change (SE)	-2.02 (0.442)	-4.35 (0.429)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.33
95% CI		(-3.54, -1.11)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-1.00, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.55 (0.443)	4.44 (0.430)
LS Mean Change (SE)	-1.86 (0.443)	-3.96 (0.430)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.11
95% CI		(-3.33, -0.88)
p-value		<0.001
Corrected Hedges g [3]		-0.59
95% CI		(-0.93, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.33 (0.455)	4.62 (0.441)
LS Mean Change (SE)	-2.07 (0.455)	-3.78 (0.441)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.71
95% CI		(-2.96, -0.45)
p-value		0.008
Corrected Hedges g [3]		-0.46
95% CI		(-0.81, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.62
Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.37 (0.460)	4.81 (0.446)
LS Mean Change (SE)	-2.03 (0.460)	-3.59 (0.446)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.56
95% CI		(-2.83, -0.29)
p-value		0.016
Corrected Hedges g [3]		-0.42
95% CI		(-0.76, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	8.87	8.52
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.77	7.76
		SD	2.722	2.508
Weeks 1-4	VAS Score	n	201	206
		Median	8.20	7.98
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.18	7.07
		SD	2.798	2.659
	Change from Baseline	n	201	206
		Median	-0.23	-0.28
		Min.	-8.00	-9.37
		Q1	-0.69	-0.82
		Q3	0.00	0.02
		Max.	1.69	2.08
		Mean	-0.59	-0.68
		SD	1.307	1.412

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	7.78	6.95
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.64	6.19
		SD	3.069	2.940
	Change from Baseline	n	201	206
		Median	-0.40	-0.87
		Min.	-9.76	-8.86
		Q1	-1.36	-2.46
		Q3	0.00	-0.01
		Max.	2.62	2.82
		Mean	-1.13	-1.56
		SD	2.055	2.123

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	7.13	6.10
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.27	5.42
		SD	3.117	3.113
	Change from Baseline	n	201	206
		Median	-0.77	-1.60
		Min.	-9.95	-9.52
		Q1	-1.94	-3.51
		Q3	-0.02	-0.33
		Max.	3.98	2.70
		Mean	-1.50	-2.33
		SD	2.331	2.577

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	6.74	5.36
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.01	4.91
		SD	3.176	3.204
	Change from Baseline	n	201	206
		Median	-1.01	-2.17
		Min.	-9.97	-10.00
		Q1	-2.71	-4.95
		Q3	-0.03	-0.46
		Max.	5.74	2.54
		Mean	-1.77	-2.85
		SD	2.514	2.839

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	6.50	4.97
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	5.79	4.62
		SD	3.306	3.312
	Change from Baseline	n	201	206
		Median	-1.08	-2.33
		Min.	-9.96	-10.00
		Q1	-3.17	-5.60
		Q3	-0.10	-0.61
		Max.	6.90	2.70
		Mean	-1.98	-3.14
		SD	2.748	3.046

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	6.50	4.57
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.69	4.39
		SD	3.331	3.366
	Change from Baseline	n	201	206
		Median	-1.08	-2.68
		Min.	-9.96	-10.00
		Q1	-3.27	-6.21
		Q3	0.00	-0.55
		Max.	6.08	3.55
		Mean	-2.08	-3.37
		SD	2.856	3.256

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	5.97	4.44
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.45	4.31
		SD	3.337	3.361
	Change from Baseline	n	201	206
		Median	-1.50	-2.87
		Min.	-9.96	-10.00
		Q1	-3.79	-6.35
		Q3	0.00	-0.52
		Max.	5.54	3.34
		Mean	-2.33	-3.45
		SD	2.907	3.266

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	5.84	4.15
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.42	4.18
		SD	3.377	3.423
	Change from Baseline	n	201	206
		Median	-1.48	-3.16
		Min.	-9.96	-10.00
		Q1	-4.20	-6.53
		Q3	0.00	-0.29
		Max.	5.88	3.18
		Mean	-2.36	-3.57
		SD	3.038	3.362

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	5.92	3.91
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.41	4.11
		SD	3.446	3.442
	Change from Baseline	n	201	206
		Median	-1.16	-3.20
		Min.	-9.96	-10.00
		Q1	-4.72	-6.71
		Q3	0.00	-0.29
		Max.	6.11	4.06
		Mean	-2.36	-3.65
		SD	3.136	3.426

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	5.72	3.54
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.38	4.15
		SD	3.487	3.535
	Change from Baseline	n	201	206
		Median	-1.27	-2.95
		Min.	-9.96	-10.00
		Q1	-4.61	-7.04
		Q3	0.00	-0.04
		Max.	5.08	4.27
		Mean	-2.39	-3.60
		SD	3.162	3.504

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	5.68	3.51
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.36	4.06
		SD	3.512	3.537
	Change from Baseline	n	201	206
		Median	-1.19	-3.64
		Min.	-9.96	-10.00
		Q1	-4.77	-6.88
		Q3	0.00	-0.01
		Max.	6.11	4.50
		Mean	-2.42	-3.70
		SD	3.245	3.513

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	5.30	2.92
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.32	3.99
		SD	3.569	3.567
	Change from Baseline	n	201	206
		Median	-1.02	-3.77
		Min.	-9.95	-9.96
		Q1	-5.36	-6.81
		Q3	0.00	-0.04
		Max.	6.11	4.50
		Mean	-2.46	-3.77
		SD	3.327	3.576

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Facial Pain

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	5.77	3.17
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	5.39	4.05
		SD	3.620	3.636
	Change from Baseline	n	201	206
		Median	-0.68	-3.63
		Min.	-9.95	-10.00
		Q1	-5.02	-6.90
		Q3	0.00	0.00
		Max.	6.11	4.50
		Mean	-2.38	-3.71
		SD	3.348	3.612

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	7.17 (0.094)	7.08 (0.093)
LS Mean Change (SE)	-0.59 (0.094)	-0.68 (0.093)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.09
95% CI		(-0.35, 0.17)
p-value		0.495
Corrected Hedges g [3]		-0.07
95% CI		(-0.26, 0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.63 (0.144)	6.21 (0.142)
LS Mean Change (SE)	-1.13 (0.144)	-1.55 (0.142)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.42
95% CI		(-0.82, -0.02)
p-value		0.039
Corrected Hedges g [3]		-0.21
95% CI		(-0.40, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.31 (0.170)	5.44 (0.168)
LS Mean Change (SE)	-1.46 (0.170)	-2.32 (0.168)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.87
95% CI		(-1.33, -0.40)
p-value		<0.001
Corrected Hedges g [3]		-0.36
95% CI		(-0.55, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.09 (0.190)	4.97 (0.188)
LS Mean Change (SE)	-1.67 (0.190)	-2.79 (0.188)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.12
95% CI		(-1.64, -0.59)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.92 (0.207)	4.69 (0.204)
LS Mean Change (SE)	-1.85 (0.207)	-3.07 (0.204)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.23
95% CI		(-1.80, -0.66)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.62, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.89 (0.223)	4.55 (0.220)
LS Mean Change (SE)	-1.88 (0.223)	-3.21 (0.220)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.33
95% CI		(-1.95, -0.72)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.62, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.85 (0.233)	4.49 (0.230)
LS Mean Change (SE)	-1.92 (0.233)	-3.27 (0.230)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.35
95% CI		(-2.00, -0.71)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.88 (0.241)	4.38 (0.238)
LS Mean Change (SE)	-1.88 (0.241)	-3.38 (0.238)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.50
95% CI		(-2.17, -0.84)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.92 (0.247)	4.32 (0.244)
LS Mean Change (SE)	-1.85 (0.247)	-3.45 (0.244)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.60
95% CI		(-2.28, -0.92)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.65, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.89 (0.253)	4.41 (0.250)
LS Mean Change (SE)	-1.87 (0.253)	-3.36 (0.250)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.49
95% CI		(-2.19, -0.79)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.95 (0.258)	4.32 (0.255)
LS Mean Change (SE)	-1.81 (0.258)	-3.45 (0.255)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.64
95% CI		(-2.35, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	5.97 (0.265)	4.30 (0.262)
LS Mean Change (SE)	-1.79 (0.265)	-3.46 (0.262)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-2.40, -0.94)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.63
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	6.07 (0.269)	4.37 (0.265)
LS Mean Change (SE)	-1.70 (0.269)	-3.40 (0.265)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.70
95% CI		(-2.44, -0.96)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	8.49	8.20
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.36	7.41
		SD	2.885	2.760
Weeks 1-4	VAS Score	n	65	69
		Median	8.05	7.60
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.15	6.83
		SD	2.796	2.766
	Change from Baseline	n	65	69
		Median	-0.15	-0.22
		Min.	-1.54	-3.57
		Q1	-0.50	-0.89
		Q3	0.04	0.03
		Max.	1.69	0.61
		Mean	-0.21	-0.59
		SD	0.538	0.955

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	7.79	6.35
		Min.	0.00	0.01
		Max.	10.00	9.99
		Mean	6.86	5.69
		SD	2.756	3.108
	Change from Baseline	n	65	69
		Median	-0.31	-0.93
		Min.	-3.17	-8.68
		Q1	-0.95	-2.86
		Q3	0.03	-0.01
		Max.	1.02	1.74
		Mean	-0.50	-1.72
		SD	0.848	2.209

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	7.13	4.88
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.52	4.74
		SD	2.720	3.319
	Change from Baseline	n	65	69
		Median	-0.52	-1.84
		Min.	-6.24	-9.52
		Q1	-1.56	-4.34
		Q3	0.00	-0.38
		Max.	1.15	0.50
		Mean	-0.83	-2.67
		SD	1.265	2.754

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	6.38	3.62
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	6.13	4.22
		SD	2.784	3.354
	Change from Baseline	n	65	69
		Median	-0.76	-2.67
		Min.	-7.16	-10.00
		Q1	-2.13	-5.16
		Q3	0.00	-0.56
		Max.	1.95	0.50
		Mean	-1.23	-3.20
		SD	1.854	2.930

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	6.50	2.67
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	5.80	3.84
		SD	3.110	3.418
	Change from Baseline	n	65	69
		Median	-0.75	-2.91
		Min.	-9.07	-10.00
		Q1	-2.78	-6.36
		Q3	-0.13	-0.85
		Max.	6.90	0.50
		Mean	-1.56	-3.58
		SD	2.552	3.082

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	5.94	2.45
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	5.55	3.56
		SD	3.179	3.344
	Change from Baseline	n	65	69
		Median	-0.89	-3.13
		Min.	-9.07	-10.00
		Q1	-3.15	-6.47
		Q3	-0.03	-0.78
		Max.	6.08	0.50
		Mean	-1.80	-3.85
		SD	2.754	3.170

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	5.30	2.29
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	5.08	3.36
		SD	3.217	3.285
	Change from Baseline	n	65	69
		Median	-1.58	-3.14
		Min.	-9.07	-10.00
		Q1	-3.80	-7.47
		Q3	0.00	-1.42
		Max.	1.69	0.50
		Mean	-2.28	-4.05
		SD	2.837	3.266

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	5.03	1.44
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	5.00	3.08
		SD	3.263	3.234
	Change from Baseline	n	65	69
		Median	-1.14	-3.66
		Min.	-9.07	-10.00
		Q1	-4.06	-7.75
		Q3	0.00	-1.70
		Max.	1.69	0.50
		Mean	-2.36	-4.33
		SD	3.013	3.296

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	5.16	1.56
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	5.09	3.07
		SD	3.245	3.222
	Change from Baseline	n	65	69
		Median	-0.72	-3.80
		Min.	-9.07	-10.00
		Q1	-4.41	-7.56
		Q3	0.04	-1.34
		Max.	5.02	0.70
		Mean	-2.27	-4.34
		SD	3.155	3.308

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	4.94	1.08
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.95	2.95
		SD	3.286	3.184
	Change from Baseline	n	65	69
		Median	-0.61	-3.91
		Min.	-9.07	-10.00
		Q1	-4.61	-7.76
		Q3	0.00	-1.84
		Max.	4.66	0.61
		Mean	-2.41	-4.46
		SD	3.267	3.286

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	4.77	1.38
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.84	2.87
		SD	3.391	3.226
	Change from Baseline	n	65	69
		Median	-0.61	-4.90
		Min.	-9.07	-10.00
		Q1	-5.49	-7.54
		Q3	0.00	-1.44
		Max.	5.19	0.61
		Mean	-2.52	-4.55
		SD	3.456	3.320

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	4.60	1.73
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.74	2.92
		SD	3.322	3.228
	Change from Baseline	n	65	69
		Median	-1.09	-5.11
		Min.	-9.07	-9.96
		Q1	-5.30	-7.14
		Q3	0.00	-1.56
		Max.	3.60	0.65
		Mean	-2.62	-4.49
		SD	3.408	3.302

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	4.65	1.49
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.75	2.85
		SD	3.407	3.274
	Change from Baseline	n	65	69
		Median	-0.83	-4.87
		Min.	-9.07	-10.00
		Q1	-5.50	-7.58
		Q3	0.00	-1.28
		Max.	2.69	2.16
		Mean	-2.61	-4.56
		SD	3.417	3.416

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	4.76	1.40
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	4.75	2.87
		SD	3.471	3.364
	Change from Baseline	n	65	69
		Median	-0.95	-5.26
		Min.	-9.07	-10.00
		Q1	-5.49	-7.38
		Q3	0.00	-0.96
		Max.	3.96	3.25
		Mean	-2.61	-4.54
		SD	3.492	3.369

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	5.26	1.50
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.85	2.90
		SD	3.442	3.324
	Change from Baseline	n	65	69
		Median	-0.60	-5.07
		Min.	-9.07	-10.00
		Q1	-5.27	-7.29
		Q3	0.00	-1.33
		Max.	4.49	2.09
		Mean	-2.51	-4.51
		SD	3.432	3.327

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	4.70	1.48
		Min.	0.00	0.00
		Max.	10.00	9.98
		Mean	4.81	3.08
		SD	3.468	3.463
	Change from Baseline	n	65	69
		Median	-0.61	-5.29
		Min.	-9.07	-10.00
		Q1	-5.49	-7.37
		Q3	0.03	-0.76
		Max.	4.98	2.43
		Mean	-2.55	-4.33
		SD	3.499	3.373

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	5.13	1.76
		Min.	0.00	0.00
		Max.	10.00	9.99
		Mean	4.89	3.21
		SD	3.505	3.476
	Change from Baseline	n	65	69
		Median	-0.60	-5.22
		Min.	-9.07	-10.00
		Q1	-5.49	-7.03
		Q3	0.00	-0.79
		Max.	5.77	3.25
		Mean	-2.47	-4.20
		SD	3.569	3.379

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	4.97	2.08
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	4.85	3.42
		SD	3.544	3.474
	Change from Baseline	n	65	69
		Median	-0.63	-4.98
		Min.	-9.07	-10.00
		Q1	-5.43	-6.48
		Q3	0.00	-0.60
		Max.	5.99	6.89
		Mean	-2.51	-3.99
		SD	3.567	3.559

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Facial Pain

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	5.12	2.13
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	4.90	3.63
		SD	3.561	3.549
	Change from Baseline	n	65	69
		Median	-0.67	-4.52
		Min.	-8.99	-10.00
		Q1	-5.30	-6.48
		Q3	0.00	-0.62
		Max.	6.01	6.89
		Mean	-2.46	-3.78
		SD	3.571	3.558

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.18 (0.097)	6.80 (0.094)
LS Mean Change (SE)	-0.21 (0.097)	-0.58 (0.094)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.37
95% CI		(-0.64, -0.11)
p-value		0.007
Corrected Hedges g [3]		-0.47
95% CI		(-0.82, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.88 (0.207)	5.67 (0.201)
LS Mean Change (SE)	-0.51 (0.207)	-1.72 (0.201)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.21
95% CI		(-1.78, -0.64)
p-value		<0.001
Corrected Hedges g [3]		-0.72
95% CI		(-1.07, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.65 (0.271)	4.72 (0.263)
LS Mean Change (SE)	-0.74 (0.271)	-2.66 (0.263)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.92
95% CI		(-2.67, -1.18)
p-value		<0.001
Corrected Hedges g [3]		-0.87
95% CI		(-1.23, -0.52)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.24 (0.319)	4.32 (0.310)
LS Mean Change (SE)	-1.14 (0.319)	-3.07 (0.310)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.93
95% CI		(-2.81, -1.05)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.10, -0.40)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	6.02 (0.367)	3.94 (0.356)
LS Mean Change (SE)	-1.37 (0.367)	-3.45 (0.356)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.08
95% CI		(-3.09, -1.07)
p-value		<0.001
Corrected Hedges g [3]		-0.70
95% CI		(-1.05, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.78 (0.377)	3.66 (0.365)
LS Mean Change (SE)	-1.61 (0.377)	-3.72 (0.365)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.11
95% CI		(-3.15, -1.08)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.04, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.65 (0.404)	3.47 (0.393)
LS Mean Change (SE)	-1.73 (0.404)	-3.92 (0.393)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.18
95% CI		(-3.30, -1.07)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.01, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.70 (0.417)	3.19 (0.405)
LS Mean Change (SE)	-1.68 (0.417)	-4.20 (0.405)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.51
95% CI		(-3.66, -1.36)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.90 (0.422)	3.18 (0.409)
LS Mean Change (SE)	-1.49 (0.422)	-4.20 (0.409)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.71
95% CI		(-3.88, -1.55)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.15, -0.44)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.76 (0.428)	3.08 (0.415)
LS Mean Change (SE)	-1.63 (0.428)	-4.30 (0.415)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.67
95% CI		(-3.85, -1.49)
p-value		<0.001
Corrected Hedges g [3]		-0.77
95% CI		(-1.12, -0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.64 (0.440)	3.00 (0.427)
LS Mean Change (SE)	-1.74 (0.440)	-4.38 (0.427)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.64
95% CI		(-3.85, -1.43)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.54 (0.437)	3.06 (0.424)
LS Mean Change (SE)	-1.84 (0.437)	-4.33 (0.424)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.48
95% CI		(-3.69, -1.28)
p-value		<0.001
Corrected Hedges g [3]		-0.70
95% CI		(-1.05, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.57 (0.445)	2.99 (0.432)
LS Mean Change (SE)	-1.82 (0.445)	-4.40 (0.432)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.58
95% CI		(-3.81, -1.35)
p-value		<0.001
Corrected Hedges g [3]		-0.72
95% CI		(-1.06, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.56 (0.462)	3.14 (0.448)
LS Mean Change (SE)	-1.82 (0.462)	-4.25 (0.448)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.42
95% CI		(-3.70, -1.15)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-0.99, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.80 (0.464)	3.31 (0.451)
LS Mean Change (SE)	-1.59 (0.464)	-4.08 (0.451)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.49
95% CI		(-3.77, -1.21)
p-value		<0.001
Corrected Hedges g [3]		-0.66
95% CI		(-1.01, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.75 (0.468)	3.37 (0.454)
LS Mean Change (SE)	-1.63 (0.468)	-4.02 (0.454)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.39
95% CI		(-3.67, -1.10)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.98, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.91 (0.480)	3.66 (0.466)
LS Mean Change (SE)	-1.48 (0.480)	-3.73 (0.466)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.25
95% CI		(-3.57, -0.93)
p-value		0.001
Corrected Hedges g [3]		-0.58
95% CI		(-0.92, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.80 (0.479)	3.82 (0.465)
LS Mean Change (SE)	-1.59 (0.479)	-3.57 (0.465)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.98
95% CI		(-3.30, -0.65)
p-value		0.004
Corrected Hedges g [3]		-0.51
95% CI		(-0.85, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.71
Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	5.84 (0.485)	4.07 (0.471)
LS Mean Change (SE)	-1.54 (0.485)	-3.32 (0.471)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.77
95% CI		(-3.11, -0.44)
p-value		0.010
Corrected Hedges g [3]		-0.45
95% CI		(-0.79, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	VAS Score	n	201	206
		Median	9.97	9.97
		Min.	6.69	0.94
		Max.	10.00	10.00
		Mean	9.68	9.63
		SD	0.596	0.830
Weeks 1-4	VAS Score	n	201	206
		Median	9.94	9.90
		Min.	2.66	0.12
		Max.	10.00	10.00
		Mean	9.50	9.35
		SD	1.002	1.289
	Change from Baseline	n	201	206
		Median	-0.01	-0.01
		Min.	-7.34	-9.64
		Q1	-0.10	-0.23
		Q3	0.00	0.00
		Max.	1.12	0.89
		Mean	-0.17	-0.28
		SD	0.797	1.011

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 5-8	VAS Score	n	201	206
		Median	9.95	9.73
		Min.	0.87	0.02
		Max.	10.00	10.00
		Mean	9.30	8.80
		SD	1.342	1.929
	Change from Baseline	n	201	206
		Median	-0.01	-0.09
		Min.	-9.10	-9.74
		Q1	-0.33	-0.82
		Q3	0.00	0.00
		Max.	1.94	0.90
		Mean	-0.37	-0.84
		SD	1.155	1.773

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 9-12	VAS Score	n	201	206
		Median	9.93	9.56
		Min.	0.19	0.01
		Max.	10.00	10.00
		Mean	9.05	8.39
		SD	1.758	2.378
	Change from Baseline	n	201	206
		Median	-0.01	-0.20
		Min.	-9.81	-9.82
		Q1	-0.60	-1.31
		Q3	0.00	0.00
		Max.	1.94	0.88
		Mean	-0.63	-1.25
		SD	1.569	2.246

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 13-16	VAS Score	n	201	206
		Median	9.84	9.22
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	8.97	8.05
		SD	1.789	2.698
	Change from Baseline	n	201	206
		Median	-0.03	-0.39
		Min.	-9.96	-10.00
		Q1	-0.75	-2.12
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-0.70	-1.58
		SD	1.581	2.589

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 17-20	VAS Score	n	201	206
		Median	9.87	9.22
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.78	7.76
		SD	2.056	2.946
	Change from Baseline	n	201	206
		Median	-0.01	-0.47
		Min.	-9.97	-10.00
		Q1	-0.87	-2.46
		Q3	0.00	-0.01
		Max.	1.94	1.27
		Mean	-0.90	-1.87
		SD	1.865	2.848

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 21-24	VAS Score	n	201	206
		Median	9.86	9.15
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.66	7.54
		SD	2.240	3.161
	Change from Baseline	n	201	206
		Median	-0.01	-0.44
		Min.	-9.97	-10.00
		Q1	-1.10	-3.12
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-1.02	-2.09
		SD	2.050	3.064

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 25-28	VAS Score	n	201	206
		Median	9.87	9.09
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.44	7.38
		SD	2.432	3.289
	Change from Baseline	n	201	206
		Median	-0.01	-0.47
		Min.	-9.97	-10.00
		Q1	-1.88	-3.75
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-1.24	-2.25
		SD	2.263	3.182

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 29-32	VAS Score	n	201	206
		Median	9.83	8.87
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.34	7.20
		SD	2.591	3.375
	Change from Baseline	n	201	206
		Median	-0.01	-0.68
		Min.	-9.97	-10.00
		Q1	-1.93	-4.60
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-1.34	-2.43
		SD	2.412	3.275

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 33-36	VAS Score	n	201	206
		Median	9.91	8.99
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.33	7.11
		SD	2.682	3.453
	Change from Baseline	n	201	206
		Median	0.00	-0.63
		Min.	-9.97	-10.00
		Q1	-2.14	-5.05
		Q3	0.00	0.00
		Max.	1.94	1.28
		Mean	-1.34	-2.52
		SD	2.503	3.355

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 37-40	VAS Score	n	201	206
		Median	9.92	8.92
		Min.	0.01	0.00
		Max.	10.00	10.00
		Mean	8.35	7.01
		SD	2.732	3.514
	Change from Baseline	n	201	206
		Median	0.00	-0.73
		Min.	-9.96	-10.00
		Q1	-1.70	-5.09
		Q3	0.00	0.00
		Max.	1.95	1.27
		Mean	-1.33	-2.62
		SD	2.550	3.439

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 41-44	VAS Score	n	201	206
		Median	9.94	8.71
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.34	6.85
		SD	2.775	3.567
	Change from Baseline	n	201	206
		Median	0.00	-0.84
		Min.	-9.95	-10.00
		Q1	-1.39	-5.67
		Q3	0.00	0.00
		Max.	2.02	1.27
		Mean	-1.34	-2.78
		SD	2.595	3.499

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 45-48	VAS Score	n	201	206
		Median	9.92	8.76
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.34	6.84
		SD	2.780	3.573
	Change from Baseline	n	201	206
		Median	0.00	-0.73
		Min.	-9.96	-10.00
		Q1	-1.41	-5.51
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-1.33	-2.79
		SD	2.586	3.502

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.14
Summary of Individual VAS Symptom Scores

VAS Symptom: Loss of Smell

Time Period			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Weeks 49-52	VAS Score	n	201	206
		Median	9.93	8.93
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.30	6.80
		SD	2.821	3.688
	Change from Baseline	n	201	206
		Median	0.00	-0.53
		Min.	-9.97	-10.00
		Q1	-1.28	-5.60
		Q3	0.00	0.00
		Max.	1.94	1.27
		Mean	-1.38	-2.83
		SD	2.651	3.610

Note: Includes data reported up to Week 52.
Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	9.48 (0.064)	9.38 (0.063)
LS Mean Change (SE)	-0.17 (0.064)	-0.28 (0.063)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.28, 0.07)
p-value		0.246
Corrected Hedges g [3]		-0.12
95% CI		(-0.31, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	9.28 (0.106)	8.83 (0.105)
LS Mean Change (SE)	-0.38 (0.106)	-0.83 (0.105)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.45
95% CI		(-0.75, -0.16)
p-value		0.003
Corrected Hedges g [3]		-0.30
95% CI		(-0.50, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	9.03 (0.137)	8.42 (0.135)
LS Mean Change (SE)	-0.63 (0.137)	-1.24 (0.135)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.61
95% CI		(-0.99, -0.23)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.51, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.95 (0.152)	8.09 (0.150)
LS Mean Change (SE)	-0.70 (0.152)	-1.56 (0.150)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.86
95% CI		(-1.28, -0.44)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.76 (0.171)	7.80 (0.169)
LS Mean Change (SE)	-0.90 (0.171)	-1.85 (0.169)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.95
95% CI		(-1.42, -0.48)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.64 (0.185)	7.60 (0.183)
LS Mean Change (SE)	-1.02 (0.185)	-2.06 (0.183)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.04
95% CI		(-1.55, -0.53)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.42 (0.196)	7.44 (0.193)
LS Mean Change (SE)	-1.23 (0.196)	-2.21 (0.193)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.98
95% CI		(-1.52, -0.44)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.55, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.33 (0.204)	7.26 (0.201)
LS Mean Change (SE)	-1.33 (0.204)	-2.40 (0.201)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-1.63, -0.50)
p-value		<0.001
Corrected Hedges g [3]		-0.37
95% CI		(-0.56, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.33 (0.210)	7.17 (0.207)
LS Mean Change (SE)	-1.33 (0.210)	-2.48 (0.207)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.15
95% CI		(-1.73, -0.57)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.58, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.34 (0.215)	7.08 (0.213)
LS Mean Change (SE)	-1.31 (0.215)	-2.57 (0.213)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.26
95% CI		(-1.86, -0.67)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.35 (0.219)	6.92 (0.217)
LS Mean Change (SE)	-1.31 (0.219)	-2.74 (0.217)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.43
95% CI		(-2.03, -0.82)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.66, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.35 (0.219)	6.91 (0.216)
LS Mean Change (SE)	-1.30 (0.219)	-2.74 (0.216)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.44
95% CI		(-2.05, -0.83)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.66, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.36
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	201	206
n [2]	201	206
LS Mean (SE)	8.31 (0.225)	6.87 (0.223)
LS Mean Change (SE)	-1.35 (0.225)	-2.78 (0.223)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.44
95% CI		(-2.06, -0.81)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.65, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	VAS Score	n	65	69
		Median	9.99	9.96
		Min.	6.69	7.66
		Max.	10.00	10.00
		Mean	9.73	9.71
		SD	0.588	0.519
Weeks 1-4	VAS Score	n	65	69
		Median	9.97	9.91
		Min.	7.03	4.57
		Max.	10.00	10.00
		Mean	9.62	9.44
		SD	0.697	0.974
	Change from Baseline	n	65	69
		Median	0.00	-0.01
		Min.	-1.65	-4.59
		Q1	-0.08	-0.35
		Q3	0.00	0.00
		Max.	0.34	0.89
		Mean	-0.11	-0.27
		SD	0.315	0.793

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 5-8	VAS Score	n	65	69
		Median	9.95	9.65
		Min.	5.48	1.86
		Max.	10.00	10.00
		Mean	9.45	8.63
		SD	0.912	2.014
	Change from Baseline	n	65	69
		Median	0.00	-0.18
		Min.	-4.12	-8.14
		Q1	-0.20	-1.07
		Q3	0.00	0.00
		Max.	1.39	0.90
		Mean	-0.28	-1.07
		SD	0.745	1.976

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 9-12	VAS Score	n	65	69
		Median	9.93	9.43
		Min.	4.16	0.62
		Max.	10.00	10.00
		Mean	9.28	8.14
		SD	1.240	2.589
	Change from Baseline	n	65	69
		Median	0.00	-0.27
		Min.	-5.44	-9.32
		Q1	-0.24	-1.64
		Q3	0.00	0.00
		Max.	0.54	0.62
		Mean	-0.45	-1.56
		SD	1.052	2.531

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 13-16	VAS Score	n	65	69
		Median	9.84	8.91
		Min.	2.90	0.00
		Max.	10.00	10.00
		Mean	9.14	7.71
		SD	1.463	2.928
	Change from Baseline	n	65	69
		Median	-0.02	-0.69
		Min.	-6.70	-10.00
		Q1	-0.52	-2.72
		Q3	0.00	-0.02
		Max.	0.74	0.37
		Mean	-0.59	-2.00
		SD	1.291	2.888

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 17-20	VAS Score	n	65	69
		Median	9.83	8.57
		Min.	2.13	0.00
		Max.	10.00	10.00
		Mean	8.85	7.27
		SD	1.867	3.139
	Change from Baseline	n	65	69
		Median	-0.01	-0.92
		Min.	-7.47	-10.00
		Q1	-0.88	-4.51
		Q3	0.00	-0.04
		Max.	0.60	0.40
		Mean	-0.88	-2.43
		SD	1.767	3.117

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 21-24	VAS Score	n	65	69
		Median	9.82	8.42
		Min.	1.88	0.00
		Max.	10.00	10.00
		Mean	8.60	7.05
		SD	2.172	3.360
	Change from Baseline	n	65	69
		Median	-0.01	-1.24
		Min.	-8.06	-10.00
		Q1	-1.67	-4.58
		Q3	0.00	-0.06
		Max.	0.28	0.34
		Mean	-1.13	-2.65
		SD	2.054	3.348

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 25-28	VAS Score	n	65	69
		Median	9.79	8.42
		Min.	0.66	0.00
		Max.	10.00	10.00
		Mean	8.25	6.86
		SD	2.506	3.566
	Change from Baseline	n	65	69
		Median	-0.01	-0.90
		Min.	-8.94	-10.00
		Q1	-2.66	-5.21
		Q3	0.00	-0.03
		Max.	1.37	0.14
		Mean	-1.49	-2.85
		SD	2.404	3.542

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 29-32	VAS Score	n	65	69
		Median	9.87	8.16
		Min.	0.23	0.00
		Max.	10.00	10.00
		Mean	8.21	6.63
		SD	2.716	3.623
	Change from Baseline	n	65	69
		Median	0.00	-1.51
		Min.	-9.37	-10.00
		Q1	-2.83	-5.55
		Q3	0.00	-0.06
		Max.	1.59	0.30
		Mean	-1.52	-3.08
		SD	2.610	3.607

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 33-36	VAS Score	n	65	69
		Median	9.92	8.03
		Min.	0.19	0.00
		Max.	10.00	10.00
		Mean	8.21	6.48
		SD	2.816	3.650
	Change from Baseline	n	65	69
		Median	0.00	-1.60
		Min.	-9.41	-10.00
		Q1	-2.38	-7.25
		Q3	0.00	-0.05
		Max.	1.75	0.32
		Mean	-1.53	-3.23
		SD	2.709	3.652

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 37-40	VAS Score	n	65	69
		Median	9.86	7.40
		Min.	0.06	0.00
		Max.	10.00	10.00
		Mean	8.20	6.12
		SD	2.787	3.745
	Change from Baseline	n	65	69
		Median	-0.01	-2.21
		Min.	-9.45	-10.00
		Q1	-2.68	-7.46
		Q3	0.00	-0.14
		Max.	1.95	0.43
		Mean	-1.53	-3.59
		SD	2.663	3.781

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 41-44	VAS Score	n	65	69
		Median	9.92	7.00
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.17	5.86
		SD	2.855	3.773
	Change from Baseline	n	65	69
		Median	0.00	-2.72
		Min.	-9.43	-10.00
		Q1	-2.53	-7.25
		Q3	0.00	-0.13
		Max.	2.02	0.43
		Mean	-1.56	-3.85
		SD	2.737	3.822

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 45-48	VAS Score	n	65	69
		Median	9.92	7.02
		Min.	0.00	0.02
		Max.	10.00	10.00
		Mean	8.15	6.04
		SD	2.857	3.657
	Change from Baseline	n	65	69
		Median	-0.02	-2.79
		Min.	-9.53	-9.97
		Q1	-2.15	-6.80
		Q3	0.00	-0.02
		Max.	0.74	0.43
		Mean	-1.59	-3.67
		SD	2.709	3.685

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 49-52	VAS Score	n	65	69
		Median	9.92	6.89
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	8.07	5.89
		SD	2.903	3.798
	Change from Baseline	n	65	69
		Median	-0.02	-2.77
		Min.	-9.62	-10.00
		Q1	-2.94	-6.74
		Q3	0.00	0.00
		Max.	0.74	0.43
		Mean	-1.66	-3.81
		SD	2.765	3.814

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 53-56	VAS Score	n	65	69
		Median	9.94	7.32
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.98	6.05
		SD	3.076	3.859
	Change from Baseline	n	65	69
		Median	0.00	-2.42
		Min.	-9.45	-10.00
		Q1	-2.34	-7.68
		Q3	0.00	0.00
		Max.	0.74	0.90
		Mean	-1.75	-3.66
		SD	2.953	3.863

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 57-60	VAS Score	n	65	69
		Median	9.89	7.55
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.97	6.22
		SD	3.021	3.789
	Change from Baseline	n	65	69
		Median	-0.02	-2.31
		Min.	-9.57	-10.00
		Q1	-2.73	-7.39
		Q3	0.00	0.00
		Max.	0.74	0.90
		Mean	-1.76	-3.49
		SD	2.911	3.778

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 61-64	VAS Score	n	65	69
		Median	9.92	7.43
		Min.	0.00	0.00
		Max.	10.00	10.00
		Mean	7.90	6.30
		SD	3.048	3.692
	Change from Baseline	n	65	69
		Median	0.00	-2.26
		Min.	-9.22	-10.00
		Q1	-4.07	-6.62
		Q3	0.00	-0.04
		Max.	0.74	0.78
		Mean	-1.83	-3.41
		SD	2.954	3.671

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 65-68	VAS Score	n	65	69
		Median	9.94	8.32
		Min.	0.03	0.00
		Max.	10.00	10.00
		Mean	8.03	6.61
		SD	2.951	3.675
	Change from Baseline	n	65	69
		Median	0.00	-1.54
		Min.	-9.41	-10.00
		Q1	-3.29	-6.25
		Q3	0.00	0.00
		Max.	0.74	0.90
		Mean	-1.70	-3.10
		SD	2.809	3.650

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

PPD

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 69-72	VAS Score	n	65	69
		Median	9.92	7.54
		Min.	0.07	0.00
		Max.	10.00	10.00
		Mean	8.00	6.59
		SD	2.972	3.666
	Change from Baseline	n	65	69
		Median	0.00	-1.71
		Min.	-8.90	-10.00
		Q1	-3.88	-6.44
		Q3	0.00	0.00
		Max.	0.74	0.91
		Mean	-1.73	-3.11
		SD	2.824	3.647

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Table 2.64
Summary of Individual VAS Symptom Scores for Subjects in the Follow-Up Period After Week 52

VAS Symptom: Loss of Smell

Time Period			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Weeks 73-76	VAS Score	n	65	69
		Median	9.94	8.57
		Min.	0.06	0.00
		Max.	10.00	10.00
		Mean	8.07	6.78
		SD	2.916	3.658
	Change from Baseline	n	65	69
		Median	0.00	-1.22
		Min.	-9.35	-10.00
		Q1	-3.56	-5.89
		Q3	0.00	0.00
		Max.	1.24	0.91
		Mean	-1.66	-2.93
		SD	2.782	3.625

Note: Higher scores indicate greater disease severity.
Note: Subjects with nasal surgery/sinuplasty prior to time period are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to time period are assigned their worst observed score prior to study withdrawal.
Note: Subjects with missing time period data are assigned their worst observed score prior to the missing

Protocol: 205687
Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 1-4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	9.60 (0.075)	9.45 (0.073)
LS Mean Change (SE)	-0.12 (0.075)	-0.27 (0.073)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-0.36, 0.05)
p-value		0.137
Corrected Hedges g [3]		-0.26
95% CI		(-0.60, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 5-8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	9.44 (0.188)	8.64 (0.183)
LS Mean Change (SE)	-0.28 (0.188)	-1.07 (0.183)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.80
95% CI		(-1.32, -0.28)
p-value		0.003
Corrected Hedges g [3]		-0.52
95% CI		(-0.87, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 9-12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	9.27 (0.243)	8.16 (0.236)
LS Mean Change (SE)	-0.45 (0.243)	-1.56 (0.236)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.11
95% CI		(-1.78, -0.44)
p-value		0.001
Corrected Hedges g [3]		-0.56
95% CI		(-0.91, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 13-16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	9.13 (0.283)	7.75 (0.275)
LS Mean Change (SE)	-0.59 (0.283)	-1.97 (0.275)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.38
95% CI		(-2.16, -0.60)
p-value		<0.001
Corrected Hedges g [3]		-0.60
95% CI		(-0.95, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 17-20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.84 (0.318)	7.31 (0.308)
LS Mean Change (SE)	-0.88 (0.318)	-2.41 (0.308)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.53
95% CI		(-2.41, -0.66)
p-value		<0.001
Corrected Hedges g [3]		-0.60
95% CI		(-0.94, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 21-24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.60 (0.348)	7.09 (0.337)
LS Mean Change (SE)	-1.12 (0.348)	-2.63 (0.337)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.51
95% CI		(-2.47, -0.55)
p-value		0.002
Corrected Hedges g [3]		-0.53
95% CI		(-0.88, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 25-28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.24 (0.378)	6.90 (0.367)
LS Mean Change (SE)	-1.48 (0.378)	-2.82 (0.367)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-2.38, -0.30)
p-value		0.012
Corrected Hedges g [3]		-0.44
95% CI		(-0.78, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 29-32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.20 (0.393)	6.66 (0.381)
LS Mean Change (SE)	-1.52 (0.393)	-3.05 (0.381)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.54
95% CI		(-2.62, -0.46)
p-value		0.006
Corrected Hedges g [3]		-0.48
95% CI		(-0.83, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 33-36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.20 (0.401)	6.52 (0.389)
LS Mean Change (SE)	-1.52 (0.401)	-3.20 (0.389)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.68
95% CI		(-2.79, -0.58)
p-value		0.003
Corrected Hedges g [3]		-0.52
95% CI		(-0.86, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 37-40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.20 (0.410)	6.17 (0.398)
LS Mean Change (SE)	-1.52 (0.410)	-3.55 (0.398)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.02
95% CI		(-3.16, -0.89)
p-value		<0.001
Corrected Hedges g [3]		-0.61
95% CI		(-0.96, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 41-44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.18 (0.417)	5.91 (0.405)
LS Mean Change (SE)	-1.54 (0.417)	-3.81 (0.405)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.26
95% CI		(-3.41, -1.11)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.02, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 45-48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.14 (0.405)	6.10 (0.393)
LS Mean Change (SE)	-1.58 (0.405)	-3.62 (0.393)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.05
95% CI		(-3.16, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.62
95% CI		(-0.97, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 49-52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.07 (0.418)	5.95 (0.406)
LS Mean Change (SE)	-1.65 (0.418)	-3.77 (0.406)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.12
95% CI		(-3.27, -0.97)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.97, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 53-56

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.98 (0.432)	6.11 (0.419)
LS Mean Change (SE)	-1.74 (0.432)	-3.61 (0.419)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.87
95% CI		(-3.06, -0.68)
p-value		0.002
Corrected Hedges g [3]		-0.53
95% CI		(-0.88, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 57-60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.97 (0.423)	6.28 (0.411)
LS Mean Change (SE)	-1.75 (0.423)	-3.44 (0.411)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.69
95% CI		(-2.86, -0.52)
p-value		0.005
Corrected Hedges g [3]		-0.49
95% CI		(-0.84, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 61-64

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.89 (0.418)	6.36 (0.405)
LS Mean Change (SE)	-1.83 (0.418)	-3.36 (0.405)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.54
95% CI		(-2.69, -0.38)
p-value		0.009
Corrected Hedges g [3]		-0.45
95% CI		(-0.80, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 65-68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.03 (0.408)	6.67 (0.396)
LS Mean Change (SE)	-1.69 (0.408)	-3.05 (0.396)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.35
95% CI		(-2.48, -0.23)
p-value		0.019
Corrected Hedges g [3]		-0.41
95% CI		(-0.75, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 69-72

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	7.99 (0.409)	6.66 (0.397)
LS Mean Change (SE)	-1.73 (0.409)	-3.06 (0.397)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-2.46, -0.21)
p-value		0.021
Corrected Hedges g [3]		-0.40
95% CI		(-0.75, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Follow-Up after Week 52

Table 27.44
Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 73-76)
Mixed Model Repeated Measures

Time Period: Weeks 73-76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	69
n [2]	65	69
LS Mean (SE)	8.06 (0.406)	6.85 (0.394)
LS Mean Change (SE)	-1.66 (0.406)	-2.87 (0.394)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.22
95% CI		(-2.33, -0.10)
p-value		0.034
Corrected Hedges g [3]		-0.37
95% CI		(-0.71, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in UK, USA and Canada [1]			54	54
Baseline	UPSIT Score	n	54	54
		Median	10.5	11.0
		Min.	0	1
		Max.	36	35
		Mean	13.4	13.0
		SD	7.45	6.81

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 4	UPSIT Score	n	54	54
		Median	10.0	11.0
		Min.	0	4
		Max.	39	34
		Mean	14.3	13.6
		SD	9.73	7.54
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-11	-22
		Q1	-2.0	-2.0
		Q3	2.0	3.0
		Max.	25	33
		Mean	0.9	0.6
		SD	7.01	7.59

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	UPSIT Score	n	54	54
		Median	11.5	12.0
		Min.	0	3
		Max.	39	37
		Mean	14.3	16.1
		SD	9.02	9.15
	Change from Baseline	n	54	54
		Median	0.0	1.0
		Min.	-21	-22
		Q1	-2.0	-3.0
		Q3	3.0	6.0
		Max.	26	35
		Mean	0.8	3.0
		SD	7.08	9.65

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	UPSIT Score	n	54	54
		Median	10.0	11.0
		Min.	0	5
		Max.	38	37
		Mean	14.3	15.9
		SD	9.76	9.29
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-19	-22
		Q1	-2.0	-1.0
		Q3	2.0	8.0
		Max.	28	34
		Mean	0.9	2.9
		SD	7.28	9.54

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	UPSIT Score	n	54	54
		Median	10.0	11.0
		Min.	0	3
		Max.	37	37
		Mean	14.8	14.9
		SD	10.34	8.42
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-21	-23
		Q1	-2.0	-3.0
		Q3	3.0	5.0
		Max.	25	28
		Mean	1.4	1.9
		SD	7.58	9.67

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	UPSIT Score	n	54	54
		Median	10.0	12.0
		Min.	0	6
		Max.	39	36
		Mean	13.4	15.8
		SD	9.53	8.91
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-22	-22
		Q1	-3.0	-2.0
		Q3	1.0	9.0
		Max.	23	31
		Mean	0.0	2.8
		SD	8.22	10.95

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	UPSIT Score	n	54	54
		Median	10.0	11.0
		Min.	0	5
		Max.	37	36
		Mean	14.1	15.2
		SD	10.11	9.33
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-21	-22
		Q1	-3.0	-2.0
		Q3	2.0	6.0
		Max.	23	33
		Mean	0.7	2.2
		SD	7.78	10.48

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.49
Summary of University of Pennsylvania Smell Identification Test (UPSIT)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	UPSIT Score	n	54	54
		Median	10.0	11.0
		Min.	0	5
		Max.	37	36
		Mean	13.8	14.8
		SD	10.45	8.89
	Change from Baseline	n	54	54
		Median	0.0	0.0
		Min.	-21	-26
		Q1	-3.0	-3.0
		Q3	0.0	7.0
		Max.	24	30
		Mean	0.4	1.7
		SD	8.63	10.79

[1] Performed at sites in UK, USA and Canada only.
Note: Includes data reported up to Week 52.
Note: Lower scores indicate a worse outcome.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
missing visit.

PPD

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in UK, USA and Canada [1]	54	54
n [2]	54	54
n [3]	54	54
LS Mean (SE)	13.8 (1.01)	13.5 (1.01)
LS Mean Change (SE)	0.5 (1.01)	0.3 (1.01)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.21
95% CI		(-3.05, 2.63)
p-value		0.885
Corrected Hedges g [4]		-0.03
95% CI		(-0.40, 0.35)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	13.3 (1.19)	15.7 (1.19)
LS Mean Change (SE)	0.0 (1.19)	2.5 (1.19)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.42
95% CI		(-0.91, 5.75)
p-value		0.152
Corrected Hedges g [4]		0.28
95% CI		(-0.10, 0.65)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	12.7 (1.31)	14.5 (1.31)
LS Mean Change (SE)	-0.5 (1.31)	1.3 (1.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		1.76
95% CI		(-1.91, 5.42)
p-value		0.344
Corrected Hedges g [4]		0.18
95% CI		(-0.20, 0.56)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	12.2 (1.37)	13.5 (1.37)
LS Mean Change (SE)	-1.0 (1.37)	0.3 (1.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		1.35
95% CI		(-2.48, 5.18)
p-value		0.487
Corrected Hedges g [4]		0.13
95% CI		(-0.24, 0.51)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	9.9 (1.48)	13.9 (1.48)
LS Mean Change (SE)	-3.3 (1.48)	0.7 (1.48)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		4.01
95% CI		(-0.14, 8.16)
p-value		0.058
Corrected Hedges g [4]		0.37
95% CI		(-0.01, 0.75)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	10.3 (1.53)	12.7 (1.53)
LS Mean Change (SE)	-2.9 (1.53)	-0.5 (1.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.38
95% CI		(-1.92, 6.68)
p-value		0.275
Corrected Hedges g [4]		0.21
95% CI		(-0.17, 0.59)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.134
Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [2]	54	54
n [3]	54	54
LS Mean (SE)	9.8 (1.56)	12.2 (1.56)
LS Mean Change (SE)	-3.4 (1.56)	-1.0 (1.56)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.40
95% CI		(-1.96, 6.77)
p-value		0.278
Corrected Hedges g [4]		0.21
95% CI		(-0.17, 0.59)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SNOT-22 Score	n	198	205
		Median	64.0	64.0
		Min.	19	17
		Max.	110	105
		Mean	64.4	63.7
		SD	19.04	17.64
Week 4	SNOT-22 Score	n	200	206
		Median	52.5	47.0
		Min.	8	4
		Max.	101	106
		Mean	52.6	48.2
		SD	19.43	19.75
	Change from Baseline	n	198	205
		Median	-10.0	-14.0
		Min.	-67	-77
		Q1	-20.0	-26.0
		Q3	-2.0	-5.0
		Max.	31	24
		Mean	-11.6	-15.6
		SD	16.20	16.97

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 8	SNOT-22 Score	n	201	206
		Median	47.0	41.0
		Min.	5	4
		Max.	104	109
		Mean	48.3	41.9
		SD	21.01	19.92
	Change from Baseline	n	198	205
		Median	-14.0	-20.0
		Min.	-81	-77
		Q1	-26.0	-32.0
		Q3	-5.0	-10.0
		Max.	38	25
		Mean	-16.1	-21.9
		SD	18.70	18.05

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SNOT-22 Score	n	201	206
		Median	43.0	36.0
		Min.	4	2
		Max.	106	105
		Mean	46.4	38.6
		SD	22.36	20.11
	Change from Baseline	n	198	205
		Median	-16.0	-23.0
		Min.	-85	-80
		Q1	-31.0	-37.0
		Q3	-3.0	-13.0
		Max.	31	27
		Mean	-17.9	-25.2
		SD	20.76	19.36

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 16	SNOT-22 Score	n	201	206
		Median	43.0	34.0
		Min.	5	0
		Max.	100	108
		Mean	44.8	36.4
		SD	23.00	21.39
	Change from Baseline	n	198	205
		Median	-18.0	-27.0
		Min.	-103	-80
		Q1	-34.0	-42.0
		Q3	-4.0	-12.0
		Max.	31	28
		Mean	-19.6	-27.4
		SD	21.37	20.49

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SNOT-22 Score	n	201	206
		Median	43.0	33.0
		Min.	5	0
		Max.	108	98
		Mean	44.9	36.1
		SD	24.27	22.31
	Change from Baseline	n	198	205
		Median	-18.0	-27.0
		Min.	-81	-86
		Q1	-34.0	-43.0
		Q3	-3.0	-11.0
		Max.	38	19
		Mean	-19.4	-27.6
		SD	22.26	21.40

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 24	SNOT-22 Score	n	201	206
		Median	42.0	32.0
		Min.	1	1
		Max.	102	101
		Mean	45.7	35.0
		SD	25.10	22.28
	Change from Baseline	n	198	205
		Median	-16.0	-27.0
		Min.	-85	-89
		Q1	-35.0	-44.0
		Q3	0.0	-12.0
		Max.	38	42
		Mean	-18.7	-28.6
		SD	23.19	22.09

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SNOT-22 Score	n	201	206
		Median	39.0	30.0
		Min.	3	0
		Max.	108	103
		Mean	44.4	34.8
		SD	24.44	22.11
	Change from Baseline	n	198	205
		Median	-19.0	-27.0
		Min.	-78	-93
		Q1	-37.0	-45.0
		Q3	0.0	-14.0
		Max.	38	15
		Mean	-20.1	-28.9
		SD	22.89	21.81

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 32	SNOT-22 Score	n	201	206
		Median	43.0	31.0
		Min.	2	0
		Max.	110	101
		Mean	45.6	34.6
		SD	25.65	23.06
	Change from Baseline	n	198	205
		Median	-16.0	-27.0
		Min.	-98	-92
		Q1	-36.0	-44.0
		Q3	0.0	-12.0
		Max.	38	14
		Mean	-18.8	-29.3
		SD	23.93	22.94

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SNOT-22 Score	n	201	206
		Median	46.0	30.0
		Min.	3	0
		Max.	110	101
		Mean	47.1	34.6
		SD	25.50	23.37
	Change from Baseline	n	198	205
		Median	-15.0	-29.0
		Min.	-86	-93
		Q1	-33.0	-45.0
		Q3	0.0	-9.0
		Max.	38	22
		Mean	-17.2	-28.9
		SD	22.67	23.50

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 40	SNOT-22 Score	n	201	206
		Median	46.0	30.0
		Min.	0	0
		Max.	110	101
		Mean	46.5	35.3
		SD	26.91	23.90
	Change from Baseline	n	198	205
		Median	-16.0	-29.0
		Min.	-88	-92
		Q1	-33.0	-43.0
		Q3	0.0	-6.0
		Max.	38	17
		Mean	-17.8	-28.3
		SD	24.87	23.28

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SNOT-22 Score	n	201	206
		Median	49.0	29.5
		Min.	1	0
		Max.	110	101
		Mean	48.1	35.5
		SD	26.94	24.69
	Change from Baseline	n	198	205
		Median	-12.0	-28.0
		Min.	-90	-93
		Q1	-33.0	-44.0
		Q3	0.0	-9.0
		Max.	38	42
		Mean	-16.2	-28.1
		SD	24.79	24.07

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 48	SNOT-22 Score	n	201	206
		Median	48.0	31.0
		Min.	2	0
		Max.	110	101
		Mean	48.5	35.2
		SD	26.76	24.48
	Change from Baseline	n	198	205
		Median	-11.0	-29.0
		Min.	-97	-93
		Q1	-32.0	-45.0
		Q3	0.0	-5.0
		Max.	38	42
		Mean	-15.9	-28.3
		SD	24.50	24.54

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.31
Summary of SNOT-22 Total Score

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SNOT-22 Score	n	201	206
		Median	50.0	29.0
		Min.	2	0
		Max.	110	101
		Mean	48.7	34.1
		SD	26.69	24.89
	Change from Baseline	n	198	205
		Median	-14.0	-30.0
		Min.	-86	-93
		Q1	-31.0	-46.0
		Q3	0.0	-4.0
		Max.	38	42
		Mean	-15.7	-29.4
		SD	23.93	24.67

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.
issing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	52.9 (1.11)	48.4 (1.10)
LS Mean Change (SE)	-11.2 (1.11)	-15.7 (1.10)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.53
95% CI		(-7.61, -1.46)
p-value		0.004
Corrected Hedges g [3]		-0.29
95% CI		(-0.48, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	49.6 (1.40)	43.0 (1.38)
LS Mean Change (SE)	-14.5 (1.40)	-21.1 (1.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.60
95% CI		(-10.47, -2.72)
p-value		<0.001
Corrected Hedges g [3]		-0.33
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	48.7 (1.60)	40.0 (1.57)
LS Mean Change (SE)	-15.4 (1.60)	-24.1 (1.57)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.68
95% CI		(-13.09, -4.27)
p-value		<0.001
Corrected Hedges g [3]		-0.38
95% CI		(-0.58, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	47.3 (1.72)	38.3 (1.69)
LS Mean Change (SE)	-16.7 (1.72)	-25.7 (1.69)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.02
95% CI		(-13.77, -4.27)
p-value		<0.001
Corrected Hedges g [3]		-0.37
95% CI		(-0.57, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	48.7 (1.97)	39.7 (1.94)
LS Mean Change (SE)	-15.3 (1.97)	-24.3 (1.94)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.99
95% CI		(-14.43, -3.56)
p-value		0.001
Corrected Hedges g [3]		-0.32
95% CI		(-0.52, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	51.3 (2.14)	39.4 (2.10)
LS Mean Change (SE)	-12.7 (2.14)	-24.6 (2.10)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.92
95% CI		(-17.82, -6.01)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	51.2 (2.22)	39.6 (2.18)
LS Mean Change (SE)	-12.8 (2.22)	-24.4 (2.18)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.58
95% CI		(-17.70, -5.47)
p-value		<0.001
Corrected Hedges g [3]		-0.37
95% CI		(-0.57, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	54.0 (2.39)	40.6 (2.34)
LS Mean Change (SE)	-10.1 (2.39)	-23.5 (2.34)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-13.40
95% CI		(-19.97, -6.82)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.60, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	55.9 (2.41)	41.4 (2.37)
LS Mean Change (SE)	-8.1 (2.41)	-22.7 (2.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-14.58
95% CI		(-21.23, -7.94)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.63, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	56.1 (2.51)	42.7 (2.47)
LS Mean Change (SE)	-7.9 (2.51)	-21.4 (2.47)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-13.42
95% CI		(-20.36, -6.49)
p-value		<0.001
Corrected Hedges g [3]		-0.38
95% CI		(-0.58, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	58.9 (2.57)	43.2 (2.52)
LS Mean Change (SE)	-5.2 (2.57)	-20.9 (2.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-15.70
95% CI		(-22.78, -8.63)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.63, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	59.9 (2.61)	43.6 (2.56)
LS Mean Change (SE)	-4.2 (2.61)	-20.5 (2.56)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-16.32
95% CI		(-23.51, -9.12)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.95
Analysis of Mean Change from Baseline SNOT-22 Total Score
at Week 52
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	60.4 (2.63)	42.5 (2.58)
LS Mean Change (SE)	-3.6 (2.63)	-21.6 (2.58)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-17.94
95% CI		(-25.19, -10.70)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Baseline	SNOT-22 Score	n	65	68
		Median	64.0	69.0
		Min.	21	34
		Max.	99	105
		Mean	63.1	67.9
		SD	19.41	17.16
Week 4	SNOT-22 Score	n	65	69
		Median	57.0	44.0
		Min.	8	12
		Max.	94	106
		Mean	55.1	49.3
		SD	17.80	22.06
	Change from Baseline	n	65	68
		Median	-6.0	-17.0
		Min.	-45	-65
		Q1	-14.0	-28.5
		Q3	1.0	-6.5
		Max.	31	15
		Mean	-8.0	-18.8
		SD	14.28	16.51

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 8	SNOT-22 Score	n	65	69
		Median	49.0	40.0
		Min.	7	6
		Max.	87	109
		Mean	49.9	41.5
		SD	18.56	21.51
	Change from Baseline	n	65	68
		Median	-12.0	-25.5
		Min.	-50	-77
		Q1	-22.0	-39.0
		Q3	-4.0	-13.5
		Max.	31	10
		Mean	-13.2	-26.6
		SD	14.77	18.94

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 12	SNOT-22 Score	n	65	69
		Median	43.0	35.0
		Min.	8	2
		Max.	106	105
		Mean	46.8	38.6
		SD	21.51	21.08
	Change from Baseline	n	65	68
		Median	-14.0	-27.5
		Min.	-59	-77
		Q1	-30.0	-39.0
		Q3	0.0	-17.0
		Max.	31	9
		Mean	-16.3	-29.5
		SD	19.38	17.85

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 16	SNOT-22 Score	n	65	69
		Median	44.0	33.0
		Min.	8	0
		Max.	97	108
		Mean	46.9	34.6
		SD	23.07	21.61
	Change from Baseline	n	65	68
		Median	-16.0	-33.0
		Min.	-70	-80
		Q1	-28.0	-46.0
		Q3	0.0	-18.0
		Max.	31	3
		Mean	-16.3	-33.5
		SD	20.97	20.00

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 20	SNOT-22 Score	n	65	69
		Median	42.0	28.0
		Min.	8	0
		Max.	108	94
		Mean	44.8	33.6
		SD	24.42	20.57
	Change from Baseline	n	65	68
		Median	-18.0	-34.0
		Min.	-66	-86
		Q1	-31.0	-44.5
		Q3	0.0	-20.0
		Max.	31	3
		Mean	-18.3	-34.5
		SD	22.57	19.90

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 24	SNOT-22 Score	n	65	69
		Median	40.0	27.0
		Min.	8	1
		Max.	94	98
		Mean	44.4	31.3
		SD	25.13	21.30
	Change from Baseline	n	65	68
		Median	-16.0	-34.0
		Min.	-64	-89
		Q1	-34.0	-50.5
		Q3	0.0	-19.5
		Max.	31	7
		Mean	-18.8	-36.4
		SD	23.02	21.18

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 28	SNOT-22 Score	n	65	69
		Median	38.0	27.0
		Min.	3	0
		Max.	104	103
		Mean	43.4	31.1
		SD	25.11	20.96
	Change from Baseline	n	65	68
		Median	-19.0	-35.5
		Min.	-71	-93
		Q1	-34.0	-50.5
		Q3	0.0	-22.0
		Max.	31	12
		Mean	-19.7	-37.0
		SD	23.29	22.30

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 32	SNOT-22 Score	n	65	69
		Median	48.0	27.0
		Min.	4	0
		Max.	110	88
		Mean	45.3	29.7
		SD	25.40	21.29
	Change from Baseline	n	65	68
		Median	-15.0	-37.0
		Min.	-71	-92
		Q1	-33.0	-53.5
		Q3	0.0	-23.0
		Max.	31	0
		Mean	-17.8	-38.8
		SD	24.03	22.36

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 36	SNOT-22 Score	n	65	69
		Median	48.0	24.0
		Min.	3	0
		Max.	110	88
		Mean	46.1	28.7
		SD	25.28	21.26
	Change from Baseline	n	65	68
		Median	-15.0	-41.5
		Min.	-68	-93
		Q1	-36.0	-54.5
		Q3	0.0	-20.0
		Max.	31	6
		Mean	-17.0	-38.9
		SD	24.33	22.83

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 40	SNOT-22 Score	n	65	69
		Median	50.0	24.0
		Min.	2	0
		Max.	110	88
		Mean	45.1	28.5
		SD	26.54	21.13
	Change from Baseline	n	65	68
		Median	-13.0	-39.0
		Min.	-76	-92
		Q1	-32.0	-55.5
		Q3	0.0	-26.0
		Max.	31	6
		Mean	-18.0	-39.2
		SD	24.73	22.74

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 44	SNOT-22 Score	n	65	69
		Median	55.0	25.0
		Min.	1	0
		Max.	110	89
		Mean	46.4	29.1
		SD	27.97	21.41
	Change from Baseline	n	65	68
		Median	-18.0	-40.0
		Min.	-74	-93
		Q1	-31.0	-54.0
		Q3	0.0	-23.0
		Max.	31	6
		Mean	-16.7	-38.6
		SD	24.62	22.33

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 48	SNOT-22 Score	n	65	69
		Median	47.0	24.0
		Min.	2	0
		Max.	110	88
		Mean	46.0	28.0
		SD	26.55	20.48
	Change from Baseline	n	65	68
		Median	-15.0	-39.0
		Min.	-71	-93
		Q1	-32.0	-54.5
		Q3	0.0	-24.0
		Max.	31	6
		Mean	-17.1	-39.6
		SD	23.90	23.11

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 52	SNOT-22 Score	n	65	69
		Median	49.0	22.0
		Min.	2	0
		Max.	110	88
		Mean	46.0	26.8
		SD	27.04	21.02
	Change from Baseline	n	65	68
		Median	-18.0	-41.5
		Min.	-77	-93
		Q1	-32.0	-57.0
		Q3	0.0	-27.0
		Max.	31	6
		Mean	-17.1	-40.7
		SD	24.66	22.40

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 60	SNOT-22 Score	n	65	69
		Median	39.0	32.0
		Min.	2	1
		Max.	110	88
		Mean	44.7	33.4
		SD	27.68	22.09
	Change from Baseline	n	65	68
		Median	-17.0	-33.0
		Min.	-74	-85
		Q1	-35.0	-50.5
		Q3	0.0	-19.0
		Max.	31	11
		Mean	-18.4	-34.4
		SD	25.16	22.46

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 68	SNOT-22 Score	n	65	69
		Median	46.0	34.0
		Min.	7	1
		Max.	110	89
		Mean	45.1	38.6
		SD	27.72	22.34
	Change from Baseline	n	65	68
		Median	-19.0	-30.5
		Min.	-76	-95
		Q1	-36.0	-47.0
		Q3	0.0	-5.5
		Max.	31	21
		Mean	-18.0	-29.1
		SD	24.90	25.23

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 2.65
Summary of SNOT-22 Total Score for Subjects in the Follow-Up Period After Week 52

Visit			Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Week 76	SNOT-22 Score	n	65	69
		Median	42.0	37.0
		Min.	1	2
		Max.	110	108
		Mean	46.4	39.3
		SD	28.41	24.25
	Change from Baseline	n	65	68
		Median	-10.0	-26.5
		Min.	-78	-97
		Q1	-32.0	-46.0
		Q3	0.0	-11.5
		Max.	31	45
		Mean	-16.7	-28.5
		SD	25.80	26.76

Note: Higher scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

ing visit.

PPD

Protocol: 205687
Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.9 (1.83)	47.3 (1.79)
LS Mean Change (SE)	-8.6 (1.83)	-18.2 (1.79)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.61
95% CI		(-14.69, -4.53)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-1.00, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	53.0 (2.23)	39.7 (2.18)
LS Mean Change (SE)	-12.5 (2.23)	-25.8 (2.18)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-13.32
95% CI		(-19.52, -7.11)
p-value		<0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.09, -0.38)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	49.4 (2.59)	38.1 (2.53)
LS Mean Change (SE)	-16.2 (2.59)	-27.5 (2.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.32
95% CI		(-18.51, -4.12)
p-value		0.002
Corrected Hedges g [3]		-0.54
95% CI		(-0.89, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	50.7 (2.91)	34.2 (2.85)
LS Mean Change (SE)	-14.8 (2.91)	-31.4 (2.85)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-16.58
95% CI		(-24.68, -8.48)
p-value		<0.001
Corrected Hedges g [3]		-0.70
95% CI		(-1.05, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	48.1 (2.93)	33.3 (2.86)
LS Mean Change (SE)	-17.5 (2.93)	-32.3 (2.86)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-14.80
95% CI		(-22.94, -6.66)
p-value		<0.001
Corrected Hedges g [3]		-0.62
95% CI		(-0.97, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	51.0 (3.36)	31.4 (3.28)
LS Mean Change (SE)	-14.6 (3.36)	-34.2 (3.28)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.59
95% CI		(-28.92, -10.26)
p-value		<0.001
Corrected Hedges g [3]		-0.72
95% CI		(-1.07, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	52.3 (3.62)	31.0 (3.54)
LS Mean Change (SE)	-13.3 (3.62)	-34.6 (3.54)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-21.29
95% CI		(-31.35, -11.24)
p-value		<0.001
Corrected Hedges g [3]		-0.73
95% CI		(-1.08, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.0 (3.82)	29.8 (3.73)
LS Mean Change (SE)	-9.5 (3.82)	-35.8 (3.73)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-26.28
95% CI		(-36.88, -15.68)
p-value		<0.001
Corrected Hedges g [3]		-0.85
95% CI		(-1.20, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.9 (3.90)	30.3 (3.81)
LS Mean Change (SE)	-8.6 (3.90)	-35.2 (3.81)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-26.63
95% CI		(-37.46, -15.80)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.20, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	55.3 (4.00)	30.8 (3.91)
LS Mean Change (SE)	-10.2 (4.00)	-34.8 (3.91)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-24.57
95% CI		(-35.68, -13.46)
p-value		<0.001
Corrected Hedges g [3]		-0.76
95% CI		(-1.11, -0.41)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.8 (4.01)	31.2 (3.92)
LS Mean Change (SE)	-8.8 (4.01)	-34.4 (3.92)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-25.61
95% CI		(-36.77, -14.46)
p-value		<0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.14, -0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.4 (4.00)	30.4 (3.91)
LS Mean Change (SE)	-9.1 (4.00)	-35.2 (3.91)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-26.04
95% CI		(-37.15, -14.93)
p-value		<0.001
Corrected Hedges g [3]		-0.80
95% CI		(-1.16, -0.45)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.9 (4.06)	29.2 (3.97)
LS Mean Change (SE)	-8.7 (4.06)	-36.4 (3.97)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-27.75
95% CI		(-39.03, -16.47)
p-value		<0.001
Corrected Hedges g [3]		-0.84
95% CI		(-1.20, -0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 60

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.3 (4.25)	36.7 (4.16)
LS Mean Change (SE)	-9.2 (4.25)	-28.9 (4.16)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.65
95% CI		(-31.47, -7.83)
p-value		0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.92, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 68

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	56.4 (4.48)	45.0 (4.38)
LS Mean Change (SE)	-9.2 (4.48)	-20.6 (4.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.43
95% CI		(-23.88, 1.02)
p-value		0.072
Corrected Hedges g [3]		-0.31
95% CI		(-0.66, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Population: Follow-Up after Week 52

Table 27.103
Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 76
Mixed Model Repeated Measures

Visit: Week 76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
n [1]	65	68
n [2]	65	68
LS Mean (SE)	58.3 (4.55)	45.0 (4.45)
LS Mean Change (SE)	-7.3 (4.55)	-20.5 (4.45)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-13.29
95% CI		(-25.93, -0.64)
p-value		0.040
Corrected Hedges g [3]		-0.36
95% CI		(-0.70, -0.02)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab subject with missing baseline score is excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	19.2 (0.32)	17.8 (0.31)
LS Mean Change (SE)	-3.3 (0.32)	-4.7 (0.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.41
95% CI		(-2.28, -0.54)
p-value		0.002
Corrected Hedges g [3]		-0.32
95% CI		(-0.51, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	18.0 (0.40)	15.7 (0.39)
LS Mean Change (SE)	-4.5 (0.40)	-6.8 (0.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.23
95% CI		(-3.33, -1.13)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	17.5 (0.44)	14.6 (0.43)
LS Mean Change (SE)	-5.0 (0.44)	-7.9 (0.43)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.94
95% CI		(-4.14, -1.73)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	17.1 (0.48)	13.9 (0.47)
LS Mean Change (SE)	-5.4 (0.48)	-8.6 (0.47)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.22
95% CI		(-4.53, -1.91)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	17.5 (0.52)	14.2 (0.51)
LS Mean Change (SE)	-5.0 (0.52)	-8.3 (0.51)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.22
95% CI		(-4.65, -1.79)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.64, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	17.7 (0.55)	13.9 (0.54)
LS Mean Change (SE)	-4.8 (0.55)	-8.6 (0.54)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.76
95% CI		(-5.29, -2.23)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.68, -0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	17.5 (0.57)	13.9 (0.56)
LS Mean Change (SE)	-5.0 (0.57)	-8.6 (0.56)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.62
95% CI		(-5.19, -2.05)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.65, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	18.1 (0.60)	13.8 (0.59)
LS Mean Change (SE)	-4.4 (0.60)	-8.7 (0.59)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.33
95% CI		(-5.98, -2.68)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.71, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	18.7 (0.61)	14.0 (0.60)
LS Mean Change (SE)	-3.8 (0.61)	-8.5 (0.60)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.72
95% CI		(-6.39, -3.05)
p-value		<0.001
Corrected Hedges g [3]		-0.55
95% CI		(-0.75, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	18.6 (0.63)	14.2 (0.61)
LS Mean Change (SE)	-3.9 (0.63)	-8.3 (0.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.35
95% CI		(-6.08, -2.63)
p-value		<0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.69, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	19.3 (0.63)	14.3 (0.62)
LS Mean Change (SE)	-3.1 (0.63)	-8.2 (0.62)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.02
95% CI		(-6.75, -3.29)
p-value		<0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.77, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	19.4 (0.64)	14.5 (0.63)
LS Mean Change (SE)	-3.1 (0.64)	-8.0 (0.63)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.87
95% CI		(-6.65, -3.09)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.73, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.219
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Nasal
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	19.2 (0.65)	14.3 (0.64)
LS Mean Change (SE)	-3.3 (0.65)	-8.2 (0.64)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.93
95% CI		(-6.72, -3.14)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.74, -0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.0 (0.13)	4.5 (0.13)
LS Mean Change (SE)	-0.9 (0.13)	-1.4 (0.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-0.87, -0.14)
p-value		0.007
Corrected Hedges g [3]		-0.27
95% CI		(-0.47, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.8 (0.16)	4.0 (0.15)
LS Mean Change (SE)	-1.1 (0.16)	-1.8 (0.15)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.72
95% CI		(-1.15, -0.30)
p-value		<0.001
Corrected Hedges g [3]		-0.33
95% CI		(-0.53, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.7 (0.17)	3.8 (0.16)
LS Mean Change (SE)	-1.2 (0.17)	-2.1 (0.16)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.93
95% CI		(-1.39, -0.47)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.5 (0.18)	3.7 (0.18)
LS Mean Change (SE)	-1.3 (0.18)	-2.2 (0.18)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.88
95% CI		(-1.38, -0.38)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.54, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.8 (0.19)	3.8 (0.19)
LS Mean Change (SE)	-1.0 (0.19)	-2.1 (0.19)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.06
95% CI		(-1.59, -0.53)
p-value		<0.001
Corrected Hedges g [3]		-0.39
95% CI		(-0.59, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.9 (0.20)	3.8 (0.20)
LS Mean Change (SE)	-0.9 (0.20)	-2.1 (0.20)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.18
95% CI		(-1.74, -0.61)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.1 (0.21)	3.8 (0.21)
LS Mean Change (SE)	-0.8 (0.21)	-2.1 (0.21)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.27
95% CI		(-1.85, -0.69)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.63, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.3 (0.22)	3.7 (0.22)
LS Mean Change (SE)	-0.6 (0.22)	-2.1 (0.22)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.53
95% CI		(-2.15, -0.92)
p-value		<0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.68, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.4 (0.23)	3.8 (0.22)
LS Mean Change (SE)	-0.5 (0.23)	-2.1 (0.22)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.64
95% CI		(-2.26, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.71, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.4 (0.23)	4.0 (0.23)
LS Mean Change (SE)	-0.5 (0.23)	-1.9 (0.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.39
95% CI		(-2.03, -0.75)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.62, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.5 (0.24)	4.0 (0.23)
LS Mean Change (SE)	-0.3 (0.24)	-1.8 (0.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.52
95% CI		(-2.18, -0.86)
p-value		<0.001
Corrected Hedges g [3]		-0.45
95% CI		(-0.65, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.8 (0.24)	4.0 (0.24)
LS Mean Change (SE)	-0.1 (0.24)	-1.8 (0.24)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.74
95% CI		(-2.41, -1.08)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.71, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.220
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Non-nasal Symptoms
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.7 (0.24)	3.9 (0.24)
LS Mean Change (SE)	-0.1 (0.24)	-1.9 (0.24)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.79
95% CI		(-2.46, -1.11)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.72, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.9 (0.25)	6.2 (0.25)
LS Mean Change (SE)	-1.8 (0.25)	-2.5 (0.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.74
95% CI		(-1.43, -0.04)
p-value		0.037
Corrected Hedges g [3]		-0.21
95% CI		(-0.40, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.7 (0.30)	5.6 (0.30)
LS Mean Change (SE)	-2.0 (0.30)	-3.1 (0.30)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.14
95% CI		(-1.97, -0.31)
p-value		0.007
Corrected Hedges g [3]		-0.27
95% CI		(-0.46, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.6 (0.33)	5.2 (0.33)
LS Mean Change (SE)	-2.1 (0.33)	-3.5 (0.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.41
95% CI		(-2.32, -0.50)
p-value		0.003
Corrected Hedges g [3]		-0.30
95% CI		(-0.50, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.5 (0.35)	5.1 (0.35)
LS Mean Change (SE)	-2.2 (0.35)	-3.6 (0.35)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.37
95% CI		(-2.34, -0.40)
p-value		0.006
Corrected Hedges g [3]		-0.28
95% CI		(-0.47, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.7 (0.41)	5.3 (0.40)
LS Mean Change (SE)	-2.0 (0.41)	-3.4 (0.40)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.45
95% CI		(-2.57, -0.33)
p-value		0.011
Corrected Hedges g [3]		-0.25
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.6 (0.44)	5.5 (0.43)
LS Mean Change (SE)	-1.1 (0.44)	-3.2 (0.43)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.13
95% CI		(-3.33, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.54, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.5 (0.46)	5.6 (0.45)
LS Mean Change (SE)	-1.2 (0.46)	-3.1 (0.45)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.86
95% CI		(-3.12, -0.60)
p-value		0.004
Corrected Hedges g [3]		-0.29
95% CI		(-0.49, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.9 (0.49)	5.8 (0.48)
LS Mean Change (SE)	-0.8 (0.49)	-2.9 (0.48)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.16
95% CI		(-3.52, -0.80)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.51, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.3 (0.50)	6.0 (0.49)
LS Mean Change (SE)	-0.4 (0.50)	-2.7 (0.49)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.24
95% CI		(-3.61, -0.86)
p-value		0.002
Corrected Hedges g [3]		-0.32
95% CI		(-0.51, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.6 (0.51)	6.2 (0.50)
LS Mean Change (SE)	-0.1 (0.51)	-2.5 (0.50)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.40
95% CI		(-3.80, -1.00)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.0 (0.52)	6.3 (0.52)
LS Mean Change (SE)	0.3 (0.52)	-2.3 (0.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.67
95% CI		(-4.12, -1.23)
p-value		<0.001
Corrected Hedges g [3]		-0.36
95% CI		(-0.56, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.3 (0.53)	6.4 (0.53)
LS Mean Change (SE)	0.6 (0.53)	-2.2 (0.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.83
95% CI		(-4.31, -1.36)
p-value		<0.001
Corrected Hedges g [3]		-0.38
95% CI		(-0.57, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.221
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Ear/Facial Symptoms
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.5 (0.53)	6.3 (0.52)
LS Mean Change (SE)	0.8 (0.53)	-2.4 (0.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.26
95% CI		(-4.73, -1.79)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.63, -0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.1 (0.22)	6.3 (0.22)
LS Mean Change (SE)	-1.7 (0.22)	-2.5 (0.22)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.78
95% CI		(-1.39, -0.16)
p-value		0.013
Corrected Hedges g [3]		-0.25
95% CI		(-0.44, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.5 (0.26)	5.6 (0.25)
LS Mean Change (SE)	-2.3 (0.26)	-3.2 (0.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.92
95% CI		(-1.63, -0.21)
p-value		0.012
Corrected Hedges g [3]		-0.25
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.5 (0.28)	5.4 (0.27)
LS Mean Change (SE)	-2.3 (0.28)	-3.4 (0.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.10
95% CI		(-1.87, -0.34)
p-value		0.005
Corrected Hedges g [3]		-0.28
95% CI		(-0.48, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.3 (0.28)	5.1 (0.27)
LS Mean Change (SE)	-2.5 (0.28)	-3.7 (0.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.19
95% CI		(-1.95, -0.43)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.50, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.4 (0.31)	5.3 (0.31)
LS Mean Change (SE)	-2.4 (0.31)	-3.6 (0.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.14
95% CI		(-2.01, -0.28)
p-value		0.010
Corrected Hedges g [3]		-0.26
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.8 (0.33)	5.3 (0.33)
LS Mean Change (SE)	-2.0 (0.33)	-3.5 (0.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-2.49, -0.66)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.8 (0.34)	5.1 (0.33)
LS Mean Change (SE)	-2.0 (0.34)	-3.7 (0.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-2.59, -0.75)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.55, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.2 (0.36)	5.5 (0.35)
LS Mean Change (SE)	-1.6 (0.36)	-3.3 (0.35)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.71
95% CI		(-2.70, -0.73)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.54, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.5 (0.37)	5.4 (0.36)
LS Mean Change (SE)	-1.3 (0.37)	-3.4 (0.36)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.08
95% CI		(-3.09, -1.07)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.60, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.5 (0.38)	5.7 (0.37)
LS Mean Change (SE)	-1.3 (0.38)	-3.1 (0.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.78
95% CI		(-2.83, -0.73)
p-value		<0.001
Corrected Hedges g [3]		-0.33
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.0 (0.38)	5.8 (0.38)
LS Mean Change (SE)	-0.8 (0.38)	-3.0 (0.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.21
95% CI		(-3.27, -1.16)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.61, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.9 (0.39)	5.8 (0.38)
LS Mean Change (SE)	-0.9 (0.39)	-3.0 (0.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.16
95% CI		(-3.23, -1.09)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.59, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.222
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Sleep
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.2 (0.39)	5.7 (0.38)
LS Mean Change (SE)	-0.6 (0.39)	-3.1 (0.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.51
95% CI		(-3.58, -1.44)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.66, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.6 (0.27)	8.7 (0.27)
LS Mean Change (SE)	-1.7 (0.27)	-2.5 (0.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.85
95% CI		(-1.60, -0.10)
p-value		0.026
Corrected Hedges g [3]		-0.22
95% CI		(-0.42, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.7 (0.31)	7.8 (0.31)
LS Mean Change (SE)	-2.6 (0.31)	-3.5 (0.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.92
95% CI		(-1.79, -0.05)
p-value		0.037
Corrected Hedges g [3]		-0.21
95% CI		(-0.40, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.4 (0.35)	7.0 (0.34)
LS Mean Change (SE)	-2.8 (0.35)	-4.3 (0.34)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.45
95% CI		(-2.42, -0.49)
p-value		0.003
Corrected Hedges g [3]		-0.29
95% CI		(-0.49, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.1 (0.37)	6.7 (0.36)
LS Mean Change (SE)	-3.1 (0.37)	-4.6 (0.36)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.45
95% CI		(-2.47, -0.43)
p-value		0.005
Corrected Hedges g [3]		-0.28
95% CI		(-0.47, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.5 (0.40)	7.0 (0.39)
LS Mean Change (SE)	-2.7 (0.40)	-4.2 (0.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.48
95% CI		(-2.59, -0.38)
p-value		0.008
Corrected Hedges g [3]		-0.26
95% CI		(-0.46, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	8.9 (0.44)	6.8 (0.44)
LS Mean Change (SE)	-2.4 (0.44)	-4.4 (0.44)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.07
95% CI		(-3.29, -0.85)
p-value		<0.001
Corrected Hedges g [3]		-0.33
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.0 (0.45)	7.0 (0.44)
LS Mean Change (SE)	-2.3 (0.45)	-4.3 (0.44)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.98
95% CI		(-3.22, -0.74)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.51, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.6 (0.48)	7.3 (0.47)
LS Mean Change (SE)	-1.6 (0.48)	-3.9 (0.47)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.29
95% CI		(-3.60, -0.98)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.54, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.8 (0.48)	7.5 (0.47)
LS Mean Change (SE)	-1.5 (0.48)	-3.8 (0.47)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.29
95% CI		(-3.63, -0.96)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.53, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	9.8 (0.50)	7.7 (0.49)
LS Mean Change (SE)	-1.4 (0.50)	-3.6 (0.49)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.17
95% CI		(-3.56, -0.78)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.50, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	10.3 (0.51)	7.8 (0.50)
LS Mean Change (SE)	-1.0 (0.51)	-3.5 (0.50)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.52
95% CI		(-3.93, -1.12)
p-value		<0.001
Corrected Hedges g [3]		-0.35
95% CI		(-0.55, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	10.5 (0.51)	7.8 (0.50)
LS Mean Change (SE)	-0.8 (0.51)	-3.5 (0.50)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.69
95% CI		(-4.10, -1.28)
p-value		<0.001
Corrected Hedges g [3]		-0.37
95% CI		(-0.57, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.223
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Fatigue
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	10.7 (0.52)	7.5 (0.51)
LS Mean Change (SE)	-0.6 (0.52)	-3.8 (0.51)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.17
95% CI		(-4.61, -1.73)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.63, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.2 (0.20)	4.9 (0.20)
LS Mean Change (SE)	-1.8 (0.20)	-2.0 (0.20)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.23
95% CI		(-0.79, 0.34)
p-value		0.428
Corrected Hedges g [3]		-0.08
95% CI		(-0.27, 0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.9 (0.24)	4.3 (0.24)
LS Mean Change (SE)	-2.1 (0.24)	-2.7 (0.24)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.62
95% CI		(-1.28, 0.05)
p-value		0.068
Corrected Hedges g [3]		-0.18
95% CI		(-0.38, 0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.8 (0.27)	4.0 (0.26)
LS Mean Change (SE)	-2.1 (0.27)	-2.9 (0.26)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.80
95% CI		(-1.54, -0.05)
p-value		0.036
Corrected Hedges g [3]		-0.21
95% CI		(-0.41, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.8 (0.28)	3.9 (0.27)
LS Mean Change (SE)	-2.1 (0.28)	-3.0 (0.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.89
95% CI		(-1.66, -0.12)
p-value		0.024
Corrected Hedges g [3]		-0.23
95% CI		(-0.42, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	4.8 (0.32)	4.2 (0.31)
LS Mean Change (SE)	-2.1 (0.32)	-2.8 (0.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.62
95% CI		(-1.50, 0.26)
p-value		0.166
Corrected Hedges g [3]		-0.14
95% CI		(-0.33, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.3 (0.34)	4.2 (0.34)
LS Mean Change (SE)	-1.6 (0.34)	-2.7 (0.34)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.13
95% CI		(-2.07, -0.18)
p-value		0.019
Corrected Hedges g [3]		-0.23
95% CI		(-0.43, -0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.4 (0.35)	4.3 (0.35)
LS Mean Change (SE)	-1.5 (0.35)	-2.6 (0.35)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.10
95% CI		(-2.07, -0.13)
p-value		0.026
Corrected Hedges g [3]		-0.22
95% CI		(-0.42, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	5.8 (0.37)	4.5 (0.37)
LS Mean Change (SE)	-1.1 (0.37)	-2.4 (0.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-2.37, -0.31)
p-value		0.011
Corrected Hedges g [3]		-0.25
95% CI		(-0.45, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.3 (0.38)	4.7 (0.37)
LS Mean Change (SE)	-0.6 (0.38)	-2.2 (0.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-2.63, -0.53)
p-value		0.003
Corrected Hedges g [3]		-0.29
95% CI		(-0.49, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.2 (0.40)	4.9 (0.39)
LS Mean Change (SE)	-0.7 (0.40)	-2.0 (0.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.30
95% CI		(-2.39, -0.20)
p-value		0.021
Corrected Hedges g [3]		-0.23
95% CI		(-0.43, -0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	6.6 (0.41)	5.0 (0.40)
LS Mean Change (SE)	-0.3 (0.41)	-2.0 (0.40)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.68
95% CI		(-2.80, -0.56)
p-value		0.003
Corrected Hedges g [3]		-0.29
95% CI		(-0.49, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.0 (0.41)	5.1 (0.40)
LS Mean Change (SE)	0.1 (0.41)	-1.9 (0.40)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.96
95% CI		(-3.09, -0.84)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.54, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.224
Analysis of Mean Change from Baseline in SNOT-22 Domain Score at Week 52: Emotional Consequences
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	7.0 (0.41)	4.8 (0.41)
LS Mean Change (SE)	0.1 (0.41)	-2.1 (0.41)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.23
95% CI		(-3.36, -1.09)
p-value		<0.001
Corrected Hedges g [3]		-0.38
95% CI		(-0.58, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Figure 27.20
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Nasal
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Protocol: 205687
Population: Intent-to-Treat

Figure 27.21
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Non-nasal Symptoms
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Protocol: 205687
Population: Intent-to-Treat

Figure 27.22
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Ear/Facial Symptoms
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Figure 27.23
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Sleep
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Figure 27.24
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Fatigue
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Protocol: 205687
Population: Intent-to-Treat

Figure 27.25
Figure of Mean Change from Baseline in SNOT-22 Domain Score by Visit: Emotional Consequences
(Mixed Model Repeated Measures)



Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.55
Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 8		
Subjects with event	13 (6%)	9 (4%)
Probability of surgery or steroid use [1]	6.5%	4.4%
95% CI	(3.8%, 10.9%)	(2.3%, 8.3%)
By week 16		
Subjects with event	30 (15%)	26 (13%)
Probability of surgery or steroid use [1]	15.0%	12.7%
95% CI	(10.7%, 20.7%)	(8.8%, 18.1%)
By week 24		
Subjects with event	51 (25%)	41 (20%)
Probability of surgery or steroid use [1]	25.6%	20.2%
95% CI	(20.1%, 32.3%)	(15.3%, 26.4%)
By week 32		
Subjects with event	62 (31%)	46 (22%)
Probability of surgery or steroid use [1]	31.2%	22.7%
95% CI	(25.3%, 38.2%)	(17.5%, 29.1%)
By week 40		
Subjects with event	71 (35%)	50 (24%)
Probability of surgery or steroid use [1]	35.8%	24.8%
95% CI	(29.6%, 42.9%)	(19.4%, 31.3%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.55
Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	83 (41%)	56 (27%)
Probability of surgery or steroid use [1]	42.0%	27.9%
95% CI	(35.5%, 49.2%)	(22.2%, 34.7%)
By week 52		
Subjects with event	84 (42%)	56 (27%)
Probability of surgery or steroid use [1]	42.6%	27.9%
95% CI	(36.0%, 49.8%)	(22.2%, 34.7%)
Event [2]	84 (42%)	57 (28%)
Course of systemic steroids prior to Week 52	65 (32%)	49 (24%)
Nasal surgery prior to Week 52	19 (9%)	8 (4%)
Censored	117 (58%)	149 (72%)
Censored at Week 52	106 (53%)	136 (66%)
Censored at study withdrawal	11 (5%)	13 (6%)
Hazard ratio (Mepo/Placebo) [3]		0.71
95% CI		(0.50, 1.00)
p-value		0.050

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.27
Analysis of Time to First Nasal Surgery

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 8		
Subjects with event	2 (<1%)	1 (<1%)
Probability of surgery [1]	1.0%	0.5%
95% CI	(0.3%, 3.9%)	(0.1%, 3.4%)
By week 16		
Subjects with event	7 (3%)	2 (<1%)
Probability of surgery [1]	3.5%	1.0%
95% CI	(1.7%, 7.2%)	(0.2%, 3.8%)
By week 24		
Subjects with event	18 (9%)	8 (4%)
Probability of surgery [1]	9.1%	4.0%
95% CI	(5.8%, 14.0%)	(2.0%, 7.8%)
By week 32		
Subjects with event	28 (14%)	12 (6%)
Probability of surgery [1]	14.2%	6.0%
95% CI	(10.0%, 19.9%)	(3.5%, 10.4%)
By week 40		
Subjects with event	37 (18%)	15 (7%)
Probability of surgery [1]	18.9%	7.6%
95% CI	(14.0%, 25.1%)	(4.6%, 12.3%)

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.27
Analysis of Time to First Nasal Surgery

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	43 (21%)	18 (9%)
Probability of surgery [1]	22.0%	9.2%
95% CI	(16.8%, 28.5%)	(5.9%, 14.2%)
By week 52		
Subjects with event	46 (23%)	18 (9%)
Probability of surgery [1]	23.6%	9.2%
95% CI	(18.3%, 30.3%)	(5.9%, 14.2%)
Event: Nasal surgery prior to Week 52	46 (23%)	18 (9%)
Censored	155 (77%)	188 (91%)
Censored at Week 52	140 (70%)	172 (83%)
Censored at study withdrawal	15 (7%)	16 (8%)
Hazard ratio (Mepo/Placebo) [2]		0.43
95% CI		(0.25, 0.76)
p-value		0.003

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Follow-up after Week 52

Table 27.86
Analysis of Time to First Nasal Surgery up to Week 76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
By week 8		
Subjects with event	2 (3%)	0
Probability of surgery [1]	3.1%	
95% CI	(0.8%, 11.7%)	
By week 16		
Subjects with event	3 (5%)	1 (1%)
Probability of surgery [1]	4.6%	1.4%
95% CI	(1.5%, 13.6%)	(0.2%, 9.8%)
By week 24		
Subjects with event	9 (14%)	1 (1%)
Probability of surgery [1]	13.8%	1.4%
95% CI	(7.5%, 24.9%)	(0.2%, 9.8%)
By week 32		
Subjects with event	13 (20%)	2 (3%)
Probability of surgery [1]	20.0%	2.9%
95% CI	(12.1%, 31.9%)	(0.7%, 11.1%)
By week 40		
Subjects with event	15 (23%)	3 (4%)
Probability of surgery [1]	23.1%	4.3%
95% CI	(14.6%, 35.3%)	(1.4%, 12.9%)

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.86
Analysis of Time to First Nasal Surgery up to Week 76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
By week 48		
Subjects with event	16 (25%)	3 (4%)
Probability of surgery [1]	24.6%	4.3%
95% CI	(15.9%, 37.0%)	(1.4%, 12.9%)
By week 52		
Subjects with event	16 (25%)	3 (4%)
Probability of surgery [1]	24.6%	4.3%
95% CI	(15.9%, 37.0%)	(1.4%, 12.9%)
By week 60		
Subjects with event	18 (28%)	5 (7%)
Probability of surgery [1]	27.7%	7.2%
95% CI	(18.4%, 40.3%)	(3.1%, 16.5%)
By week 68		
Subjects with event	18 (28%)	6 (9%)
Probability of surgery [1]	27.7%	8.7%
95% CI	(18.4%, 40.3%)	(4.0%, 18.4%)
By week 76		
Subjects with event	20 (31%)	6 (9%)
Probability of surgery [1]	30.8%	8.7%
95% CI	(21.1%, 43.6%)	(4.0%, 18.4%)

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Follow-up after Week 52

Table 27.86
Analysis of Time to First Nasal Surgery up to Week 76

	Placebo (N=65)	Mepolizumab 100mg SC (N=69)
Event: Nasal surgery prior to Week 76	20 (31%)	6 (9%)
Censored	45 (69%)	63 (91%)
Censored at Week 76	45 (69%)	61 (88%)
Censored at study withdrawal	0	2 (3%)
Hazard ratio (Mepo/Placebo) [2]		0.26
95% CI		(0.10, 0.67)
p-value		0.005

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Intent-to-Treat

Table 27.115
Time to First Course of Systemic Steroids for Nasal Polyps up to Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 8		
Subjects with event	13 (6%)	9 (4%)
Probability of steroid use [1]	6.5%	4.4%
95% CI	(3.8%, 10.9%)	(2.3%, 8.3%)
By week 16		
Subjects with event	30 (15%)	26 (13%)
Probability of steroid use [1]	15.0%	12.7%
95% CI	(10.7%, 20.7%)	(8.8%, 18.1%)
By week 24		
Subjects with event	46 (23%)	37 (18%)
Probability of steroid use [1]	23.1%	18.2%
95% CI	(17.8%, 29.6%)	(13.5%, 24.2%)
By week 32		
Subjects with event	55 (27%)	42 (20%)
Probability of steroid use [1]	27.7%	20.7%
95% CI	(22.0%, 34.5%)	(15.8%, 27.0%)
By week 40		
Subjects with event	62 (31%)	45 (22%)
Probability of steroid use [1]	31.3%	22.3%
95% CI	(25.3%, 38.2%)	(17.1%, 28.7%)

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total nasal polyps endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of OCS courses for NP in last 12 months (0, 1, >1 as ordinal).

Table 27.115
Time to First Course of Systemic Steroids for Nasal Polyps up to Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	73 (36%)	51 (25%)
Probability of steroid use [1]	36.9%	25.4%
95% CI	(30.6%, 44.1%)	(20.0%, 32.1%)
By week 52		
Subjects with event	74 (37%)	51 (25%)
Probability of steroid use [1]	37.5%	25.4%
95% CI	(31.1%, 44.6%)	(20.0%, 32.1%)
Event: Course of systemic steroids prior to Week 52	74 (37%)	52 (25%)
Censored	127 (63%)	154 (75%)
Censored at Week 52	115 (57%)	140 (68%)
Censored at study withdrawal	12 (6%)	14 (7%)
Hazard ratio (Mepo/Placebo) [2]		0.69
95% CI		(0.48, 0.98)
p-value		0.039

[1] Kaplan-Meier estimate.
[2] Estimated from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total nasal polyps endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of OCS courses for NP in last 12 months (0, 1, >1 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects with concurrent asthma			149	140
Baseline	ACQ-5 Score	n	144	138
		Median	2.00	2.20
		Min.	0.0	0.0
		Max.	5.2	5.6
		Mean	2.15	2.38
		SD	1.364	1.356
Week 4	ACQ-5 Score	n	146	138
		Median	1.60	1.20
		Min.	0.0	0.0
		Max.	5.4	5.8
		Mean	1.72	1.49
		SD	1.280	1.141
	Change from Baseline	n	144	138
		Median	-0.40	-0.80
		Min.	-4.6	-4.6
		Q1	-1.00	-1.60
		Q3	0.20	0.00
		Max.	2.6	1.8
		Mean	-0.41	-0.89
		SD	1.052	1.126

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 8	ACQ-5 Score	n	147	139
		Median	1.40	1.00
		Min.	0.0	0.0
		Max.	4.6	5.8
		Mean	1.56	1.24
		SD	1.200	1.084
	Change from Baseline	n	144	138
		Median	-0.40	-0.90
		Min.	-4.6	-5.2
		Q1	-1.10	-1.80
		Q3	0.00	-0.20
		Max.	2.4	2.6
		Mean	-0.57	-1.13
		SD	1.177	1.263

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	ACQ-5 Score	n	147	139
		Median	1.20	1.00
		Min.	0.0	0.0
		Max.	5.8	5.8
		Mean	1.53	1.20
		SD	1.239	1.076
	Change from Baseline	n	144	138
		Median	-0.40	-1.00
		Min.	-4.8	-4.8
		Q1	-1.40	-2.00
		Q3	0.00	-0.40
		Max.	4.8	2.4
		Mean	-0.61	-1.18
		SD	1.276	1.311

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 16	ACQ-5 Score	n	148	139
		Median	1.20	0.80
		Min.	0.0	0.0
		Max.	5.6	6.0
		Mean	1.44	1.06
		SD	1.192	1.140
	Change from Baseline	n	144	138
		Median	-0.60	-1.20
		Min.	-4.4	-4.8
		Q1	-1.40	-2.20
		Q3	0.00	-0.40
		Max.	2.8	2.4
		Mean	-0.69	-1.31
		SD	1.267	1.281

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	ACQ-5 Score	n	148	139
		Median	1.20	0.80
		Min.	0.0	0.0
		Max.	6.0	5.4
		Mean	1.54	1.17
		SD	1.260	1.157
	Change from Baseline	n	144	138
		Median	-0.50	-1.00
		Min.	-4.2	-4.6
		Q1	-1.40	-2.00
		Q3	0.20	-0.20
		Max.	4.2	2.4
		Mean	-0.60	-1.21
		SD	1.362	1.271

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 24	ACQ-5 Score	n	148	139
		Median	1.20	0.60
		Min.	0.0	0.0
		Max.	6.0	5.8
		Mean	1.49	1.08
		SD	1.253	1.165
	Change from Baseline	n	144	138
		Median	-0.50	-1.20
		Min.	-4.4	-5.0
		Q1	-1.40	-2.20
		Q3	0.00	-0.20
		Max.	4.0	2.4
		Mean	-0.64	-1.29
		SD	1.303	1.316

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	ACQ-5 Score	n	148	139
		Median	1.20	0.80
		Min.	0.0	0.0
		Max.	5.2	5.4
		Mean	1.52	1.18
		SD	1.280	1.155
	Change from Baseline	n	144	138
		Median	-0.30	-1.00
		Min.	-4.8	-5.2
		Q1	-1.60	-2.00
		Q3	0.20	-0.20
		Max.	2.6	2.4
		Mean	-0.61	-1.19
		SD	1.390	1.292

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 32	ACQ-5 Score	n	148	139
		Median	1.40	0.80
		Min.	0.0	0.0
		Max.	5.6	5.4
		Mean	1.61	1.14
		SD	1.374	1.193
	Change from Baseline	n	144	138
		Median	-0.40	-1.00
		Min.	-4.8	-5.2
		Q1	-1.20	-2.20
		Q3	0.20	0.00
		Max.	2.6	2.6
		Mean	-0.54	-1.23
		SD	1.264	1.372

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	ACQ-5 Score	n	149	139
		Median	1.40	0.80
		Min.	0.0	0.0
		Max.	6.0	5.4
		Mean	1.76	1.09
		SD	1.480	1.173
	Change from Baseline	n	144	138
		Median	-0.20	-1.00
		Min.	-3.8	-5.0
		Q1	-1.10	-2.00
		Q3	0.40	0.00
		Max.	2.6	1.0
		Mean	-0.37	-1.29
		SD	1.190	1.348

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 40	ACQ-5 Score	n	149	139
		Median	1.40	1.00
		Min.	0.0	0.0
		Max.	6.0	5.4
		Mean	1.73	1.21
		SD	1.416	1.174
	Change from Baseline	n	144	138
		Median	0.00	-0.90
		Min.	-4.8	-4.6
		Q1	-1.20	-2.00
		Q3	0.40	0.00
		Max.	2.6	1.6
		Mean	-0.40	-1.17
		SD	1.280	1.317

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	ACQ-5 Score	n	149	139
		Median	1.40	0.80
		Min.	0.0	0.0
		Max.	6.0	6.0
		Mean	1.71	1.20
		SD	1.444	1.229
	Change from Baseline	n	144	138
		Median	0.00	-1.00
		Min.	-4.8	-5.0
		Q1	-1.30	-2.20
		Q3	0.20	0.00
		Max.	3.8	1.6
		Mean	-0.43	-1.17
		SD	1.358	1.385

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 48	ACQ-5 Score	n	149	139
		Median	1.60	0.80
		Min.	0.0	0.0
		Max.	6.0	5.4
		Mean	1.81	1.18
		SD	1.394	1.212
	Change from Baseline	n	144	138
		Median	0.00	-1.00
		Min.	-4.8	-5.0
		Q1	-1.00	-2.00
		Q3	0.40	0.00
		Max.	2.6	1.6
		Mean	-0.34	-1.19
		SD	1.234	1.377

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.61
Summary of ACQ-5 in Participants with Asthma

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	ACQ-5 Score	n	149	139
		Median	1.40	0.80
		Min.	0.0	0.0
		Max.	6.0	5.4
		Mean	1.74	1.19
		SD	1.419	1.207
	Change from Baseline	n	144	138
		Median	0.00	-0.80
		Min.	-4.8	-5.2
		Q1	-1.10	-2.20
		Q3	0.20	0.00
		Max.	2.6	1.6
		Mean	-0.40	-1.18
		SD	1.209	1.378

Note: Includes data reported up to Week 52.
Note: Higher scores indicate worse asthma control.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects with concurrent asthma	149	140
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.84 (0.081)	1.42 (0.083)
LS Mean Change (SE)	-0.43 (0.081)	-0.84 (0.083)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.41
95% CI		(-0.64, -0.18)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.66, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.76 (0.108)	1.34 (0.110)
LS Mean Change (SE)	-0.50 (0.108)	-0.92 (0.110)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.42
95% CI		(-0.73, -0.12)
p-value		0.007
Corrected Hedges g [3]		-0.32
95% CI		(-0.56, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.78 (0.113)	1.27 (0.116)
LS Mean Change (SE)	-0.48 (0.113)	-1.00 (0.116)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.52
95% CI		(-0.84, -0.19)
p-value		0.002
Corrected Hedges g [3]		-0.38
95% CI		(-0.61, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.78 (0.124)	1.15 (0.127)
LS Mean Change (SE)	-0.48 (0.124)	-1.11 (0.127)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.63
95% CI		(-0.98, -0.28)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.66, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.92 (0.137)	1.36 (0.140)
LS Mean Change (SE)	-0.34 (0.137)	-0.91 (0.140)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.57
95% CI		(-0.95, -0.18)
p-value		0.004
Corrected Hedges g [3]		-0.34
95% CI		(-0.58, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	1.99 (0.150)	1.37 (0.153)
LS Mean Change (SE)	-0.28 (0.150)	-0.89 (0.153)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.61
95% CI		(-1.04, -0.19)
p-value		0.005
Corrected Hedges g [3]		-0.34
95% CI		(-0.57, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.09 (0.157)	1.50 (0.160)
LS Mean Change (SE)	-0.17 (0.157)	-0.76 (0.160)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.59
95% CI		(-1.04, -0.15)
p-value		0.009
Corrected Hedges g [3]		-0.32
95% CI		(-0.55, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.34 (0.168)	1.51 (0.172)
LS Mean Change (SE)	0.08 (0.168)	-0.75 (0.172)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.83
95% CI		(-1.31, -0.36)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.65, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.59 (0.174)	1.52 (0.177)
LS Mean Change (SE)	0.32 (0.174)	-0.74 (0.177)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-1.56, -0.58)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.75, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.65 (0.180)	1.75 (0.183)
LS Mean Change (SE)	0.38 (0.180)	-0.51 (0.183)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.89
95% CI		(-1.40, -0.39)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.65, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.64 (0.186)	1.80 (0.190)
LS Mean Change (SE)	0.38 (0.186)	-0.47 (0.190)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.85
95% CI		(-1.37, -0.32)
p-value		0.002
Corrected Hedges g [3]		-0.38
95% CI		(-0.61, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.84 (0.187)	1.81 (0.191)
LS Mean Change (SE)	0.58 (0.187)	-0.45 (0.191)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.03
95% CI		(-1.56, -0.51)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.70, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.133
Analysis of Mean Change from Baseline in ACQ-5 at Week 52 in Participants with Asthma
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	138
n [2]	144	138
LS Mean (SE)	2.80 (0.192)	1.89 (0.196)
LS Mean Change (SE)	0.54 (0.192)	-0.38 (0.196)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.92
95% CI		(-1.46, -0.38)
p-value		<0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.63, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE. Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	75.00	70.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	69.34	66.83
		SD	24.041	24.483
Week 4	SF-36 Score	n	200	205
		Median	79.99	79.99
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	73.92	75.34
		SD	22.077	21.679
	Change from Baseline	n	198	205
		Median	5.00	5.00
		Min.	-50.0	-40.0
		Q1	-5.00	0.00
		Q3	10.00	15.00
		Max.	80.0	80.0
		Mean	4.32	8.51
		SD	17.601	16.973

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	85.00	85.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	77.65	80.56
		SD	23.214	19.860
	Change from Baseline	n	198	205
		Median	5.01	10.00
		Min.	-55.0	-30.0
		Q1	0.00	0.00
		Q3	15.01	25.00
		Max.	90.0	75.0
		Mean	8.11	13.78
		SD	21.405	19.696

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	85.00	90.00
		Min.	0.0	5.0
		Max.	100.0	100.0
		Mean	78.00	81.97
		SD	22.942	20.028
	Change from Baseline	n	198	205
		Median	5.00	10.00
		Min.	-65.0	-30.0
		Q1	0.00	0.00
		Q3	15.00	25.00
		Max.	95.0	90.0
		Mean	8.43	15.05
		SD	21.459	19.591

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	85.00	87.50
		Min.	0.0	20.0
		Max.	100.0	100.0
		Mean	78.15	83.13
		SD	23.437	16.704
	Change from Baseline	n	198	205
		Median	5.00	10.00
		Min.	-85.0	-40.0
		Q1	0.00	0.00
		Q3	15.00	25.00
		Max.	95.0	80.0
		Mean	8.59	16.32
		SD	22.575	20.809

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	85.00	90.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	77.75	82.50
		SD	23.273	19.036
	Change from Baseline	n	198	205
		Median	5.00	10.00
		Min.	-60.0	-25.0
		Q1	0.00	0.00
		Q3	15.01	29.99
		Max.	90.0	85.0
		Mean	8.18	16.07
		SD	20.887	21.220

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	82.50	90.00
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	75.62	83.15
		SD	23.786	19.686
	Change from Baseline	n	198	205
		Median	0.00	10.00
		Min.	-50.0	-30.0
		Q1	-5.00	0.00
		Q3	15.00	30.00
		Max.	90.0	85.0
		Mean	6.03	16.24
		SD	19.159	21.016

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Physical Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	85.00	90.00
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	75.85	82.98
		SD	23.575	19.062
	Change from Baseline	n	198	205
		Median	0.00	10.00
		Min.	-50.0	-30.0
		Q1	-4.99	0.00
		Q3	14.98	25.00
		Max.	90.0	90.0
		Mean	6.29	16.07
		SD	20.905	21.964

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	72.24 (1.135)	76.06 (1.115)
LS Mean Change (SE)	4.17 (1.135)	7.99 (1.115)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.82
95% CI		(0.69, 6.95)
p-value		0.017
Corrected Hedges g [3]		0.24
95% CI		(0.04, 0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	72.31 (1.740)	78.81 (1.710)
LS Mean Change (SE)	4.25 (1.740)	10.75 (1.710)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		6.50
95% CI		(1.70, 11.30)
p-value		0.008
Corrected Hedges g [3]		0.26
95% CI		(0.07, 0.46)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	69.75 (2.058)	77.25 (2.023)
LS Mean Change (SE)	1.68 (2.058)	9.18 (2.023)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.50
95% CI		(1.82, 13.18)
p-value		0.010
Corrected Hedges g [3]		0.26
95% CI		(0.06, 0.45)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	65.32 (2.359)	75.74 (2.318)
LS Mean Change (SE)	-2.74 (2.359)	7.67 (2.318)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		10.41
95% CI		(3.91, 16.92)
p-value		0.002
Corrected Hedges g [3]		0.31
95% CI		(0.12, 0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	61.09 (2.594)	72.72 (2.549)
LS Mean Change (SE)	-6.97 (2.594)	4.66 (2.549)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.63
95% CI		(4.48, 18.79)
p-value		0.002
Corrected Hedges g [3]		0.32
95% CI		(0.12, 0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	56.29 (2.691)	71.82 (2.644)
LS Mean Change (SE)	-11.77 (2.691)	3.76 (2.644)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		15.53
95% CI		(8.11, 22.95)
p-value		<0.001
Corrected Hedges g [3]		0.41
95% CI		(0.21, 0.61)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.170
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Physical Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	54.37 (2.769)	70.48 (2.722)
LS Mean Change (SE)	-13.69 (2.769)	2.42 (2.722)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		16.11
95% CI		(8.47, 23.75)
p-value		<0.001
Corrected Hedges g [3]		0.41
95% CI		(0.22, 0.61)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	70.00	65.00
		Min.	0.0	5.0
		Max.	100.0	100.0
		Mean	64.62	62.15
		SD	20.202	19.573
Week 4	SF-36 Score	n	200	205
		Median	70.00	70.00
		Min.	5.0	0.0
		Max.	100.0	100.0
		Mean	67.43	68.78
		SD	19.054	18.929
	Change from Baseline	n	198	205
		Median	0.00	5.00
		Min.	-50.0	-45.0
		Q1	-5.00	0.00
		Q3	10.00	15.00
		Max.	50.0	80.0
		Mean	2.60	6.63
		SD	14.934	16.031

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	70.00	75.00
		Min.	10.0	15.0
		Max.	100.0	100.0
		Mean	69.63	71.31
		SD	19.001	16.549
	Change from Baseline	n	198	205
		Median	5.00	5.00
		Min.	-45.0	-40.0
		Q1	-5.00	0.00
		Q3	15.00	20.00
		Max.	60.0	60.0
		Mean	4.87	9.15
		SD	17.600	16.952

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	75.00	75.00
		Min.	15.0	5.0
		Max.	100.0	100.0
		Mean	69.70	70.87
		SD	19.281	18.720
	Change from Baseline	n	198	205
		Median	5.00	5.00
		Min.	-45.0	-35.0
		Q1	-5.00	0.00
		Q3	15.00	20.00
		Max.	60.0	80.0
		Mean	4.90	8.71
		SD	17.776	18.012

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	70.00	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	67.75	70.90
		SD	19.739	18.113
	Change from Baseline	n	198	205
		Median	0.00	5.00
		Min.	-50.0	-35.0
		Q1	-5.00	0.00
		Q3	10.00	15.00
		Max.	45.0	75.0
		Mean	2.95	8.73
		SD	17.017	17.534

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	70.00	75.00
		Min.	0.0	20.0
		Max.	100.0	100.0
		Mean	66.08	70.34
		SD	20.794	18.495
	Change from Baseline	n	198	205
		Median	0.00	5.00
		Min.	-50.0	-45.0
		Q1	-10.00	0.00
		Q3	10.00	20.00
		Max.	60.0	80.0
		Mean	1.26	8.24
		SD	17.156	17.818

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	70.00	75.00
		Min.	0.0	5.0
		Max.	100.0	100.0
		Mean	66.05	70.85
		SD	21.435	19.509
	Change from Baseline	n	198	205
		Median	0.00	5.00
		Min.	-50.0	-45.0
		Q1	-10.00	0.00
		Q3	10.00	20.00
		Max.	60.0	75.0
		Mean	1.21	8.76
		SD	17.735	17.630

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Mental Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	70.00	75.00
		Min.	0.0	5.0
		Max.	100.0	100.0
		Mean	66.58	70.87
		SD	21.633	20.700
	Change from Baseline	n	198	205
		Median	0.00	5.00
		Min.	-50.0	-45.0
		Q1	-10.00	-5.00
		Q3	10.00	20.00
		Max.	70.0	80.0
		Mean	1.84	8.59
		SD	18.387	19.609

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	65.71 (1.052)	69.43 (1.034)
LS Mean Change (SE)	2.35 (1.052)	6.07 (1.034)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.72
95% CI		(0.82, 6.63)
p-value		0.012
Corrected Hedges g [3]		0.25
95% CI		(0.05, 0.45)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	65.48 (1.441)	70.13 (1.416)
LS Mean Change (SE)	2.11 (1.441)	6.76 (1.416)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		4.65
95% CI		(0.67, 8.63)
p-value		0.022
Corrected Hedges g [3]		0.23
95% CI		(0.03, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	63.11 (1.766)	67.51 (1.735)
LS Mean Change (SE)	-0.25 (1.766)	4.15 (1.735)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		4.40
95% CI		(-0.47, 9.27)
p-value		0.076
Corrected Hedges g [3]		0.18
95% CI		(-0.02, 0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	57.31 (2.024)	64.87 (1.989)
LS Mean Change (SE)	-6.06 (2.024)	1.51 (1.989)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.56
95% CI		(1.98, 13.15)
p-value		0.008
Corrected Hedges g [3]		0.27
95% CI		(0.07, 0.46)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	52.84 (2.206)	62.16 (2.168)
LS Mean Change (SE)	-10.52 (2.206)	-1.20 (2.168)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		9.32
95% CI		(3.23, 15.40)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.10, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	50.05 (2.357)	61.51 (2.316)
LS Mean Change (SE)	-13.31 (2.357)	-1.85 (2.316)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.45
95% CI		(4.95, 17.96)
p-value		<0.001
Corrected Hedges g [3]		0.34
95% CI		(0.15, 0.54)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.177
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Mental Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	49.31 (2.475)	60.13 (2.432)
LS Mean Change (SE)	-14.05 (2.475)	-3.23 (2.432)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		10.82
95% CI		(3.99, 17.65)
p-value		0.002
Corrected Hedges g [3]		0.31
95% CI		(0.11, 0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	62.50	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	64.61	60.24
		SD	24.415	24.353
Week 4	SF-36 Score	n	200	205
		Median	75.00	68.75
		Min.	18.8	6.3
		Max.	100.0	100.0
		Mean	69.69	70.61
		SD	21.172	21.414
	Change from Baseline	n	198	205
		Median	6.25	6.25
		Min.	-68.8	-50.0
		Q1	-6.25	0.00
		Q3	18.75	25.00
		Max.	75.0	93.8
		Mean	4.89	10.37
		SD	20.627	20.291

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	75.00	81.25
		Min.	18.8	12.5
		Max.	100.0	100.0
		Mean	74.63	77.03
		SD	22.352	21.058
	Change from Baseline	n	198	205
		Median	6.25	18.75
		Min.	-68.8	-62.5
		Q1	0.00	0.00
		Q3	25.00	31.25
		Max.	81.3	93.8
		Mean	10.01	16.80
		SD	22.537	23.262

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	75.00	81.25
		Min.	6.3	6.3
		Max.	100.0	100.0
		Mean	73.75	78.64
		SD	22.556	21.651
	Change from Baseline	n	198	205
		Median	6.25	18.75
		Min.	-68.8	-62.5
		Q1	0.00	0.00
		Q3	25.00	31.25
		Max.	81.3	93.8
		Mean	9.00	18.29
		SD	23.312	24.055

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	75.00	81.25
		Min.	0.0	12.5
		Max.	100.0	100.0
		Mean	73.94	79.31
		SD	23.411	20.090
	Change from Baseline	n	198	205
		Median	0.00	18.75
		Min.	-81.3	-62.5
		Q1	-6.25	0.00
		Q3	25.00	37.50
		Max.	81.3	100.0
		Mean	9.19	18.99
		SD	25.547	25.865

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	75.00	81.25
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	70.41	78.00
		SD	24.886	21.815
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-81.3	-62.5
		Q1	-6.25	0.00
		Q3	18.75	37.50
		Max.	81.3	93.8
		Mean	5.59	18.14
		SD	26.542	26.610

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	75.00	87.50
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	69.75	79.10
		SD	25.152	22.918
	Change from Baseline	n	198	205
		Median	0.00	18.75
		Min.	-81.3	-62.5
		Q1	-6.25	0.00
		Q3	18.75	37.50
		Max.	75.0	93.8
		Mean	4.83	18.75
		SD	25.019	26.255

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	75.00	81.25
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	68.59	79.04
		SD	24.862	22.434
	Change from Baseline	n	198	205
		Median	0.00	18.75
		Min.	-81.3	-62.5
		Q1	-6.25	0.00
		Q3	12.50	37.50
		Max.	81.3	93.8
		Mean	3.91	18.69
		SD	24.930	27.889

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	43.68	43.68
		Min.	21.2	21.2
		Max.	57.2	57.2
		Mean	44.44	42.87
		SD	8.773	8.750
Week 4	SF-36 Score	n	200	205
		Median	48.17	45.93
		Min.	28.0	23.5
		Max.	57.2	57.2
		Mean	46.26	46.60
		SD	7.607	7.694
	Change from Baseline	n	198	205
		Median	2.24	2.25
		Min.	-24.7	-18.0
		Q1	-2.25	0.00
		Q3	6.73	8.98
		Max.	27.0	33.7
		Mean	1.76	3.72
		SD	7.411	7.290

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	48.17	50.42
		Min.	28.0	25.7
		Max.	57.2	57.2
		Mean	48.04	48.90
		SD	8.032	7.567
	Change from Baseline	n	198	205
		Median	2.24	6.73
		Min.	-24.7	-22.5
		Q1	0.00	0.00
		Q3	8.98	11.23
		Max.	29.2	33.7
		Mean	3.60	6.04
		SD	8.098	8.358

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	48.17	50.42
		Min.	23.5	23.5
		Max.	57.2	57.2
		Mean	47.73	49.48
		SD	8.105	7.780
	Change from Baseline	n	198	205
		Median	2.25	6.73
		Min.	-24.7	-22.5
		Q1	0.00	0.00
		Q3	8.98	11.23
		Max.	29.2	33.7
		Mean	3.23	6.57
		SD	8.376	8.643

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	48.17	50.42
		Min.	21.2	25.7
		Max.	57.2	57.2
		Mean	47.79	49.72
		SD	8.412	7.219
	Change from Baseline	n	198	205
		Median	0.00	6.73
		Min.	-29.2	-22.5
		Q1	-2.24	0.00
		Q3	8.98	13.47
		Max.	29.2	35.9
		Mean	3.30	6.82
		SD	9.179	9.293

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	48.17	50.42
		Min.	21.2	21.2
		Max.	57.2	57.2
		Mean	46.52	49.25
		SD	8.942	7.839
	Change from Baseline	n	198	205
		Median	0.00	4.50
		Min.	-29.2	-22.5
		Q1	-2.25	0.00
		Q3	6.74	13.47
		Max.	29.2	33.7
		Mean	2.01	6.52
		SD	9.537	9.561

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	48.17	52.66
		Min.	21.2	21.2
		Max.	57.2	57.2
		Mean	46.29	49.65
		SD	9.038	8.235
	Change from Baseline	n	198	205
		Median	0.00	6.73
		Min.	-29.2	-22.5
		Q1	-2.25	0.00
		Q3	6.74	13.48
		Max.	27.0	33.7
		Mean	1.74	6.74
		SD	8.990	9.434

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Physical (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	48.17	50.42
		Min.	21.2	21.2
		Max.	57.2	57.2
		Mean	45.87	49.62
		SD	8.933	8.061
	Change from Baseline	n	198	205
		Median	0.00	6.73
		Min.	-29.2	-22.5
		Q1	-2.25	0.00
		Q3	4.50	13.47
		Max.	29.2	33.7
		Mean	1.41	6.72
		SD	8.958	10.021

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	62.00	62.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	60.70	59.05
		SD	25.191	23.866
Week 4	SF-36 Score	n	200	205
		Median	63.00	72.00
		Min.	10.0	10.0
		Max.	100.0	100.0
		Mean	65.67	65.94
		SD	22.491	21.954
	Change from Baseline	n	198	205
		Median	0.00	2.00
		Min.	-78.0	-49.0
		Q1	-9.00	0.00
		Q3	19.00	20.00
		Max.	78.0	68.0
		Mean	4.70	6.88
		SD	22.348	20.096

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	72.00	74.00
		Min.	10.0	10.0
		Max.	100.0	100.0
		Mean	69.10	73.01
		SD	23.170	22.016
	Change from Baseline	n	198	205
		Median	0.00	12.00
		Min.	-78.0	-69.0
		Q1	-1.00	0.00
		Q3	23.00	30.00
		Max.	78.0	78.0
		Mean	8.46	13.82
		SD	26.369	23.394

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	74.00	74.00
		Min.	0.0	12.0
		Max.	100.0	100.0
		Mean	69.77	74.40
		SD	23.059	22.010
	Change from Baseline	n	198	205
		Median	1.00	12.00
		Min.	-78.0	-42.0
		Q1	0.00	0.00
		Q3	22.00	32.00
		Max.	79.0	84.0
		Mean	8.95	15.22
		SD	25.452	25.239

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	72.00	74.00
		Min.	0.0	21.0
		Max.	100.0	100.0
		Mean	67.86	74.83
		SD	24.948	22.055
	Change from Baseline	n	198	205
		Median	0.00	16.00
		Min.	-78.0	-69.0
		Q1	0.00	0.00
		Q3	23.00	33.00
		Max.	79.0	84.0
		Mean	7.10	15.83
		SD	27.395	25.019

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	72.00	74.00
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	65.90	73.22
		SD	25.544	23.744
	Change from Baseline	n	198	205
		Median	0.00	10.00
		Min.	-78.0	-69.0
		Q1	-10.00	0.00
		Q3	21.00	33.00
		Max.	78.0	78.0
		Mean	5.01	14.04
		SD	25.906	25.588

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	74.00	77.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	66.43	75.17
		SD	26.779	24.511
	Change from Baseline	n	198	205
		Median	0.00	12.00
		Min.	-78.0	-69.0
		Q1	-9.00	0.00
		Q3	22.00	31.00
		Max.	78.0	78.0
		Mean	5.55	15.99
		SD	27.011	25.878

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	64.00	74.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	64.92	75.06
		SD	26.723	23.732
	Change from Baseline	n	198	205
		Median	0.00	11.00
		Min.	-78.0	-69.0
		Q1	-10.00	0.00
		Q3	20.00	38.00
		Max.	78.0	78.0
		Mean	4.24	15.89
		SD	27.441	26.796

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	46.68	46.68
		Min.	21.7	21.7
		Max.	62.0	62.0
		Mean	46.15	45.49
		SD	10.157	9.623
Week 4	SF-36 Score	n	200	205
		Median	47.08	50.71
		Min.	25.7	25.7
		Max.	62.0	62.0
		Mean	48.16	48.26
		SD	9.069	8.852
	Change from Baseline	n	198	205
		Median	0.00	0.81
		Min.	-31.5	-19.8
		Q1	-3.63	0.00
		Q3	7.66	8.07
		Max.	31.5	27.4
		Mean	1.90	2.78
		SD	9.011	8.103

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	50.71	51.51
		Min.	25.7	25.7
		Max.	62.0	62.0
		Mean	49.54	51.12
		SD	9.343	8.877
	Change from Baseline	n	198	205
		Median	0.00	4.83
		Min.	-31.5	-27.8
		Q1	-0.40	0.00
		Q3	9.27	12.10
		Max.	31.5	31.5
		Mean	3.41	5.57
		SD	10.632	9.433

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	51.51	51.51
		Min.	21.7	26.5
		Max.	62.0	62.0
		Mean	49.81	51.68
		SD	9.298	8.875
	Change from Baseline	n	198	205
		Median	0.41	4.83
		Min.	-31.5	-16.9
		Q1	0.00	0.00
		Q3	8.87	12.91
		Max.	31.9	33.9
		Mean	3.61	6.14
		SD	10.262	10.177

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	50.71	51.51
		Min.	21.7	30.1
		Max.	62.0	62.0
		Mean	49.04	51.85
		SD	10.059	8.893
	Change from Baseline	n	198	205
		Median	0.00	6.45
		Min.	-31.5	-27.8
		Q1	0.00	0.00
		Q3	9.27	13.30
		Max.	31.9	33.9
		Mean	2.86	6.39
		SD	11.046	10.088

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	50.71	51.51
		Min.	21.7	25.7
		Max.	62.0	62.0
		Mean	48.25	51.20
		SD	10.300	9.574
	Change from Baseline	n	198	205
		Median	0.00	4.04
		Min.	-31.5	-27.8
		Q1	-4.03	0.00
		Q3	8.47	13.30
		Max.	31.5	31.5
		Mean	2.02	5.66
		SD	10.445	10.317

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	51.51	52.72
		Min.	21.7	21.7
		Max.	62.0	62.0
		Mean	48.46	51.99
		SD	10.798	9.883
	Change from Baseline	n	198	205
		Median	0.00	4.83
		Min.	-31.5	-27.8
		Q1	-3.63	0.00
		Q3	8.87	12.50
		Max.	31.5	31.5
		Mean	2.24	6.45
		SD	10.892	10.435

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Bodily Pain (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	47.48	51.51
		Min.	21.7	21.7
		Max.	62.0	62.0
		Mean	47.85	51.94
		SD	10.775	9.570
	Change from Baseline	n	198	205
		Median	0.00	4.44
		Min.	-31.5	-27.8
		Q1	-4.03	0.00
		Q3	8.06	15.32
		Max.	31.5	31.5
		Mean	1.71	6.41
		SD	11.064	10.804

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	45.00	45.00
		Min.	0.0	5.0
		Max.	97.0	97.0
		Mean	47.28	45.31
		SD	21.011	18.563
Week 4	SF-36 Score	n	200	205
		Median	52.00	52.00
		Min.	5.0	15.0
		Max.	97.0	95.0
		Mean	52.74	54.16
		SD	19.389	18.608
	Change from Baseline	n	198	205
		Median	3.00	8.00
		Min.	-40.0	-37.0
		Q1	-5.00	0.00
		Q3	15.00	17.00
		Max.	57.0	77.0
		Mean	5.27	8.85
		SD	15.185	15.465

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	52.00	57.00
		Min.	0.0	15.0
		Max.	97.0	97.0
		Mean	54.20	59.51
		SD	20.460	19.620
	Change from Baseline	n	198	205
		Median	5.00	15.00
		Min.	-52.0	-25.0
		Q1	-5.00	2.00
		Q3	15.00	27.00
		Max.	65.0	67.0
		Mean	6.82	14.09
		SD	18.083	17.216

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	52.00	62.00
		Min.	0.0	15.0
		Max.	97.0	100.0
		Mean	55.24	59.15
		SD	22.220	20.288
	Change from Baseline	n	198	205
		Median	5.00	10.00
		Min.	-40.0	-35.0
		Q1	-5.00	0.00
		Q3	17.00	27.00
		Max.	67.0	70.0
		Mean	7.74	13.70
		SD	17.969	18.051

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	52.00	60.00
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	54.35	59.74
		SD	20.788	19.396
	Change from Baseline	n	198	205
		Median	1.00	12.00
		Min.	-22.0	-25.0
		Q1	-5.00	0.00
		Q3	17.00	25.00
		Max.	67.0	77.0
		Mean	6.84	14.38
		SD	17.059	18.527

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	52.00	62.00
		Min.	0.0	15.0
		Max.	100.0	100.0
		Mean	51.84	59.67
		SD	21.601	20.869
	Change from Baseline	n	198	205
		Median	0.00	15.00
		Min.	-35.0	-25.0
		Q1	-5.00	0.00
		Q3	10.00	27.00
		Max.	67.0	75.0
		Mean	4.33	14.36
		SD	17.253	18.374

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	50.00	57.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	50.05	59.12
		SD	21.189	21.332
	Change from Baseline	n	198	205
		Median	0.00	10.00
		Min.	-47.0	-30.0
		Q1	-10.00	0.00
		Q3	10.00	25.00
		Max.	72.0	75.0
		Mean	2.50	13.71
		SD	17.211	19.928

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	47.00	57.00
		Min.	0.0	10.0
		Max.	100.0	100.0
		Mean	49.09	58.57
		SD	21.494	21.462
	Change from Baseline	n	198	205
		Median	0.00	10.00
		Min.	-40.0	-35.0
		Q1	-10.00	0.00
		Q3	7.00	25.00
		Max.	77.0	82.0
		Mean	1.72	13.06
		SD	17.373	19.584

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	40.35	40.35
		Min.	19.0	21.3
		Max.	65.1	65.1
		Mean	41.43	40.49
		SD	9.991	8.826
Week 4	SF-36 Score	n	200	205
		Median	43.68	43.68
		Min.	21.3	26.1
		Max.	65.1	64.1
		Mean	44.03	44.70
		SD	9.219	8.848
	Change from Baseline	n	198	205
		Median	1.42	3.81
		Min.	-19.0	-17.6
		Q1	-2.38	0.00
		Q3	7.13	8.08
		Max.	27.1	36.6
		Mean	2.51	4.21
		SD	7.220	7.354

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	43.68	46.05
		Min.	19.0	26.1
		Max.	65.1	65.1
		Mean	44.72	47.25
		SD	9.728	9.329
	Change from Baseline	n	198	205
		Median	2.37	7.13
		Min.	-24.7	-11.9
		Q1	-2.38	0.95
		Q3	7.13	12.83
		Max.	30.9	31.9
		Mean	3.24	6.70
		SD	8.598	8.186

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	43.68	48.43
		Min.	19.0	26.1
		Max.	65.1	66.5
		Mean	45.22	47.07
		SD	10.565	9.647
	Change from Baseline	n	198	205
		Median	2.38	4.76
		Min.	-19.0	-16.6
		Q1	-2.37	0.00
		Q3	8.08	12.84
		Max.	31.9	33.3
		Mean	3.68	6.52
		SD	8.544	8.583

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	43.68	47.48
		Min.	19.0	23.7
		Max.	66.5	66.5
		Mean	44.79	47.36
		SD	9.884	9.223
	Change from Baseline	n	198	205
		Median	0.48	5.70
		Min.	-10.5	-11.9
		Q1	-2.38	0.00
		Q3	8.08	11.89
		Max.	31.9	36.6
		Mean	3.25	6.84
		SD	8.111	8.809

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	43.68	48.43
		Min.	19.0	26.1
		Max.	66.5	66.5
		Mean	43.60	47.32
		SD	10.271	9.923
	Change from Baseline	n	198	205
		Median	0.00	7.13
		Min.	-16.7	-11.9
		Q1	-2.38	0.00
		Q3	4.76	12.83
		Max.	31.9	35.7
		Mean	2.06	6.83
		SD	8.204	8.736

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	42.73	46.05
		Min.	19.0	19.0
		Max.	66.5	66.5
		Mean	42.75	47.06
		SD	10.075	10.143
	Change from Baseline	n	198	205
		Median	0.00	4.76
		Min.	-22.4	-14.3
		Q1	-4.75	0.00
		Q3	4.76	11.89
		Max.	34.2	35.7
		Mean	1.19	6.52
		SD	8.184	9.475

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: General Health (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	41.30	46.05
		Min.	19.0	23.7
		Max.	66.5	66.5
		Mean	42.29	46.80
		SD	10.220	10.204
	Change from Baseline	n	198	205
		Median	0.00	4.76
		Min.	-19.0	-16.6
		Q1	-4.75	0.00
		Q3	3.33	11.88
		Max.	36.6	39.0
		Mean	0.82	6.21
		SD	8.261	9.311

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	48.55	45.79
		SD	20.644	21.406
Week 4	SF-36 Score	n	200	205
		Median	50.00	56.25
		Min.	6.3	0.0
		Max.	100.0	100.0
		Mean	53.00	53.93
		SD	19.774	21.067
	Change from Baseline	n	198	205
		Median	6.25	6.25
		Min.	-50.0	-25.0
		Q1	-6.25	0.00
		Q3	12.50	18.75
		Max.	50.0	81.3
		Mean	4.39	8.14
		SD	15.149	15.990

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	56.25	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	55.63	59.62
		SD	20.988	19.808
	Change from Baseline	n	198	205
		Median	6.25	12.50
		Min.	-81.3	-31.3
		Q1	-6.25	0.00
		Q3	18.75	25.00
		Max.	87.5	75.0
		Mean	6.98	13.69
		SD	20.649	18.697

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	56.25	62.50
		Min.	6.3	0.0
		Max.	100.0	100.0
		Mean	56.06	59.34
		SD	21.024	20.996
	Change from Baseline	n	198	205
		Median	6.25	12.50
		Min.	-50.0	-31.3
		Q1	-6.25	0.00
		Q3	18.75	25.00
		Max.	56.3	81.3
		Mean	7.26	13.45
		SD	18.812	20.601

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	56.25	62.50
		Min.	0.0	6.3
		Max.	100.0	100.0
		Mean	55.09	59.95
		SD	21.460	20.050
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-50.0	-25.0
		Q1	-6.25	0.00
		Q3	18.75	25.00
		Max.	56.3	93.8
		Mean	6.22	14.12
		SD	18.918	20.135

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	53.13	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	52.78	58.86
		SD	22.563	21.448
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-50.0	-43.8
		Q1	-6.25	0.00
		Q3	12.50	25.00
		Max.	68.8	93.8
		Mean	4.01	13.11
		SD	19.611	20.867

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	53.13	62.50
		Min.	0.0	6.3
		Max.	100.0	100.0
		Mean	52.16	59.62
		SD	23.499	21.717
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-50.0	-37.5
		Q1	-6.25	0.00
		Q3	12.50	25.00
		Max.	56.3	93.8
		Mean	3.38	13.75
		SD	19.117	21.126

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	53.13	62.50
		Min.	0.0	6.3
		Max.	100.0	100.0
		Mean	51.91	60.47
		SD	23.828	21.665
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-50.0	-37.5
		Q1	-6.25	0.00
		Q3	12.50	25.00
		Max.	75.0	93.8
		Mean	3.28	14.51
		SD	20.070	21.935

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	46.66	46.66
		Min.	22.9	22.9
		Max.	70.4	70.4
		Mean	45.97	44.66
		SD	9.813	10.176
Week 4	SF-36 Score	n	200	205
		Median	46.66	49.63
		Min.	25.9	22.9
		Max.	70.4	70.4
		Mean	48.08	48.53
		SD	9.399	10.014
	Change from Baseline	n	198	205
		Median	2.97	2.97
		Min.	-23.8	-11.9
		Q1	-2.97	0.00
		Q3	5.94	8.91
		Max.	23.8	38.6
		Mean	2.09	3.87
		SD	7.201	7.601

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	49.63	52.60
		Min.	22.9	22.9
		Max.	70.4	70.4
		Mean	49.33	51.23
		SD	9.976	9.415
	Change from Baseline	n	198	205
		Median	2.97	5.94
		Min.	-38.6	-14.9
		Q1	-2.97	0.00
		Q3	8.91	11.88
		Max.	41.6	35.7
		Mean	3.32	6.51
		SD	9.816	8.887

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	49.63	52.60
		Min.	25.9	22.9
		Max.	70.4	70.4
		Mean	49.54	51.10
		SD	9.993	9.980
	Change from Baseline	n	198	205
		Median	2.97	5.94
		Min.	-23.8	-14.9
		Q1	-2.97	0.00
		Q3	8.91	11.88
		Max.	26.7	38.6
		Mean	3.45	6.39
		SD	8.942	9.792

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	49.63	52.60
		Min.	22.9	25.9
		Max.	70.4	70.4
		Mean	49.08	51.39
		SD	10.200	9.530
	Change from Baseline	n	198	205
		Median	0.00	5.94
		Min.	-23.8	-11.9
		Q1	-2.97	0.00
		Q3	8.91	11.88
		Max.	26.7	44.6
		Mean	2.96	6.71
		SD	8.993	9.571

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	48.15	52.60
		Min.	22.9	22.9
		Max.	70.4	70.4
		Mean	47.98	50.87
		SD	10.725	10.194
	Change from Baseline	n	198	205
		Median	0.00	5.94
		Min.	-23.8	-20.8
		Q1	-2.97	0.00
		Q3	5.94	11.88
		Max.	32.7	44.6
		Mean	1.91	6.23
		SD	9.322	9.918

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	48.15	52.60
		Min.	22.9	25.9
		Max.	70.4	70.4
		Mean	47.68	51.23
		SD	11.170	10.323
	Change from Baseline	n	198	205
		Median	0.00	5.94
		Min.	-23.8	-17.8
		Q1	-2.97	0.00
		Q3	5.94	11.89
		Max.	26.7	44.6
		Mean	1.61	6.54
		SD	9.087	10.041

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Vitality (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	48.15	52.60
		Min.	22.9	25.9
		Max.	70.4	70.4
		Mean	47.56	51.63
		SD	11.326	10.298
	Change from Baseline	n	198	205
		Median	0.00	5.94
		Min.	-23.8	-17.8
		Q1	-2.97	0.00
		Q3	5.94	11.89
		Max.	35.7	44.6
		Mean	1.56	6.90
		SD	9.540	10.426

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	75.00	75.00
		Min.	0.0	12.5
		Max.	100.0	100.0
		Mean	68.94	68.11
		SD	25.649	24.796
Week 4	SF-36 Score	n	200	205
		Median	75.00	87.50
		Min.	0.0	12.5
		Max.	100.0	100.0
		Mean	76.13	77.26
		SD	22.874	21.336
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-62.5	-37.5
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	87.5	75.0
		Mean	6.94	9.15
		SD	21.575	22.317

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	87.50	87.50
		Min.	12.5	0.0
		Max.	100.0	100.0
		Mean	77.81	79.92
		SD	22.008	21.370
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-62.5	-50.0
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	87.5	87.5
		Mean	8.84	11.77
		SD	24.439	24.774

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	87.50	87.50
		Min.	0.0	25.0
		Max.	100.0	100.0
		Mean	78.44	82.16
		SD	23.808	20.630
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-62.5	-62.5
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	87.5	87.5
		Mean	9.34	13.96
		SD	25.771	25.950

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	87.50	87.50
		Min.	0.0	12.5
		Max.	100.0	100.0
		Mean	77.31	81.98
		SD	24.205	20.114
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-75.0	-62.5
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	87.5	87.5
		Mean	8.14	13.96
		SD	25.579	27.302

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	75.00	87.50
		Min.	0.0	25.0
		Max.	100.0	100.0
		Mean	73.44	80.76
		SD	25.710	21.047
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-75.0	-50.0
		Q1	-12.50	0.00
		Q3	25.00	25.00
		Max.	87.5	87.5
		Mean	4.29	12.56
		SD	24.498	27.467

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	75.00	87.50
		Min.	0.0	12.5
		Max.	100.0	100.0
		Mean	72.31	80.64
		SD	27.708	21.651
	Change from Baseline	n	198	205
		Median	0.00	12.50
		Min.	-62.5	-50.0
		Q1	-12.50	0.00
		Q3	12.50	25.00
		Max.	87.5	87.5
		Mean	3.09	12.44
		SD	24.919	27.017

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	75.00	87.50
		Min.	0.0	25.0
		Max.	100.0	100.0
		Mean	72.69	80.52
		SD	26.967	22.712
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-75.0	-50.0
		Q1	-12.50	0.00
		Q3	12.50	25.00
		Max.	87.5	87.5
		Mean	3.66	12.32
		SD	25.206	27.017

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	47.31	47.31
		Min.	17.2	22.3
		Max.	57.3	57.3
		Mean	44.88	44.55
		SD	10.287	9.945
Week 4	SF-36 Score	n	200	205
		Median	47.31	52.33
		Min.	17.2	22.3
		Max.	57.3	57.3
		Mean	47.77	48.22
		SD	9.174	8.557
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-25.1	-15.0
		Q1	0.00	0.00
		Q3	10.02	10.03
		Max.	35.1	30.1
		Mean	2.79	3.67
		SD	8.653	8.951

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	52.33	52.33
		Min.	22.3	17.2
		Max.	57.3	57.3
		Mean	48.44	49.28
		SD	8.827	8.571
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-25.1	-20.1
		Q1	0.00	0.00
		Q3	10.02	10.03
		Max.	35.1	35.1
		Mean	3.55	4.72
		SD	9.802	9.936

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	52.33	52.33
		Min.	17.2	27.3
		Max.	57.3	57.3
		Mean	48.69	50.19
		SD	9.548	8.274
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-25.1	-25.1
		Q1	0.00	0.00
		Q3	10.03	10.03
		Max.	35.1	35.1
		Mean	3.75	5.60
		SD	10.336	10.408

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	52.33	52.33
		Min.	17.2	22.3
		Max.	57.3	57.3
		Mean	48.24	50.11
		SD	9.708	8.067
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-30.1	-25.1
		Q1	0.00	0.00
		Q3	10.02	10.03
		Max.	35.1	35.1
		Mean	3.27	5.60
		SD	10.259	10.950

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	47.31	52.33
		Min.	17.2	27.3
		Max.	57.3	57.3
		Mean	46.69	49.63
		SD	10.311	8.441
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-30.1	-20.1
		Q1	-5.01	0.00
		Q3	10.02	10.03
		Max.	35.1	35.1
		Mean	1.72	5.04
		SD	9.825	11.016

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	47.31	52.33
		Min.	17.2	22.3
		Max.	57.3	57.3
		Mean	46.24	49.58
		SD	11.112	8.684
	Change from Baseline	n	198	205
		Median	0.00	5.01
		Min.	-25.1	-20.1
		Q1	-5.01	0.00
		Q3	5.02	10.03
		Max.	35.1	35.1
		Mean	1.24	4.99
		SD	9.994	10.836

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Social Functioning (norm-based score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	47.31	52.33
		Min.	17.2	27.3
		Max.	57.3	57.3
		Mean	46.39	49.53
		SD	10.815	9.109
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-30.1	-20.1
		Q1	-5.01	0.00
		Q3	5.02	10.03
		Max.	35.1	35.1
		Mean	1.47	4.94
		SD	10.109	10.835

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Baseline	SF-36 Score	n	198	205
		Median	75.00	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	73.48	71.83
		SD	25.547	25.434
Week 4	SF-36 Score	n	200	205
		Median	83.33	83.33
		Min.	0.0	8.3
		Max.	100.0	100.0
		Mean	78.54	79.55
		SD	21.856	21.853
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-50.0	-58.3
		Q1	0.00	0.00
		Q3	16.67	16.67
		Max.	75.0	100.0
		Mean	4.84	7.72
		SD	20.466	21.924

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	SF-36 Score	n	200	206
		Median	83.33	91.67
		Min.	25.0	8.3
		Max.	100.0	100.0
		Mean	78.96	84.30
		SD	22.556	19.506
	Change from Baseline	n	198	205
		Median	0.00	8.33
		Min.	-50.0	-50.0
		Q1	0.00	0.00
		Q3	16.67	25.00
		Max.	75.0	100.0
		Mean	5.39	12.40
		SD	22.727	22.165

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	SF-36 Score	n	200	206
		Median	91.67	91.67
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	82.83	83.70
		SD	21.779	20.681
	Change from Baseline	n	198	205
		Median	0.00	8.33
		Min.	-50.0	-50.0
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	75.0	100.0
		Mean	9.30	11.79
		SD	23.603	25.188

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	SF-36 Score	n	200	206
		Median	91.67	91.67
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	80.58	83.25
		SD	23.289	20.279
	Change from Baseline	n	198	205
		Median	0.00	8.33
		Min.	-75.0	-50.0
		Q1	0.00	0.00
		Q3	25.00	25.00
		Max.	75.0	100.0
		Mean	7.03	11.42
		SD	24.611	24.379

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	SF-36 Score	n	200	206
		Median	87.50	91.67
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	78.75	81.88
		SD	24.581	21.367
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-100.0	-50.0
		Q1	0.00	0.00
		Q3	16.67	25.00
		Max.	75.0	100.0
		Mean	5.18	10.45
		SD	26.410	23.963

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	SF-36 Score	n	200	206
		Median	83.33	91.67
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	77.13	82.24
		SD	25.736	22.067
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-100.0	-50.0
		Q1	-8.33	0.00
		Q3	16.67	25.00
		Max.	75.0	100.0
		Mean	3.41	10.33
		SD	26.776	25.253

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.59
Summary of SF-36 Domain Scores and Component Summary Scores

Domain or Component: Role Emotional (0-100 score)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	SF-36 Score	n	200	206
		Median	83.33	91.67
		Min.	0.0	0.0
		Max.	100.0	100.0
		Mean	76.96	81.80
		SD	25.229	22.201
	Change from Baseline	n	198	205
		Median	0.00	0.00
		Min.	-100.0	-50.0
		Q1	-8.33	0.00
		Q3	16.67	25.00
		Max.	83.3	100.0
		Mean	3.37	9.88
		SD	26.310	25.612

Note: Includes data reported up to Week 52.
Note: Lower scores indicate worse quality of life.
Note: Subjects with nasal surgery/sinuplasty prior to visit are assigned their worst observed score prior to nasal surgery/sinuplasty.
Note: Subjects with no surgery/sinuplasty who withdrew from study prior to visit are assigned their worst observed score prior to study withdrawal.

the missing visit.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	67.80 (1.262)	71.53 (1.240)
LS Mean Change (SE)	5.41 (1.262)	9.14 (1.240)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.73
95% CI		(0.24, 7.21)
p-value		0.036
Corrected Hedges g [3]		0.21
95% CI		(0.01, 0.41)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	70.77 (1.669)	76.40 (1.641)
LS Mean Change (SE)	8.38 (1.669)	14.01 (1.641)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.64
95% CI		(1.02, 10.25)
p-value		0.017
Corrected Hedges g [3]		0.24
95% CI		(0.04, 0.44)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	67.21 (1.999)	75.57 (1.964)
LS Mean Change (SE)	4.82 (1.999)	13.18 (1.964)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		8.36
95% CI		(2.84, 13.88)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.10, 0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	63.56 (2.325)	73.73 (2.285)
LS Mean Change (SE)	1.17 (2.325)	11.34 (2.285)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		10.17
95% CI		(3.75, 16.59)
p-value		0.002
Corrected Hedges g [3]		0.31
95% CI		(0.11, 0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	57.48 (2.541)	70.55 (2.497)
LS Mean Change (SE)	-4.91 (2.541)	8.16 (2.497)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		13.07
95% CI		(6.05, 20.09)
p-value		<0.001
Corrected Hedges g [3]		0.36
95% CI		(0.17, 0.56)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	54.08 (2.654)	70.57 (2.608)
LS Mean Change (SE)	-8.31 (2.654)	8.18 (2.608)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		16.49
95% CI		(9.16, 23.82)
p-value		<0.001
Corrected Hedges g [3]		0.44
95% CI		(0.24, 0.64)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.171
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Physical (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	51.79 (2.716)	69.25 (2.670)
LS Mean Change (SE)	-10.61 (2.716)	6.86 (2.670)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		17.46
95% CI		(9.96, 24.97)
p-value		<0.001
Corrected Hedges g [3]		0.46
95% CI		(0.26, 0.65)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	64.30 (1.339)	66.17 (1.316)
LS Mean Change (SE)	4.43 (1.339)	6.30 (1.316)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		1.87
95% CI		(-1.82, 5.56)
p-value		0.320
Corrected Hedges g [3]		0.10
95% CI		(-0.10, 0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	65.57 (1.766)	71.25 (1.736)
LS Mean Change (SE)	5.71 (1.766)	11.38 (1.736)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.67
95% CI		(0.80, 10.54)
p-value		0.023
Corrected Hedges g [3]		0.23
95% CI		(0.03, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	64.02 (2.016)	70.32 (1.982)
LS Mean Change (SE)	4.15 (2.016)	10.46 (1.982)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		6.31
95% CI		(0.75, 11.87)
p-value		0.026
Corrected Hedges g [3]		0.22
95% CI		(0.03, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	59.05 (2.284)	69.01 (2.245)
LS Mean Change (SE)	-0.82 (2.284)	9.15 (2.245)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		9.96
95% CI		(3.67, 16.26)
p-value		0.002
Corrected Hedges g [3]		0.31
95% CI		(0.11, 0.51)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	54.36 (2.450)	65.46 (2.408)
LS Mean Change (SE)	-5.50 (2.450)	5.60 (2.408)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.10
95% CI		(4.34, 17.86)
p-value		0.001
Corrected Hedges g [3]		0.32
95% CI		(0.12, 0.52)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	52.59 (2.602)	66.63 (2.557)
LS Mean Change (SE)	-7.27 (2.602)	6.76 (2.557)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		14.03
95% CI		(6.86, 21.21)
p-value		<0.001
Corrected Hedges g [3]		0.38
95% CI		(0.19, 0.58)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.172
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52: Bodily Pain (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	49.98 (2.646)	65.51 (2.601)
LS Mean Change (SE)	-9.88 (2.646)	5.65 (2.601)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		15.53
95% CI		(8.24, 22.83)
p-value		<0.001
Corrected Hedges g [3]		0.42
95% CI		(0.22, 0.61)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	51.35 (1.037)	54.59 (1.019)
LS Mean Change (SE)	5.07 (1.037)	8.31 (1.019)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.24
95% CI		(0.38, 6.10)
p-value		0.027
Corrected Hedges g [3]		0.22
95% CI		(0.03, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	50.78 (1.411)	58.59 (1.387)
LS Mean Change (SE)	4.51 (1.411)	12.32 (1.387)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.81
95% CI		(3.92, 11.70)
p-value		<0.001
Corrected Hedges g [3]		0.39
95% CI		(0.20, 0.59)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	49.62 (1.672)	56.49 (1.643)
LS Mean Change (SE)	3.34 (1.672)	10.21 (1.643)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		6.87
95% CI		(2.26, 11.48)
p-value		0.004
Corrected Hedges g [3]		0.29
95% CI		(0.10, 0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	45.90 (1.832)	55.21 (1.800)
LS Mean Change (SE)	-0.37 (1.832)	8.93 (1.800)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		9.30
95% CI		(4.25, 14.36)
p-value		<0.001
Corrected Hedges g [3]		0.36
95% CI		(0.16, 0.56)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	41.48 (1.962)	53.69 (1.928)
LS Mean Change (SE)	-4.79 (1.962)	7.42 (1.928)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		12.21
95% CI		(6.80, 17.62)
p-value		<0.001
Corrected Hedges g [3]		0.44
95% CI		(0.24, 0.64)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	37.91 (2.019)	52.26 (1.985)
LS Mean Change (SE)	-8.37 (2.019)	5.99 (1.985)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		14.35
95% CI		(8.78, 19.92)
p-value		<0.001
Corrected Hedges g [3]		0.50
95% CI		(0.31, 0.70)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.173
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
General Health (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	36.18 (2.060)	50.60 (2.024)
LS Mean Change (SE)	-10.10 (2.060)	4.32 (2.024)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		14.42
95% CI		(8.74, 20.10)
p-value		<0.001
Corrected Hedges g [3]		0.50
95% CI		(0.30, 0.69)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	51.52 (1.049)	54.72 (1.031)
LS Mean Change (SE)	4.37 (1.049)	7.57 (1.031)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.20
95% CI		(0.30, 6.09)
p-value		0.030
Corrected Hedges g [3]		0.22
95% CI		(0.02, 0.41)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	52.28 (1.484)	58.65 (1.459)
LS Mean Change (SE)	5.13 (1.484)	11.50 (1.459)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		6.37
95% CI		(2.27, 10.46)
p-value		0.002
Corrected Hedges g [3]		0.30
95% CI		(0.11, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	50.88 (1.690)	56.68 (1.661)
LS Mean Change (SE)	3.73 (1.690)	9.53 (1.661)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.80
95% CI		(1.14, 10.46)
p-value		0.015
Corrected Hedges g [3]		0.24
95% CI		(0.05, 0.44)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	47.33 (1.878)	55.20 (1.846)
LS Mean Change (SE)	0.18 (1.878)	8.06 (1.846)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.87
95% CI		(2.69, 13.06)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.10, 0.49)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	43.77 (2.030)	52.39 (1.995)
LS Mean Change (SE)	-3.38 (2.030)	5.25 (1.995)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		8.63
95% CI		(3.03, 14.23)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.11, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	41.51 (2.116)	52.17 (2.079)
LS Mean Change (SE)	-5.64 (2.116)	5.02 (2.079)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		10.66
95% CI		(4.82, 16.50)
p-value		<0.001
Corrected Hedges g [3]		0.36
95% CI		(0.16, 0.55)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.174
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Vitality (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	40.64 (2.193)	52.03 (2.155)
LS Mean Change (SE)	-6.51 (2.193)	4.88 (2.155)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.39
95% CI		(5.34, 17.44)
p-value		<0.001
Corrected Hedges g [3]		0.37
95% CI		(0.17, 0.57)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	74.97 (1.364)	77.23 (1.341)
LS Mean Change (SE)	6.45 (1.364)	8.71 (1.341)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.26
95% CI		(-1.50, 6.02)
p-value		0.238
Corrected Hedges g [3]		0.12
95% CI		(-0.08, 0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	74.01 (1.767)	78.21 (1.737)
LS Mean Change (SE)	5.49 (1.767)	9.69 (1.737)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		4.20
95% CI		(-0.67, 9.07)
p-value		0.091
Corrected Hedges g [3]		0.17
95% CI		(-0.03, 0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	72.39 (2.106)	78.13 (2.069)
LS Mean Change (SE)	3.88 (2.106)	9.61 (2.069)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.74
95% CI		(-0.07, 11.54)
p-value		0.053
Corrected Hedges g [3]		0.19
95% CI		(0.00, 0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	67.50 (2.378)	75.41 (2.337)
LS Mean Change (SE)	-1.01 (2.378)	6.89 (2.337)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.91
95% CI		(1.35, 14.46)
p-value		0.018
Corrected Hedges g [3]		0.24
95% CI		(0.04, 0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	60.36 (2.576)	71.52 (2.531)
LS Mean Change (SE)	-8.16 (2.576)	3.00 (2.531)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.16
95% CI		(4.06, 18.26)
p-value		0.002
Corrected Hedges g [3]		0.31
95% CI		(0.11, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	56.68 (2.708)	70.44 (2.662)
LS Mean Change (SE)	-11.84 (2.708)	1.92 (2.662)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		13.76
95% CI		(6.29, 21.22)
p-value		<0.001
Corrected Hedges g [3]		0.36
95% CI		(0.16, 0.56)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.175
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Social Functioning (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	55.80 (2.792)	69.21 (2.744)
LS Mean Change (SE)	-12.71 (2.792)	0.69 (2.744)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		13.41
95% CI		(5.71, 21.11)
p-value		<0.001
Corrected Hedges g [3]		0.34
95% CI		(0.14, 0.54)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	77.35 (1.298)	79.76 (1.276)
LS Mean Change (SE)	4.71 (1.298)	7.12 (1.276)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.41
95% CI		(-1.17, 5.99)
p-value		0.187
Corrected Hedges g [3]		0.13
95% CI		(-0.06, 0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	74.99 (1.688)	82.61 (1.659)
LS Mean Change (SE)	2.35 (1.688)	9.97 (1.659)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.62
95% CI		(2.97, 12.27)
p-value		0.001
Corrected Hedges g [3]		0.32
95% CI		(0.12, 0.52)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	76.09 (2.080)	79.72 (2.045)
LS Mean Change (SE)	3.45 (2.080)	7.07 (2.045)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.62
95% CI		(-2.11, 9.36)
p-value		0.215
Corrected Hedges g [3]		0.12
95% CI		(-0.07, 0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	68.89 (2.418)	76.59 (2.377)
LS Mean Change (SE)	-3.75 (2.418)	3.95 (2.377)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		7.70
95% CI		(1.04, 14.37)
p-value		0.024
Corrected Hedges g [3]		0.23
95% CI		(0.03, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	63.79 (2.646)	72.69 (2.601)
LS Mean Change (SE)	-8.85 (2.646)	0.05 (2.601)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		8.90
95% CI		(1.60, 16.20)
p-value		0.017
Corrected Hedges g [3]		0.24
95% CI		(0.04, 0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	59.30 (2.794)	71.10 (2.745)
LS Mean Change (SE)	-13.34 (2.794)	-1.54 (2.745)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		11.80
95% CI		(4.10, 19.50)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.10, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.176
Analysis of Mean Change from Baseline in SF-36 Domain Score at Week 52:
Role Emotional (0-100 Score)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	198	205
n [2]	198	205
LS Mean (SE)	57.28 (2.862)	69.39 (2.813)
LS Mean Change (SE)	-15.36 (2.862)	-3.25 (2.813)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		12.12
95% CI		(4.22, 20.01)
p-value		0.003
Corrected Hedges g [3]		0.30
95% CI		(0.10, 0.50)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Day 1	Work time missed due to health (%)	n	151	153
		Mean	5.0	4.9
		SD	12.88	12.91
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	148	151
		Mean	50.1	48.1
		SD	30.77	28.95
		Median	55.0	50.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	151	153
		Mean	50.8	49.5
		SD	31.82	29.76
		Median	57.1	50.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	198	204
		Mean	53.2	53.4
		SD	29.07	27.99
		Median	60.0	60.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 4	Work time missed due to health (%)	n	145	150
		Mean	6.2	4.9
		SD	17.89	13.55
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	139	147
		Mean	38.8	33.6
		SD	28.70	25.48
		Median	30.0	30.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	145	150
		Mean	41.0	35.4
		SD	30.89	27.30
		Median	40.0	30.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	198	204
		Mean	41.5	37.6
		SD	28.46	25.36
		Median	40.0	40.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 8	Work time missed due to health (%)	n	143	146
		Mean	5.7	5.7
		SD	15.61	15.09
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	136	138
		Mean	32.5	29.6
		SD	27.75	24.28
		Median	30.0	30.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	143	146
		Mean	34.2	31.5
		SD	29.68	26.98
		Median	30.0	30.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	196	203
		Mean	36.7	31.2
		SD	27.84	25.25
		Median	30.0	30.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 12	Work time missed due to health (%)	n	137	143
		Mean	8.0	4.1
		SD	20.77	13.97
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	130	138
		Mean	33.5	27.0
		SD	28.74	25.50
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	137	143
		Mean	37.4	28.8
		SD	31.16	27.89
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	193	203
		Mean	36.1	28.6
		SD	29.53	25.41
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 16	Work time missed due to health (%)	n	134	146
		Mean	6.6	4.3
		SD	17.93	11.84
		Median	0.0	0.0
		Min.	0	0
		Max.	100	59
	Impairment while working due to health (%)	n	130	144
		Mean	29.7	23.3
		SD	27.67	22.72
		Median	20.0	20.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	134	146
		Mean	32.7	26.0
		SD	30.51	24.38
		Median	25.9	20.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	193	201
		Mean	32.6	25.9
		SD	29.02	23.61
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 20	Work time missed due to health (%)	n	139	141
		Mean	8.0	5.5
		SD	20.10	17.01
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	131	134
		Mean	29.8	23.7
		SD	28.66	24.57
		Median	20.0	20.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	139	141
		Mean	32.5	25.7
		SD	31.39	27.44
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	191	196
		Mean	33.0	24.5
		SD	29.22	24.61
		Median	30.0	20.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 24	Work time missed due to health (%)	n	135	140
		Mean	5.8	5.8
		SD	16.22	18.19
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	134	133
		Mean	29.1	19.5
		SD	28.82	23.53
		Median	20.0	10.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	135	140
		Mean	32.1	22.8
		SD	30.46	27.14
		Median	23.8	10.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	191	195
		Mean	29.8	22.3
		SD	28.68	22.22
		Median	20.0	20.0
		Min.	0	0
		Max.	100	90

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 28	Work time missed due to health (%)	n	130	137
		Mean	7.3	3.9
		SD	19.47	13.42
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	127	130
		Mean	25.7	22.3
		SD	27.99	24.23
		Median	20.0	20.0
		Min.	0	0
		Max.	100	100
	Overall work impairment due to health (%)	n	130	137
		Mean	29.7	24.1
		SD	30.87	26.34
		Median	20.0	20.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	188	193
		Mean	28.8	24.5
		SD	28.55	25.45
		Median	20.0	20.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 32	Work time missed due to health (%)	n	122	133
		Mean	6.0	4.2
		SD	19.49	14.97
		Median	0.0	0.0
		Min.	0	0
		Max.	100	96
	Impairment while working due to health (%)	n	115	127
		Mean	26.7	21.6
		SD	28.49	23.35
		Median	20.0	10.0
		Min.	0	0
		Max.	100	90
	Overall work impairment due to health (%)	n	122	133
		Mean	28.5	23.3
		SD	30.72	26.45
		Median	20.0	10.0
		Min.	0	0
		Max.	100	98
	Activity impairment due to health (%)	n	184	189
		Mean	28.4	22.5
		SD	28.48	23.49
		Median	20.0	10.0
		Min.	0	0
		Max.	100	80

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 36	Work time missed due to health (%)	n	121	134
		Mean	4.8	3.9
		SD	16.77	12.97
		Median	0.0	0.0
		Min.	0	0
		Max.	100	100
	Impairment while working due to health (%)	n	117	127
		Mean	21.9	20.6
		SD	24.67	23.58
		Median	10.0	10.0
		Min.	0	0
		Max.	90	100
	Overall work impairment due to health (%)	n	121	134
		Mean	24.9	22.2
		SD	27.91	25.98
		Median	20.0	10.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	182	189
		Mean	26.9	22.8
		SD	26.14	24.50
		Median	20.0	20.0
		Min.	0	0
		Max.	90	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 40	Work time missed due to health (%)	n	121	130
		Mean	4.9	5.8
		SD	16.25	14.77
		Median	0.0	0.0
		Min.	0	0
		Max.	100	60
	Impairment while working due to health (%)	n	112	127
		Mean	22.7	20.9
		SD	25.47	23.31
		Median	15.0	10.0
		Min.	0	0
		Max.	80	90
	Overall work impairment due to health (%)	n	121	130
		Mean	25.1	24.1
		SD	27.60	26.64
		Median	20.0	10.0
		Min.	0	0
		Max.	100	91
	Activity impairment due to health (%)	n	183	187
		Mean	27.4	21.6
		SD	27.55	22.61
		Median	20.0	20.0
		Min.	0	0
		Max.	100	90

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 44	Work time missed due to health (%)	n	120	131
		Mean	6.2	4.9
		SD	19.91	13.95
		Median	0.0	0.0
		Min.	0	0
		Max.	100	61
	Impairment while working due to health (%)	n	112	129
		Mean	22.8	19.5
		SD	25.41	23.60
		Median	20.0	10.0
		Min.	0	0
		Max.	90	100
	Overall work impairment due to health (%)	n	120	131
		Mean	26.4	21.9
		SD	29.08	26.65
		Median	20.0	10.0
		Min.	0	0
		Max.	100	100
	Activity impairment due to health (%)	n	182	186
		Mean	28.1	20.1
		SD	28.73	23.20
		Median	20.0	10.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 48	Work time missed due to health (%)	n	121	133
		Mean	4.5	5.3
		SD	15.50	15.63
		Median	0.0	0.0
		Min.	0	0
		Max.	81	77
	Impairment while working due to health (%)	n	120	129
		Mean	22.8	19.8
		SD	25.54	22.74
		Median	15.0	10.0
		Min.	0	0
		Max.	100	80
	Overall work impairment due to health (%)	n	121	133
		Mean	25.2	22.8
		SD	28.00	26.09
		Median	20.0	10.0
		Min.	0	0
		Max.	100	88
	Activity impairment due to health (%)	n	178	185
		Mean	27.0	19.3
		SD	27.63	22.17
		Median	20.0	10.0
		Min.	0	0
		Max.	100	90

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 2.60
Summary of Work Productivity and Activity Impairment Questionnaire (WPAI)

Visit			Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Week 52	Work time missed due to health (%)	n	115	130
		Mean	6.4	4.3
		SD	17.59	12.63
		Median	0.0	0.0
		Min.	0	0
		Max.	100	51
	Impairment while working due to health (%)	n	113	128
		Mean	22.9	18.5
		SD	25.45	23.71
		Median	10.0	10.0
		Min.	0	0
		Max.	100	90
	Overall work impairment due to health (%)	n	115	130
		Mean	27.0	20.6
		SD	28.69	26.40
		Median	20.0	10.0
		Min.	0	0
		Max.	100	91
	Activity impairment due to health (%)	n	176	185
		Mean	27.1	19.2
		SD	28.14	24.09
		Median	20.0	10.0
		Min.	0	0
		Max.	100	100

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	142	146
LS Mean (SE)	6.1 (1.33)	4.9 (1.31)
LS Mean Change (SE)	1.1 (1.33)	-0.1 (1.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.21
95% CI		(-4.87, 2.46)
p-value		0.517
Corrected Hedges g [3]		-0.08
95% CI		(-0.31, 0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	138	141
LS Mean (SE)	6.0 (1.28)	5.5 (1.27)
LS Mean Change (SE)	0.9 (1.28)	0.4 (1.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.49
95% CI		(-4.03, 3.06)
p-value		0.787
Corrected Hedges g [3]		-0.03
95% CI		(-0.27, 0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	132	139
LS Mean (SE)	8.4 (1.55)	4.2 (1.51)
LS Mean Change (SE)	3.4 (1.55)	-0.8 (1.51)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.22
95% CI		(-8.47, 0.03)
p-value		0.052
Corrected Hedges g [3]		-0.24
95% CI		(-0.48, 0.00)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	129	140
LS Mean (SE)	7.4 (1.36)	4.6 (1.31)
LS Mean Change (SE)	2.4 (1.36)	-0.4 (1.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.83
95% CI		(-6.54, 0.88)
p-value		0.135
Corrected Hedges g [3]		-0.18
95% CI		(-0.42, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	133	135
LS Mean (SE)	7.8 (1.59)	5.3 (1.58)
LS Mean Change (SE)	2.7 (1.59)	0.3 (1.58)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.45
95% CI		(-6.86, 1.97)
p-value		0.277
Corrected Hedges g [3]		-0.13
95% CI		(-0.37, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	129	134
LS Mean (SE)	5.6 (1.49)	6.0 (1.46)
LS Mean Change (SE)	0.5 (1.49)	0.9 (1.46)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.39
95% CI		(-3.72, 4.50)
p-value		0.853
Corrected Hedges g [3]		0.02
95% CI		(-0.22, 0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	124	129
LS Mean (SE)	7.2 (1.48)	3.7 (1.45)
LS Mean Change (SE)	2.2 (1.48)	-1.3 (1.45)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.51
95% CI		(-7.59, 0.57)
p-value		0.092
Corrected Hedges g [3]		-0.21
95% CI		(-0.46, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	119	126
LS Mean (SE)	6.7 (1.57)	4.4 (1.53)
LS Mean Change (SE)	1.6 (1.57)	-0.6 (1.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.27
95% CI		(-6.60, 2.05)
p-value		0.302
Corrected Hedges g [3]		-0.13
95% CI		(-0.38, 0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	126
LS Mean (SE)	6.4 (1.44)	4.1 (1.39)
LS Mean Change (SE)	1.3 (1.44)	-1.0 (1.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.29
95% CI		(-6.23, 1.64)
p-value		0.252
Corrected Hedges g [3]		-0.15
95% CI		(-0.40, 0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	122
LS Mean (SE)	6.1 (1.43)	5.8 (1.39)
LS Mean Change (SE)	1.0 (1.43)	0.7 (1.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.30
95% CI		(-4.25, 3.64)
p-value		0.880
Corrected Hedges g [3]		-0.02
95% CI		(-0.27, 0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	116	123
LS Mean (SE)	7.9 (1.64)	5.4 (1.58)
LS Mean Change (SE)	2.8 (1.64)	0.4 (1.58)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.43
95% CI		(-6.92, 2.07)
p-value		0.288
Corrected Hedges g [3]		-0.14
95% CI		(-0.39, 0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	124
LS Mean (SE)	4.9 (1.50)	5.7 (1.44)
LS Mean Change (SE)	-0.1 (1.50)	0.7 (1.44)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.81
95% CI		(-3.28, 4.90)
p-value		0.696
Corrected Hedges g [3]		0.05
95% CI		(-0.20, 0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.178
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	111	121
LS Mean (SE)	7.9 (1.46)	4.7 (1.40)
LS Mean Change (SE)	2.9 (1.46)	-0.3 (1.40)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.18
95% CI		(-7.16, 0.81)
p-value		0.118
Corrected Hedges g [3]		-0.21
95% CI		(-0.46, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	133	142
LS Mean (SE)	38.4 (1.93)	34.8 (1.87)
LS Mean Change (SE)	-10.7 (1.93)	-14.3 (1.87)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.63
95% CI		(-8.92, 1.66)
p-value		0.178
Corrected Hedges g [3]		-0.16
95% CI		(-0.40, 0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	128	132
LS Mean (SE)	33.0 (1.93)	30.1 (1.90)
LS Mean Change (SE)	-16.1 (1.93)	-18.9 (1.90)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.86
95% CI		(-8.19, 2.47)
p-value		0.291
Corrected Hedges g [3]		-0.13
95% CI		(-0.37, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	122	133
LS Mean (SE)	32.7 (2.20)	27.3 (2.13)
LS Mean Change (SE)	-16.3 (2.20)	-21.8 (2.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.44
95% CI		(-11.49, 0.60)
p-value		0.077
Corrected Hedges g [3]		-0.22
95% CI		(-0.47, 0.02)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	122	137
LS Mean (SE)	30.1 (2.01)	24.4 (1.95)
LS Mean Change (SE)	-18.9 (2.01)	-24.6 (1.95)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.72
95% CI		(-11.24, -0.21)
p-value		0.042
Corrected Hedges g [3]		-0.25
95% CI		(-0.50, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	122	127
LS Mean (SE)	28.3 (2.11)	25.2 (2.07)
LS Mean Change (SE)	-20.8 (2.11)	-23.9 (2.07)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.08
95% CI		(-8.92, 2.75)
p-value		0.299
Corrected Hedges g [3]		-0.13
95% CI		(-0.38, 0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	125	127
LS Mean (SE)	28.3 (2.12)	20.8 (2.08)
LS Mean Change (SE)	-20.8 (2.12)	-28.3 (2.08)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.54
95% CI		(-13.39, -1.68)
p-value		0.012
Corrected Hedges g [3]		-0.32
95% CI		(-0.57, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	118	122
LS Mean (SE)	25.3 (2.12)	24.0 (2.08)
LS Mean Change (SE)	-23.7 (2.12)	-25.1 (2.08)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.37
95% CI		(-7.22, 4.49)
p-value		0.646
Corrected Hedges g [3]		-0.06
95% CI		(-0.31, 0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	110	120
LS Mean (SE)	26.9 (2.10)	22.6 (2.04)
LS Mean Change (SE)	-22.2 (2.10)	-26.4 (2.04)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.24
95% CI		(-10.01, 1.54)
p-value		0.150
Corrected Hedges g [3]		-0.19
95% CI		(-0.45, 0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	111	118
LS Mean (SE)	24.0 (2.05)	22.5 (2.01)
LS Mean Change (SE)	-25.1 (2.05)	-26.6 (2.01)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.50
95% CI		(-7.14, 4.15)
p-value		0.603
Corrected Hedges g [3]		-0.07
95% CI		(-0.33, 0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	106	119
LS Mean (SE)	24.0 (2.03)	22.0 (1.97)
LS Mean Change (SE)	-25.0 (2.03)	-27.1 (1.97)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.08
95% CI		(-7.66, 3.49)
p-value		0.463
Corrected Hedges g [3]		-0.10
95% CI		(-0.36, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	106	121
LS Mean (SE)	24.7 (2.07)	21.2 (2.00)
LS Mean Change (SE)	-24.4 (2.07)	-27.9 (2.00)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.51
95% CI		(-9.18, 2.16)
p-value		0.224
Corrected Hedges g [3]		-0.16
95% CI		(-0.42, 0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	114	119
LS Mean (SE)	23.8 (1.99)	21.2 (1.94)
LS Mean Change (SE)	-25.3 (1.99)	-27.9 (1.94)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.60
95% CI		(-8.08, 2.87)
p-value		0.350
Corrected Hedges g [3]		-0.12
95% CI		(-0.38, 0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.186
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	144	150
n [2]	107	118
LS Mean (SE)	23.9 (2.06)	20.6 (2.00)
LS Mean Change (SE)	-25.2 (2.06)	-28.4 (2.00)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.21
95% CI		(-8.86, 2.43)
p-value		0.264
Corrected Hedges g [3]		-0.15
95% CI		(-0.41, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Protocol: 205687
Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	142	146
LS Mean (SE)	40.7 (2.06)	36.3 (2.03)
LS Mean Change (SE)	-9.6 (2.06)	-14.1 (2.03)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.45
95% CI		(-10.14, 1.24)
p-value		0.125
Corrected Hedges g [3]		-0.18
95% CI		(-0.41, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	138	141
LS Mean (SE)	34.4 (2.12)	31.9 (2.10)
LS Mean Change (SE)	-16.0 (2.12)	-18.5 (2.10)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.53
95% CI		(-8.40, 3.34)
p-value		0.398
Corrected Hedges g [3]		-0.10
95% CI		(-0.34, 0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	132	139
LS Mean (SE)	37.1 (2.39)	29.0 (2.34)
LS Mean Change (SE)	-13.3 (2.39)	-21.3 (2.34)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.02
95% CI		(-14.61, -1.42)
p-value		0.017
Corrected Hedges g [3]		-0.29
95% CI		(-0.53, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Protocol: 205687
Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	129	140
LS Mean (SE)	33.5 (2.19)	27.3 (2.13)
LS Mean Change (SE)	-16.9 (2.19)	-23.0 (2.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.17
95% CI		(-12.19, -0.15)
p-value		0.045
Corrected Hedges g [3]		-0.25
95% CI		(-0.49, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	133	135
LS Mean (SE)	32.1 (2.35)	26.5 (2.33)
LS Mean Change (SE)	-18.3 (2.35)	-23.9 (2.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.64
95% CI		(-12.15, 0.87)
p-value		0.089
Corrected Hedges g [3]		-0.21
95% CI		(-0.45, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	129	134
LS Mean (SE)	31.3 (2.35)	23.9 (2.31)
LS Mean Change (SE)	-19.1 (2.35)	-26.5 (2.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.40
95% CI		(-13.89, -0.91)
p-value		0.026
Corrected Hedges g [3]		-0.28
95% CI		(-0.52, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	124	129
LS Mean (SE)	29.4 (2.36)	25.2 (2.33)
LS Mean Change (SE)	-21.0 (2.36)	-25.2 (2.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.16
95% CI		(-10.69, 2.37)
p-value		0.211
Corrected Hedges g [3]		-0.16
95% CI		(-0.40, 0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	119	126
LS Mean (SE)	28.9 (2.35)	24.3 (2.31)
LS Mean Change (SE)	-21.5 (2.35)	-26.1 (2.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.56
95% CI		(-11.05, 1.93)
p-value		0.168
Corrected Hedges g [3]		-0.18
95% CI		(-0.43, 0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	126
LS Mean (SE)	27.6 (2.30)	23.7 (2.25)
LS Mean Change (SE)	-22.7 (2.30)	-26.7 (2.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.94
95% CI		(-10.28, 2.40)
p-value		0.222
Corrected Hedges g [3]		-0.16
95% CI		(-0.41, 0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	122
LS Mean (SE)	26.6 (2.27)	24.9 (2.23)
LS Mean Change (SE)	-23.7 (2.27)	-25.5 (2.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.75
95% CI		(-8.02, 4.51)
p-value		0.582
Corrected Hedges g [3]		-0.07
95% CI		(-0.32, 0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	116	123
LS Mean (SE)	28.4 (2.35)	23.7 (2.30)
LS Mean Change (SE)	-22.0 (2.35)	-26.7 (2.30)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.69
95% CI		(-11.16, 1.77)
p-value		0.154
Corrected Hedges g [3]		-0.18
95% CI		(-0.44, 0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	117	124
LS Mean (SE)	26.5 (2.31)	24.0 (2.26)
LS Mean Change (SE)	-23.9 (2.31)	-26.3 (2.26)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.46
95% CI		(-8.82, 3.91)
p-value		0.448
Corrected Hedges g [3]		-0.10
95% CI		(-0.35, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.194
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	148	151
n [2]	111	121
LS Mean (SE)	28.5 (2.35)	22.7 (2.29)
LS Mean Change (SE)	-21.9 (2.35)	-27.7 (2.29)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.80
95% CI		(-12.25, 0.64)
p-value		0.078
Corrected Hedges g [3]		-0.23
95% CI		(-0.49, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Protocol: 205687
Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 4

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	196	203
LS Mean (SE)	41.9 (1.63)	37.5 (1.60)
LS Mean Change (SE)	-11.4 (1.63)	-15.8 (1.60)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.40
95% CI		(-8.89, 0.09)
p-value		0.055
Corrected Hedges g [3]		-0.19
95% CI		(-0.39, 0.00)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 8

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	193	201
LS Mean (SE)	36.6 (1.67)	31.2 (1.64)
LS Mean Change (SE)	-16.7 (1.67)	-22.0 (1.64)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.38
95% CI		(-9.98, -0.78)
p-value		0.022
Corrected Hedges g [3]		-0.23
95% CI		(-0.43, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 12

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	190	201
LS Mean (SE)	36.5 (1.84)	28.5 (1.79)
LS Mean Change (SE)	-16.7 (1.84)	-24.7 (1.79)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.99
95% CI		(-13.04, -2.94)
p-value		0.002
Corrected Hedges g [3]		-0.31
95% CI		(-0.51, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 16

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	190	199
LS Mean (SE)	33.0 (1.76)	25.9 (1.72)
LS Mean Change (SE)	-20.2 (1.76)	-27.3 (1.72)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.11
95% CI		(-11.94, -2.27)
p-value		0.004
Corrected Hedges g [3]		-0.29
95% CI		(-0.49, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 20

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	188	194
LS Mean (SE)	33.1 (1.73)	25.1 (1.70)
LS Mean Change (SE)	-20.1 (1.73)	-28.2 (1.70)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.05
95% CI		(-12.83, -3.28)
p-value		<0.001
Corrected Hedges g [3]		-0.34
95% CI		(-0.54, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 24

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	189	193
LS Mean (SE)	30.1 (1.70)	22.6 (1.68)
LS Mean Change (SE)	-23.2 (1.70)	-30.6 (1.68)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.43
95% CI		(-12.13, -2.73)
p-value		0.002
Corrected Hedges g [3]		-0.32
95% CI		(-0.52, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 28

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	187	191
LS Mean (SE)	29.3 (1.80)	24.7 (1.77)
LS Mean Change (SE)	-24.0 (1.80)	-28.6 (1.77)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.59
95% CI		(-9.55, 0.38)
p-value		0.070
Corrected Hedges g [3]		-0.19
95% CI		(-0.39, 0.02)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 32

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	183	187
LS Mean (SE)	29.0 (1.72)	22.5 (1.70)
LS Mean Change (SE)	-24.2 (1.72)	-30.7 (1.70)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.51
95% CI		(-11.27, -1.76)
p-value		0.007
Corrected Hedges g [3]		-0.28
95% CI		(-0.48, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 36

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	181	187
LS Mean (SE)	27.6 (1.72)	23.5 (1.69)
LS Mean Change (SE)	-25.7 (1.72)	-29.8 (1.69)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.08
95% CI		(-8.82, 0.66)
p-value		0.092
Corrected Hedges g [3]		-0.18
95% CI		(-0.38, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	182	185
LS Mean (SE)	28.2 (1.64)	22.1 (1.62)
LS Mean Change (SE)	-25.0 (1.64)	-31.1 (1.62)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.11
95% CI		(-10.65, -1.57)
p-value		0.008
Corrected Hedges g [3]		-0.28
95% CI		(-0.48, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 44

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	181	184
LS Mean (SE)	28.8 (1.77)	20.9 (1.75)
LS Mean Change (SE)	-24.5 (1.77)	-32.4 (1.75)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.89
95% CI		(-12.78, -3.00)
p-value		0.002
Corrected Hedges g [3]		-0.33
95% CI		(-0.54, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 48

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	177	183
LS Mean (SE)	27.5 (1.68)	20.1 (1.66)
LS Mean Change (SE)	-25.8 (1.68)	-33.1 (1.66)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.35
95% CI		(-12.00, -2.71)
p-value		0.002
Corrected Hedges g [3]		-0.33
95% CI		(-0.54, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.202
Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%)
Mixed Model Repeated Measures

Visit: Week 52

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
n [1]	197	204
n [2]	175	183
LS Mean (SE)	28.0 (1.77)	20.2 (1.74)
LS Mean Change (SE)	-25.3 (1.77)	-33.1 (1.74)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.80
95% CI		(-12.67, -2.93)
p-value		0.002
Corrected Hedges g [3]		-0.33
95% CI		(-0.54, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.2
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	5.8 (0.28)	5.1 (0.25)
LS Mean Change (SE)	0.4 (0.28)	-0.3 (0.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.73
95% CI		(-1.47, 0.00)
p-value		0.051
Corrected Hedges g [3]		-0.37
95% CI		(-0.74, 0.00)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.2
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	5.9 (0.18)	4.8 (0.19)
LS Mean Change (SE)	0.4 (0.18)	-0.7 (0.19)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-1.60, -0.55)
p-value		<0.001
Corrected Hedges g [3]		-0.53
95% CI		(-0.79, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.2
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	5.1 (0.39)	4.5 (0.38)
LS Mean Change (SE)	-0.4 (0.39)	-1.0 (0.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.60
95% CI		(-1.69, 0.49)
p-value		0.272
Corrected Hedges g [3]		-0.29
95% CI		(-0.82, 0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.3
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	5.7 (0.18)	5.1 (0.17)
LS Mean Change (SE)	0.1 (0.18)	-0.5 (0.17)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.66
95% CI		(-1.15, -0.17)
p-value		0.008
Corrected Hedges g [3]		-0.33
95% CI		(-0.57, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.3
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	5.8 (0.23)	4.5 (0.25)
LS Mean Change (SE)	0.6 (0.23)	-0.8 (0.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.34
95% CI		(-2.01, -0.68)
p-value		<0.001
Corrected Hedges g [3]		-0.67
95% CI		(-1.00, -0.33)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.4
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	5.6 (0.23)	4.7 (0.23)
LS Mean Change (SE)	0.3 (0.23)	-0.6 (0.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.89
95% CI		(-1.52, -0.25)
p-value		0.006
Corrected Hedges g [3]		-0.42
95% CI		(-0.73, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.4
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	6.7 (0.38)	5.3 (0.38)
LS Mean Change (SE)	1.0 (0.38)	-0.3 (0.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.32
95% CI		(-2.42, -0.23)
p-value		0.018
Corrected Hedges g [3]		-0.64
95% CI		(-1.18, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.4
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	5.7 (0.21)	4.9 (0.20)
LS Mean Change (SE)	0.1 (0.21)	-0.7 (0.20)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.79
95% CI		(-1.37, -0.21)
p-value		0.008
Corrected Hedges g [3]		-0.40
95% CI		(-0.70, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.5
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	6.2 (0.25)	4.7 (0.29)
LS Mean Change (SE)	0.6 (0.25)	-0.9 (0.29)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.49
95% CI		(-2.25, -0.73)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.15, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.5
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	5.6 (0.17)	4.9 (0.16)
LS Mean Change (SE)	0.2 (0.17)	-0.5 (0.16)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.68
95% CI		(-1.15, -0.22)
p-value		0.004
Corrected Hedges g [3]		-0.33
95% CI		(-0.56, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.6
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	5.6 (0.21)	4.8 (0.18)
LS Mean Change (SE)	0.1 (0.21)	-0.7 (0.18)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.84
95% CI		(-1.40, -0.28)
p-value		0.003
Corrected Hedges g [3]		-0.44
95% CI		(-0.73, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.6
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	5.6 (0.29)	4.9 (0.29)
LS Mean Change (SE)	0.3 (0.29)	-0.4 (0.29)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.73
95% CI		(-1.55, 0.09)
p-value		0.081
Corrected Hedges g [3]		-0.36
95% CI		(-0.77, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.6
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	6.1 (0.26)	5.1 (0.31)
LS Mean Change (SE)	0.5 (0.26)	-0.5 (0.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.97
95% CI		(-1.77, -0.16)
p-value		0.019
Corrected Hedges g [3]		-0.43
95% CI		(-0.79, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.7
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	4.3 (0.31)	4.6 (0.33)
LS Mean Change (SE)	0.7 (0.31)	1.0 (0.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.32
95% CI		(-0.58, 1.22)
p-value		0.482
Corrected Hedges g [3]		0.16
95% CI		(-0.29, 0.62)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.7
Subgroup Analysis of Mean Change from Baseline Total Endoscopic Nasal Polyps Score (Centrally Read) at Week 52 by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	6.1 (0.16)	5.0 (0.15)
LS Mean Change (SE)	0.2 (0.16)	-0.9 (0.15)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.15
95% CI		(-1.59, -0.71)
p-value		<0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.79, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.11
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	52	64
Responder [1]	17 (33%)	32 (50%)
Non-responder	35 (67%)	32 (50%)
No change/worsening	16 (31%)	19 (30%)
Nasal surgery/sinuplasty prior to visit	10 (19%)	6 (9%)
Withdrawal from study prior to visit	7 (13%)	6 (9%)
Missing visit	2 (4%)	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.42 (0.19, 0.94)
p-value		0.034
Inverse unadjusted odds ratio (95% CI) [3]		0.49 (0.21, 1.11)
Inverse relative risk (95% CI) [4]		0.65 (0.38, 1.04)
Risk difference (95% CI) [4]		-0.17 (-0.35, 0.01)
Fisher’s Exact p-value (2-sided)		0.089

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.11
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	122	113
Responder [1]	30 (25%)	56 (50%)
Non-responder	92 (75%)	57 (50%)
No change/worsening	50 (41%)	35 (31%)
Nasal surgery/sinuplasty prior to visit	32 (26%)	10 (9%)
Withdrawal from study prior to visit	8 (7%)	7 (6%)
Missing visit	2 (2%)	5 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.32 (0.18, 0.57)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.33 (0.18, 0.60)
Inverse relative risk (95% CI) [4]		0.50 (0.32, 0.72)
Risk difference (95% CI) [4]		-0.25 (-0.37, -0.12)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.11
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Responder [1]	10 (37%)	16 (55%)
Non-responder	17 (63%)	13 (45%)
No change/worsening	11 (41%)	8 (28%)
Nasal surgery/sinuplasty prior to visit	4 (15%)	2 (7%)
Withdrawal from study prior to visit	0	3 (10%)
Missing visit	2 (7%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.47 (0.15, 1.44)
p-value		0.187
Inverse unadjusted odds ratio (95% CI) [3]		0.48 (0.14, 1.58)
Inverse relative risk (95% CI) [4]		0.67 (0.33, 1.21)
Risk difference (95% CI) [4]		-0.18 (-0.43, 0.09)
Fisher’s Exact p-value (2-sided)		0.193

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.12
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	125	139
Responder [1]	36 (29%)	65 (47%)
Non-responder	89 (71%)	74 (53%)
No change/worsening	50 (40%)	44 (32%)
Nasal surgery/sinuplasty prior to visit	28 (22%)	15 (11%)
Withdrawal from study prior to visit	10 (8%)	11 (8%)
Missing visit	1 (<1%)	4 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.43 (0.25, 0.73)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [3]		0.46 (0.27, 0.79)
Inverse relative risk (95% CI) [4]		0.62 (0.41, 0.88)
Risk difference (95% CI) [4]		-0.18 (-0.29, -0.05)
Fisher’s Exact p-value (2-sided)		0.003

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.12
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	76	67
Responder [1]	21 (28%)	39 (58%)
Non-responder	55 (72%)	28 (42%)
No change/worsening	27 (36%)	18 (27%)
Nasal surgery/sinuplasty prior to visit	18 (24%)	3 (4%)
Withdrawal from study prior to visit	5 (7%)	5 (7%)
Missing visit	5 (7%)	2 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.25 (0.12, 0.53)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.28 (0.13, 0.58)
Inverse relative risk (95% CI) [4]		0.47 (0.28, 0.73)
Risk difference (95% CI) [4]		-0.31 (-0.46, -0.13)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Table 27.13
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Responder [1]	24 (28%)	45 (52%)
Non-responder	61 (72%)	41 (48%)
No change/worsening	36 (42%)	25 (29%)
Nasal surgery/sinuplasty prior to visit	18 (21%)	5 (6%)
Withdrawal from study prior to visit	3 (4%)	8 (9%)
Missing visit	4 (5%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.35 (0.19, 0.67)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [3]		0.36 (0.18, 0.71)
Inverse relative risk (95% CI) [4]		0.54 (0.33, 0.82)
Risk difference (95% CI) [4]		-0.24 (-0.38, -0.07)
Fisher’s Exact p-value (2-sided)		0.002

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.13
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	28	28
Responder [1]	6 (21%)	11 (39%)
Non-responder	22 (79%)	17 (61%)
No change/worsening	4 (14%)	8 (29%)
Nasal surgery/sinuplasty prior to visit	10 (36%)	3 (11%)
Withdrawal from study prior to visit	8 (29%)	5 (18%)
Missing visit	0	1 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.37 (0.11, 1.26)
p-value		0.112
Inverse unadjusted odds ratio (95% CI) [3]		0.43 (0.11, 1.57)
Inverse relative risk (95% CI) [4]		0.55 (0.19, 1.30)
Risk difference (95% CI) [4]		-0.18 (-0.41, 0.07)
Fisher's Exact p-value (2-sided)		0.245

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.13
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	88	92
Responder [1]	27 (31%)	48 (52%)
Non-responder	61 (69%)	44 (48%)
No change/worsening	37 (42%)	29 (32%)
Nasal surgery/sinuplasty prior to visit	18 (20%)	10 (11%)
Withdrawal from study prior to visit	4 (5%)	3 (3%)
Missing visit	2 (2%)	2 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.37 (0.19, 0.69)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [3]		0.41 (0.21, 0.78)
Inverse relative risk (95% CI) [4]		0.59 (0.38, 0.88)
Risk difference (95% CI) [4]		-0.21 (-0.36, -0.05)
Fisher’s Exact p-value (2-sided)		0.004

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.14
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	63	45
Responder [1]	13 (21%)	23 (51%)
Non-responder	50 (79%)	22 (49%)
No change/worsening	24 (38%)	13 (29%)
Nasal surgery/sinuplasty prior to visit	18 (29%)	5 (11%)
Withdrawal from study prior to visit	6 (10%)	3 (7%)
Missing visit	2 (3%)	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.24 (0.10, 0.58)
p-value		0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.25 (0.10, 0.63)
Inverse relative risk (95% CI) [4]		0.40 (0.21, 0.72)
Risk difference (95% CI) [4]		-0.30 (-0.48, -0.11)
Fisher's Exact p-value (2-sided)		0.002

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.14
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	138	161
Responder [1]	44 (32%)	81 (50%)
Non-responder	94 (68%)	80 (50%)
No change/worsening	53 (38%)	49 (30%)
Nasal surgery/sinuplasty prior to visit	28 (20%)	13 (8%)
Withdrawal from study prior to visit	9 (7%)	13 (8%)
Missing visit	4 (3%)	5 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.41 (0.25, 0.68)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.46 (0.28, 0.76)
Inverse relative risk (95% CI) [4]		0.63 (0.45, 0.86)
Risk difference (95% CI) [4]		-0.18 (-0.29, -0.06)
Fisher's Exact p-value (2-sided)		0.001

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.15
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	81	108
Responder [1]	29 (36%)	60 (56%)
Non-responder	52 (64%)	48 (44%)
No change/worsening	29 (36%)	32 (30%)
Nasal surgery/sinuplasty prior to visit	16 (20%)	6 (6%)
Withdrawal from study prior to visit	4 (5%)	8 (7%)
Missing visit	3 (4%)	2 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.42 (0.23, 0.77)
p-value		0.005
Inverse unadjusted odds ratio (95% CI) [3]		0.45 (0.24, 0.84)
Inverse relative risk (95% CI) [4]		0.64 (0.42, 0.96)
Risk difference (95% CI) [4]		-0.20 (-0.33, -0.03)
Fisher’s Exact p-value (2-sided)		0.008

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Table 27.15
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	47	47
Responder [1]	15 (32%)	19 (40%)
Non-responder	32 (68%)	28 (60%)
No change/worsening	18 (38%)	16 (34%)
Nasal surgery/sinuplasty prior to visit	9 (19%)	5 (11%)
Withdrawal from study prior to visit	5 (11%)	7 (15%)
Missing visit	0	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.68 (0.29, 1.60)
p-value		0.372
Inverse unadjusted odds ratio (95% CI) [3]		0.69 (0.27, 1.75)
Inverse relative risk (95% CI) [4]		0.79 (0.43, 1.39)
Risk difference (95% CI) [4]		-0.09 (-0.28, 0.11)
Fisher’s Exact p-value (2-sided)		0.520

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.15
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	73	51
Responder [1]	13 (18%)	25 (49%)
Non-responder	60 (82%)	26 (51%)
No change/worsening	30 (41%)	14 (27%)
Nasal surgery/sinuplasty prior to visit	21 (29%)	7 (14%)
Withdrawal from study prior to visit	6 (8%)	1 (2%)
Missing visit	3 (4%)	4 (8%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.20 (0.08, 0.46)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.23 (0.09, 0.55)
Inverse relative risk (95% CI) [4]		0.36 (0.19, 0.65)
Risk difference (95% CI) [4]		-0.31 (-0.47, -0.13)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.16
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	35
Responder [1]	9 (23%)	8 (23%)
Non-responder	31 (78%)	27 (77%)
No change/worsening	26 (65%)	20 (57%)
Nasal surgery/sinuplasty prior to visit	2 (5%)	1 (3%)
Withdrawal from study prior to visit	3 (8%)	4 (11%)
Missing visit	0	2 (6%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		1.02 (0.34, 3.09)
p-value		0.968
Inverse unadjusted odds ratio (95% CI) [3]		0.98 (0.29, 3.37)
Inverse relative risk (95% CI) [4]		0.98 (0.41, 2.70)
Risk difference (95% CI) [4]		0.00 (-0.21, 0.19)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 27.16
Subgroup Analysis of Total Endoscopic Nasal Polyps Score (Centrally Read) Responders at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	161	171
Responder [1]	48 (30%)	96 (56%)
Non-responder	113 (70%)	75 (44%)
No change/worsening	51 (32%)	42 (25%)
Nasal surgery/sinuplasty prior to visit	44 (27%)	17 (10%)
Withdrawal from study prior to visit	12 (7%)	12 (7%)
Missing visit	6 (4%)	4 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.32 (0.20, 0.51)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [3]		0.33 (0.21, 0.53)
Inverse relative risk (95% CI) [4]		0.53 (0.39, 0.70)
Risk difference (95% CI) [4]		-0.26 (-0.36, -0.15)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Defined as a subject with a >=1-point improvement from baseline in the absence of surgery/sinuplasty prior to that visit.
[2] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[3] Exact CI.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Protocol: 205687
Population: Intent-to-Treat

Table 27.28
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	7.36 (0.438)	5.61 (0.395)
LS Mean Change (SE)	-1.85 (0.438)	-3.59 (0.395)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.74
95% CI		(-2.91, -0.57)
p-value		0.004
Corrected Hedges g [3]		-0.55
95% CI		(-0.92, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
PPD

Table 27.28
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	6.86 (0.314)	4.59 (0.327)
LS Mean Change (SE)	-2.15 (0.314)	-4.42 (0.327)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.27
95% CI		(-3.16, -1.37)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-0.91, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.28
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	5.41 (0.705)	4.76 (0.680)
LS Mean Change (SE)	-3.65 (0.705)	-4.30 (0.680)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.65
95% CI		(-2.62, 1.32)
p-value		0.510
Corrected Hedges g [3]		-0.18
95% CI		(-0.70, 0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.29
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	6.61 (0.305)	4.98 (0.290)
LS Mean Change (SE)	-2.42 (0.305)	-4.05 (0.290)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.63
95% CI		(-2.46, -0.80)
p-value		<0.001
Corrected Hedges g [3]		-0.48
95% CI		(-0.72, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.29
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	7.06 (0.400)	4.86 (0.426)
LS Mean Change (SE)	-2.08 (0.400)	-4.28 (0.426)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.19
95% CI		(-3.35, -1.04)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.96, -0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.30
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	6.91 (0.359)	4.98 (0.357)
LS Mean Change (SE)	-2.12 (0.359)	-4.06 (0.357)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.93
95% CI		(-2.93, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.58
95% CI		(-0.89, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.30
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	7.63 (0.568)	6.61 (0.568)
LS Mean Change (SE)	-1.28 (0.568)	-2.30 (0.568)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.02
95% CI		(-2.64, 0.60)
p-value		0.212
Corrected Hedges g [3]		-0.34
95% CI		(-0.86, 0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.30
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	6.35 (0.383)	4.43 (0.375)
LS Mean Change (SE)	-2.80 (0.383)	-4.72 (0.375)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.92
95% CI		(-2.98, -0.86)
p-value		<0.001
Corrected Hedges g [3]		-0.53
95% CI		(-0.83, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.31
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	7.42 (0.428)	4.85 (0.507)
LS Mean Change (SE)	-1.77 (0.428)	-4.34 (0.507)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.57
95% CI		(-3.89, -1.25)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.15, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.31
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52)
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	6.52 (0.291)	4.95 (0.270)
LS Mean Change (SE)	-2.51 (0.291)	-4.08 (0.270)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.57
95% CI		(-2.35, -0.79)
p-value		<0.001
Corrected Hedges g [3]		-0.46
95% CI		(-0.69, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.32
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	6.25 (0.393)	4.67 (0.340)
LS Mean Change (SE)	-2.78 (0.393)	-4.37 (0.340)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-2.61, -0.56)
p-value		0.003
Corrected Hedges g [3]		-0.45
95% CI		(-0.74, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.32
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	6.83 (0.508)	5.17 (0.508)
LS Mean Change (SE)	-2.22 (0.508)	-3.88 (0.508)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-3.12, -0.22)
p-value		0.025
Corrected Hedges g [3]		-0.47
95% CI		(-0.88, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.32
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	7.32 (0.391)	5.32 (0.468)
LS Mean Change (SE)	-1.81 (0.391)	-3.81 (0.468)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.00
95% CI		(-3.21, -0.79)
p-value		0.001
Corrected Hedges g [3]		-0.59
95% CI		(-0.96, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.33
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	5.55 (0.512)	4.80 (0.547)
LS Mean Change (SE)	-3.33 (0.512)	-4.08 (0.547)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.75
95% CI		(-2.25, 0.75)
p-value		0.323
Corrected Hedges g [3]		-0.23
95% CI		(-0.68, 0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.33
Subgroup Analysis of Mean Change from Baseline Overall VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	7.13 (0.271)	4.93 (0.263)
LS Mean Change (SE)	-1.98 (0.271)	-4.18 (0.263)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.21
95% CI		(-2.95, -1.46)
p-value		<0.001
Corrected Hedges g [3]		-0.64
95% CI		(-0.86, -0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.19
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	7.20 (0.442)	5.74 (0.398)
LS Mean Change (SE)	-1.94 (0.442)	-3.40 (0.398)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.45
95% CI		(-2.64, -0.27)
p-value		0.016
Corrected Hedges g [3]		-0.45
95% CI		(-0.82, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.19
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	6.79 (0.318)	4.49 (0.331)
LS Mean Change (SE)	-2.10 (0.318)	-4.40 (0.331)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.30
95% CI		(-3.20, -1.39)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-0.91, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.19
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	5.36 (0.713)	4.44 (0.688)
LS Mean Change (SE)	-3.61 (0.713)	-4.54 (0.688)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.92
95% CI		(-2.92, 1.08)
p-value		0.358
Corrected Hedges g [3]		-0.25
95% CI		(-0.77, 0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.20
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	6.50 (0.308)	4.97 (0.292)
LS Mean Change (SE)	-2.45 (0.308)	-3.98 (0.292)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.53
95% CI		(-2.37, -0.69)
p-value		<0.001
Corrected Hedges g [3]		-0.44
95% CI		(-0.69, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.20
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	6.99 (0.405)	4.73 (0.432)
LS Mean Change (SE)	-2.02 (0.405)	-4.28 (0.432)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.26
95% CI		(-3.43, -1.09)
p-value		<0.001
Corrected Hedges g [3]		-0.64
95% CI		(-0.97, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.21
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	6.83 (0.367)	4.88 (0.365)
LS Mean Change (SE)	-2.09 (0.367)	-4.04 (0.365)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.95
95% CI		(-2.98, -0.93)
p-value		<0.001
Corrected Hedges g [3]		-0.58
95% CI		(-0.88, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.21
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	7.47 (0.578)	6.59 (0.578)
LS Mean Change (SE)	-1.32 (0.578)	-2.21 (0.578)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.89
95% CI		(-2.53, 0.76)
p-value		0.284
Corrected Hedges g [3]		-0.29
95% CI		(-0.81, 0.24)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.21
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	6.29 (0.383)	4.38 (0.375)
LS Mean Change (SE)	-2.79 (0.383)	-4.69 (0.375)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.91
95% CI		(-2.96, -0.85)
p-value		<0.001
Corrected Hedges g [3]		-0.53
95% CI		(-0.83, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.22
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	7.33 (0.436)	4.64 (0.516)
LS Mean Change (SE)	-1.78 (0.436)	-4.47 (0.516)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.69
95% CI		(-4.03, -1.35)
p-value		<0.001
Corrected Hedges g [3]		-0.77
95% CI		(-1.17, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.22
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	6.42 (0.295)	4.93 (0.273)
LS Mean Change (SE)	-2.50 (0.295)	-3.99 (0.273)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.49
95% CI		(-2.28, -0.70)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.66, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.23
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	6.22 (0.390)	4.61 (0.338)
LS Mean Change (SE)	-2.69 (0.390)	-4.31 (0.338)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.62
95% CI		(-2.64, -0.60)
p-value		0.002
Corrected Hedges g [3]		-0.46
95% CI		(-0.75, -0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.23
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	6.55 (0.520)	5.27 (0.520)
LS Mean Change (SE)	-2.44 (0.520)	-3.72 (0.520)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.28
95% CI		(-2.77, 0.21)
p-value		0.090
Corrected Hedges g [3]		-0.36
95% CI		(-0.76, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.23
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	7.23 (0.401)	5.20 (0.480)
LS Mean Change (SE)	-1.81 (0.401)	-3.84 (0.480)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.03
95% CI		(-3.27, -0.79)
p-value		0.002
Corrected Hedges g [3]		-0.59
95% CI		(-0.95, -0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.24
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	5.42 (0.525)	4.77 (0.561)
LS Mean Change (SE)	-3.32 (0.525)	-3.97 (0.561)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.65
95% CI		(-2.18, 0.89)
p-value		0.403
Corrected Hedges g [3]		-0.19
95% CI		(-0.65, 0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.24
Subgroup Analysis of Mean Change from Baseline Nasal Obstruction VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	7.04 (0.275)	4.87 (0.267)
LS Mean Change (SE)	-1.98 (0.275)	-4.15 (0.267)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.17
95% CI		(-2.92, -1.41)
p-value		<0.001
Corrected Hedges g [3]		-0.62
95% CI		(-0.84, -0.40)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.46
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	7.07 (0.464)	5.49 (0.418)
LS Mean Change (SE)	-1.84 (0.464)	-3.42 (0.418)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-2.82, -0.35)
p-value		0.013
Corrected Hedges g [3]		-0.47
95% CI		(-0.84, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.46
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	6.68 (0.322)	4.36 (0.335)
LS Mean Change (SE)	-2.03 (0.322)	-4.35 (0.335)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.32
95% CI		(-3.23, -1.40)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-0.91, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.46
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	5.13 (0.728)	4.43 (0.702)
LS Mean Change (SE)	-3.66 (0.728)	-4.35 (0.702)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.70
95% CI		(-2.75, 1.35)
p-value		0.498
Corrected Hedges g [3]		-0.18
95% CI		(-0.71, 0.34)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.47
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	6.31 (0.318)	4.80 (0.302)
LS Mean Change (SE)	-2.43 (0.318)	-3.94 (0.302)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.50
95% CI		(-2.37, -0.64)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.67, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
PPD

Table 27.47
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	6.95 (0.405)	4.63 (0.431)
LS Mean Change (SE)	-1.90 (0.405)	-4.22 (0.431)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.32
95% CI		(-3.49, -1.14)
p-value		<0.001
Corrected Hedges g [3]		-0.65
95% CI		(-0.99, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.48
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	6.81 (0.374)	4.70 (0.371)
LS Mean Change (SE)	-1.97 (0.374)	-4.08 (0.371)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.11
95% CI		(-3.15, -1.07)
p-value		<0.001
Corrected Hedges g [3]		-0.61
95% CI		(-0.92, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.48
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	7.33 (0.640)	6.26 (0.640)
LS Mean Change (SE)	-1.24 (0.640)	-2.31 (0.640)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-2.88, 0.75)
p-value		0.244
Corrected Hedges g [3]		-0.31
95% CI		(-0.84, 0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.48
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	6.08 (0.387)	4.31 (0.379)
LS Mean Change (SE)	-2.77 (0.387)	-4.54 (0.379)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.77
95% CI		(-2.84, -0.70)
p-value		0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.78, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.49
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	7.12 (0.451)	4.43 (0.534)
LS Mean Change (SE)	-1.72 (0.451)	-4.41 (0.534)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.69
95% CI		(-4.08, -1.31)
p-value		<0.001
Corrected Hedges g [3]		-0.75
95% CI		(-1.14, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.49
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52)
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	6.32 (0.300)	4.81 (0.278)
LS Mean Change (SE)	-2.44 (0.300)	-3.95 (0.278)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.51
95% CI		(-2.31, -0.70)
p-value		<0.001
Corrected Hedges g [3]		-0.43
95% CI		(-0.66, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.50
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	6.02 (0.397)	4.50 (0.343)
LS Mean Change (SE)	-2.74 (0.397)	-4.25 (0.343)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.51
95% CI		(-2.55, -0.48)
p-value		0.005
Corrected Hedges g [3]		-0.42
95% CI		(-0.71, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.50
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	6.74 (0.538)	5.00 (0.538)
LS Mean Change (SE)	-1.97 (0.538)	-3.71 (0.538)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.74
95% CI		(-3.26, -0.22)
p-value		0.025
Corrected Hedges g [3]		-0.47
95% CI		(-0.88, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.50
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	7.10 (0.406)	4.90 (0.486)
LS Mean Change (SE)	-1.76 (0.406)	-3.96 (0.486)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.20
95% CI		(-3.45, -0.94)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-1.00, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.51
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	5.04 (0.554)	4.73 (0.592)
LS Mean Change (SE)	-3.41 (0.554)	-3.72 (0.592)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.30
95% CI		(-1.92, 1.31)
p-value		0.709
Corrected Hedges g [3]		-0.09
95% CI		(-0.54, 0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.51
Subgroup Analysis of Mean Change from Baseline Nasal Discharge VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	6.95 (0.278)	4.73 (0.270)
LS Mean Change (SE)	-1.90 (0.278)	-4.13 (0.270)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.22
95% CI		(-2.99, -1.46)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.85, -0.41)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.55
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	6.78 (0.492)	5.51 (0.443)
LS Mean Change (SE)	-1.71 (0.492)	-2.98 (0.443)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.27
95% CI		(-2.59, 0.05)
p-value		0.059
Corrected Hedges g [3]		-0.36
95% CI		(-0.72, 0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.55
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	6.72 (0.324)	4.44 (0.337)
LS Mean Change (SE)	-1.85 (0.324)	-4.12 (0.337)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.28
95% CI		(-3.20, -1.36)
p-value		<0.001
Corrected Hedges g [3]		-0.63
95% CI		(-0.90, -0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.55
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	5.18 (0.762)	4.82 (0.735)
LS Mean Change (SE)	-3.42 (0.762)	-3.78 (0.735)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.36
95% CI		(-2.51, 1.78)
p-value		0.734
Corrected Hedges g [3]		-0.09
95% CI		(-0.62, 0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.56
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	6.20 (0.327)	4.74 (0.310)
LS Mean Change (SE)	-2.33 (0.327)	-3.79 (0.310)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.46
95% CI		(-2.34, -0.57)
p-value		0.001
Corrected Hedges g [3]		-0.40
95% CI		(-0.64, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.56
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	7.05 (0.409)	5.04 (0.435)
LS Mean Change (SE)	-1.54 (0.409)	-3.55 (0.435)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.01
95% CI		(-3.19, -0.83)
p-value		<0.001
Corrected Hedges g [3]		-0.56
95% CI		(-0.90, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.57
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	6.73 (0.383)	4.83 (0.381)
LS Mean Change (SE)	-1.89 (0.383)	-3.79 (0.381)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.90
95% CI		(-2.97, -0.83)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.84, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.57
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	7.39 (0.658)	6.31 (0.658)
LS Mean Change (SE)	-1.13 (0.658)	-2.21 (0.658)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.08
95% CI		(-2.96, 0.80)
p-value		0.253
Corrected Hedges g [3]		-0.31
95% CI		(-0.83, 0.22)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.57
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	6.02 (0.399)	4.41 (0.390)
LS Mean Change (SE)	-2.47 (0.399)	-4.08 (0.390)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.61
95% CI		(-2.71, -0.51)
p-value		0.004
Corrected Hedges g [3]		-0.43
95% CI		(-0.72, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.58
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	7.00 (0.467)	4.80 (0.552)
LS Mean Change (SE)	-1.56 (0.467)	-3.77 (0.552)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.20
95% CI		(-3.64, -0.77)
p-value		0.003
Corrected Hedges g [3]		-0.59
95% CI		(-0.98, -0.20)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.58
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	6.31 (0.308)	4.84 (0.285)
LS Mean Change (SE)	-2.23 (0.308)	-3.71 (0.285)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.48
95% CI		(-2.30, -0.65)
p-value		<0.001
Corrected Hedges g [3]		-0.41
95% CI		(-0.64, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.59
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	5.86 (0.407)	4.70 (0.353)
LS Mean Change (SE)	-2.63 (0.407)	-3.79 (0.353)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.16
95% CI		(-2.22, -0.10)
p-value		0.033
Corrected Hedges g [3]		-0.32
95% CI		(-0.60, -0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.59
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	6.90 (0.536)	5.18 (0.536)
LS Mean Change (SE)	-1.68 (0.536)	-3.40 (0.536)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.72
95% CI		(-3.23, -0.21)
p-value		0.026
Corrected Hedges g [3]		-0.46
95% CI		(-0.87, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.59
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	7.05 (0.423)	4.73 (0.506)
LS Mean Change (SE)	-1.55 (0.423)	-3.88 (0.506)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.33
95% CI		(-3.64, -1.02)
p-value		<0.001
Corrected Hedges g [3]		-0.64
95% CI		(-1.01, -0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.60
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	5.07 (0.547)	4.87 (0.584)
LS Mean Change (SE)	-3.33 (0.547)	-3.53 (0.584)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-1.80, 1.39)
p-value		0.801
Corrected Hedges g [3]		-0.06
95% CI		(-0.51, 0.40)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.60
Subgroup Analysis of Mean Change from Baseline Mucus in Throat VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	6.90 (0.287)	4.81 (0.278)
LS Mean Change (SE)	-1.68 (0.287)	-3.77 (0.278)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.09
95% CI		(-2.88, -1.31)
p-value		<0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.79, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.64
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	6.54 (0.519)	4.87 (0.468)
LS Mean Change (SE)	-1.13 (0.519)	-2.81 (0.468)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.68
95% CI		(-3.06, -0.29)
p-value		0.018
Corrected Hedges g [3]		-0.44
95% CI		(-0.81, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
PPD

Population: Intent-to-Treat

Table 27.64
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	6.20 (0.345)	4.05 (0.359)
LS Mean Change (SE)	-1.56 (0.345)	-3.70 (0.359)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.14
95% CI		(-3.13, -1.16)
p-value		<0.001
Corrected Hedges g [3]		-0.56
95% CI		(-0.82, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.64
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	4.64 (0.742)	4.43 (0.715)
LS Mean Change (SE)	-3.36 (0.742)	-3.58 (0.715)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.22
95% CI		(-2.32, 1.89)
p-value		0.838
Corrected Hedges g [3]		-0.06
95% CI		(-0.58, 0.47)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.65
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	5.75 (0.341)	4.28 (0.324)
LS Mean Change (SE)	-1.95 (0.341)	-3.43 (0.324)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.47
95% CI		(-2.40, -0.55)
p-value		0.002
Corrected Hedges g [3]		-0.38
95% CI		(-0.63, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.65
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	6.58 (0.439)	4.57 (0.467)
LS Mean Change (SE)	-1.30 (0.439)	-3.31 (0.467)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.01
95% CI		(-3.28, -0.74)
p-value		0.002
Corrected Hedges g [3]		-0.52
95% CI		(-0.86, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.66
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	6.14 (0.406)	4.28 (0.404)
LS Mean Change (SE)	-1.77 (0.406)	-3.63 (0.404)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.86
95% CI		(-2.99, -0.73)
p-value		0.001
Corrected Hedges g [3]		-0.49
95% CI		(-0.80, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.66
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	7.39 (0.690)	5.71 (0.690)
LS Mean Change (SE)	-0.17 (0.690)	-1.84 (0.690)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.68
95% CI		(-3.63, 0.28)
p-value		0.091
Corrected Hedges g [3]		-0.45
95% CI		(-0.98, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.66
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	5.57 (0.413)	4.04 (0.404)
LS Mean Change (SE)	-2.12 (0.413)	-3.65 (0.404)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.54
95% CI		(-2.68, -0.39)
p-value		0.009
Corrected Hedges g [3]		-0.39
95% CI		(-0.69, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.67
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	6.71 (0.477)	4.01 (0.564)
LS Mean Change (SE)	-1.10 (0.477)	-3.79 (0.564)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.69
95% CI		(-4.16, -1.23)
p-value		<0.001
Corrected Hedges g [3]		-0.71
95% CI		(-1.10, -0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.67
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	5.77 (0.325)	4.47 (0.301)
LS Mean Change (SE)	-1.98 (0.325)	-3.28 (0.301)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.30
95% CI		(-2.17, -0.43)
p-value		0.004
Corrected Hedges g [3]		-0.34
95% CI		(-0.57, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.68
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	5.46 (0.413)	4.17 (0.358)
LS Mean Change (SE)	-2.44 (0.413)	-3.73 (0.358)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.30
95% CI		(-2.37, -0.22)
p-value		0.019
Corrected Hedges g [3]		-0.35
95% CI		(-0.64, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.68
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	6.47 (0.567)	4.82 (0.567)
LS Mean Change (SE)	-0.98 (0.567)	-2.62 (0.567)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.65
95% CI		(-3.25, -0.04)
p-value		0.045
Corrected Hedges g [3]		-0.42
95% CI		(-0.83, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.68
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	6.45 (0.462)	4.42 (0.554)
LS Mean Change (SE)	-1.35 (0.462)	-3.38 (0.554)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.03
95% CI		(-3.46, -0.60)
p-value		0.006
Corrected Hedges g [3]		-0.51
95% CI		(-0.87, -0.15)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.69
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	4.63 (0.565)	4.51 (0.604)
LS Mean Change (SE)	-3.28 (0.565)	-3.40 (0.604)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.12
95% CI		(-1.77, 1.53)
p-value		0.886
Corrected Hedges g [3]		-0.03
95% CI		(-0.49, 0.42)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.69
Subgroup Analysis of Mean Change from Baseline Facial Pain VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	6.42 (0.302)	4.34 (0.293)
LS Mean Change (SE)	-1.31 (0.302)	-3.39 (0.293)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.08
95% CI		(-2.90, -1.25)
p-value		<0.001
Corrected Hedges g [3]		-0.54
95% CI		(-0.76, -0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.37
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	52	64
n [2]	52	64
LS Mean (SE)	8.69 (0.378)	7.53 (0.341)
LS Mean Change (SE)	-1.08 (0.378)	-2.24 (0.341)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.15
95% CI		(-2.16, -0.15)
p-value		0.025
Corrected Hedges g [3]		-0.42
95% CI		(-0.79, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.37
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	122	113
n [2]	122	113
LS Mean (SE)	8.20 (0.303)	6.61 (0.315)
LS Mean Change (SE)	-1.40 (0.303)	-2.99 (0.315)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.59
95% CI		(-2.45, -0.73)
p-value		<0.001
Corrected Hedges g [3]		-0.47
95% CI		(-0.73, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.37
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	8.14 (0.680)	6.36 (0.656)
LS Mean Change (SE)	-1.48 (0.680)	-3.26 (0.656)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.78
95% CI		(-3.70, 0.14)
p-value		0.068
Corrected Hedges g [3]		-0.50
95% CI		(-1.03, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.38
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	125	139
n [2]	125	139
LS Mean (SE)	8.09 (0.292)	6.96 (0.277)
LS Mean Change (SE)	-1.55 (0.292)	-2.67 (0.277)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.12
95% CI		(-1.92, -0.33)
p-value		0.006
Corrected Hedges g [3]		-0.34
95% CI		(-0.59, -0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.38
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	76	67
n [2]	76	67
LS Mean (SE)	8.74 (0.352)	6.61 (0.375)
LS Mean Change (SE)	-0.95 (0.352)	-3.09 (0.375)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.13
95% CI		(-3.16, -1.11)
p-value		<0.001
Corrected Hedges g [3]		-0.69
95% CI		(-1.03, -0.35)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.39
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	8.55 (0.332)	6.81 (0.330)
LS Mean Change (SE)	-1.11 (0.332)	-2.86 (0.330)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.75
95% CI		(-2.67, -0.82)
p-value		<0.001
Corrected Hedges g [3]		-0.57
95% CI		(-0.87, -0.26)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.39
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	28	28
n [2]	28	28
LS Mean (SE)	8.83 (0.501)	7.84 (0.501)
LS Mean Change (SE)	-0.68 (0.501)	-1.66 (0.501)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.98
95% CI		(-2.40, 0.44)
p-value		0.172
Corrected Hedges g [3]		-0.36
95% CI		(-0.89, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.39
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	88	92
n [2]	88	92
LS Mean (SE)	7.91 (0.366)	6.63 (0.358)
LS Mean Change (SE)	-1.78 (0.366)	-3.06 (0.358)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.28
95% CI		(-2.29, -0.27)
p-value		0.014
Corrected Hedges g [3]		-0.37
95% CI		(-0.67, -0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.40
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	63	45
n [2]	63	45
LS Mean (SE)	8.94 (0.383)	6.97 (0.455)
LS Mean Change (SE)	-0.88 (0.383)	-2.86 (0.455)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.98
95% CI		(-3.17, -0.78)
p-value		0.001
Corrected Hedges g [3]		-0.64
95% CI		(-1.04, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.40
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	138	161
n [2]	138	161
LS Mean (SE)	8.03 (0.278)	6.84 (0.257)
LS Mean Change (SE)	-1.57 (0.278)	-2.75 (0.257)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.18
95% CI		(-1.93, -0.44)
p-value		0.002
Corrected Hedges g [3]		-0.36
95% CI		(-0.59, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.41
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	81	108
n [2]	81	108
LS Mean (SE)	7.79 (0.385)	6.38 (0.333)
LS Mean Change (SE)	-1.74 (0.385)	-3.15 (0.333)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.40
95% CI		(-2.41, -0.40)
p-value		0.006
Corrected Hedges g [3]		-0.40
95% CI		(-0.69, -0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.41
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	47	47
n [2]	47	47
LS Mean (SE)	8.21 (0.459)	7.16 (0.459)
LS Mean Change (SE)	-1.53 (0.459)	-2.58 (0.459)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.05
95% CI		(-2.34, 0.24)
p-value		0.109
Corrected Hedges g [3]		-0.33
95% CI		(-0.74, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.41
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	73	51
n [2]	73	51
LS Mean (SE)	9.00 (0.329)	7.58 (0.394)
LS Mean Change (SE)	-0.78 (0.329)	-2.20 (0.394)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.42
95% CI		(-2.44, -0.40)
p-value		0.007
Corrected Hedges g [3]		-0.50
95% CI		(-0.86, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.42
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	35
n [2]	40	35
LS Mean (SE)	7.70 (0.507)	6.78 (0.543)
LS Mean Change (SE)	-1.84 (0.507)	-2.76 (0.543)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.92
95% CI		(-2.42, 0.57)
p-value		0.223
Corrected Hedges g [3]		-0.28
95% CI		(-0.74, 0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.42
Subgroup Analysis of Mean Change from Baseline Loss of Smell VAS Score (Weeks 49-52) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	161	171
n [2]	161	171
LS Mean (SE)	8.51 (0.251)	6.84 (0.244)
LS Mean Change (SE)	-1.17 (0.251)	-2.84 (0.244)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.67
95% CI		(-2.36, -0.98)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.74, -0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.135
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	15	18
n [2]	15	18
n [3]	15	18
LS Mean (SE)	9.9 (3.01)	10.3 (2.74)
LS Mean Change (SE)	-3.6 (3.01)	-3.3 (2.74)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.38
95% CI		(-8.00, 8.77)
p-value		0.927
Corrected Hedges g [4]		0.03
95% CI		(-0.65, 0.72)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.135
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	32	27
n [2]	32	27
n [3]	32	27
LS Mean (SE)	8.2 (2.07)	14.0 (2.25)
LS Mean Change (SE)	-4.6 (2.07)	1.1 (2.25)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.74
95% CI		(-0.40, 11.89)
p-value		0.066
Corrected Hedges g [4]		0.48
95% CI		(-0.04, 1.00)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.135
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	7	9
n [2]	7	9
n [3]	7	9
LS Mean (SE)	15.8 (3.96)	11.6 (3.44)
LS Mean Change (SE)	1.8 (3.96)	-2.4 (3.44)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.29
95% CI		(-16.26, 7.68)
p-value		0.454
Corrected Hedges g [4]		-0.39
95% CI		(-1.39, 0.61)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.136
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	34	41
n [2]	34	41
n [3]	34	41
LS Mean (SE)	11.4 (2.14)	12.1 (1.95)
LS Mean Change (SE)	-2.1 (2.14)	-1.4 (1.95)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.69
95% CI		(-5.10, 6.48)
p-value		0.813
Corrected Hedges g [4]		0.05
95% CI		(-0.40, 0.51)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.136
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	20	13
n [2]	20	13
n [3]	20	13
LS Mean (SE)	7.1 (2.00)	12.6 (2.49)
LS Mean Change (SE)	-5.5 (2.00)	-0.1 (2.49)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.42
95% CI		(-1.17, 12.00)
p-value		0.103
Corrected Hedges g [4]		0.59
95% CI		(-0.12, 1.30)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.137
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	9	9
n [2]	9	9
n [3]	9	9
LS Mean (SE)	6.8 (2.74)	9.6 (2.74)
LS Mean Change (SE)	-4.3 (2.74)	-1.5 (2.74)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.81
95% CI		(-5.51, 11.13)
p-value		0.482
Corrected Hedges g [4]		0.33
95% CI		(-0.60, 1.26)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.137
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	28	28
n [2]	28	28
n [3]	28	28
LS Mean (SE)	7.8 (2.26)	12.7 (2.26)
LS Mean Change (SE)	-5.7 (2.26)	-0.9 (2.26)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		4.81
95% CI		(-1.61, 11.22)
p-value		0.139
Corrected Hedges g [4]		0.40
95% CI		(-0.13, 0.93)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.137
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	17	17
n [2]	17	17
n [3]	17	17
LS Mean (SE)	14.6 (2.99)	13.0 (2.99)
LS Mean Change (SE)	0.8 (2.99)	-0.7 (2.99)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.58
95% CI		(-10.19, 7.04)
p-value		0.712
Corrected Hedges g [4]		-0.12
95% CI		(-0.80, 0.55)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.138
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	19	13
n [2]	19	13
n [3]	19	13
LS Mean (SE)	7.2 (2.68)	12.5 (3.24)
LS Mean Change (SE)	-4.9 (2.68)	0.4 (3.24)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		5.23
95% CI		(-3.43, 13.90)
p-value		0.226
Corrected Hedges g [4]		0.44
95% CI		(-0.28, 1.15)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.138
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	35	41
n [2]	35	41
n [3]	35	41
LS Mean (SE)	11.3 (1.95)	12.1 (1.80)
LS Mean Change (SE)	-2.4 (1.95)	-1.6 (1.80)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.88
95% CI		(-4.41, 6.18)
p-value		0.741
Corrected Hedges g [4]		0.08
95% CI		(-0.38, 0.53)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.139
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	21	23
n [2]	21	23
n [3]	21	23
LS Mean (SE)	11.3 (2.49)	11.5 (2.38)
LS Mean Change (SE)	-3.0 (2.49)	-2.8 (2.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.19
95% CI		(-6.78, 7.16)
p-value		0.957
Corrected Hedges g [4]		0.02
95% CI		(-0.58, 0.61)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.139
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	9	15
n [2]	9	15
n [3]	9	15
LS Mean (SE)	12.6 (4.41)	12.1 (3.38)
LS Mean Change (SE)	1.5 (4.41)	1.0 (3.38)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.52
95% CI		(-12.32, 11.28)
p-value		0.928
Corrected Hedges g [4]		-0.04
95% CI		(-0.86, 0.79)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.139
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	24	16
n [2]	24	16
n [3]	24	16
LS Mean (SE)	7.5 (2.23)	13.6 (2.74)
LS Mean Change (SE)	-5.9 (2.23)	0.2 (2.74)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		6.10
95% CI		(-1.10, 13.29)
p-value		0.094
Corrected Hedges g [4]		0.55
95% CI		(-0.10, 1.19)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point. [3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.140
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	11	7
n [2]	11	7
n [3]	11	7
LS Mean (SE)	14.7 (3.49)	13.5 (4.42)
LS Mean Change (SE)	-2.3 (3.49)	-3.5 (4.42)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.25
95% CI		(-13.47, 10.97)
p-value		0.830
Corrected Hedges g [4]		-0.10
95% CI		(-1.05, 0.85)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.140
Subgroup Analysis of Mean Change from Baseline University of Pennsylvania Smell Identification Test (UPSIT) at Week 52 by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup in UK, USA and Canada [1]	43	47
n [2]	43	47
n [3]	43	47
LS Mean (SE)	8.5 (1.76)	12.1 (1.69)
LS Mean Change (SE)	-3.9 (1.76)	-0.4 (1.69)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.55
95% CI		(-1.31, 8.40)
p-value		0.150
Corrected Hedges g [4]		0.30
95% CI		(-0.11, 0.72)

[1] Performed at sites in UK, USA and Canada only. [2] No. with analysable data for one/more time point.
[3] No. with analysable data at given time point. [4] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.96
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	50	63
n [2]	50	63
LS Mean (SE)	64.6 (5.18)	44.9 (4.61)
LS Mean Change (SE)	-1.8 (5.18)	-21.5 (4.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.69
95% CI		(-33.44, -5.94)
p-value		0.005
Corrected Hedges g [3]		-0.53
95% CI		(-0.91, -0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.96
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	121	113
n [2]	121	113
LS Mean (SE)	61.3 (3.40)	42.2 (3.52)
LS Mean Change (SE)	-2.7 (3.40)	-21.8 (3.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.07
95% CI		(-28.71, -9.43)
p-value		<0.001
Corrected Hedges g [3]		-0.51
95% CI		(-0.77, -0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.96
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	27	29
LS Mean (SE)	48.2 (7.38)	38.9 (7.12)
LS Mean Change (SE)	-11.3 (7.38)	-20.6 (7.12)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.24
95% CI		(-29.86, 11.38)
p-value		0.373
Corrected Hedges g [3]		-0.24
95% CI		(-0.76, 0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.97
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	123	138
n [2]	123	138
LS Mean (SE)	57.6 (3.40)	43.4 (3.21)
LS Mean Change (SE)	-5.0 (3.40)	-19.2 (3.21)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-14.18
95% CI		(-23.38, -4.97)
p-value		0.003
Corrected Hedges g [3]		-0.38
95% CI		(-0.62, -0.13)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.97
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	75	67
n [2]	75	67
LS Mean (SE)	65.8 (4.09)	39.8 (4.33)
LS Mean Change (SE)	-1.0 (4.09)	-26.9 (4.33)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-25.92
95% CI		(-37.72, -14.12)
p-value		<0.001
Corrected Hedges g [3]		-0.73
95% CI		(-1.07, -0.39)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.98
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	86
n [2]	85	86
LS Mean (SE)	58.4 (3.89)	43.0 (3.87)
LS Mean Change (SE)	-5.4 (3.89)	-20.8 (3.87)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-15.39
95% CI		(-26.25, -4.52)
p-value		0.006
Corrected Hedges g [3]		-0.43
95% CI		(-0.73, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.98
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	26	28
n [2]	26	28
LS Mean (SE)	77.6 (8.03)	56.1 (7.74)
LS Mean Change (SE)	13.8 (8.03)	-7.6 (7.74)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-21.43
95% CI		(-43.83, 0.96)
p-value		0.060
Corrected Hedges g [3]		-0.52
95% CI		(-1.06, 0.03)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.98
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52 by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	87	91
n [2]	87	91
LS Mean (SE)	57.1 (3.89)	38.0 (3.80)
LS Mean Change (SE)	-7.2 (3.89)	-26.3 (3.80)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.09
95% CI		(-29.82, -8.35)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.82, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.99
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	61	45
n [2]	61	45
LS Mean (SE)	69.0 (4.74)	47.6 (5.52)
LS Mean Change (SE)	-0.7 (4.74)	-22.1 (5.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-21.37
95% CI		(-35.82, -6.92)
p-value		0.004
Corrected Hedges g [3]		-0.57
95% CI		(-0.97, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.99
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	137	160
n [2]	137	160
LS Mean (SE)	56.7 (3.16)	41.0 (2.93)
LS Mean Change (SE)	-5.3 (3.16)	-21.1 (2.93)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-15.74
95% CI		(-24.22, -7.26)
p-value		<0.001
Corrected Hedges g [3]		-0.42
95% CI		(-0.65, -0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.100
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	80	107
n [2]	80	107
LS Mean (SE)	56.7 (3.94)	38.2 (3.41)
LS Mean Change (SE)	-5.9 (3.94)	-24.3 (3.41)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-18.49
95% CI		(-28.77, -8.21)
p-value		<0.001
Corrected Hedges g [3]		-0.52
95% CI		(-0.82, -0.23)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.100
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	46	47
n [2]	46	47
LS Mean (SE)	55.5 (5.77)	47.8 (5.71)
LS Mean Change (SE)	-7.1 (5.77)	-14.8 (5.71)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.74
95% CI		(-23.88, 8.40)
p-value		0.343
Corrected Hedges g [3]		-0.20
95% CI		(-0.60, 0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.100
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	72	51
n [2]	72	51
LS Mean (SE)	68.0 (4.43)	46.4 (5.27)
LS Mean Change (SE)	0.5 (4.43)	-21.1 (5.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-21.64
95% CI		(-35.30, -7.98)
p-value		0.002
Corrected Hedges g [3]		-0.57
95% CI		(-0.94, -0.21)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.101
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	34
n [2]	40	34
LS Mean (SE)	43.7 (4.95)	40.7 (5.37)
LS Mean Change (SE)	-18.3 (4.95)	-21.2 (5.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.94
95% CI		(-17.55, 11.66)
p-value		0.689
Corrected Hedges g [3]		-0.09
95% CI		(-0.55, 0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.101
Subgroup Analysis of Mean Change from Baseline SNOT-22 Total Score at Week 52
by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	158	171
n [2]	158	171
LS Mean (SE)	64.7 (2.99)	42.9 (2.88)
LS Mean Change (SE)	0.2 (2.99)	-21.7 (2.88)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-21.83
95% CI		(-29.99, -13.66)
p-value		<0.001
Corrected Hedges g [3]		-0.58
95% CI		(-0.80, -0.36)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions. Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.105
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	50	63
Responder	27 (54%)	41 (65%)
Non-responder	23 (46%)	22 (35%)
>=1 to <8.9-point improvement	2 (4%)	5 (8%)
No change/worsening	3 (6%)	5 (8%)
Nasal surgery prior to visit	9 (18%)	6 (10%)
Withdrawn from study prior to visit	6 (12%)	6 (10%)
Missing visit data	3 (6%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.63 (0.29, 1.35)
p-value		0.230
Inverse unadjusted odds ratio (95% CI) [2]		0.63 (0.27, 1.44)
Inverse relative risk (95% CI) [3]		0.83 (0.58, 1.13)
Risk difference (95% CI) [3]		-0.11 (-0.29, 0.08)
Fisher’s Exact p-value (2-sided)		0.251

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.105
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	121	113
Responder	61 (50%)	86 (76%)
Non-responder	60 (50%)	27 (24%)
>=1 to <8.9-point improvement	8 (7%)	3 (3%)
No change/worsening	12 (10%)	4 (4%)
Nasal surgery prior to visit	32 (26%)	10 (9%)
Withdrawn from study prior to visit	7 (6%)	7 (6%)
Missing visit data	1 (<1%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.31 (0.18, 0.56)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.32 (0.17, 0.58)
Inverse relative risk (95% CI) [3]		0.66 (0.53, 0.82)
Risk difference (95% CI) [3]		-0.26 (-0.38, -0.12)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.105
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Responder	18 (67%)	23 (79%)
Non-responder	9 (33%)	6 (21%)
>=1 to <8.9-point improvement	3 (11%)	0
No change/worsening	0	0
Nasal surgery prior to visit	4 (15%)	2 (7%)
Withdrawn from study prior to visit	0	3 (10%)
Missing visit data	2 (7%)	1 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.34 (0.08, 1.51)
p-value		0.158
Inverse unadjusted odds ratio (95% CI) [2]		0.53 (0.13, 2.02)
Inverse relative risk (95% CI) [3]		0.84 (0.55, 1.17)
Risk difference (95% CI) [3]		-0.13 (-0.37, 0.11)
Fisher's Exact p-value (2-sided)		0.370

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.106
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	123	138
Responder	70 (57%)	96 (70%)
Non-responder	53 (43%)	42 (30%)
>=1 to <8.9-point improvement	8 (7%)	7 (5%)
No change/worsening	8 (7%)	7 (5%)
Nasal surgery prior to visit	28 (23%)	15 (11%)
Withdrawn from study prior to visit	8 (7%)	11 (8%)
Missing visit data	1 (<1%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.56 (0.33, 0.95)
p-value		0.031
Inverse unadjusted odds ratio (95% CI) [2]		0.58 (0.34, 0.99)
Inverse relative risk (95% CI) [3]		0.82 (0.67, 0.99)
Risk difference (95% CI) [3]		-0.13 (-0.24, -0.01)
Fisher’s Exact p-value (2-sided)		0.039

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.106
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	75	67
Responder	36 (48%)	54 (81%)
Non-responder	39 (52%)	13 (19%)
>=1 to <8.9-point improvement	5 (7%)	1 (1%)
No change/worsening	7 (9%)	2 (3%)
Nasal surgery prior to visit	17 (23%)	3 (4%)
Withdrawn from study prior to visit	5 (7%)	5 (7%)
Missing visit data	5 (7%)	2 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.21 (0.09, 0.46)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.22 (0.10, 0.50)
Inverse relative risk (95% CI) [3]		0.60 (0.44, 0.78)
Risk difference (95% CI) [3]		-0.33 (-0.47, -0.16)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.107
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Responder	48 (56%)	66 (77%)
Non-responder	37 (44%)	20 (23%)
>=1 to <8.9-point improvement	7 (8%)	2 (2%)
No change/worsening	6 (7%)	2 (2%)
Nasal surgery prior to visit	18 (21%)	5 (6%)
Withdrawn from study prior to visit	3 (4%)	8 (9%)
Missing visit data	3 (4%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.38 (0.20, 0.74)
p-value		0.005
Inverse unadjusted odds ratio (95% CI) [2]		0.40 (0.19, 0.80)
Inverse relative risk (95% CI) [3]		0.74 (0.58, 0.94)
Risk difference (95% CI) [3]		-0.20 (-0.34, -0.05)
Fisher’s Exact p-value (2-sided)		0.006

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.107
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	26	28
Responder	8 (31%)	17 (61%)
Non-responder	18 (69%)	11 (39%)
>=1 to <8.9-point improvement	2 (8%)	0
No change/worsening	0	2 (7%)
Nasal surgery prior to visit	10 (38%)	3 (11%)
Withdrawn from study prior to visit	6 (23%)	5 (18%)
Missing visit data	0	1 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.28 (0.09, 0.90)
p-value		0.032
Inverse unadjusted odds ratio (95% CI) [2]		0.29 (0.08, 1.01)
Inverse relative risk (95% CI) [3]		0.51 (0.23, 0.96)
Risk difference (95% CI) [3]		-0.30 (-0.54, -0.03)
Fisher’s Exact p-value (2-sided)		0.033

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.107
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	87	91
Responder	50 (57%)	67 (74%)
Non-responder	37 (43%)	24 (26%)
>=1 to <8.9-point improvement	4 (5%)	6 (7%)
No change/worsening	9 (10%)	5 (5%)
Nasal surgery prior to visit	17 (20%)	10 (11%)
Withdrawn from study prior to visit	4 (5%)	3 (3%)
Missing visit data	3 (3%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.49 (0.26, 0.92)
p-value		0.027
Inverse unadjusted odds ratio (95% CI) [2]		0.49 (0.24, 0.95)
Inverse relative risk (95% CI) [3]		0.78 (0.62, 0.98)
Risk difference (95% CI) [3]		-0.16 (-0.30, -0.02)
Fisher’s Exact p-value (2-sided)		0.027

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.108
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	61	45
Responder	31 (51%)	32 (71%)
Non-responder	30 (49%)	13 (29%)
>=1 to <8.9-point improvement	1 (2%)	1 (2%)
No change/worsening	4 (7%)	2 (4%)
Nasal surgery prior to visit	17 (28%)	5 (11%)
Withdrawn from study prior to visit	5 (8%)	3 (7%)
Missing visit data	3 (5%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.40 (0.17, 0.93)
p-value		0.034
Inverse unadjusted odds ratio (95% CI) [2]		0.42 (0.17, 1.02)
Inverse relative risk (95% CI) [3]		0.71 (0.51, 0.99)
Risk difference (95% CI) [3]		-0.20 (-0.38, -0.01)
Fisher’s Exact p-value (2-sided)		0.046

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.108
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	137	160
Responder	75 (55%)	118 (74%)
Non-responder	62 (45%)	42 (26%)
>=1 to <8.9-point improvement	12 (9%)	7 (4%)
No change/worsening	11 (8%)	7 (4%)
Nasal surgery prior to visit	28 (20%)	13 (8%)
Withdrawn from study prior to visit	8 (6%)	13 (8%)
Missing visit data	3 (2%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.42 (0.26, 0.69)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.43 (0.26, 0.72)
Inverse relative risk (95% CI) [3]		0.74 (0.61, 0.90)
Risk difference (95% CI) [3]		-0.19 (-0.30, -0.07)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.109
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	80	107
Responder	44 (55%)	80 (75%)
Non-responder	36 (45%)	27 (25%)
>=1 to <8.9-point improvement	4 (5%)	5 (5%)
No change/worsening	10 (13%)	7 (7%)
Nasal surgery prior to visit	15 (19%)	6 (6%)
Withdrawn from study prior to visit	4 (5%)	8 (7%)
Missing visit data	3 (4%)	1 (<1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.39 (0.20, 0.75)
p-value		0.005
Inverse unadjusted odds ratio (95% CI) [2]		0.41 (0.21, 0.80)
Inverse relative risk (95% CI) [3]		0.74 (0.56, 0.96)
Risk difference (95% CI) [3]		-0.20 (-0.33, -0.04)
Fisher's Exact p-value (2-sided)		0.005

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.109
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52
by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	46	47
Responder	29 (63%)	31 (66%)
Non-responder	17 (37%)	16 (34%)
>=1 to <8.9-point improvement	3 (7%)	2 (4%)
No change/worsening	1 (2%)	1 (2%)
Nasal surgery prior to visit	9 (20%)	5 (11%)
Withdrawn from study prior to visit	4 (9%)	7 (15%)
Missing visit data	0	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.86 (0.36, 2.04)
p-value		0.734
Inverse unadjusted odds ratio (95% CI) [2]		0.88 (0.34, 2.24)
Inverse relative risk (95% CI) [3]		0.96 (0.68, 1.31)
Risk difference (95% CI) [3]		-0.03 (-0.22, 0.17)
Fisher’s Exact p-value (2-sided)		0.830

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.109
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52
by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	72	51
Responder	33 (46%)	39 (76%)
Non-responder	39 (54%)	12 (24%)
>=1 to <8.9-point improvement	6 (8%)	1 (2%)
No change/worsening	4 (6%)	1 (2%)
Nasal surgery prior to visit	21 (29%)	7 (14%)
Withdrawn from study prior to visit	5 (7%)	1 (2%)
Missing visit data	3 (4%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.26 (0.11, 0.58)
p-value		0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.26 (0.11, 0.61)
Inverse relative risk (95% CI) [3]		0.60 (0.43, 0.82)
Risk difference (95% CI) [3]		-0.31 (-0.46, -0.11)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.110
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	34
Responder	31 (78%)	24 (71%)
Non-responder	9 (23%)	10 (29%)
>=1 to <8.9-point improvement	1 (3%)	3 (9%)
No change/worsening	3 (8%)	2 (6%)
Nasal surgery prior to visit	2 (5%)	1 (3%)
Withdrawn from study prior to visit	3 (8%)	4 (12%)
Missing visit data	0	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		1.26 (0.42, 3.81)
p-value		0.678
Inverse unadjusted odds ratio (95% CI) [2]		1.43 (0.44, 4.68)
Inverse relative risk (95% CI) [3]		1.10 (0.82, 1.52)
Risk difference (95% CI) [3]		0.07 (-0.14, 0.28)
Fisher’s Exact p-value (2-sided)		0.596

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.110
Subgroup Analysis of SNOT-22 Total Score Responders (>=8.9-point improvement) at Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	158	171
Responder	75 (47%)	126 (74%)
Non-responder	83 (53%)	45 (26%)
>=1 to <8.9-point improvement	12 (8%)	5 (3%)
No change/worsening	12 (8%)	7 (4%)
Nasal surgery prior to visit	43 (27%)	17 (10%)
Withdrawn from study prior to visit	10 (6%)	12 (7%)
Missing visit data	6 (4%)	4 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.31 (0.20, 0.50)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.32 (0.20, 0.53)
Inverse relative risk (95% CI) [3]		0.64 (0.52, 0.78)
Risk difference (95% CI) [3]		-0.26 (-0.36, -0.15)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
By week 8		
Subjects with event	1 (2%)	1 (2%)
Probability of surgery or steroid use [1]	1.9%	1.6%
95% CI	(0.3%, 12.9%)	(0.2%, 10.6%)
By week 16		
Subjects with event	7 (13%)	7 (11%)
Probability of surgery or steroid use [1]	13.7%	11.0%
95% CI	(6.8%, 26.7%)	(5.4%, 21.7%)
By week 24		
Subjects with event	11 (21%)	13 (20%)
Probability of surgery or steroid use [1]	21.9%	20.9%
95% CI	(12.7%, 36.0%)	(12.7%, 33.3%)
By week 32		
Subjects with event	14 (27%)	16 (25%)
Probability of surgery or steroid use [1]	28.2%	25.8%
95% CI	(17.7%, 43.0%)	(16.7%, 38.7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	18 (35%)	18 (28%)
Probability of surgery or steroid use [1]	36.6%	29.2%
95% CI	(24.9%, 51.8%)	(19.5%, 42.3%)
By week 48		
Subjects with event	20 (38%)	21 (33%)
Probability of surgery or steroid use [1]	40.9%	34.3%
95% CI	(28.6%, 56.0%)	(23.8%, 47.6%)
By week 52		
Subjects with event	20 (38%)	21 (33%)
Probability of surgery or steroid use [1]	40.9%	34.3%
95% CI	(28.6%, 56.0%)	(23.8%, 47.6%)
Event [2]	20 (38%)	21 (33%)
Course of systemic steroids prior to Week 52	15 (29%)	16 (25%)
Nasal surgery prior to Week 52	5 (10%)	5 (8%)
Censored	32 (62%)	43 (67%)
Censored at Week 52	27 (52%)	39 (61%)
Censored at study withdrawal	5 (10%)	4 (6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.89
95% CI		(0.47, 1.69)
p-value		0.728

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
By week 8		
Subjects with event	11 (9%)	8 (7%)
Probability of surgery or steroid use [1]	9.0%	7.1%
95% CI	(5.1%, 15.7%)	(3.6%, 13.7%)
By week 16		
Subjects with event	20 (16%)	15 (13%)
Probability of surgery or steroid use [1]	16.4%	13.3%
95% CI	(10.9%, 24.2%)	(8.2%, 21.0%)
By week 24		
Subjects with event	36 (30%)	23 (20%)
Probability of surgery or steroid use [1]	29.5%	20.4%
95% CI	(22.3%, 38.5%)	(14.1%, 29.1%)
By week 32		
Subjects with event	43 (35%)	25 (22%)
Probability of surgery or steroid use [1]	35.2%	22.3%
95% CI	(27.5%, 44.4%)	(15.6%, 31.1%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	46 (38%)	26 (23%)
Probability of surgery or steroid use [1]	37.7%	23.2%
95% CI	(29.8%, 46.9%)	(16.4%, 32.2%)
By week 48		
Subjects with event	53 (43%)	28 (25%)
Probability of surgery or steroid use [1]	43.6%	25.1%
95% CI	(35.3%, 52.8%)	(18.0%, 34.2%)
By week 52		
Subjects with event	54 (44%)	28 (25%)
Probability of surgery or steroid use [1]	44.4%	25.1%
95% CI	(36.1%, 53.7%)	(18.0%, 34.2%)
Event [2]	54 (44%)	28 (25%)
Course of systemic steroids prior to Week 52	43 (35%)	26 (23%)
Nasal surgery prior to Week 52	11 (9%)	2 (2%)
Censored	68 (56%)	85 (75%)
Censored at Week 52	62 (51%)	78 (69%)
Censored at study withdrawal	6 (5%)	7 (6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.63
95% CI		(0.39, 1.01)
p-value		0.057

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
By week 8		
Subjects with event	1 (4%)	0
Probability of surgery or steroid use [1]	3.7%	
95% CI	(0.5%, 23.5%)	
By week 16		
Subjects with event	3 (11%)	4 (14%)
Probability of surgery or steroid use [1]	11.1%	14.3%
95% CI	(3.7%, 30.6%)	(5.6%, 33.7%)
By week 24		
Subjects with event	4 (15%)	5 (17%)
Probability of surgery or steroid use [1]	14.8%	17.9%
95% CI	(5.8%, 34.8%)	(7.9%, 37.7%)
By week 32		
Subjects with event	5 (19%)	5 (17%)
Probability of surgery or steroid use [1]	18.5%	17.9%
95% CI	(8.2%, 38.9%)	(7.9%, 37.7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	7 (26%)	6 (21%)
Probability of surgery or steroid use [1]	25.9%	21.6%
95% CI	(13.3%, 46.8%)	(10.3%, 41.9%)
By week 48		
Subjects with event	10 (37%)	7 (24%)
Probability of surgery or steroid use [1]	37.0%	25.3%
95% CI	(21.9%, 57.9%)	(12.9%, 45.9%)
By week 52		
Subjects with event	10 (37%)	7 (24%)
Probability of surgery or steroid use [1]	37.0%	25.3%
95% CI	(21.9%, 57.9%)	(12.9%, 45.9%)
Event [2]	10 (37%)	8 (28%)
Course of systemic steroids prior to Week 52	7 (26%)	7 (24%)
Nasal surgery prior to Week 52	3 (11%)	1 (3%)
Censored	17 (63%)	21 (72%)
Censored at Week 52	17 (63%)	19 (66%)
Censored at study withdrawal	0	2 (7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.79
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.66
95% CI		(0.23, 1.92)
p-value		0.443

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Intent-to-Treat

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
By week 8		
Subjects with event	7 (6%)	6 (4%)
Probability of surgery or steroid use [1]	5.6%	4.3%
95% CI	(2.7%, 11.4%)	(2.0%, 9.4%)
By week 16		
Subjects with event	18 (14%)	19 (14%)
Probability of surgery or steroid use [1]	14.5%	13.7%
95% CI	(9.4%, 22.0%)	(9.0%, 20.6%)
By week 24		
Subjects with event	32 (26%)	32 (23%)
Probability of surgery or steroid use [1]	25.9%	23.2%
95% CI	(19.1%, 34.6%)	(17.0%, 31.2%)
By week 32		
Subjects with event	40 (32%)	35 (25%)
Probability of surgery or steroid use [1]	32.5%	25.5%
95% CI	(25.0%, 41.5%)	(19.0%, 33.6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	48 (38%)	38 (27%)
Probability of surgery or steroid use [1]	39.1%	27.7%
95% CI	(31.1%, 48.3%)	(21.0%, 36.1%)
By week 48		
Subjects with event	57 (46%)	43 (31%)
Probability of surgery or steroid use [1]	46.5%	31.6%
95% CI	(38.2%, 55.8%)	(24.5%, 40.2%)
By week 52		
Subjects with event	57 (46%)	43 (31%)
Probability of surgery or steroid use [1]	46.5%	31.6%
95% CI	(38.2%, 55.8%)	(24.5%, 40.2%)
Event [2]	57 (46%)	44 (32%)
Course of systemic steroids prior to Week 52	45 (36%)	37 (27%)
Nasal surgery prior to Week 52	12 (10%)	7 (5%)
Censored	68 (54%)	95 (68%)
Censored at Week 52	60 (48%)	86 (62%)
Censored at study withdrawal	8 (6%)	9 (6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.79
95% CI		(0.53, 1.19)
p-value		0.259

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
By week 8		
Subjects with event	6 (8%)	3 (4%)
Probability of surgery or steroid use [1]	7.9%	4.5%
95% CI	(3.6%, 16.7%)	(1.5%, 13.4%)
By week 16		
Subjects with event	12 (16%)	7 (10%)
Probability of surgery or steroid use [1]	15.9%	10.6%
95% CI	(9.3%, 26.3%)	(5.2%, 21.0%)
By week 24		
Subjects with event	19 (25%)	9 (13%)
Probability of surgery or steroid use [1]	25.2%	13.7%
95% CI	(16.9%, 36.6%)	(7.4%, 24.7%)
By week 32		
Subjects with event	22 (29%)	11 (16%)
Probability of surgery or steroid use [1]	29.2%	16.9%
95% CI	(20.3%, 40.9%)	(9.7%, 28.4%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	23 (30%)	12 (18%)
Probability of surgery or steroid use [1]	30.6%	18.5%
95% CI	(21.5%, 42.3%)	(10.9%, 30.3%)
By week 48		
Subjects with event	26 (34%)	13 (19%)
Probability of surgery or steroid use [1]	34.6%	20.1%
95% CI	(25.1%, 46.6%)	(12.2%, 32.1%)
By week 52		
Subjects with event	27 (36%)	13 (19%)
Probability of surgery or steroid use [1]	36.0%	20.1%
95% CI	(26.3%, 48.0%)	(12.2%, 32.1%)
Event [2]	27 (36%)	13 (19%)
Course of systemic steroids prior to Week 52	20 (26%)	12 (18%)
Nasal surgery prior to Week 52	7 (9%)	1 (1%)
Censored	49 (64%)	54 (81%)
Censored at Week 52	46 (61%)	50 (75%)
Censored at study withdrawal	3 (4%)	4 (6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.80
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.64
95% CI		(0.32, 1.27)
p-value		0.199

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
By week 8		
Subjects with event	5 (6%)	5 (6%)
Probability of surgery or steroid use [1]	5.9%	5.9%
95% CI	(2.5%, 13.6%)	(2.5%, 13.5%)
By week 16		
Subjects with event	13 (15%)	9 (10%)
Probability of surgery or steroid use [1]	15.3%	10.6%
95% CI	(9.2%, 24.9%)	(5.7%, 19.4%)
By week 24		
Subjects with event	21 (25%)	15 (17%)
Probability of surgery or steroid use [1]	24.7%	17.9%
95% CI	(16.9%, 35.3%)	(11.2%, 27.9%)
By week 32		
Subjects with event	27 (32%)	18 (21%)
Probability of surgery or steroid use [1]	31.8%	21.6%
95% CI	(23.0%, 42.8%)	(14.2%, 32.1%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	30 (35%)	19 (22%)
Probability of surgery or steroid use [1]	35.3%	22.9%
95% CI	(26.2%, 46.4%)	(15.3%, 33.5%)
By week 48		
Subjects with event	33 (39%)	20 (23%)
Probability of surgery or steroid use [1]	38.8%	24.2%
95% CI	(29.4%, 50.0%)	(16.3%, 35.0%)
By week 52		
Subjects with event	33 (39%)	20 (23%)
Probability of surgery or steroid use [1]	38.8%	24.2%
95% CI	(29.4%, 50.0%)	(16.3%, 35.0%)
Event [2]	33 (39%)	21 (24%)
Course of systemic steroids prior to Week 52	25 (29%)	20 (23%)
Nasal surgery prior to Week 52	8 (9%)	1 (1%)
Censored	52 (61%)	65 (76%)
Censored at Week 52	49 (58%)	58 (67%)
Censored at study withdrawal	3 (4%)	7 (8%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.59
95% CI		(0.33, 1.05)
p-value		0.073

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
By week 8		
Subjects with event	4 (14%)	1 (4%)
Probability of surgery or steroid use [1]	14.4%	3.6%
95% CI	(5.7%, 34.0%)	(0.5%, 22.8%)
By week 16		
Subjects with event	7 (25%)	8 (29%)
Probability of surgery or steroid use [1]	26.1%	28.9%
95% CI	(13.4%, 47.2%)	(15.6%, 49.6%)
By week 24		
Subjects with event	9 (32%)	9 (32%)
Probability of surgery or steroid use [1]	34.1%	32.7%
95% CI	(19.4%, 55.5%)	(18.5%, 53.4%)
By week 32		
Subjects with event	12 (43%)	9 (32%)
Probability of surgery or steroid use [1]	46.5%	32.7%
95% CI	(29.5%, 67.3%)	(18.5%, 53.4%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	16 (57%)	10 (36%)
Probability of surgery or steroid use [1]	63.4%	36.6%
95% CI	(45.0%, 81.6%)	(21.6%, 57.5%)
By week 48		
Subjects with event	18 (64%)	11 (39%)
Probability of surgery or steroid use [1]	72.5%	40.8%
95% CI	(54.0%, 88.4%)	(25.0%, 61.7%)
By week 52		
Subjects with event	18 (64%)	11 (39%)
Probability of surgery or steroid use [1]	72.5%	40.8%
95% CI	(54.0%, 88.4%)	(25.0%, 61.7%)
Event [2]	18 (64%)	11 (39%)
Course of systemic steroids prior to Week 52	16 (57%)	9 (32%)
Nasal surgery prior to Week 52	2 (7%)	2 (7%)
Censored	10 (36%)	17 (61%)
Censored at Week 52	5 (18%)	13 (46%)
Censored at study withdrawal	5 (18%)	4 (14%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.66
95% CI		(0.30, 1.47)
p-value		0.314

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
By week 8		
Subjects with event	4 (5%)	3 (3%)
Probability of surgery or steroid use [1]	4.5%	3.3%
95% CI	(1.7%, 11.7%)	(1.1%, 9.8%)
By week 16		
Subjects with event	10 (11%)	9 (10%)
Probability of surgery or steroid use [1]	11.4%	9.8%
95% CI	(6.3%, 20.1%)	(5.2%, 18.0%)
By week 24		
Subjects with event	21 (24%)	17 (18%)
Probability of surgery or steroid use [1]	24.0%	18.5%
95% CI	(16.3%, 34.4%)	(11.9%, 28.1%)
By week 32		
Subjects with event	23 (26%)	19 (21%)
Probability of surgery or steroid use [1]	26.3%	20.7%
95% CI	(18.3%, 36.8%)	(13.7%, 30.5%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	25 (28%)	21 (23%)
Probability of surgery or steroid use [1]	28.6%	22.9%
95% CI	(20.3%, 39.3%)	(15.6%, 33.0%)
By week 48		
Subjects with event	32 (36%)	25 (27%)
Probability of surgery or steroid use [1]	36.7%	27.4%
95% CI	(27.6%, 47.7%)	(19.4%, 37.8%)
By week 52		
Subjects with event	33 (38%)	25 (27%)
Probability of surgery or steroid use [1]	37.9%	27.4%
95% CI	(28.6%, 49.0%)	(19.4%, 37.8%)
Event [2]	33 (38%)	25 (27%)
Course of systemic steroids prior to Week 52	24 (27%)	20 (22%)
Nasal surgery prior to Week 52	9 (10%)	5 (5%)
Censored	55 (63%)	67 (73%)
Censored at Week 52	52 (59%)	65 (71%)
Censored at study withdrawal	3 (3%)	2 (2%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.81
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.78
95% CI		(0.46, 1.32)
p-value		0.355

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Intent-to-Treat

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
By week 8		
Subjects with event	5 (8%)	4 (9%)
Probability of surgery or steroid use [1]	7.9%	8.9%
95% CI	(3.4%, 18.0%)	(3.4%, 22.0%)
By week 16		
Subjects with event	10 (16%)	6 (13%)
Probability of surgery or steroid use [1]	15.9%	13.3%
95% CI	(8.9%, 27.5%)	(6.2%, 27.3%)
By week 24		
Subjects with event	19 (30%)	8 (18%)
Probability of surgery or steroid use [1]	30.2%	17.9%
95% CI	(20.4%, 43.1%)	(9.4%, 32.6%)
By week 32		
Subjects with event	24 (38%)	10 (22%)
Probability of surgery or steroid use [1]	38.1%	22.5%
95% CI	(27.4%, 51.2%)	(12.8%, 37.7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	28 (44%)	10 (22%)
Probability of surgery or steroid use [1]	44.4%	22.5%
95% CI	(33.2%, 57.5%)	(12.8%, 37.7%)
By week 48		
Subjects with event	32 (51%)	13 (29%)
Probability of surgery or steroid use [1]	50.8%	29.5%
95% CI	(39.2%, 63.6%)	(18.3%, 45.4%)
By week 52		
Subjects with event	32 (51%)	13 (29%)
Probability of surgery or steroid use [1]	50.8%	29.5%
95% CI	(39.2%, 63.6%)	(18.3%, 45.4%)
Event [2]	32 (51%)	14 (31%)
Course of systemic steroids prior to Week 52	28 (44%)	11 (24%)
Nasal surgery prior to Week 52	4 (6%)	3 (7%)
Censored	31 (49%)	31 (69%)
Censored at Week 52	28 (44%)	28 (62%)
Censored at study withdrawal	3 (5%)	3 (7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.53
95% CI		(0.27, 1.02)
p-value		0.057

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
By week 8		
Subjects with event	8 (6%)	5 (3%)
Probability of surgery or steroid use [1]	5.8%	3.1%
95% CI	(2.9%, 11.3%)	(1.3%, 7.3%)
By week 16		
Subjects with event	20 (14%)	20 (12%)
Probability of surgery or steroid use [1]	14.6%	12.5%
95% CI	(9.7%, 21.7%)	(8.3%, 18.7%)
By week 24		
Subjects with event	32 (23%)	33 (20%)
Probability of surgery or steroid use [1]	23.5%	20.8%
95% CI	(17.2%, 31.6%)	(15.3%, 28.0%)
By week 32		
Subjects with event	38 (28%)	36 (22%)
Probability of surgery or steroid use [1]	28.0%	22.8%
95% CI	(21.2%, 36.4%)	(17.0%, 30.1%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	43 (31%)	40 (25%)
Probability of surgery or steroid use [1]	31.8%	25.4%
95% CI	(24.6%, 40.3%)	(19.3%, 33.0%)
By week 48		
Subjects with event	51 (37%)	43 (27%)
Probability of surgery or steroid use [1]	37.9%	27.4%
95% CI	(30.3%, 46.7%)	(21.1%, 35.2%)
By week 52		
Subjects with event	52 (38%)	43 (27%)
Probability of surgery or steroid use [1]	38.7%	27.4%
95% CI	(31.0%, 47.5%)	(21.1%, 35.2%)
Event [2]	52 (38%)	43 (27%)
Course of systemic steroids prior to Week 52	37 (27%)	38 (24%)
Nasal surgery prior to Week 52	15 (11%)	5 (3%)
Censored	86 (62%)	118 (73%)
Censored at Week 52	78 (57%)	108 (67%)
Censored at study withdrawal	8 (6%)	10 (6%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.82
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.80
95% CI		(0.53, 1.21)
p-value		0.298

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
By week 8		
Subjects with event	4 (5%)	2 (2%)
Probability of surgery or steroid use [1]	5.0%	1.9%
95% CI	(1.9%, 12.7%)	(0.5%, 7.2%)
By week 16		
Subjects with event	11 (14%)	6 (6%)
Probability of surgery or steroid use [1]	13.7%	5.6%
95% CI	(7.8%, 23.4%)	(2.6%, 12.0%)
By week 24		
Subjects with event	18 (22%)	13 (12%)
Probability of surgery or steroid use [1]	22.5%	12.3%
95% CI	(14.8%, 33.3%)	(7.4%, 20.3%)
By week 32		
Subjects with event	23 (28%)	16 (15%)
Probability of surgery or steroid use [1]	28.7%	15.3%
95% CI	(20.1%, 40.0%)	(9.7%, 23.8%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	26 (32%)	18 (17%)
Probability of surgery or steroid use [1]	32.5%	17.3%
95% CI	(23.4%, 43.9%)	(11.3%, 26.0%)
By week 48		
Subjects with event	32 (40%)	21 (19%)
Probability of surgery or steroid use [1]	40.1%	20.3%
95% CI	(30.3%, 51.7%)	(13.7%, 29.4%)
By week 52		
Subjects with event	33 (41%)	21 (19%)
Probability of surgery or steroid use [1]	41.4%	20.3%
95% CI	(31.5%, 52.9%)	(13.7%, 29.4%)
Event [2]	33 (41%)	21 (19%)
Course of systemic steroids prior to Week 52	27 (33%)	17 (16%)
Nasal surgery prior to Week 52	6 (7%)	4 (4%)
Censored	48 (59%)	87 (81%)
Censored at Week 52	46 (57%)	79 (73%)
Censored at study withdrawal	2 (2%)	8 (7%)
Hazard ratio (Mepo/Placebo) [3]		0.43
95% CI		(0.25, 0.74)
p-value		0.002

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
By week 8		
Subjects with event	1 (2%)	1 (2%)
Probability of surgery or steroid use [1]	2.1%	2.1%
95% CI	(0.3%, 14.2%)	(0.3%, 14.2%)
By week 16		
Subjects with event	6 (13%)	9 (19%)
Probability of surgery or steroid use [1]	12.8%	19.1%
95% CI	(5.9%, 26.2%)	(10.5%, 33.6%)
By week 24		
Subjects with event	12 (26%)	12 (26%)
Probability of surgery or steroid use [1]	26.0%	25.7%
95% CI	(15.7%, 41.2%)	(15.5%, 40.8%)
By week 32		
Subjects with event	14 (30%)	14 (30%)
Probability of surgery or steroid use [1]	30.5%	30.1%
95% CI	(19.3%, 46.0%)	(19.0%, 45.5%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	17 (36%)	15 (32%)
Probability of surgery or steroid use [1]	37.2%	32.3%
95% CI	(25.0%, 52.9%)	(20.9%, 47.8%)
By week 48		
Subjects with event	18 (38%)	15 (32%)
Probability of surgery or steroid use [1]	39.4%	32.3%
95% CI	(26.9%, 55.1%)	(20.9%, 47.8%)
By week 52		
Subjects with event	18 (38%)	15 (32%)
Probability of surgery or steroid use [1]	39.4%	32.3%
95% CI	(26.9%, 55.1%)	(20.9%, 47.8%)
Event [2]	18 (38%)	15 (32%)
Course of systemic steroids prior to Week 52	11 (23%)	14 (30%)
Nasal surgery prior to Week 52	7 (15%)	1 (2%)
Censored	29 (62%)	32 (68%)
Censored at Week 52	25 (53%)	28 (60%)
Censored at study withdrawal	4 (9%)	4 (9%)
Hazard ratio (Mepo/Placebo) [3]		1.32
95% CI		(0.62, 2.78)
p-value		0.471

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
By week 8		
Subjects with event	8 (11%)	6 (12%)
Probability of surgery or steroid use [1]	11.0%	11.8%
95% CI	(5.6%, 20.7%)	(5.5%, 24.3%)
By week 16		
Subjects with event	13 (18%)	11 (22%)
Probability of surgery or steroid use [1]	17.9%	21.6%
95% CI	(10.8%, 28.8%)	(12.6%, 35.6%)
By week 24		
Subjects with event	21 (29%)	16 (31%)
Probability of surgery or steroid use [1]	29.0%	31.4%
95% CI	(20.0%, 40.9%)	(20.5%, 46.0%)
By week 32		
Subjects with event	25 (34%)	16 (31%)
Probability of surgery or steroid use [1]	34.6%	31.4%
95% CI	(24.9%, 46.7%)	(20.5%, 46.0%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.83
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	28 (38%)	17 (33%)
Probability of surgery or steroid use [1]	38.8%	33.4%
95% CI	(28.6%, 51.0%)	(22.3%, 48.1%)
By week 48		
Subjects with event	33 (45%)	20 (39%)
Probability of surgery or steroid use [1]	45.9%	39.4%
95% CI	(35.2%, 58.1%)	(27.5%, 54.2%)
By week 52		
Subjects with event	33 (45%)	20 (39%)
Probability of surgery or steroid use [1]	45.9%	39.4%
95% CI	(35.2%, 58.1%)	(27.5%, 54.2%)
Event [2]	33 (45%)	21 (41%)
Course of systemic steroids prior to Week 52	27 (37%)	18 (35%)
Nasal surgery prior to Week 52	6 (8%)	3 (6%)
Censored	40 (55%)	30 (59%)
Censored at Week 52	35 (48%)	29 (57%)
Censored at study withdrawal	5 (7%)	1 (2%)
Hazard ratio (Mepo/Placebo) [3]		1.01
95% CI		(0.58, 1.78)
p-value		0.966

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
By week 8		
Subjects with event	0	1 (3%)
Probability of surgery or steroid use [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 16		
Subjects with event	0	1 (3%)
Probability of surgery or steroid use [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 24		
Subjects with event	2 (5%)	2 (6%)
Probability of surgery or steroid use [1]	5.1%	6.0%
95% CI	(1.3%, 19.0%)	(1.5%, 21.8%)
By week 32		
Subjects with event	3 (8%)	3 (9%)
Probability of surgery or steroid use [1]	7.7%	9.0%
95% CI	(2.5%, 22.0%)	(3.0%, 25.4%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	4 (10%)	5 (14%)
Probability of surgery or steroid use [1]	10.3%	15.5%
95% CI	(4.0%, 25.1%)	(6.8%, 33.4%)
By week 48		
Subjects with event	5 (13%)	6 (17%)
Probability of surgery or steroid use [1]	12.9%	18.8%
95% CI	(5.6%, 28.3%)	(8.9%, 37.1%)
By week 52		
Subjects with event	6 (15%)	6 (17%)
Probability of surgery or steroid use [1]	15.6%	18.8%
95% CI	(7.3%, 31.5%)	(8.9%, 37.1%)
Event [2]	6 (15%)	6 (17%)
Course of systemic steroids prior to Week 52	5 (13%)	5 (14%)
Nasal surgery prior to Week 52	1 (3%)	1 (3%)
Censored	34 (85%)	29 (83%)
Censored at Week 52	31 (78%)	25 (71%)
Censored at study withdrawal	3 (8%)	4 (11%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		1.43
95% CI		(0.43, 4.71)
p-value		0.561

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Population: Intent-to-Treat

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
By week 8		
Subjects with event	13 (8%)	8 (5%)
Probability of surgery or steroid use [1]	8.1%	4.7%
95% CI	(4.8%, 13.5%)	(2.4%, 9.1%)
By week 16		
Subjects with event	30 (19%)	25 (15%)
Probability of surgery or steroid use [1]	18.7%	14.6%
95% CI	(13.5%, 25.7%)	(10.1%, 20.9%)
By week 24		
Subjects with event	49 (30%)	39 (23%)
Probability of surgery or steroid use [1]	30.7%	23.0%
95% CI	(24.2%, 38.5%)	(17.4%, 30.1%)
By week 32		
Subjects with event	59 (37%)	43 (25%)
Probability of surgery or steroid use [1]	37.0%	25.4%
95% CI	(30.1%, 45.1%)	(19.5%, 32.7%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	67 (42%)	45 (26%)
Probability of surgery or steroid use [1]	42.1%	26.7%
95% CI	(34.9%, 50.2%)	(20.6%, 34.0%)
By week 48		
Subjects with event	78 (48%)	50 (29%)
Probability of surgery or steroid use [1]	49.2%	29.8%
95% CI	(41.7%, 57.2%)	(23.5%, 37.3%)
By week 52		
Subjects with event	78 (48%)	50 (29%)
Probability of surgery or steroid use [1]	49.2%	29.8%
95% CI	(41.7%, 57.2%)	(23.5%, 37.3%)
Event [2]	78 (48%)	51 (30%)
Course of systemic steroids prior to Week 52	60 (37%)	44 (26%)
Nasal surgery prior to Week 52	18 (11%)	7 (4%)
Censored	83 (52%)	120 (70%)
Censored at Week 52	75 (47%)	111 (65%)
Censored at study withdrawal	8 (5%)	9 (5%)

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.84
Subgroup Analysis of Time to First Nasal Surgery or Course of Systemic Steroids for Nasal Polyps up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Hazard ratio (Mepo/Placebo) [3]		0.67
95% CI		(0.46, 0.96)
p-value		0.029

[1] Kaplan-Meier estimate.
[2] Subjects that experienced both events are only counted in the event that occurred first.
[3] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
By week 8		
Subjects with event	0	1 (2%)
Probability of surgery [1]		1.6%
95% CI		(0.2%, 10.6%)
By week 16		
Subjects with event	1 (2%)	1 (2%)
Probability of surgery [1]	2.0%	1.6%
95% CI	(0.3%, 13.1%)	(0.2%, 10.6%)
By week 24		
Subjects with event	4 (8%)	4 (6%)
Probability of surgery [1]	8.1%	6.6%
95% CI	(3.1%, 20.1%)	(2.5%, 16.6%)
By week 32		
Subjects with event	7 (13%)	4 (6%)
Probability of surgery [1]	14.5%	6.6%
95% CI	(7.2%, 28.0%)	(2.5%, 16.6%)
By week 40		
Subjects with event	8 (15%)	5 (8%)
Probability of surgery [1]	16.6%	8.3%
95% CI	(8.7%, 30.5%)	(3.5%, 18.8%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	10 (19%)	6 (9%)
Probability of surgery [1]	20.9%	10.0%
95% CI	(11.8%, 35.4%)	(4.6%, 21.0%)
By week 52		
Subjects with event	10 (19%)	6 (9%)
Probability of surgery [1]	20.9%	10.0%
95% CI	(11.8%, 35.4%)	(4.6%, 21.0%)
Event: Nasal surgery prior to Week 52	10 (19%)	6 (9%)
Censored	42 (81%)	58 (91%)
Censored at Week 52	35 (67%)	52 (81%)
Censored at study withdrawal	7 (13%)	6 (9%)
Hazard ratio (Mepo/Placebo) [2]		0.50
95% CI		(0.17, 1.45)
p-value		0.201

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
By week 8		
Subjects with event	2 (2%)	0
Probability of surgery [1]	1.6%	
95% CI	(0.4%, 6.4%)	
By week 16		
Subjects with event	6 (5%)	1 (<1%)
Probability of surgery [1]	4.9%	0.9%
95% CI	(2.2%, 10.6%)	(0.1%, 6.1%)
By week 24		
Subjects with event	13 (11%)	4 (4%)
Probability of surgery [1]	10.7%	3.6%
95% CI	(6.3%, 17.6%)	(1.4%, 9.2%)
By week 32		
Subjects with event	19 (16%)	7 (6%)
Probability of surgery [1]	15.6%	6.3%
95% CI	(10.3%, 23.4%)	(3.1%, 12.8%)
By week 40		
Subjects with event	26 (21%)	9 (8%)
Probability of surgery [1]	21.5%	8.1%
95% CI	(15.2%, 29.9%)	(4.3%, 15.1%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	29 (24%)	10 (9%)
Probability of surgery [1]	24.1%	9.1%
95% CI	(17.4%, 32.7%)	(5.0%, 16.2%)
By week 52		
Subjects with event	32 (26%)	10 (9%)
Probability of surgery [1]	26.7%	9.1%
95% CI	(19.7%, 35.6%)	(5.0%, 16.2%)
Event: Nasal surgery prior to Week 52	32 (26%)	10 (9%)
Censored	90 (74%)	103 (91%)
Censored at Week 52	82 (67%)	96 (85%)
Censored at study withdrawal	8 (7%)	7 (6%)
Hazard ratio (Mepo/Placebo) [2]		0.40
95% CI		(0.19, 0.84)
p-value		0.015

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
By week 8		
Subjects with event	0	0
Probability of surgery [1]		
95% CI		
By week 16		
Subjects with event	0	0
Probability of surgery [1]		
95% CI		
By week 24		
Subjects with event	1 (4%)	0
Probability of surgery [1]	3.7%	
95% CI	(0.5%, 23.5%)	
By week 32		
Subjects with event	2 (7%)	1 (3%)
Probability of surgery [1]	7.4%	3.7%
95% CI	(1.9%, 26.5%)	(0.5%, 23.5%)
By week 40		
Subjects with event	3 (11%)	1 (3%)
Probability of surgery [1]	11.1%	3.7%
95% CI	(3.7%, 30.6%)	(0.5%, 23.5%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.72
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	4 (15%)	2 (7%)
Probability of surgery [1]	14.8%	7.6%
95% CI	(5.8%, 34.8%)	(1.9%, 27.0%)
By week 52		
Subjects with event	4 (15%)	2 (7%)
Probability of surgery [1]	14.8%	7.6%
95% CI	(5.8%, 34.8%)	(1.9%, 27.0%)
Event: Nasal surgery prior to Week 52	4 (15%)	2 (7%)
Censored	23 (85%)	27 (93%)
Censored at Week 52	23 (85%)	24 (83%)
Censored at study withdrawal	0	3 (10%)
Hazard ratio (Mepo/Placebo) [2]		0.31
95% CI		(0.02, 4.00)
p-value		0.370

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.73
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
By week 8		
Subjects with event	1 (<1%)	1 (<1%)
Probability of surgery [1]	0.8%	0.7%
95% CI	(0.1%, 5.6%)	(0.1%, 5.0%)
By week 16		
Subjects with event	5 (4%)	2 (1%)
Probability of surgery [1]	4.0%	1.4%
95% CI	(1.7%, 9.4%)	(0.4%, 5.6%)
By week 24		
Subjects with event	11 (9%)	7 (5%)
Probability of surgery [1]	8.9%	5.1%
95% CI	(5.0%, 15.5%)	(2.5%, 10.4%)
By week 32		
Subjects with event	17 (14%)	10 (7%)
Probability of surgery [1]	13.9%	7.4%
95% CI	(8.9%, 21.4%)	(4.0%, 13.3%)
By week 40		
Subjects with event	23 (18%)	12 (9%)
Probability of surgery [1]	18.8%	8.9%
95% CI	(12.9%, 27.0%)	(5.2%, 15.2%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.73
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	27 (22%)	15 (11%)
Probability of surgery [1]	22.2%	11.3%
95% CI	(15.8%, 30.7%)	(6.9%, 18.0%)
By week 52		
Subjects with event	28 (22%)	15 (11%)
Probability of surgery [1]	23.1%	11.3%
95% CI	(16.5%, 31.7%)	(6.9%, 18.0%)
Event: Nasal surgery prior to Week 52	28 (22%)	15 (11%)
Censored	97 (78%)	124 (89%)
Censored at Week 52	87 (70%)	113 (81%)
Censored at study withdrawal	10 (8%)	11 (8%)
Hazard ratio (Mepo/Placebo) [2]		0.61
95% CI		(0.32, 1.17)
p-value		0.137

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.73
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
By week 8		
Subjects with event	1 (1%)	0
Probability of surgery [1]	1.3%	
95% CI	(0.2%, 9.0%)	
By week 16		
Subjects with event	2 (3%)	0
Probability of surgery [1]	2.6%	
95% CI	(0.7%, 10.2%)	
By week 24		
Subjects with event	7 (9%)	1 (1%)
Probability of surgery [1]	9.3%	1.6%
95% CI	(4.6%, 18.6%)	(0.2%, 10.7%)
By week 32		
Subjects with event	11 (14%)	2 (3%)
Probability of surgery [1]	14.7%	3.2%
95% CI	(8.4%, 25.0%)	(0.8%, 12.1%)
By week 40		
Subjects with event	14 (18%)	3 (4%)
Probability of surgery [1]	18.9%	4.8%
95% CI	(11.6%, 29.8%)	(1.6%, 14.1%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.73
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	16 (21%)	3 (4%)
Probability of surgery [1]	21.7%	4.8%
95% CI	(13.9%, 32.9%)	(1.6%, 14.1%)
By week 52		
Subjects with event	18 (24%)	3 (4%)
Probability of surgery [1]	24.5%	4.8%
95% CI	(16.2%, 36.1%)	(1.6%, 14.1%)
Event: Nasal surgery prior to Week 52	18 (24%)	3 (4%)
Censored	58 (76%)	64 (96%)
Censored at Week 52	53 (70%)	59 (88%)
Censored at study withdrawal	5 (7%)	5 (7%)
Hazard ratio (Mepo/Placebo) [2]		0.21
95% CI		(0.06, 0.73)
p-value		0.014

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
By week 8		
Subjects with event	1 (1%)	0
Probability of surgery [1]	1.2%	
95% CI	(0.2%, 8.1%)	
By week 16		
Subjects with event	1 (1%)	0
Probability of surgery [1]	1.2%	
95% CI	(0.2%, 8.1%)	
By week 24		
Subjects with event	6 (7%)	0
Probability of surgery [1]	7.1%	
95% CI	(3.2%, 15.0%)	
By week 32		
Subjects with event	12 (14%)	2 (2%)
Probability of surgery [1]	14.1%	2.5%
95% CI	(8.3%, 23.5%)	(0.6%, 9.6%)
By week 40		
Subjects with event	15 (18%)	3 (3%)
Probability of surgery [1]	17.6%	3.8%
95% CI	(11.0%, 27.6%)	(1.2%, 11.2%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	17 (20%)	5 (6%)
Probability of surgery [1]	20.0%	6.3%
95% CI	(12.9%, 30.2%)	(2.7%, 14.5%)
By week 52		
Subjects with event	18 (21%)	5 (6%)
Probability of surgery [1]	21.3%	6.3%
95% CI	(14.0%, 31.6%)	(2.7%, 14.5%)
Event: Nasal surgery prior to Week 52	18 (21%)	5 (6%)
Censored	67 (79%)	81 (94%)
Censored at Week 52	64 (75%)	73 (85%)
Censored at study withdrawal	3 (4%)	8 (9%)
Hazard ratio (Mepo/Placebo) [2]		0.27
95% CI		(0.10, 0.74)
p-value		0.011

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
By week 8		
Subjects with event	0	0
Probability of surgery [1]		
95% CI		
By week 16		
Subjects with event	2 (7%)	0
Probability of surgery [1]	7.6%	
95% CI	(1.9%, 27.0%)	
By week 24		
Subjects with event	2 (7%)	1 (4%)
Probability of surgery [1]	7.6%	3.8%
95% CI	(1.9%, 27.0%)	(0.6%, 24.3%)
By week 32		
Subjects with event	4 (14%)	2 (7%)
Probability of surgery [1]	16.4%	7.7%
95% CI	(6.4%, 38.1%)	(2.0%, 27.4%)
By week 40		
Subjects with event	9 (32%)	2 (7%)
Probability of surgery [1]	38.7%	7.7%
95% CI	(22.2%, 61.4%)	(2.0%, 27.4%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	10 (36%)	3 (11%)
Probability of surgery [1]	43.4%	11.9%
95% CI	(26.0%, 65.9%)	(4.0%, 32.5%)
By week 52		
Subjects with event	10 (36%)	3 (11%)
Probability of surgery [1]	43.4%	11.9%
95% CI	(26.0%, 65.9%)	(4.0%, 32.5%)
Event: Nasal surgery prior to Week 52	10 (36%)	3 (11%)
Censored	18 (64%)	25 (89%)
Censored at Week 52	10 (36%)	20 (71%)
Censored at study withdrawal	8 (29%)	5 (18%)
Hazard ratio (Mepo/Placebo) [2]		0.28
95% CI		(0.07, 1.05)
p-value		0.059

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
By week 8		
Subjects with event	1 (1%)	1 (1%)
Probability of surgery [1]	1.1%	1.1%
95% CI	(0.2%, 7.8%)	(0.2%, 7.5%)
By week 16		
Subjects with event	4 (5%)	2 (2%)
Probability of surgery [1]	4.5%	2.2%
95% CI	(1.7%, 11.7%)	(0.5%, 8.4%)
By week 24		
Subjects with event	10 (11%)	7 (8%)
Probability of surgery [1]	11.4%	7.7%
95% CI	(6.3%, 20.2%)	(3.7%, 15.5%)
By week 32		
Subjects with event	12 (14%)	8 (9%)
Probability of surgery [1]	13.7%	8.8%
95% CI	(8.0%, 22.9%)	(4.5%, 16.8%)
By week 40		
Subjects with event	13 (15%)	10 (11%)
Probability of surgery [1]	14.9%	11.1%
95% CI	(8.9%, 24.3%)	(6.1%, 19.6%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Table 27.74
Subgroup Analysis of Time to First Nasal Surgery up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	16 (18%)	10 (11%)
Probability of surgery [1]	18.5%	11.1%
95% CI	(11.7%, 28.4%)	(6.1%, 19.6%)
By week 52		
Subjects with event	18 (20%)	10 (11%)
Probability of surgery [1]	20.9%	11.1%
95% CI	(13.7%, 31.1%)	(6.1%, 19.6%)
Event: Nasal surgery prior to Week 52	18 (20%)	10 (11%)
Censored	70 (80%)	82 (89%)
Censored at Week 52	66 (75%)	79 (86%)
Censored at study withdrawal	4 (5%)	3 (3%)
Hazard ratio (Mepo/Placebo) [2]		0.68
95% CI		(0.30, 1.50)
p-value		0.334

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.75
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
By week 8		
Subjects with event	1 (2%)	1 (2%)
Probability of surgery [1]	1.6%	2.2%
95% CI	(0.2%, 10.7%)	(0.3%, 14.7%)
By week 16		
Subjects with event	4 (6%)	1 (2%)
Probability of surgery [1]	6.3%	2.2%
95% CI	(2.4%, 16.0%)	(0.3%, 14.7%)
By week 24		
Subjects with event	5 (8%)	3 (7%)
Probability of surgery [1]	7.9%	6.8%
95% CI	(3.4%, 18.0%)	(2.2%, 19.5%)
By week 32		
Subjects with event	11 (17%)	4 (9%)
Probability of surgery [1]	17.8%	9.0%
95% CI	(10.3%, 29.8%)	(3.5%, 22.3%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.75
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	15 (24%)	5 (11%)
Probability of surgery [1]	24.5%	11.3%
95% CI	(15.6%, 37.4%)	(4.9%, 25.1%)
By week 48		
Subjects with event	17 (27%)	5 (11%)
Probability of surgery [1]	28.0%	11.3%
95% CI	(18.4%, 41.1%)	(4.9%, 25.1%)
By week 52		
Subjects with event	18 (29%)	5 (11%)
Probability of surgery [1]	29.8%	11.3%
95% CI	(19.9%, 43.1%)	(4.9%, 25.1%)
Event: Nasal surgery prior to Week 52	18 (29%)	5 (11%)
Censored	45 (71%)	40 (89%)
Censored at Week 52	39 (62%)	37 (82%)
Censored at study withdrawal	6 (10%)	3 (7%)
Hazard ratio (Mepo/Placebo) [2]		0.32
95% CI		(0.11, 0.89)
p-value		0.030

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.75
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
By week 8		
Subjects with event	1 (<1%)	0
Probability of surgery [1]	0.7%	
95% CI	(0.1%, 5.1%)	
By week 16		
Subjects with event	3 (2%)	1 (<1%)
Probability of surgery [1]	2.2%	0.6%
95% CI	(0.7%, 6.7%)	(0.1%, 4.4%)
By week 24		
Subjects with event	13 (9%)	5 (3%)
Probability of surgery [1]	9.6%	3.2%
95% CI	(5.7%, 16.0%)	(1.3%, 7.5%)
By week 32		
Subjects with event	17 (12%)	8 (5%)
Probability of surgery [1]	12.6%	5.2%
95% CI	(8.0%, 19.5%)	(2.6%, 10.1%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Intent-to-Treat

Table 27.75
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	22 (16%)	10 (6%)
Probability of surgery [1]	16.3%	6.5%
95% CI	(11.1%, 23.8%)	(3.6%, 11.8%)
By week 48		
Subjects with event	26 (19%)	13 (8%)
Probability of surgery [1]	19.4%	8.6%
95% CI	(13.6%, 27.1%)	(5.1%, 14.3%)
By week 52		
Subjects with event	28 (20%)	13 (8%)
Probability of surgery [1]	20.9%	8.6%
95% CI	(14.9%, 28.9%)	(5.1%, 14.3%)
Event: Nasal surgery prior to Week 52	28 (20%)	13 (8%)
Censored	110 (80%)	148 (92%)
Censored at Week 52	101 (73%)	135 (84%)
Censored at study withdrawal	9 (7%)	13 (8%)
Hazard ratio (Mepo/Placebo) [2]		0.47
95% CI		(0.24, 0.92)
p-value		0.028

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
By week 8		
Subjects with event	0	1 (<1%)
Probability of surgery [1]		0.9%
95% CI		(0.1%, 6.4%)
By week 16		
Subjects with event	1 (1%)	1 (<1%)
Probability of surgery [1]	1.3%	0.9%
95% CI	(0.2%, 8.5%)	(0.1%, 6.4%)
By week 24		
Subjects with event	6 (7%)	3 (3%)
Probability of surgery [1]	7.5%	2.8%
95% CI	(3.4%, 15.9%)	(0.9%, 8.6%)
By week 32		
Subjects with event	11 (14%)	3 (3%)
Probability of surgery [1]	13.8%	2.8%
95% CI	(7.9%, 23.6%)	(0.9%, 8.6%)
By week 40		
Subjects with event	12 (15%)	4 (4%)
Probability of surgery [1]	15.1%	3.8%
95% CI	(8.9%, 25.1%)	(1.5%, 9.9%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Population: Intent-to-Treat

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	15 (19%)	6 (6%)
Probability of surgery [1]	18.9%	5.8%
95% CI	(11.9%, 29.4%)	(2.7%, 12.5%)
By week 52		
Subjects with event	16 (20%)	6 (6%)
Probability of surgery [1]	20.3%	5.8%
95% CI	(12.9%, 30.9%)	(2.7%, 12.5%)
Event: Nasal surgery prior to Week 52	16 (20%)	6 (6%)
Censored	65 (80%)	102 (94%)
Censored at Week 52	61 (75%)	94 (87%)
Censored at study withdrawal	4 (5%)	8 (7%)
Hazard ratio (Mepo/Placebo) [2]		0.27
95% CI		(0.10, 0.69)
p-value		0.006

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
By week 8		
Subjects with event	0	0
Probability of surgery [1]		
95% CI		
By week 16		
Subjects with event	1 (2%)	1 (2%)
Probability of surgery [1]	2.1%	2.1%
95% CI	(0.3%, 14.2%)	(0.3%, 14.2%)
By week 24		
Subjects with event	3 (6%)	2 (4%)
Probability of surgery [1]	6.6%	4.4%
95% CI	(2.2%, 19.0%)	(1.1%, 16.5%)
By week 32		
Subjects with event	5 (11%)	4 (9%)
Probability of surgery [1]	11.0%	9.1%
95% CI	(4.7%, 24.5%)	(3.5%, 22.4%)
By week 40		
Subjects with event	8 (17%)	5 (11%)
Probability of surgery [1]	17.9%	11.5%
95% CI	(9.4%, 32.6%)	(4.9%, 25.4%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Population: Intent-to-Treat

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	9 (19%)	5 (11%)
Probability of surgery [1]	20.2%	11.5%
95% CI	(11.0%, 35.2%)	(4.9%, 25.4%)
By week 52		
Subjects with event	9 (19%)	5 (11%)
Probability of surgery [1]	20.2%	11.5%
95% CI	(11.0%, 35.2%)	(4.9%, 25.4%)
Event: Nasal surgery prior to Week 52	9 (19%)	5 (11%)
Censored	38 (81%)	42 (89%)
Censored at Week 52	33 (70%)	35 (74%)
Censored at study withdrawal	5 (11%)	7 (15%)
Hazard ratio (Mepo/Placebo) [2]		0.79
95% CI		(0.24, 2.61)
p-value		0.700

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
By week 8		
Subjects with event	2 (3%)	0
Probability of surgery [1]	2.7%	
95% CI	(0.7%, 10.5%)	
By week 16		
Subjects with event	5 (7%)	0
Probability of surgery [1]	6.9%	
95% CI	(2.9%, 15.8%)	
By week 24		
Subjects with event	9 (12%)	3 (6%)
Probability of surgery [1]	12.5%	5.9%
95% CI	(6.7%, 22.6%)	(1.9%, 17.1%)
By week 32		
Subjects with event	12 (16%)	5 (10%)
Probability of surgery [1]	16.7%	9.8%
95% CI	(9.8%, 27.5%)	(4.2%, 22.0%)
By week 40		
Subjects with event	17 (23%)	6 (12%)
Probability of surgery [1]	23.8%	11.8%
95% CI	(15.5%, 35.5%)	(5.5%, 24.4%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Population: Intent-to-Treat

Table 27.76
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 48		
Subjects with event	19 (26%)	7 (14%)
Probability of surgery [1]	26.7%	13.8%
95% CI	(17.9%, 38.7%)	(6.8%, 26.8%)
By week 52		
Subjects with event	21 (29%)	7 (14%)
Probability of surgery [1]	29.7%	13.8%
95% CI	(20.5%, 41.9%)	(6.8%, 26.8%)
Event: Nasal surgery prior to Week 52	21 (29%)	7 (14%)
Censored	52 (71%)	44 (86%)
Censored at Week 52	46 (63%)	43 (84%)
Censored at study withdrawal	6 (8%)	1 (2%)
Hazard ratio (Mepo/Placebo) [2]		0.48
95% CI		(0.20, 1.16)
p-value		0.102

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS and log(e) baseline blood eosinophil count.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.77
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
By week 8		
Subjects with event	0	1 (3%)
Probability of surgery [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 16		
Subjects with event	0	1 (3%)
Probability of surgery [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 24		
Subjects with event	0	1 (3%)
Probability of surgery [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 32		
Subjects with event	0	1 (3%)
Probability of surgery [1]		2.9%
95% CI		(0.4%, 19.1%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.77
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	0	1 (3%)
Probability of surgery [1]		2.9%
95% CI		(0.4%, 19.1%)
By week 48		
Subjects with event	1 (3%)	1 (3%)
Probability of surgery [1]	2.6%	2.9%
95% CI	(0.4%, 17.2%)	(0.4%, 19.1%)
By week 52		
Subjects with event	2 (5%)	1 (3%)
Probability of surgery [1]	5.4%	2.9%
95% CI	(1.4%, 20.0%)	(0.4%, 19.1%)
Event: Nasal surgery prior to Week 52	2 (5%)	1 (3%)
Censored	38 (95%)	34 (97%)
Censored at Week 52	35 (88%)	30 (86%)
Censored at study withdrawal	3 (8%)	4 (11%)
Hazard ratio (Mepo/Placebo) [2]		0.65
95% CI		(0.02, 20.60)
p-value		0.809

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Population: Intent-to-Treat

Table 27.77
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
By week 8		
Subjects with event	2 (1%)	0
Probability of surgery [1]	1.3%	
95% CI	(0.3%, 4.9%)	
By week 16		
Subjects with event	7 (4%)	1 (<1%)
Probability of surgery [1]	4.4%	0.6%
95% CI	(2.1%, 9.0%)	(0.1%, 4.1%)
By week 24		
Subjects with event	18 (11%)	7 (4%)
Probability of surgery [1]	11.3%	4.2%
95% CI	(7.3%, 17.3%)	(2.0%, 8.6%)
By week 32		
Subjects with event	28 (17%)	11 (6%)
Probability of surgery [1]	17.7%	6.7%
95% CI	(12.6%, 24.6%)	(3.7%, 11.7%)

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

Protocol: 205687
Population: Intent-to-Treat

Table 27.77
Subgroup Analysis of Time to First Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
By week 40		
Subjects with event	37 (23%)	14 (8%)
Probability of surgery [1]	23.6%	8.5%
95% CI	(17.7%, 31.0%)	(5.1%, 14.0%)
By week 48		
Subjects with event	42 (26%)	17 (10%)
Probability of surgery [1]	26.8%	10.4%
95% CI	(20.6%, 34.5%)	(6.6%, 16.2%)
By week 52		
Subjects with event	44 (27%)	17 (10%)
Probability of surgery [1]	28.2%	10.4%
95% CI	(21.8%, 36.0%)	(6.6%, 16.2%)
Event: Nasal surgery prior to Week 52	44 (27%)	17 (10%)
Censored	117 (73%)	154 (90%)
Censored at Week 52	105 (65%)	142 (83%)
Censored at study withdrawal	12 (7%)	12 (7%)
Hazard ratio (Mepo/Placebo) [2]		0.42
95% CI		(0.23, 0.74)
p-value		0.003

[1] Kaplan-Meier estimate.
[2] Estimated separately for each subgroup from a Cox Proportional Hazards Model with covariates of treatment group, geographic region, baseline total endoscopic score (centrally read), baseline nasal obstruction VAS, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal).

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.88
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	52	64
Subjects with nasal surgery	10 (19%)	6 (9%)
Annualised rate of surgery [1]	0.19	0.09
95% CI	(0.10,0.36)	(0.04,0.21)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.47
95% CI		(0.17,1.33)
p-value		0.155

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.88
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	122	113
Subjects with nasal surgery	32 (26%)	10 (9%)
Annualised rate of surgery [1]	0.24	0.10
95% CI	(0.17,0.35)	(0.06,0.18)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.41
95% CI		(0.21,0.79)
p-value		0.008

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.88
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Subjects with nasal surgery	4 (15%)	2 (7%)
Annualised rate of surgery [1]	0.14	0.07
95% CI	(0.05,0.41)	(0.02,0.29)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.49
95% CI		(0.08,2.86)
p-value		0.428

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.89
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	125	139
Subjects with nasal surgery	28 (22%)	15 (11%)
Annualised rate of surgery [1]	0.23	0.12
95% CI	(0.16,0.33)	(0.07,0.19)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.51
95% CI		(0.28,0.94)
p-value		0.031

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.89
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	76	67
Subjects with nasal surgery	18 (24%)	3 (4%)
Annualised rate of surgery [1]	0.19	0.06
95% CI	(0.11,0.33)	(0.02,0.16)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.30
95% CI		(0.10,0.90)
p-value		0.032

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.90
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Subjects with nasal surgery	18 (21%)	5 (6%)
Annualised rate of surgery [1]	0.21	0.09
95% CI	(0.13,0.34)	(0.04,0.18)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.40
95% CI		(0.17,0.96)
p-value		0.041

[1] Analysis performed using negative binomial model with covariates of treatment group, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.90
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	28	28
Subjects with nasal surgery	10 (36%)	3 (11%)
Annualised rate of surgery [1]	0.41	0.11
95% CI	(0.22,0.77)	(0.03,0.34)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.27
95% CI		(0.07,0.96)
p-value		0.044

[1] Analysis performed using negative binomial model with covariates of treatment group, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.90
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	88	92
Subjects with nasal surgery	18 (20%)	10 (11%)
Annualised rate of surgery [1]	0.19	0.11
95% CI	(0.12,0.31)	(0.06,0.21)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.59
95% CI		(0.27,1.27)
p-value		0.176

[1] Analysis performed using negative binomial model with covariates of treatment group, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

Protocol: 205687
Population: Intent-to-Treat

Table 27.91
Subgroup Analysis of Rate of Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	63	45
Subjects with nasal surgery	18 (29%)	5 (11%)
Annualised rate of surgery [1]	0.32	0.13
95% CI	(0.20,0.50)	(0.06,0.30)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.42
95% CI		(0.17,1.06)
p-value		0.065

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.91
Subgroup Analysis of Rate of Nasal Surgery up to Week 52
by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	138	161
Subjects with nasal surgery	28 (20%)	13 (8%)
Annualised rate of surgery [1]	0.19	0.08
95% CI	(0.13,0.28)	(0.05,0.14)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.44
95% CI		(0.23,0.84)
p-value		0.013

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Population: Intent-to-Treat

Table 27.92
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	81	108
Subjects with nasal surgery	16 (20%)	6 (6%)
Annualised rate of surgery [1]	0.19	0.05
95% CI	(0.12,0.32)	(0.02,0.12)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.28
95% CI		(0.11,0.71)
p-value		0.007

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.92
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	47	47
Subjects with nasal surgery	9 (19%)	5 (11%)
Annualised rate of surgery [1]	0.19	0.14
95% CI	(0.10,0.37)	(0.06,0.30)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.71
95% CI		(0.25,2.02)
p-value		0.524

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.92
Subgroup Analysis of Rate of Nasal Surgery up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	73	51
Subjects with nasal surgery	21 (29%)	7 (14%)
Annualised rate of surgery [1]	0.31	0.15
95% CI	(0.20,0.47)	(0.07,0.30)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.49
95% CI		(0.22,1.09)
p-value		0.081

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.93
Subgroup Analysis of Rate of Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	35
Subjects with nasal surgery	2 (5%)	1 (3%)
Annualised rate of surgery [1]	0.01	0.01
95% CI	(0.00,>999.99)	(0.00,>999.99)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.70
95% CI		(0.06,8.13)
p-value		0.774

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Table 27.93
Subgroup Analysis of Rate of Nasal Surgery up to Week 52
by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	161	171
Subjects with nasal surgery	44 (27%)	17 (10%)
Annualised rate of surgery [1]	0.27	0.11
95% CI	(0.20,0.37)	(0.07,0.18)
Mepolizumab 100mg SC vs Placebo		
Rate Ratio (Mepo/Placebo) [1]		0.41
95% CI		(0.24,0.70)
p-value		0.001

[1] Analysis performed using negative binomial model with covariates of treatment group, geographic region, log(e) baseline blood eosinophil count and number of previous surgeries (1, 2, >2 as ordinal), and with logarithm of time (year) on-study up to Week 52 as offset variable.

PPD

Population: Intent-to-Treat

Table 27.143
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	52	64
Number of subjects with >= 1 course	21 (40%)	25 (39%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.92 (0.43, 1.99)
p-value		0.836
Unadjusted odds ratio (95% CI) [2]		0.95 (0.42, 2.14)
Relative risk (95% CI) [3]		0.97 (0.61, 1.61)
Risk difference (95% CI) [3]		-0.01 (-0.20, 0.17)
Fisher's Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.143
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	122	113
Number of subjects with >= 1 course	68 (56%)	46 (41%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.56 (0.33, 0.94)
p-value		0.028
Unadjusted odds ratio (95% CI) [2]		0.55 (0.31, 0.95)
Relative risk (95% CI) [3]		0.73 (0.53, 0.98)
Risk difference (95% CI) [3]		-0.15 (-0.28, -0.02)
Fisher's Exact p-value (2-sided)		0.026

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.143
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Number of subjects with >= 1 course	11 (41%)	13 (45%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		1.05 (0.33, 3.33)
p-value		0.933
Unadjusted odds ratio (95% CI) [2]		1.18 (0.36, 3.90)
Relative risk (95% CI) [3]		1.10 (0.58, 2.24)
Risk difference (95% CI) [3]		0.04 (-0.22, 0.31)
Fisher’s Exact p-value (2-sided)		0.793

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Protocol: 205687
Population: Intent-to-Treat

Table 27.144
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	125	139
Number of subjects with >= 1 course	61 (49%)	51 (37%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.61 (0.37, 1.01)
p-value		0.052
Unadjusted odds ratio (95% CI) [2]		0.61 (0.36, 1.02)
Relative risk (95% CI) [3]		0.75 (0.56, 1.00)
Risk difference (95% CI) [3]		-0.12 (-0.24, 0.00)
Fisher's Exact p-value (2-sided)		0.061

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.144
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	76	67
Number of subjects with >= 1 course	39 (51%)	33 (49%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.96 (0.48, 1.92)
p-value		0.908
Unadjusted odds ratio (95% CI) [2]		0.92 (0.45, 1.87)
Relative risk (95% CI) [3]		0.96 (0.68, 1.34)
Risk difference (95% CI) [3]		-0.02 (-0.19, 0.15)
Fisher’s Exact p-value (2-sided)		0.868

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Protocol: 205687
Population: Intent-to-Treat

Table 27.145
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Number of subjects with >= 1 course	34 (40%)	34 (40%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.98 (0.53, 1.82)
p-value		0.959
Unadjusted odds ratio (95% CI) [2]		0.98 (0.51, 1.89)
Relative risk (95% CI) [3]		0.99 (0.67, 1.46)
Risk difference (95% CI) [3]		0.00 (-0.15, 0.14)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.145
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	28	28
Number of subjects with >= 1 course	16 (57%)	14 (50%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.81 (0.27, 2.39)
p-value		0.703
Unadjusted odds ratio (95% CI) [2]		0.75 (0.23, 2.44)
Relative risk (95% CI) [3]		0.88 (0.51, 1.50)
Risk difference (95% CI) [3]		-0.07 (-0.33, 0.20)
Fisher’s Exact p-value (2-sided)		0.789

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.145
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	88	92
Number of subjects with >= 1 course	50 (57%)	36 (39%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.51 (0.28, 0.92)
p-value		0.027
Unadjusted odds ratio (95% CI) [2]		0.49 (0.26, 0.92)
Relative risk (95% CI) [3]		0.69 (0.48, 0.96)
Risk difference (95% CI) [3]		-0.18 (-0.32, -0.03)
Fisher’s Exact p-value (2-sided)		0.025

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Protocol: 205687
Population: Intent-to-Treat

Table 27.146
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	63	45
Number of subjects with >= 1 course	36 (57%)	17 (38%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.47 (0.21, 1.04)
p-value		0.063
Unadjusted odds ratio (95% CI) [2]		0.46 (0.19, 1.07)
Relative risk (95% CI) [3]		0.66 (0.39, 1.00)
Risk difference (95% CI) [3]		-0.19 (-0.38, 0.00)
Fisher's Exact p-value (2-sided)		0.053

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Table 27.146
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	138	161
Number of subjects with >= 1 course	64 (46%)	67 (42%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.82 (0.51, 1.30)
p-value		0.399
Unadjusted odds ratio (95% CI) [2]		0.82 (0.51, 1.34)
Relative risk (95% CI) [3]		0.90 (0.69, 1.17)
Risk difference (95% CI) [3]		-0.05 (-0.16, 0.07)
Fisher’s Exact p-value (2-sided)		0.416

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

PPD

Table 27.147
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	81	108
Number of subjects with >= 1 course	37 (46%)	36 (33%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.59 (0.32, 1.09)
p-value		0.091
Unadjusted odds ratio (95% CI) [2]		0.60 (0.32, 1.12)
Relative risk (95% CI) [3]		0.73 (0.50, 1.07)
Risk difference (95% CI) [3]		-0.12 (-0.26, 0.02)
Fisher’s Exact p-value (2-sided)		0.098

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Table 27.147
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	47	47
Number of subjects with >= 1 course	25 (53%)	22 (47%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.69 (0.29, 1.64)
p-value		0.404
Unadjusted odds ratio (95% CI) [2]		0.78 (0.32, 1.88)
Relative risk (95% CI) [3]		0.88 (0.56, 1.34)
Risk difference (95% CI) [3]		-0.06 (-0.27, 0.15)
Fisher's Exact p-value (2-sided)		0.680

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.147
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	73	51
Number of subjects with >= 1 course	38 (52%)	26 (51%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.98 (0.45, 2.11)
p-value		0.958
Unadjusted odds ratio (95% CI) [2]		0.96 (0.44, 2.08)
Relative risk (95% CI) [3]		0.98 (0.66, 1.39)
Risk difference (95% CI) [3]		-0.01 (-0.19, 0.17)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Table 27.148
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	35
Number of subjects with >= 1 course	19 (48%)	15 (43%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.93 (0.36, 2.42)
p-value		0.882
Unadjusted odds ratio (95% CI) [2]		0.83 (0.30, 2.27)
Relative risk (95% CI) [3]		0.90 (0.51, 1.54)
Risk difference (95% CI) [3]		-0.05 (-0.27, 0.18)
Fisher’s Exact p-value (2-sided)		0.817

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.148
Subgroup Analysis of Proportion of Subjects with >=1 Course of Antibiotics up to Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	161	171
Number of subjects with >= 1 course	81 (50%)	69 (40%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.68 (0.44, 1.07)
p-value		0.096
Unadjusted odds ratio (95% CI) [2]		0.67 (0.42, 1.06)
Relative risk (95% CI) [3]		0.80 (0.62, 1.02)
Risk difference (95% CI) [3]		-0.10 (-0.21, 0.01)
Fisher’s Exact p-value (2-sided)		0.078

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline total endoscopic NP score (centrally read), baseline nasal obstruction VAS score and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: Includes antibiotic use for any reason.

Population: Intent-to-Treat

Table 27.117
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	41	45
n	41	45
Number of subjects with >= 1 exacerbation	3 (7%)	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.31 (0.03, 3.21)
p-value		0.324
Unadjusted odds ratio (95% CI) [2]		0.29 (0.01, 3.81)
Relative risk (95% CI) [3]		0.30 (0.01, 2.92)
Risk difference (95% CI) [3]		-0.05 (-0.18, 0.06)
Fisher’s Exact p-value (2-sided)		0.344

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.117
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	89	77
n	89	77
Number of subjects with >= 1 exacerbation	6 (7%)	4 (5%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.60 (0.15, 2.35)
p-value		0.464
Unadjusted odds ratio (95% CI) [2]		0.76 (0.15, 3.35)
Relative risk (95% CI) [3]		0.77 (0.17, 2.82)
Risk difference (95% CI) [3]		-0.02 (-0.10, 0.07)
Fisher’s Exact p-value (2-sided)		0.753

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.117
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	19	18
n	19	18
Number of subjects with >= 1 exacerbation	2 (11%)	1 (6%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.29 (0.02, 5.72)
p-value		0.418
Unadjusted odds ratio (95% CI) [2]		0.51 (0.01, 10.65)
Relative risk (95% CI) [3]		0.53 (0.02, 5.54)
Risk difference (95% CI) [3]		-0.05 (-0.28, 0.18)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Table 27.118
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	84	92
n	84	92
Number of subjects with >= 1 exacerbation	5 (6%)	4 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.69 (0.17, 2.84)
p-value		0.604
Unadjusted odds ratio (95% CI) [2]		0.72 (0.14, 3.47)
Relative risk (95% CI) [3]		0.73 (0.17, 2.98)
Risk difference (95% CI) [3]		-0.02 (-0.10, 0.06)
Fisher’s Exact p-value (2-sided)		0.738

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.118
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	65	48
n	65	48
Number of subjects with >= 1 exacerbation	6 (9%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.31 (0.05, 1.77)
p-value		0.186
Unadjusted odds ratio (95% CI) [2]		0.43 (0.04, 2.55)
Relative risk (95% CI) [3]		0.45 (0.04, 2.04)
Risk difference (95% CI) [3]		-0.05 (-0.16, 0.06)
Fisher’s Exact p-value (2-sided)		0.463

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.119
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	62	51
n	62	51
Number of subjects with >= 1 exacerbation	4 (6%)	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.24 (0.02, 2.37)
p-value		0.222
Unadjusted odds ratio (95% CI) [2]		0.29 (0.01, 3.09)
Relative risk (95% CI) [3]		0.30 (0.01, 2.18)
Risk difference (95% CI) [3]		-0.04 (-0.14, 0.05)
Fisher’s Exact p-value (2-sided)		0.376

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Table 27.119
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	22	22
n	22	22
Number of subjects with >= 1 exacerbation	2 (9%)	1 (5%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.57 (0.04, 7.23)
p-value		0.662
Unadjusted odds ratio (95% CI) [2]		0.48 (0.01, 9.98)
Relative risk (95% CI) [3]		0.50 (0.02, 5.31)
Risk difference (95% CI) [3]		-0.05 (-0.25, 0.14)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.119
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	65	67
n	65	67
Number of subjects with >= 1 exacerbation	5 (8%)	4 (6%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.67 (0.16, 2.75)
p-value		0.582
Unadjusted odds ratio (95% CI) [2]		0.76 (0.14, 3.73)
Relative risk (95% CI) [3]		0.78 (0.18, 3.15)
Risk difference (95% CI) [3]		-0.02 (-0.12, 0.08)
Fisher’s Exact p-value (2-sided)		0.742

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Protocol: 205687
Population: Intent-to-Treat

Table 27.120
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	60	43
n	60	43
Number of subjects with >= 1 exacerbation	5 (8%)	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.20 (0.02, 2.20)
p-value		0.187
Unadjusted odds ratio (95% CI) [2]		0.26 (0.01, 2.49)
Relative risk (95% CI) [3]		0.28 (0.01, 1.83)
Risk difference (95% CI) [3]		-0.06 (-0.16, 0.05)
Fisher’s Exact p-value (2-sided)		0.397

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Table 27.120
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	89	97
n	89	97
Number of subjects with >= 1 exacerbation	6 (7%)	5 (5%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.73 (0.21, 2.58)
p-value		0.629
Unadjusted odds ratio (95% CI) [2]		0.75 (0.17, 3.08)
Relative risk (95% CI) [3]		0.76 (0.22, 2.78)
Risk difference (95% CI) [3]		-0.02 (-0.10, 0.06)
Fisher’s Exact p-value (2-sided)		0.760

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.121
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	54	69
n	54	69
Number of subjects with >= 1 exacerbation	4 (7%)	3 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.56 (0.12, 2.66)
p-value		0.467
Unadjusted odds ratio (95% CI) [2]		0.57 (0.08, 3.54)
Relative risk (95% CI) [3]		0.59 (0.08, 2.67)
Risk difference (95% CI) [3]		-0.03 (-0.14, 0.06)
Fisher’s Exact p-value (2-sided)		0.698

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.121
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	36	34
n	36	34
Number of subjects with >= 1 exacerbation	4 (11%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.00 (0.00, 0.00)
p-value		
Unadjusted odds ratio (95% CI) [2]		0.19 (0.00, 1.13)
Relative risk (95% CI) [3]		0.00 (0.00, 1.04)
Risk difference (95% CI) [3]		-0.11 (-0.26, 0.00)
Fisher’s Exact p-value (2-sided)		0.115

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.121
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	59	37
n	59	37
Number of subjects with >= 1 exacerbation	3 (5%)	3 (8%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		1.20 (0.18, 7.93)
p-value		0.852
Unadjusted odds ratio (95% CI) [2]		1.64 (0.21, 12.94)
Relative risk (95% CI) [3]		1.59 (0.27, 9.34)
Risk difference (95% CI) [3]		0.03 (-0.08, 0.17)
Fisher’s Exact p-value (2-sided)		0.673

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Protocol: 205687
Population: Intent-to-Treat

Table 27.122
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	27	15
n	27	15
Number of subjects with >= 1 exacerbation	1 (4%)	1 (7%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.80 (0.02, 25.97)
p-value		0.898
Unadjusted odds ratio (95% CI) [2]		1.83 (0.02, 151.29)
Relative risk (95% CI) [3]		1.80 (0.05, 59.13)
Risk difference (95% CI) [3]		0.03 (-0.14, 0.28)
Fisher’s Exact p-value (2-sided)		>0.999

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.122
Subgroup Analysis of Proportion of Subjects with >=1 Clinically Significant Exacerbation up to Week 52 in Participants with Asthma by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	122	125
n	122	125
Number of subjects with >= 1 exacerbation	10 (8%)	5 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Odds ratio (95% CI)		0.42 (0.14, 1.30)
p-value		0.133
Unadjusted odds ratio (95% CI) [2]		0.47 (0.12, 1.56)
Relative risk (95% CI) [3]		0.49 (0.12, 1.41)
Risk difference (95% CI) [3]		-0.04 (-0.11, 0.02)
Fisher’s Exact p-value (2-sided)		0.192

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, number of exacerbations in the last 12 months (0, 1, >1 as ordinal) and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Odds ratio <1, relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.

Population: Intent-to-Treat

Table 27.125
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	41	45
n	38	45
Number of subjects with reduction of 0.5 or more	15 (39%)	26 (58%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.47 (0.19, 1.18)
p-value		0.109
Inverse unadjusted odds ratio (95% CI) [2]		0.48 (0.18, 1.25)
Inverse relative risk (95% CI) [3]		0.68 (0.37, 1.08)
Risk difference (95% CI) [3]		-0.18 (-0.39, 0.04)
Fisher’s Exact p-value (2-sided)		0.124

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.125
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	89	77
n	87	75
Number of subjects with reduction of 0.5 or more	31 (36%)	43 (57%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.47 (0.23, 0.95)
p-value		0.036
Inverse unadjusted odds ratio (95% CI) [2]		0.41 (0.21, 0.81)
Inverse relative risk (95% CI) [3]		0.62 (0.42, 0.92)
Risk difference (95% CI) [3]		-0.22 (-0.37, -0.05)
Fisher’s Exact p-value (2-sided)		0.007

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.125
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	19	18
n	19	18
Number of subjects with reduction of 0.5 or more	5 (26%)	9 (50%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.09 (0.01, 0.83)
p-value		0.033
Inverse unadjusted odds ratio (95% CI) [2]		0.37 (0.07, 1.71)
Inverse relative risk (95% CI) [3]		0.53 (0.17, 1.30)
Risk difference (95% CI) [3]		-0.24 (-0.53, 0.09)
Fisher’s Exact p-value (2-sided)		0.184

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.126
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	84	92
n	81	91
Number of subjects with reduction of 0.5 or more	26 (32%)	46 (51%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.49 (0.24, 1.00)
p-value		0.049
Inverse unadjusted odds ratio (95% CI) [2]		0.46 (0.24, 0.90)
Inverse relative risk (95% CI) [3]		0.63 (0.41, 0.96)
Risk difference (95% CI) [3]		-0.18 (-0.33, -0.02)
Fisher’s Exact p-value (2-sided)		0.020

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.126
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	65	48
n	63	47
Number of subjects with reduction of 0.5 or more	25 (40%)	32 (68%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.32 (0.14, 0.74)
p-value		0.008
Inverse unadjusted odds ratio (95% CI) [2]		0.31 (0.13, 0.73)
Inverse relative risk (95% CI) [3]		0.58 (0.38, 0.87)
Risk difference (95% CI) [3]		-0.28 (-0.46, -0.07)
Fisher’s Exact p-value (2-sided)		0.004

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.127
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	62	51
n	62	50
Number of subjects with reduction of 0.5 or more	25 (40%)	29 (58%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.48 (0.21, 1.08)
p-value		0.076
Inverse unadjusted odds ratio (95% CI) [2]		0.49 (0.21, 1.11)
Inverse relative risk (95% CI) [3]		0.70 (0.46, 1.03)
Risk difference (95% CI) [3]		-0.18 (-0.36, 0.01)
Fisher’s Exact p-value (2-sided)		0.087

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.127
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	22	22
n	20	22
Number of subjects with reduction of 0.5 or more	5 (25%)	9 (41%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.48 (0.12, 1.93)
p-value		0.301
Inverse unadjusted odds ratio (95% CI) [2]		0.49 (0.10, 2.14)
Inverse relative risk (95% CI) [3]		0.61 (0.19, 1.56)
Risk difference (95% CI) [3]		-0.16 (-0.44, 0.14)
Fisher’s Exact p-value (2-sided)		0.338

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.127
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	65	67
n	62	66
Number of subjects with reduction of 0.5 or more	21 (34%)	40 (61%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.29 (0.12, 0.68)
p-value		0.005
Inverse unadjusted odds ratio (95% CI) [2]		0.34 (0.15, 0.73)
Inverse relative risk (95% CI) [3]		0.56 (0.33, 0.86)
Risk difference (95% CI) [3]		-0.27 (-0.43, -0.07)
Fisher’s Exact p-value (2-sided)		0.003

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.128
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	60	43
n	57	43
Number of subjects with reduction of 0.5 or more	18 (32%)	26 (60%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.31 (0.13, 0.74)
p-value		0.008
Inverse unadjusted odds ratio (95% CI) [2]		0.31 (0.12, 0.75)
Inverse relative risk (95% CI) [3]		0.52 (0.31, 0.86)
Risk difference (95% CI) [3]		-0.29 (-0.47, -0.07)
Fisher’s Exact p-value (2-sided)		0.005

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.128
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	89	97
n	87	95
Number of subjects with reduction of 0.5 or more	33 (38%)	52 (55%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.51 (0.26, 1.01)
p-value		0.054
Inverse unadjusted odds ratio (95% CI) [2]		0.51 (0.27, 0.95)
Inverse relative risk (95% CI) [3]		0.69 (0.48, 0.97)
Risk difference (95% CI) [3]		-0.17 (-0.31, -0.02)
Fisher’s Exact p-value (2-sided)		0.026

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.129
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	54	69
n	53	68
Number of subjects with reduction of 0.5 or more	24 (45%)	37 (54%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.62 (0.27, 1.40)
p-value		0.250
Inverse unadjusted odds ratio (95% CI) [2]		0.70 (0.32, 1.52)
Inverse relative risk (95% CI) [3]		0.83 (0.54, 1.20)
Risk difference (95% CI) [3]		-0.09 (-0.27, 0.09)
Fisher’s Exact p-value (2-sided)		0.362

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.129
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	36	34
n	33	33
Number of subjects with reduction of 0.5 or more	15 (45%)	18 (55%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.56 (0.19, 1.63)
p-value		0.285
Inverse unadjusted odds ratio (95% CI) [2]		0.70 (0.24, 2.04)
Inverse relative risk (95% CI) [3]		0.83 (0.49, 1.40)
Risk difference (95% CI) [3]		-0.09 (-0.34, 0.16)
Fisher’s Exact p-value (2-sided)		0.623

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.129
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	59	37
n	58	37
Number of subjects with reduction of 0.5 or more	12 (21%)	23 (62%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.20 (0.07, 0.55)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [2]		0.16 (0.06, 0.44)
Inverse relative risk (95% CI) [3]		0.33 (0.18, 0.58)
Risk difference (95% CI) [3]		-0.41 (-0.59, -0.20)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Table 27.130
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	27	15
n	27	15
Number of subjects with reduction of 0.5 or more	15 (56%)	10 (67%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.43 (0.08, 2.44)
p-value		0.340
Inverse unadjusted odds ratio (95% CI) [2]		0.63 (0.13, 2.74)
Inverse relative risk (95% CI) [3]		0.83 (0.50, 1.67)
Risk difference (95% CI) [3]		-0.11 (-0.40, 0.21)
Fisher’s Exact p-value (2-sided)		0.531

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Population: Intent-to-Treat

Table 27.130
Subgroup Analysis of Proportion of Subjects with Improvement (Decrease) in ACQ-5 of >=0.5 from Baseline at Week 52 in Participants with Asthma by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup with concurrent asthma	122	125
n	117	123
Number of subjects with reduction of 0.5 or more	36 (31%)	68 (55%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.34 (0.19, 0.61)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.36 (0.20, 0.63)
Inverse relative risk (95% CI) [3]		0.56 (0.39, 0.77)
Risk difference (95% CI) [3]		-0.25 (-0.37, -0.11)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count. [2] Exact CI. [3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo. Note: 2 Mepolizumab and 5 Placebo subjects with missing baseline are excluded from the analysis. Note: Subjects with nasal surgery/sinuplasty prior to visit, subjects who withdrew from study with no surgery/sinuplasty and subjects with missing visit data are assigned the worst possible score across all subjects.

Protocol: 205687
Population: Intent-to-Treat

Table 27.151
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	50	63
Met >=5-point improvement	14 (28%)	28 (44%)
Not met >=5-point improvement	36 (72%)	35 (56%)
<5-point improvement	11 (22%)	14 (22%)
No change/worsening	8 (16%)	9 (14%)
Nasal surgery prior to visit	9 (18%)	6 (10%)
Withdrawn from study prior to visit	5 (10%)	6 (10%)
Missing visit data	3 (6%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.42 (0.17, 1.05)
p-value		0.064
Inverse unadjusted odds ratio (95% CI) [2]		0.49 (0.20, 1.15)
Inverse relative risk (95% CI) [3]		0.63 (0.35, 1.06)
Risk difference (95% CI) [3]		-0.16 (-0.34, 0.02)
Fisher’s Exact p-value (2-sided)		0.081

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.151
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	121	113
Met >=5-point improvement	28 (23%)	66 (58%)
Not met >=5-point improvement	93 (77%)	47 (42%)
<5-point improvement	25 (21%)	18 (16%)
No change/worsening	28 (23%)	9 (8%)
Nasal surgery prior to visit	32 (26%)	10 (9%)
Withdrawn from study prior to visit	7 (6%)	7 (6%)
Missing visit data	1 (<1%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.19 (0.10, 0.36)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.22 (0.12, 0.39)
Inverse relative risk (95% CI) [3]		0.40 (0.26, 0.56)
Risk difference (95% CI) [3]		-0.35 (-0.47, -0.23)
Fisher's Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.151
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Met >=5-point improvement	7 (26%)	15 (52%)
Not met >=5-point improvement	20 (74%)	14 (48%)
<5-point improvement	6 (22%)	5 (17%)
No change/worsening	8 (30%)	3 (10%)
Nasal surgery prior to visit	4 (15%)	2 (7%)
Withdrawn from study prior to visit	0	3 (10%)
Missing visit data	2 (7%)	1 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.23 (0.06, 0.96)
p-value		0.044
Inverse unadjusted odds ratio (95% CI) [2]		0.33 (0.09, 1.14)
Inverse relative risk (95% CI) [3]		0.50 (0.20, 1.01)
Risk difference (95% CI) [3]		-0.26 (-0.50, 0.00)
Fisher's Exact p-value (2-sided)		0.060

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.152
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	123	138
Met >=5-point improvement	27 (22%)	71 (51%)
Not met >=5-point improvement	96 (78%)	67 (49%)
<5-point improvement	31 (25%)	24 (17%)
No change/worsening	29 (24%)	15 (11%)
Nasal surgery prior to visit	28 (23%)	15 (11%)
Withdrawn from study prior to visit	7 (6%)	11 (8%)
Missing visit data	1 (<1%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.27 (0.15, 0.48)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.27 (0.15, 0.47)
Inverse relative risk (95% CI) [3]		0.43 (0.27, 0.62)
Risk difference (95% CI) [3]		-0.29 (-0.40, -0.17)
Fisher's Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Table 27.152
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	75	67
Met >=5-point improvement	22 (29%)	38 (57%)
Not met >=5-point improvement	53 (71%)	29 (43%)
<5-point improvement	11 (15%)	13 (19%)
No change/worsening	15 (20%)	6 (9%)
Nasal surgery prior to visit	17 (23%)	3 (4%)
Withdrawn from study prior to visit	5 (7%)	5 (7%)
Missing visit data	5 (7%)	2 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.24 (0.11, 0.54)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.32 (0.15, 0.67)
Inverse relative risk (95% CI) [3]		0.52 (0.32, 0.79)
Risk difference (95% CI) [3]		-0.27 (-0.43, -0.09)
Fisher’s Exact p-value (2-sided)		0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.153
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Met >=5-point improvement	17 (20%)	50 (58%)
Not met >=5-point improvement	68 (80%)	36 (42%)
<5-point improvement	23 (27%)	12 (14%)
No change/worsening	21 (25%)	8 (9%)
Nasal surgery prior to visit	18 (21%)	5 (6%)
Withdrawn from study prior to visit	3 (4%)	8 (9%)
Missing visit data	3 (4%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.14 (0.06, 0.30)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.18 (0.09, 0.37)
Inverse relative risk (95% CI) [3]		0.34 (0.19, 0.55)
Risk difference (95% CI) [3]		-0.38 (-0.51, -0.23)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.153
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	26	28
Met >=5-point improvement	8 (31%)	10 (36%)
Not met >=5-point improvement	18 (69%)	18 (64%)
<5-point improvement	1 (4%)	6 (21%)
No change/worsening	2 (8%)	3 (11%)
Nasal surgery prior to visit	10 (38%)	3 (11%)
Withdrawn from study prior to visit	5 (19%)	5 (18%)
Missing visit data	0	1 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.86 (0.27, 2.78)
p-value		0.804
Inverse unadjusted odds ratio (95% CI) [2]		0.80 (0.22, 2.88)
Inverse relative risk (95% CI) [3]		0.86 (0.34, 1.92)
Risk difference (95% CI) [3]		-0.05 (-0.30, 0.21)
Fisher’s Exact p-value (2-sided)		0.777

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.153
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	87	91
Met >=5-point improvement	24 (28%)	49 (54%)
Not met >=5-point improvement	63 (72%)	42 (46%)
<5-point improvement	18 (21%)	19 (21%)
No change/worsening	21 (24%)	10 (11%)
Nasal surgery prior to visit	17 (20%)	10 (11%)
Withdrawn from study prior to visit	4 (5%)	3 (3%)
Missing visit data	3 (3%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.26 (0.12, 0.53)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.33 (0.17, 0.64)
Inverse relative risk (95% CI) [3]		0.51 (0.32, 0.76)
Risk difference (95% CI) [3]		-0.26 (-0.40, -0.10)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.154
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	61	45
Met >=5-point improvement	14 (23%)	23 (51%)
Not met >=5-point improvement	47 (77%)	22 (49%)
<5-point improvement	11 (18%)	11 (24%)
No change/worsening	11 (18%)	1 (2%)
Nasal surgery prior to visit	17 (28%)	5 (11%)
Withdrawn from study prior to visit	5 (8%)	3 (7%)
Missing visit data	3 (5%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.24 (0.10, 0.60)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [2]		0.29 (0.11, 0.71)
Inverse relative risk (95% CI) [3]		0.45 (0.23, 0.80)
Risk difference (95% CI) [3]		-0.28 (-0.46, -0.06)
Fisher’s Exact p-value (2-sided)		0.004

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.154
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	137	160
Met >=5-point improvement	35 (26%)	86 (54%)
Not met >=5-point improvement	102 (74%)	74 (46%)
<5-point improvement	31 (23%)	26 (16%)
No change/worsening	33 (24%)	20 (13%)
Nasal surgery prior to visit	28 (20%)	13 (8%)
Withdrawn from study prior to visit	7 (5%)	13 (8%)
Missing visit data	3 (2%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.26 (0.15, 0.45)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.30 (0.17, 0.50)
Inverse relative risk (95% CI) [3]		0.48 (0.33, 0.65)
Risk difference (95% CI) [3]		-0.28 (-0.39, -0.17)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.155
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	80	107
Met >=5-point improvement	27 (34%)	59 (55%)
Not met >=5-point improvement	53 (66%)	48 (45%)
<5-point improvement	17 (21%)	19 (18%)
No change/worsening	15 (19%)	14 (13%)
Nasal surgery prior to visit	15 (19%)	6 (6%)
Withdrawn from study prior to visit	3 (4%)	8 (7%)
Missing visit data	3 (4%)	1 (<1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.34 (0.17, 0.66)
p-value		0.002
Inverse unadjusted odds ratio (95% CI) [2]		0.42 (0.22, 0.79)
Inverse relative risk (95% CI) [3]		0.61 (0.41, 0.90)
Risk difference (95% CI) [3]		-0.21 (-0.35, -0.05)
Fisher's Exact p-value (2-sided)		0.005

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.155
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	46	47
Met >=5-point improvement	10 (22%)	19 (40%)
Not met >=5-point improvement	36 (78%)	28 (60%)
<5-point improvement	10 (22%)	10 (21%)
No change/worsening	13 (28%)	5 (11%)
Nasal surgery prior to visit	9 (20%)	5 (11%)
Withdrawn from study prior to visit	4 (9%)	7 (15%)
Missing visit data	0	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.37 (0.13, 0.99)
p-value		0.049
Inverse unadjusted odds ratio (95% CI) [2]		0.41 (0.15, 1.11)
Inverse relative risk (95% CI) [3]		0.54 (0.25, 1.02)
Risk difference (95% CI) [3]		-0.19 (-0.37, 0.01)
Fisher’s Exact p-value (2-sided)		0.073

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.155
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	72	51
Met >=5-point improvement	12 (17%)	31 (61%)
Not met >=5-point improvement	60 (83%)	20 (39%)
<5-point improvement	15 (21%)	8 (16%)
No change/worsening	16 (22%)	2 (4%)
Nasal surgery prior to visit	21 (29%)	7 (14%)
Withdrawn from study prior to visit	5 (7%)	1 (2%)
Missing visit data	3 (4%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.12 (0.04, 0.33)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.13 (0.05, 0.32)
Inverse relative risk (95% CI) [3]		0.27 (0.14, 0.48)
Risk difference (95% CI) [3]		-0.44 (-0.60, -0.26)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.156
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	34
Met >=5-point improvement	15 (38%)	21 (62%)
Not met >=5-point improvement	25 (63%)	13 (38%)
<5-point improvement	10 (25%)	4 (12%)
No change/worsening	10 (25%)	4 (12%)
Nasal surgery prior to visit	2 (5%)	1 (3%)
Withdrawn from study prior to visit	3 (8%)	4 (12%)
Missing visit data	0	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.20 (0.06, 0.68)
p-value		0.010
Inverse unadjusted odds ratio (95% CI) [2]		0.38 (0.13, 1.05)
Inverse relative risk (95% CI) [3]		0.61 (0.34, 0.99)
Risk difference (95% CI) [3]		-0.24 (-0.46, -0.01)
Fisher’s Exact p-value (2-sided)		0.061

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.156
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Physical Component Summary Score at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	158	171
Met >=5-point improvement	34 (22%)	88 (51%)
Not met >=5-point improvement	124 (78%)	83 (49%)
<5-point improvement	32 (20%)	33 (19%)
No change/worsening	34 (22%)	17 (10%)
Nasal surgery prior to visit	43 (27%)	17 (10%)
Withdrawn from study prior to visit	9 (6%)	12 (7%)
Missing visit data	6 (4%)	4 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.23 (0.14, 0.40)
p-value		<0.001
Inverse unadjusted odds ratio (95% CI) [2]		0.26 (0.15, 0.43)
Inverse relative risk (95% CI) [3]		0.42 (0.29, 0.58)
Risk difference (95% CI) [3]		-0.30 (-0.40, -0.19)
Fisher’s Exact p-value (2-sided)		<0.001

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.160
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Age

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n	50	63
Met >=5-point improvement	11 (22%)	25 (40%)
Not met >=5-point improvement	39 (78%)	38 (60%)
<5-point improvement	8 (16%)	8 (13%)
No change/worsening	14 (28%)	18 (29%)
Nasal surgery prior to visit	9 (18%)	6 (10%)
Withdrawn from study prior to visit	5 (10%)	6 (10%)
Missing visit data	3 (6%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.39 (0.16, 0.98)
p-value		0.045
Inverse unadjusted odds ratio (95% CI) [2]		0.43 (0.17, 1.06)
Inverse relative risk (95% CI) [3]		0.55 (0.28, 1.01)
Risk difference (95% CI) [3]		-0.18 (-0.34, 0.01)
Fisher's Exact p-value (2-sided)		0.067

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.160
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Age

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n	121	113
Met >=5-point improvement	34 (28%)	45 (40%)
Not met >=5-point improvement	87 (72%)	68 (60%)
<5-point improvement	25 (21%)	18 (16%)
No change/worsening	22 (18%)	30 (27%)
Nasal surgery prior to visit	32 (26%)	10 (9%)
Withdrawn from study prior to visit	7 (6%)	7 (6%)
Missing visit data	1 (<1%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.55 (0.30, 1.02)
p-value		0.057
Inverse unadjusted odds ratio (95% CI) [2]		0.59 (0.33, 1.06)
Inverse relative risk (95% CI) [3]		0.71 (0.47, 1.03)
Risk difference (95% CI) [3]		-0.12 (-0.24, 0.01)
Fisher's Exact p-value (2-sided)		0.072

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.160
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Age

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n	27	29
Met >=5-point improvement	9 (33%)	11 (38%)
Not met >=5-point improvement	18 (67%)	18 (62%)
<5-point improvement	4 (15%)	6 (21%)
No change/worsening	8 (30%)	6 (21%)
Nasal surgery prior to visit	4 (15%)	2 (7%)
Withdrawn from study prior to visit	0	3 (10%)
Missing visit data	2 (7%)	1 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.73 (0.20, 2.60)
p-value		0.622
Inverse unadjusted odds ratio (95% CI) [2]		0.82 (0.24, 2.80)
Inverse relative risk (95% CI) [3]		0.88 (0.38, 1.86)
Risk difference (95% CI) [3]		-0.05 (-0.30, 0.21)
Fisher’s Exact p-value (2-sided)		0.785

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.161
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n	123	138
Met >=5-point improvement	35 (28%)	51 (37%)
Not met >=5-point improvement	88 (72%)	87 (63%)
<5-point improvement	25 (20%)	26 (19%)
No change/worsening	27 (22%)	33 (24%)
Nasal surgery prior to visit	28 (23%)	15 (11%)
Withdrawn from study prior to visit	7 (6%)	11 (8%)
Missing visit data	1 (<1%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.66 (0.37, 1.17)
p-value		0.151
Inverse unadjusted odds ratio (95% CI) [2]		0.68 (0.39, 1.18)
Inverse relative risk (95% CI) [3]		0.77 (0.53, 1.10)
Risk difference (95% CI) [3]		-0.09 (-0.20, 0.03)
Fisher's Exact p-value (2-sided)		0.150

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.161
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n	75	67
Met >=5-point improvement	19 (25%)	30 (45%)
Not met >=5-point improvement	56 (75%)	37 (55%)
<5-point improvement	12 (16%)	6 (9%)
No change/worsening	17 (23%)	21 (31%)
Nasal surgery prior to visit	17 (23%)	3 (4%)
Withdrawn from study prior to visit	5 (7%)	5 (7%)
Missing visit data	5 (7%)	2 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.40 (0.18, 0.87)
p-value		0.021
Inverse unadjusted odds ratio (95% CI) [2]		0.42 (0.19, 0.90)
Inverse relative risk (95% CI) [3]		0.57 (0.33, 0.94)
Risk difference (95% CI) [3]		-0.19 (-0.35, -0.03)
Fisher’s Exact p-value (2-sided)		0.021

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.162
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n	85	86
Met >=5-point improvement	27 (32%)	30 (35%)
Not met >=5-point improvement	58 (68%)	56 (65%)
<5-point improvement	15 (18%)	18 (21%)
No change/worsening	19 (22%)	22 (26%)
Nasal surgery prior to visit	18 (21%)	5 (6%)
Withdrawn from study prior to visit	3 (4%)	8 (9%)
Missing visit data	3 (4%)	3 (3%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.86 (0.44, 1.71)
p-value		0.672
Inverse unadjusted odds ratio (95% CI) [2]		0.87 (0.44, 1.72)
Inverse relative risk (95% CI) [3]		0.91 (0.58, 1.42)
Risk difference (95% CI) [3]		-0.03 (-0.17, 0.11)
Fisher’s Exact p-value (2-sided)		0.746

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Table 27.162
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n	26	28
Met >=5-point improvement	2 (8%)	6 (21%)
Not met >=5-point improvement	24 (92%)	22 (79%)
<5-point improvement	2 (8%)	4 (14%)
No change/worsening	7 (27%)	9 (32%)
Nasal surgery prior to visit	10 (38%)	3 (11%)
Withdrawn from study prior to visit	5 (19%)	5 (18%)
Missing visit data	0	1 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.33 (0.06, 1.93)
p-value		0.220
Inverse unadjusted odds ratio (95% CI) [2]		0.31 (0.03, 1.98)
Inverse relative risk (95% CI) [3]		0.36 (0.03, 1.56)
Risk difference (95% CI) [3]		-0.14 (-0.35, 0.07)
Fisher’s Exact p-value (2-sided)		0.253

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.162
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n	87	91
Met >=5-point improvement	25 (29%)	45 (49%)
Not met >=5-point improvement	62 (71%)	46 (51%)
<5-point improvement	20 (23%)	10 (11%)
No change/worsening	18 (21%)	23 (25%)
Nasal surgery prior to visit	17 (20%)	10 (11%)
Withdrawn from study prior to visit	4 (5%)	3 (3%)
Missing visit data	3 (3%)	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.38 (0.19, 0.75)
p-value		0.005
Inverse unadjusted odds ratio (95% CI) [2]		0.41 (0.21, 0.80)
Inverse relative risk (95% CI) [3]		0.58 (0.37, 0.89)
Risk difference (95% CI) [3]		-0.21 (-0.35, -0.05)
Fisher’s Exact p-value (2-sided)		0.006

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.163
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n	61	45
Met >=5-point improvement	12 (20%)	20 (44%)
Not met >=5-point improvement	49 (80%)	25 (56%)
<5-point improvement	16 (26%)	4 (9%)
No change/worsening	8 (13%)	11 (24%)
Nasal surgery prior to visit	17 (28%)	5 (11%)
Withdrawn from study prior to visit	5 (8%)	3 (7%)
Missing visit data	3 (5%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.30 (0.12, 0.73)
p-value		0.009
Inverse unadjusted odds ratio (95% CI) [2]		0.31 (0.12, 0.79)
Inverse relative risk (95% CI) [3]		0.44 (0.22, 0.87)
Risk difference (95% CI) [3]		-0.25 (-0.43, -0.05)
Fisher’s Exact p-value (2-sided)		0.010

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Table 27.163
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Aspirin Exacerbated Respiratory Disease (AERDS)

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n	137	160
Met >=5-point improvement	42 (31%)	61 (38%)
Not met >=5-point improvement	95 (69%)	99 (62%)
<5-point improvement	21 (15%)	28 (18%)
No change/worsening	36 (26%)	43 (27%)
Nasal surgery prior to visit	28 (20%)	13 (8%)
Withdrawn from study prior to visit	7 (5%)	13 (8%)
Missing visit data	3 (2%)	2 (1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.71 (0.41, 1.22)
p-value		0.215
Inverse unadjusted odds ratio (95% CI) [2]		0.72 (0.43, 1.20)
Inverse relative risk (95% CI) [3]		0.80 (0.56, 1.10)
Risk difference (95% CI) [3]		-0.07 (-0.18, 0.04)
Fisher’s Exact p-value (2-sided)		0.182

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.164
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n	80	107
Met >=5-point improvement	24 (30%)	49 (46%)
Not met >=5-point improvement	56 (70%)	58 (54%)
<5-point improvement	13 (16%)	14 (13%)
No change/worsening	22 (28%)	29 (27%)
Nasal surgery prior to visit	15 (19%)	6 (6%)
Withdrawn from study prior to visit	3 (4%)	8 (7%)
Missing visit data	3 (4%)	1 (<1%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.48 (0.25, 0.92)
p-value		0.028
Inverse unadjusted odds ratio (95% CI) [2]		0.51 (0.26, 0.97)
Inverse relative risk (95% CI) [3]		0.66 (0.41, 0.98)
Risk difference (95% CI) [3]		-0.16 (-0.29, -0.01)
Fisher’s Exact p-value (2-sided)		0.034

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

PPD

Table 27.164
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n	46	47
Met >=5-point improvement	9 (20%)	12 (26%)
Not met >=5-point improvement	37 (80%)	35 (74%)
<5-point improvement	13 (28%)	9 (19%)
No change/worsening	11 (24%)	13 (28%)
Nasal surgery prior to visit	9 (20%)	5 (11%)
Withdrawn from study prior to visit	4 (9%)	7 (15%)
Missing visit data	0	1 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.48 (0.15, 1.50)
p-value		0.206
Inverse unadjusted odds ratio (95% CI) [2]		0.71 (0.23, 2.10)
Inverse relative risk (95% CI) [3]		0.77 (0.32, 1.65)
Risk difference (95% CI) [3]		-0.06 (-0.24, 0.12)
Fisher’s Exact p-value (2-sided)		0.621

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Population: Intent-to-Treat

Table 27.164
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Number of Previous Surgeries

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n	72	51
Met >=5-point improvement	21 (29%)	20 (39%)
Not met >=5-point improvement	51 (71%)	31 (61%)
<5-point improvement	11 (15%)	9 (18%)
No change/worsening	11 (15%)	12 (24%)
Nasal surgery prior to visit	21 (29%)	7 (14%)
Withdrawn from study prior to visit	5 (7%)	1 (2%)
Missing visit data	3 (4%)	2 (4%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.73 (0.31, 1.70)
p-value		0.467
Inverse unadjusted odds ratio (95% CI) [2]		0.64 (0.28, 1.46)
Inverse relative risk (95% CI) [3]		0.74 (0.44, 1.27)
Risk difference (95% CI) [3]		-0.10 (-0.27, 0.07)
Fisher's Exact p-value (2-sided)		0.252

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.

Protocol: 205687
Population: Intent-to-Treat

Table 27.165
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n	40	34
Met >=5-point improvement	13 (33%)	15 (44%)
Not met >=5-point improvement	27 (68%)	19 (56%)
<5-point improvement	11 (28%)	3 (9%)
No change/worsening	11 (28%)	11 (32%)
Nasal surgery prior to visit	2 (5%)	1 (3%)
Withdrawn from study prior to visit	3 (8%)	4 (12%)
Missing visit data	0	0
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.54 (0.17, 1.67)
p-value		0.284
Inverse unadjusted odds ratio (95% CI) [2]		0.61 (0.21, 1.74)
Inverse relative risk (95% CI) [3]		0.74 (0.39, 1.34)
Risk difference (95% CI) [3]		-0.12 (-0.34, 0.11)
Fisher’s Exact p-value (2-sided)		0.343

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.165
Subgroup Analysis of Proportion of Subjects with >=5-point Improvement from Baseline in SF-36 Mental Component Summary Score at Week 52 by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n	158	171
Met >=5-point improvement	41 (26%)	66 (39%)
Not met >=5-point improvement	117 (74%)	105 (61%)
<5-point improvement	26 (16%)	29 (17%)
No change/worsening	33 (21%)	43 (25%)
Nasal surgery prior to visit	43 (27%)	17 (10%)
Withdrawn from study prior to visit	9 (6%)	12 (7%)
Missing visit data	6 (4%)	4 (2%)
Comparison Mepolizumab 100mg vs Placebo		
Logistic regression [1]		
Inverse odds ratio (95% CI)		0.52 (0.31, 0.87)
p-value		0.012
Inverse unadjusted odds ratio (95% CI) [2]		0.56 (0.34, 0.92)
Inverse relative risk (95% CI) [3]		0.67 (0.47, 0.97)
Risk difference (95% CI) [3]		-0.13 (-0.23, -0.02)
Fisher’s Exact p-value (2-sided)		0.018

[1] Analysis performed separately for each subgroup using a logistic regression model with covariates of treatment group, geographic region, baseline and log(e) baseline blood eosinophil count.
[2] Exact CI.
[3] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio <1, inverse relative risk <1, risk difference <0 correspond to a benefit of Mepolizumab over Placebo.
Note: 1 Mepolizumab and 3 Placebo subjects with missing baseline score are excluded from the analysis.
PPD

Population: Intent-to-Treat

Table 27.179
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	42	56
n [2]	30	48
LS Mean (SE)	2.9 (2.38)	6.5 (1.89)
LS Mean Change (SE)	-2.5 (2.38)	1.0 (1.89)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.52
95% CI		(-2.51, 9.54)
p-value		0.249
Corrected Hedges g [3]		0.27
95% CI		(-0.19, 0.72)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.179
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	100	87
n [2]	76	68
LS Mean (SE)	9.5 (1.90)	3.8 (1.99)
LS Mean Change (SE)	4.7 (1.90)	-1.0 (1.99)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.70
95% CI		(-11.14, -0.25)
p-value		0.040
Corrected Hedges g [3]		-0.34
95% CI		(-0.67, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.179
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	6	8
n [2]	5	5
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.180
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	100	112
n [2]	78	92
LS Mean (SE)	7.1 (1.75)	4.8 (1.63)
LS Mean Change (SE)	1.8 (1.75)	-0.5 (1.63)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.25
95% CI		(-6.98, 2.48)
p-value		0.349
Corrected Hedges g [3]		-0.14
95% CI		(-0.45, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.180
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	48	39
n [2]	33	29
LS Mean (SE)	9.5 (3.12)	6.2 (3.23)
LS Mean Change (SE)	5.0 (3.12)	1.7 (3.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.26
95% CI		(-11.79, 5.27)
p-value		0.447
Corrected Hedges g [3]		-0.18
95% CI		(-0.68, 0.32)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.181
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	64	59
n [2]	53	47
LS Mean (SE)	7.9 (2.13)	4.3 (2.27)
LS Mean Change (SE)	5.4 (2.13)	1.7 (2.27)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.64
95% CI		(-9.82, 2.55)
p-value		0.246
Corrected Hedges g [3]		-0.23
95% CI		(-0.63, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.181
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	20	20
n [2]	15	16
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.181
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	64	72
n [2]	43	58
LS Mean (SE)	8.0 (2.25)	4.9 (1.90)
LS Mean Change (SE)	1.7 (2.25)	-1.3 (1.90)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.05
95% CI		(-8.83, 2.72)
p-value		0.296
Corrected Hedges g [3]		-0.21
95% CI		(-0.60, 0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.182
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	47	33
n [2]	33	25
LS Mean (SE)	4.2 (2.45)	4.9 (2.78)
LS Mean Change (SE)	-3.9 (2.45)	-3.2 (2.78)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		0.70
95% CI		(-6.67, 8.08)
p-value		0.848
Corrected Hedges g [3]		0.05
95% CI		(-0.47, 0.57)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.182
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	101	118
n [2]	78	96
LS Mean (SE)	8.1 (1.84)	4.9 (1.67)
LS Mean Change (SE)	4.2 (1.84)	1.0 (1.67)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.21
95% CI		(-8.12, 1.71)
p-value		0.199
Corrected Hedges g [3]		-0.20
95% CI		(-0.50, 0.10)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.183
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	58	77
n [2]	46	63
LS Mean (SE)	9.3 (2.52)	5.7 (2.13)
LS Mean Change (SE)	3.8 (2.52)	0.2 (2.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.53
95% CI		(-10.05, 3.00)
p-value		0.286
Corrected Hedges g [3]		-0.21
95% CI		(-0.59, 0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.183
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	38	38
n [2]	27	28
LS Mean (SE)	8.4 (3.42)	3.8 (3.52)
LS Mean Change (SE)	4.6 (3.42)	0.1 (3.52)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.53
95% CI		(-14.21, 5.16)
p-value		0.346
Corrected Hedges g [3]		-0.25
95% CI		(-0.78, 0.29)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.183
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	52	36
n [2]	38	30
LS Mean (SE)	9.4 (2.69)	2.3 (3.13)
LS Mean Change (SE)	3.9 (2.69)	-3.1 (3.13)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.03
95% CI		(-15.39, 1.33)
p-value		0.097
Corrected Hedges g [3]		-0.41
95% CI		(-0.90, 0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.184
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	28	25
n [2]	22	20
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.184
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Work Time Missed Due to Health (%)
by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	120	126
n [2]	89	101
LS Mean (SE)	9.1 (1.69)	4.9 (1.61)
LS Mean Change (SE)	4.0 (1.69)	-0.2 (1.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.25
95% CI		(-8.84, 0.34)
p-value		0.069
Corrected Hedges g [3]		-0.26
95% CI		(-0.55, 0.02)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.187
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	40	56
n [2]	29	47
LS Mean (SE)	28.0 (3.84)	24.1 (3.15)
LS Mean Change (SE)	-25.3 (3.84)	-29.2 (3.15)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.89
95% CI		(-13.78, 6.00)
p-value		0.436
Corrected Hedges g [3]		-0.18
95% CI		(-0.64, 0.28)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.187
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	98	86
n [2]	73	67
LS Mean (SE)	22.7 (2.57)	18.8 (2.73)
LS Mean Change (SE)	-24.7 (2.57)	-28.5 (2.73)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.84
95% CI		(-11.26, 3.59)
p-value		0.309
Corrected Hedges g [3]		-0.17
95% CI		(-0.50, 0.16)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.187
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	6	8
n [2]	5	4
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.188
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	98	111
n [2]	75	89
LS Mean (SE)	21.9 (2.25)	17.0 (2.11)
LS Mean Change (SE)	-25.8 (2.25)	-30.7 (2.11)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.86
95% CI		(-10.94, 1.22)
p-value		0.116
Corrected Hedges g [3]		-0.25
95% CI		(-0.55, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.188
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	46	39
n [2]	32	29
LS Mean (SE)	26.6 (4.45)	30.4 (4.73)
LS Mean Change (SE)	-25.7 (4.45)	-22.0 (4.73)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.73
95% CI		(-9.33, 16.80)
p-value		0.571
Corrected Hedges g [3]		0.15
95% CI		(-0.36, 0.65)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.189
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	61	59
n [2]	50	47
LS Mean (SE)	24.8 (2.89)	20.2 (3.00)
LS Mean Change (SE)	-22.1 (2.89)	-26.7 (3.00)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.59
95% CI		(-12.85, 3.67)
p-value		0.273
Corrected Hedges g [3]		-0.22
95% CI		(-0.62, 0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.189
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	20	19
n [2]	14	15
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.189
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	63	72
n [2]	43	56
LS Mean (SE)	25.2 (3.32)	20.0 (3.03)
LS Mean Change (SE)	-25.9 (3.32)	-31.1 (3.03)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.18
95% CI		(-14.12, 3.75)
p-value		0.253
Corrected Hedges g [3]		-0.23
95% CI		(-0.63, 0.17)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.190
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	45	33
n [2]	32	25
LS Mean (SE)	24.5 (3.50)	19.2 (4.03)
LS Mean Change (SE)	-28.7 (3.50)	-34.0 (4.03)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.26
95% CI		(-16.11, 5.59)
p-value		0.336
Corrected Hedges g [3]		-0.26
95% CI		(-0.79, 0.27)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.190
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	99	117
n [2]	75	93
LS Mean (SE)	23.8 (2.53)	21.1 (2.31)
LS Mean Change (SE)	-23.7 (2.53)	-26.4 (2.31)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.68
95% CI		(-9.45, 4.08)
p-value		0.436
Corrected Hedges g [3]		-0.12
95% CI		(-0.42, 0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.191
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	57	77
n [2]	46	61
LS Mean (SE)	22.0 (2.99)	19.4 (2.59)
LS Mean Change (SE)	-26.1 (2.99)	-28.8 (2.59)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.65
95% CI		(-10.50, 5.20)
p-value		0.505
Corrected Hedges g [3]		-0.13
95% CI		(-0.51, 0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.191
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	38	38
n [2]	26	28
LS Mean (SE)	26.8 (4.15)	19.1 (4.14)
LS Mean Change (SE)	-17.9 (4.15)	-25.6 (4.14)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.73
95% CI		(-19.50, 4.03)
p-value		0.194
Corrected Hedges g [3]		-0.35
95% CI		(-0.89, 0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.191
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	49	35
n [2]	35	29
LS Mean (SE)	25.7 (4.09)	24.1 (4.61)
LS Mean Change (SE)	-28.7 (4.09)	-30.3 (4.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.56
95% CI		(-13.84, 10.73)
p-value		0.801
Corrected Hedges g [3]		-0.06
95% CI		(-0.56, 0.43)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.192
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	28	24
n [2]	21	19
LS Mean (SE)	28.0 (4.34)	22.7 (4.68)
LS Mean Change (SE)	-26.0 (4.34)	-31.3 (4.68)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.30
95% CI		(-18.33, 7.73)
p-value		0.416
Corrected Hedges g [3]		-0.26
95% CI		(-0.88, 0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
PPD

Population: Intent-to-Treat

Table 27.192
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Impairment While Working Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	116	126
n [2]	86	99
LS Mean (SE)	22.6 (2.32)	20.3 (2.20)
LS Mean Change (SE)	-25.4 (2.32)	-27.7 (2.20)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.30
95% CI		(-8.60, 4.00)
p-value		0.472
Corrected Hedges g [3]		-0.11
95% CI		(-0.39, 0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.195
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	42	56
n [2]	30	48
LS Mean (SE)	29.2 (4.27)	27.1 (3.53)
LS Mean Change (SE)	-25.3 (4.27)	-27.4 (3.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.04
95% CI		(-13.08, 8.99)
p-value		0.714
Corrected Hedges g [3]		-0.08
95% CI		(-0.54, 0.37)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.195
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	100	87
n [2]	76	68
LS Mean (SE)	28.2 (2.95)	20.7 (3.15)
LS Mean Change (SE)	-20.4 (2.95)	-27.9 (3.15)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.47
95% CI		(-16.02, 1.07)
p-value		0.086
Corrected Hedges g [3]		-0.29
95% CI		(-0.62, 0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.195
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	6	8
n [2]	5	5
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.196
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	100	112
n [2]	78	92
LS Mean (SE)	26.4 (2.61)	19.3 (2.45)
LS Mean Change (SE)	-22.9 (2.61)	-30.0 (2.45)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.13
95% CI		(-14.19, -0.06)
p-value		0.048
Corrected Hedges g [3]		-0.30
95% CI		(-0.61, 0.00)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.196
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	48	39
n [2]	33	29
LS Mean (SE)	31.1 (4.89)	33.3 (5.26)
LS Mean Change (SE)	-21.8 (4.89)	-19.6 (5.26)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		2.18
95% CI		(-12.26, 16.61)
p-value		0.764
Corrected Hedges g [3]		0.08
95% CI		(-0.42, 0.58)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.197
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	64	59
n [2]	53	47
LS Mean (SE)	29.6 (3.39)	21.3 (3.60)
LS Mean Change (SE)	-17.7 (3.39)	-25.9 (3.60)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.29
95% CI		(-18.10, 1.52)
p-value		0.097
Corrected Hedges g [3]		-0.33
95% CI		(-0.73, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.197
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	20	20
n [2]	15	16
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

Population: Intent-to-Treat

Table 27.197
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	64	72
n [2]	43	58
LS Mean (SE)	29.9 (3.77)	21.9 (3.39)
LS Mean Change (SE)	-22.9 (3.77)	-30.9 (3.39)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.00
95% CI		(-18.06, 2.05)
p-value		0.118
Corrected Hedges g [3]		-0.31
95% CI		(-0.71, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.198
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	47	33
n [2]	33	25
LS Mean (SE)	26.8 (3.78)	22.2 (4.50)
LS Mean Change (SE)	-28.0 (3.78)	-32.6 (4.50)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.62
95% CI		(-16.48, 7.24)
p-value		0.439
Corrected Hedges g [3]		-0.21
95% CI		(-0.73, 0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.198
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	101	118
n [2]	78	96
LS Mean (SE)	29.1 (2.93)	22.8 (2.67)
LS Mean Change (SE)	-19.7 (2.93)	-26.0 (2.67)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.31
95% CI		(-14.13, 1.50)
p-value		0.113
Corrected Hedges g [3]		-0.24
95% CI		(-0.54, 0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.199
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	58	77
n [2]	46	63
LS Mean (SE)	28.6 (3.65)	21.9 (3.14)
LS Mean Change (SE)	-21.5 (3.65)	-28.2 (3.14)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.69
95% CI		(-16.23, 2.85)
p-value		0.167
Corrected Hedges g [3]		-0.27
95% CI		(-0.65, 0.11)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.199
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	38	38
n [2]	27	28
LS Mean (SE)	29.5 (4.60)	21.0 (4.61)
LS Mean Change (SE)	-16.0 (4.60)	-24.5 (4.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.51
95% CI		(-21.56, 4.54)
p-value		0.198
Corrected Hedges g [3]		-0.35
95% CI		(-0.88, 0.19)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.199
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	52	36
n [2]	38	30
LS Mean (SE)	27.5 (4.23)	24.7 (4.84)
LS Mean Change (SE)	-27.5 (4.23)	-30.3 (4.84)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.75
95% CI		(-15.58, 10.08)
p-value		0.670
Corrected Hedges g [3]		-0.10
95% CI		(-0.58, 0.38)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.200
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	28	25
n [2]	22	20
LS Mean (SE)	30.6 (5.28)	22.8 (5.57)
LS Mean Change (SE)	-24.9 (5.28)	-32.7 (5.57)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.75
95% CI		(-23.37, 7.87)
p-value		0.322
Corrected Hedges g [3]		-0.31
95% CI		(-0.92, 0.30)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.200
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Overall Work Impairment Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	120	126
n [2]	89	101
LS Mean (SE)	27.7 (2.65)	22.5 (2.53)
LS Mean Change (SE)	-21.5 (2.65)	-26.7 (2.53)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.20
95% CI		(-12.42, 2.02)
p-value		0.157
Corrected Hedges g [3]		-0.21
95% CI		(-0.49, 0.08)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.203
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	52	64
n [1]	49	63
n [2]	41	57
LS Mean (SE)	27.6 (3.34)	25.5 (2.89)
LS Mean Change (SE)	-26.6 (3.34)	-28.6 (2.89)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.05
95% CI		(-10.82, 6.73)
p-value		0.645
Corrected Hedges g [3]		-0.09
95% CI		(-0.50, 0.31)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.203
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	122	113
n [1]	121	112
n [2]	110	101
LS Mean (SE)	27.3 (2.34)	19.0 (2.45)
LS Mean Change (SE)	-24.9 (2.34)	-33.2 (2.45)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.30
95% CI		(-14.99, -1.61)
p-value		0.015
Corrected Hedges g [3]		-0.34
95% CI		(-0.61, -0.06)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Table 27.203
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Age
Mixed Model Repeated Measures

Age (years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	27	29
n [1]	27	29
n [2]	24	25
LS Mean (SE)	32.3 (5.09)	13.2 (4.86)
LS Mean Change (SE)	-23.6 (5.09)	-42.7 (4.86)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.03
95% CI		(-33.93, -4.12)
p-value		0.014
Corrected Hedges g [3]		-0.76
95% CI		(-1.34, -0.18)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.204
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	125	139
n [1]	123	138
n [2]	112	124
LS Mean (SE)	25.3 (2.08)	17.9 (1.98)
LS Mean Change (SE)	-24.8 (2.08)	-32.1 (1.98)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.32
95% CI		(-12.99, -1.65)
p-value		0.012
Corrected Hedges g [3]		-0.33
95% CI		(-0.59, -0.07)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.204
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Gender
Mixed Model Repeated Measures

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	76	67
n [1]	74	66
n [2]	63	59
LS Mean (SE)	33.0 (3.28)	24.5 (3.44)
LS Mean Change (SE)	-26.2 (3.28)	-34.7 (3.44)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.48
95% CI		(-17.94, 0.98)
p-value		0.078
Corrected Hedges g [3]		-0.32
95% CI		(-0.68, 0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.205
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	85	86
n [1]	85	85
n [2]	76	74
LS Mean (SE)	28.9 (2.55)	20.6 (2.60)
LS Mean Change (SE)	-23.6 (2.55)	-31.9 (2.60)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.28
95% CI		(-15.47, -1.08)
p-value		0.024
Corrected Hedges g [3]		-0.37
95% CI		(-0.69, -0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.205
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	28	28
n [1]	26	28
n [2]	20	22
LS Mean (SE)	21.4 (5.45)	25.1 (5.23)
LS Mean Change (SE)	-27.7 (5.45)	-24.0 (5.23)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		3.66
95% CI		(-11.57, 18.89)
p-value		0.630
Corrected Hedges g [3]		0.15
95% CI		(-0.46, 0.75)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.205
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Region
Mixed Model Repeated Measures

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	88	92
n [1]	86	91
n [2]	79	87
LS Mean (SE)	29.1 (2.72)	18.1 (2.61)
LS Mean Change (SE)	-26.2 (2.72)	-37.1 (2.61)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-10.97
95% CI		(-18.42, -3.52)
p-value		0.004
Corrected Hedges g [3]		-0.45
95% CI		(-0.76, -0.14)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.206
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	63	45
n [1]	60	45
n [2]	52	40
LS Mean (SE)	27.6 (3.14)	20.1 (3.62)
LS Mean Change (SE)	-26.7 (3.14)	-34.3 (3.62)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.57
95% CI		(-17.13, 1.99)
p-value		0.119
Corrected Hedges g [3]		-0.33
95% CI		(-0.74, 0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.206
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Aspirin Exacerbated Respiratory Disease (AERDS)
Mixed Model Repeated Measures

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	138	161
n [1]	137	159
n [2]	123	143
LS Mean (SE)	28.1 (2.15)	20.1 (2.00)
LS Mean Change (SE)	-24.7 (2.15)	-32.7 (2.00)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.02
95% CI		(-13.81, -2.23)
p-value		0.007
Corrected Hedges g [3]		-0.34
95% CI		(-0.58, -0.09)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.207
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	81	108
n [1]	79	106
n [2]	71	97
LS Mean (SE)	27.0 (2.75)	19.7 (2.37)
LS Mean Change (SE)	-26.0 (2.75)	-33.4 (2.37)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.34
95% CI		(-14.51, -0.17)
p-value		0.045
Corrected Hedges g [3]		-0.31
95% CI		(-0.62, -0.01)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.207
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	47	47
n [1]	46	47
n [2]	41	39
LS Mean (SE)	28.9 (3.62)	17.7 (3.66)
LS Mean Change (SE)	-20.5 (3.62)	-31.7 (3.66)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.17
95% CI		(-21.46, -0.89)
p-value		0.034
Corrected Hedges g [3]		-0.48
95% CI		(-0.93, -0.04)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Population: Intent-to-Treat

Table 27.207
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Number of Previous Surgeries
Mixed Model Repeated Measures

Number of previous surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	73	51
n [1]	72	51
n [2]	63	47
LS Mean (SE)	30.4 (3.10)	22.3 (3.62)
LS Mean Change (SE)	-26.1 (3.10)	-34.2 (3.62)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.10
95% CI		(-17.57, 1.37)
p-value		0.093
Corrected Hedges g [3]		-0.33
95% CI		(-0.71, 0.05)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Intent-to-Treat

Table 27.208
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	40	35
n [1]	40	34
n [2]	37	30
LS Mean (SE)	27.6 (3.99)	21.9 (4.40)
LS Mean Change (SE)	-28.0 (3.99)	-33.6 (4.40)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.64
95% CI		(-17.55, 6.27)
p-value		0.348
Corrected Hedges g [3]		-0.23
95% CI		(-0.71, 0.25)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.
PPD

Population: Intent-to-Treat

Table 27.208
Subgroup Analysis of Mean Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 52: Activity Impairment Due to Health (%) by Baseline Total Endoscopic Nasal Polyps Score
Mixed Model Repeated Measures

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)
Number of subjects in subgroup	161	171
n [1]	157	170
n [2]	138	153
LS Mean (SE)	28.1 (2.00)	19.8 (1.91)
LS Mean Change (SE)	-24.7 (2.00)	-33.0 (1.91)
Mepolizumab 100mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.32
95% CI		(-13.77, -2.87)
p-value		0.003
Corrected Hedges g [3]		-0.35
95% CI		(-0.58, -0.12)

[1] No. with analysable data for one/more time point. [2] No. with analysable data at given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment group, geographic region, baseline, log(e) baseline blood eosinophil count, visit plus interaction terms for visit by baseline and visit by treatment group. Estimates are based on weighting applied to each level of class variable determined from observed proportions.

PPD

Protocol: 205687
Population: Safety

Table 37.1
Summary and Analysis of Proportion of Subjects with an On-Treatment Adverse Event by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
All Subjects	168 (84%)	169 (82%)	0.90 (0.52,1.55)	0.98 (0.89,1.08)	-0.02 (-0.09,0.06)	0.696
Subgroups						
Age (Years)						
18-<40	44/52 (85%)	55/64 (86%)	1.11 (0.34,3.55)	1.02 (0.87,1.23)	0.01 (-0.12,0.16)	>0.999
40-<65	102/122 (84%)	92/113 (81%)	0.86 (0.41,1.78)	0.97 (0.86,1.10)	-0.02 (-0.12,0.08)	0.732
>=65	22/27 (81%)	22/29 (76%)	0.71 (0.15,3.10)	0.93 (0.67,1.28)	-0.06 (-0.28,0.17)	0.748
Gender						
Male	101/125 (81%)	109/139 (78%)	0.86 (0.45,1.64)	0.97 (0.85,1.10)	-0.02 (-0.12,0.08)	0.650
Female	67/76 (88%)	60/67 (90%)	1.15 (0.36,3.88)	1.02 (0.89,1.15)	0.01 (-0.10,0.12)	>0.999
Region						
Europe	75/85 (88%)	78/86 (91%)	1.30 (0.43,4.01)	1.03 (0.92,1.16)	0.02 (-0.07,0.13)	0.628
United States	22/28 (79%)	22/28 (79%)	1.00 (0.23,4.39)	1.00 (0.72,1.39)	0.00 (-0.23,0.23)	>0.999
Rest of World	71/88 (81%)	69/92 (75%)	0.72 (0.33,1.55)	0.93 (0.79,1.09)	-0.06 (-0.18,0.07)	0.376
AERDS						
Current	57/63 (90%)	42/45 (93%)	1.47 (0.29,9.59)	1.03 (0.89,1.17)	0.03 (-0.10,0.14)	0.732
No current	111/138 (80%)	127/161 (79%)	0.91 (0.49,1.66)	0.98 (0.87,1.11)	-0.02 (-0.11,0.08)	0.775

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher’s Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.
PPD

Protocol: 205687
Population: Safety

Table 37.1
Summary and Analysis of Proportion of Subjects with an On-Treatment Adverse Event by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Number of Previous Surgeries						
1	66/81 (81%)	86/108 (80%)	0.89 (0.40,1.95)	0.98 (0.85,1.15)	-0.02 (-0.13,0.10)	0.854
2	42/47 (89%)	37/47 (79%)	0.44 (0.11,1.58)	0.88 (0.71,1.06)	-0.11 (-0.27,0.05)	0.260
>2	60/73 (82%)	46/51 (90%)	1.99 (0.61,7.63)	1.10 (0.93,1.28)	0.08 (-0.05,0.20)	0.301
Baseline NP Score [3]						
<5	32/40 (80%)	26/35 (74%)	0.72 (0.21,2.46)	0.93 (0.70,1.21)	-0.06 (-0.26,0.14)	0.591
>=5	136/161 (84%)	143/171 (84%)	0.94 (0.50,1.76)	0.99 (0.90,1.09)	-0.01 (-0.09,0.07)	0.881

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher’s Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Protocol: 205687
Population: Safety

Table 37.4
Summary and Analysis of Proportion of Subjects with On-Treatment Adverse Events by Subgroup
Occurring in >=10% of patients or in >=10 patients and >=1% of patients

System Organ Class: Infections and infestations
Preferred Term: Sinusitis

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Subgroups						
Age (Years)						
18-<40	3/ 52 (6%)	2/ 64 (3%)	0.53 (0.04,4.81)	0.54 (0.05,3.29)	-0.03 (-0.13,0.06)	0.656
40-<65	15/122 (12%)	7/113 (6%)	0.47 (0.16,1.29)	0.50 (0.18,1.19)	-0.06 (-0.14,0.02)	0.122
>=65	4/ 27 (15%)	1/ 29 (3%)	0.21 (0.00,2.32)	0.23 (0.01,1.62)	-0.11 (-0.31,0.05)	0.185
Gender						
Male	12/125 (10%)	5/139 (4%)	0.35 (0.09,1.12)	0.37 (0.07,1.00)	-0.06 (-0.13,0.00)	0.076
Female	10/ 76 (13%)	5/ 67 (7%)	0.53 (0.14,1.83)	0.57 (0.14,1.58)	-0.06 (-0.16,0.05)	0.291
Region						
Europe	7/ 85 (8%)	8/ 86 (9%)	1.14 (0.34,3.90)	1.13 (0.39,3.23)	0.01 (-0.08,0.10)	>0.999
United States	7/ 28 (25%)	0/ 28	0.00 (0.00,0.45)	0.00 (0.00,0.59)	-0.25 (-0.45,-0.09)	0.010
Rest of World	8/ 88 (9%)	2/ 92 (2%)	0.22 (0.02,1.17)	0.24 (0.03,1.00)	-0.07 (-0.15,0.00)	0.054
AERDS						
Current	7/ 63 (11%)	0/ 45	0.00 (0.00,0.70)	0.00 (0.00,0.95)	-0.11 (-0.22,-0.01)	0.040
No current	15/138 (11%)	10/161 (6%)	0.54 (0.21,1.35)	0.57 (0.25,1.28)	-0.05 (-0.12,0.02)	0.208

Note: Includes all SOC and PT which meet the given criteria in any treatment arm and where Fisher's Exact p-value <0.05.
Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Table 37.4
Summary and Analysis of Proportion of Subjects with On-Treatment Adverse Events by Subgroup
Occurring in >=10% of patients or in >=10 patients and >=1% of patients

System Organ Class: Infections and infestations
Preferred Term: Sinusitis

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Number of Previous Surgeries						
1	6/ 81 (7%)	3/108 (3%)	0.36 (0.06,1.74)	0.38 (0.05,1.55)	-0.05 (-0.13,0.02)	0.175
2	7/ 47 (15%)	4/ 47 (9%)	0.53 (0.11,2.29)	0.57 (0.11,1.82)	-0.06 (-0.21,0.08)	0.523
>2	9/ 73 (12%)	3/ 51 (6%)	0.44 (0.07,1.92)	0.48 (0.10,1.58)	-0.06 (-0.17,0.05)	0.356
Baseline NP Score [3]						
<5	5/ 40 (13%)	1/ 35 (3%)	0.21 (0.00,2.01)	0.23 (0.01,1.49)	-0.10 (-0.24,0.04)	0.206
>=5	17/161 (11%)	9/171 (5%)	0.47 (0.18,1.16)	0.50 (0.21,1.09)	-0.05 (-0.12,0.01)	0.101

Note: Includes all SOC and PT which meet the given criteria in any treatment arm and where Fisher's Exact p-value <0.05.
Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

Protocol: 205687
Population: Safety

Table 37.4
Summary and Analysis of Proportion of Subjects with On-Treatment Adverse Events by Subgroup
Occurring in >=10% of patients or in >=10 patients and >=1% of patients

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Asthma

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Subgroups						
Age (Years)						
18-<40	4/ 52 (8%)	3/ 64 (5%)	0.59 (0.08,3.69)	0.61 (0.08,2.76)	-0.03 (-0.15,0.07)	0.699
40-<65	12/122 (10%)	1/113 (<1%)	0.08 (0.00,0.57)	0.09 (0.00,0.56)	-0.09 (-0.16,-0.03)	0.003
>=65	2/ 27 (7%)	0/ 29	0.00 (0.00,3.20)	0.00 (0.00,2.44)	-0.07 (-0.24,0.05)	0.228
Gender						
Male	7/125 (6%)	2/139 (1%)	0.25 (0.02,1.33)	0.26 (0.03,1.10)	-0.04 (-0.10,0.00)	0.089
Female	11/ 76 (14%)	2/ 67 (3%)	0.18 (0.02,0.89)	0.21 (0.02,0.94)	-0.11 (-0.22,-0.02)	0.020
Region						
Europe	11/ 85 (13%)	2/ 86 (2%)	0.16 (0.02,0.78)	0.18 (0.02,0.77)	-0.11 (-0.20,-0.03)	0.010
United States	3/ 28 (11%)	1/ 28 (4%)	0.31 (0.01,4.22)	0.33 (0.01,3.14)	-0.07 (-0.25,0.10)	0.611
Rest of World	4/ 88 (5%)	1/ 92 (1%)	0.23 (0.00,2.41)	0.24 (0.01,1.74)	-0.03 (-0.10,0.02)	0.203
AERDS						
Current	7/ 63 (11%)	1/ 45 (2%)	0.18 (0.00,1.52)	0.20 (0.01,1.25)	-0.09 (-0.20,0.02)	0.136
No current	11/138 (8%)	3/161 (2%)	0.22 (0.04,0.86)	0.23 (0.04,0.82)	-0.06 (-0.12,-0.01)	0.014

Note: Includes all SOC and PT which meet the given criteria in any treatment arm and where Fisher's Exact p-value <0.05.
Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Population: Safety

Table 37.4
Summary and Analysis of Proportion of Subjects with On-Treatment Adverse Events by Subgroup
Occurring in >=10% of patients or in >=10 patients and >=1% of patients

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Asthma

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Number of Previous Surgeries						
1	7/ 81 (9%)	2/108 (2%)	0.20 (0.02,1.10)	0.21 (0.02,0.95)	-0.07 (-0.15,0.00)	0.040
2	5/ 47 (11%)	2/ 47 (4%)	0.37 (0.03,2.46)	0.40 (0.05,2.01)	-0.06 (-0.19,0.05)	0.435
>2	6/ 73 (8%)	0/ 51	0.00 (0.00,0.89)	0.00 (0.00,0.99)	-0.08 (-0.17,0.00)	0.042
Baseline NP Score [3]						
<5	5/ 40 (13%)	0/ 35	0.00 (0.00,0.89)	0.00 (0.00,0.96)	-0.13 (-0.27,-0.01)	0.057
>=5	13/161 (8%)	4/171 (2%)	0.27 (0.06,0.91)	0.29 (0.07,0.90)	-0.06 (-0.11,-0.01)	0.023

Note: Includes all SOC and PT which meet the given criteria in any treatment arm and where Fisher's Exact p-value <0.05.
Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

Protocol: 205687
Population: Safety

Table 37.9
Summary and Analysis of Proportion of Subjects with an On-Treatment Non-Fatal Serious Adverse Event by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
All Subjects	13 (6%)	12 (6%)	0.89 (0.36,2.19)	0.90 (0.38,2.04)	-0.01 (-0.06,0.04)	0.838
Subgroups						
Age (Years)						
18-<40	1/52 (2%)	1/64 (2%)	0.81 (0.01,64.78)	0.81 (0.02,27.11)	0.00 (-0.09,0.07)	>0.999
40-<65	9/122 (7%)	8/113 (7%)	0.96 (0.31,2.91)	0.96 (0.33,2.57)	0.00 (-0.07,0.07)	>0.999
>=65	3/27 (11%)	3/29 (10%)	0.92 (0.11,7.59)	0.93 (0.16,5.36)	-0.01 (-0.21,0.18)	>0.999
Gender						
Male	9/125 (7%)	11/139 (8%)	1.11 (0.40,3.14)	1.10 (0.44,2.95)	0.01 (-0.06,0.07)	>0.999
Female	4/76 (5%)	1/67 (1%)	0.27 (0.01,2.87)	0.28 (0.01,2.05)	-0.04 (-0.12,0.04)	0.371
Region						
Europe	4/85 (5%)	8/86 (9%)	2.08 (0.53,9.77)	1.98 (0.62,13.13)	0.05 (-0.04,0.14)	0.370
United States	2/28 (7%)	1/28 (4%)	0.48 (0.01,9.90)	0.50 (0.02,5.37)	-0.04 (-0.21,0.12)	>0.999
Rest of World	7/88 (8%)	3/92 (3%)	0.39 (0.06,1.79)	0.41 (0.07,1.51)	-0.05 (-0.13,0.02)	0.205
AERDS						
Current	7/63 (11%)	3/45 (7%)	0.57 (0.09,2.70)	0.60 (0.10,2.16)	-0.04 (-0.16,0.08)	0.517
No current	6/138 (4%)	9/161 (6%)	1.30 (0.40,4.57)	1.29 (0.47,3.80)	0.01 (-0.04,0.07)	0.792

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher’s Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Protocol: 205687
Population: Safety

Table 37.9
Summary and Analysis of Proportion of Subjects with an On-Treatment Non-Fatal Serious Adverse Event by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Number of Previous Surgeries						
1	3/81 (4%)	4/108 (4%)	1.00 (0.16,7.02)	1.00 (0.22,7.85)	0.00 (-0.07,0.06)	>0.999
2	6/47 (13%)	1/47 (2%)	0.15 (0.00,1.33)	0.17 (0.01,1.06)	-0.11 (-0.24,0.00)	0.111
>2	4/73 (5%)	7/51 (14%)	2.74 (0.65,13.44)	2.50 (0.77,12.77)	0.08 (-0.02,0.21)	0.197
Baseline NP Score [3]						
<5	0/40	2/35 (6%)	Inf (0.33,Inf)	Inf (0.43,Inf)	0.06 (-0.04,0.19)	0.214
>=5	13/161 (8%)	10/171 (6%)	0.71 (0.27,1.81)	0.72 (0.29,1.61)	-0.02 (-0.08,0.04)	0.518

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

Protocol: 205687
Population: Safety

Table 37.6
Summary and Analysis of Proportion of Subjects with On-Treatment AEs Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
All Subjects	4 (2%)	4 (2%)	0.98 (0.18,5.31)	0.98 (0.22,4.33)	0.00 (-0.03,0.03)	>0.999
Subgroups						
Age (Years)						
18-<40	3/52 (6%)	0/64	0.00 (0.00,1.37)	0.00 (0.00,1.19)	-0.06 (-0.16,0.01)	0.087
40-<65	0/122	3/113 (3%)	Inf (0.63,Inf)	Inf (0.73,Inf)	0.03 (-0.01,0.08)	0.110
>=65	1/27 (4%)	1/29 (3%)	0.93 (0.01,75.66)	0.93 (0.03,30.88)	0.00 (-0.16,0.14)	>0.999
Gender						
Male	2/125 (2%)	1/139 (<1%)	0.45 (0.01,8.68)	0.45 (0.02,4.99)	-0.01 (-0.05,0.03)	0.605
Female	2/76 (3%)	3/67 (4%)	1.73 (0.19,21.29)	1.70 (0.28,16.99)	0.02 (-0.05,0.11)	0.665
Region						
Europe	1/85 (1%)	2/86 (2%)	2.00 (0.10,119.38)	1.98 (0.18,53.72)	0.01 (-0.04,0.07)	>0.999
United States	0/28	1/28 (4%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.04 (-0.10,0.18)	>0.999
Rest of World	3/88 (3%)	1/92 (1%)	0.31 (0.01,3.99)	0.32 (0.01,3.12)	-0.02 (-0.09,0.03)	0.360
AERDS						
Current	3/63 (5%)	2/45 (4%)	0.93 (0.07,8.49)	0.93 (0.09,5.64)	0.00 (-0.10,0.11)	>0.999
No current	1/138 (<1%)	2/161 (1%)	1.72 (0.09,102.40)	1.71 (0.15,46.62)	0.01 (-0.03,0.04)	>0.999

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher’s Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Protocol: 205687
Population: Safety

Table 37.6
Summary and Analysis of Proportion of Subjects with On-Treatment AEs Leading to Permanent Discontinuation of Study Treatment/Study Withdrawal by Subgroup

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
Number of Previous Surgeries						
1	0/81	0/108				
2	1/47 (2%)	1/47 (2%)	1.00 (0.01,80.18)	1.00 (0.03,33.31)	0.00 (-0.09,0.09)	>0.999
>2	3/73 (4%)	3/51 (6%)	1.46 (0.19,11.32)	1.43 (0.24,8.45)	0.02 (-0.07,0.13)	0.689
Baseline NP Score [3]						
<5	1/40 (3%)	0/35	0.00 (0.00,21.71)	0.00 (0.00,16.59)	-0.03 (-0.13,0.08)	>0.999
>=5	3/161 (2%)	4/171 (2%)	1.26 (0.21,8.74)	1.26 (0.27,10.15)	0.00 (-0.03,0.04)	>0.999

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher’s Exact p-value.
[3] Baseline Total Endoscopic Nasal Polyps Score (Centrally Read).
Note: AERDS = Aspirin Exacerbated Respiratory Disease.

PPD

Protocol: 205687
Population: Safety

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	52	64				
Risks						
Serious Adverse Events	1 (2%)	1 (2%)	0.81 (0.01,64.78)	0.81 (0.02,27.11)	0.00 (-0.09,0.07)	>0.999
Systemic Reactions	1 (2%)	2 (3%)	1.65 (0.08,98.93)	1.63 (0.15,44.15)	0.01 (-0.08,0.10)	>0.999
Allergic (Type I Hypersensitivity)	0	2 (3%)	Inf (0.23,Inf)	Inf (0.30,Inf)	0.03 (-0.05,0.11)	0.501
Other Reactions	1 (2%)	0	0.00 (0.00,15.44)	0.00 (0.00,11.87)	-0.02 (-0.10,0.04)	0.448

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	4 (6%)	Inf (0.74,Inf)	Inf (0.81,Inf)	0.06 (-0.01,0.15)	0.127
All Infections [1]	34 (65%)	44 (69%)	1.16 (0.50,2.72)	1.05 (0.81,1.40)	0.03 (-0.14,0.21)	0.843
Serious Infections	0	0				
Potential Opportunistic Infections [2]	0	3 (5%)	Inf (0.48,Inf)	Inf (0.56,Inf)	0.05 (-0.03,0.13)	0.252
Neoplasms [1]	0	1 (2%)	Inf (0.04,Inf)	Inf (0.06,Inf)	0.02 (-0.06,0.08)	>0.999
Malignancies [3]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 18-<40

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	0	0				
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	0	0				
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	122	113				
Risks						
Serious Adverse Events	9 (7%)	8 (7%)	0.96 (0.31,2.91)	0.96 (0.33,2.57)	0.00 (-0.07,0.07)	>0.999
Systemic Reactions	0	0				
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (2%)	1 (<1%)	0.54 (0.01,10.45)	0.54 (0.02,5.98)	-0.01 (-0.05,0.03)	>0.999
All Infections [1]	88 (72%)	63 (56%)	0.49 (0.27,0.87)	0.77 (0.62,0.96)	-0.16 (-0.28,-0.03)	0.010
Serious Infections	3 (2%)	0	0.00 (0.00,1.84)	0.00 (0.00,1.61)	-0.02 (-0.07,0.01)	0.248
Potential Opportunistic Infections [2]	6 (5%)	0	0.00 (0.00,0.68)	0.00 (0.00,0.96)	-0.05 (-0.10,-0.01)	0.030
Neoplasms [1]	3 (2%)	4 (4%)	1.46 (0.24,10.14)	1.44 (0.31,11.39)	0.01 (-0.04,0.07)	0.713
Malignancies [3]	2 (2%)	0	0.00 (0.00,3.74)	0.00 (0.00,2.92)	-0.02 (-0.06,0.02)	0.499

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): 40-<65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	2 (2%)	0	0.00 (0.00,3.74)	0.00 (0.00,2.92)	-0.02 (-0.06,0.02)	0.499
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	1 (<1%)	0	0.00 (0.00,20.51)	0.00 (0.00,15.82)	-0.01 (-0.05,0.03)	>0.999
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	27	29				
Risks						
Serious Adverse Events	3 (11%)	3 (10%)	0.92 (0.11,7.59)	0.93 (0.16,5.36)	-0.01 (-0.21,0.18)	>0.999
Systemic Reactions	0	0				
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	0				
All Infections [1]	14 (52%)	15 (52%)	0.99 (0.31,3.22)	1.00 (0.58,1.80)	0.00 (-0.27,0.26)	>0.999
Serious Infections	1 (4%)	1 (3%)	0.93 (0.01,75.66)	0.93 (0.03,30.88)	0.00 (-0.16,0.14)	>0.999
Potential Opportunistic Infections [2]	1 (4%)	0	0.00 (0.00,17.69)	0.00 (0.00,13.47)	-0.04 (-0.19,0.09)	0.482
Neoplasms [1]	0	0				
Malignancies [3]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age (Years): >=65

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	1 (4%)	1 (3%)	0.93 (0.01,75.66)	0.93 (0.03,30.88)	0.00 (-0.16,0.14)	>0.999
Serious Cardiac Disorders	0	1 (3%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.03 (-0.10,0.18)	>0.999
Serious CVT Events [4]	1 (4%)	1 (3%)	0.93 (0.01,75.66)	0.93 (0.03,30.88)	0.00 (-0.16,0.14)	>0.999
Serious Ischemic Events [5]	1 (4%)	1 (3%)	0.93 (0.01,75.66)	0.93 (0.03,30.88)	0.00 (-0.16,0.14)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	125	139				
Risks						
Serious Adverse Events	9 (7%)	11 (8%)	1.11 (0.40,3.14)	1.10 (0.44,2.95)	0.01 (-0.06,0.07)	>0.999
Systemic Reactions	1 (<1%)	2 (1%)	1.81 (0.09,107.65)	1.80 (0.16,48.89)	0.01 (-0.03,0.04)	>0.999
Allergic (Type I Hypersensitivity)	0	2 (1%)	Inf (0.26,Inf)	Inf (0.33,Inf)	0.01 (-0.02,0.05)	0.500
Other Reactions	1 (<1%)	0	0.00 (0.00,17.09)	0.00 (0.00,13.17)	-0.01 (-0.04,0.02)	0.473

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (2%)	3 (2%)	1.36 (0.15,16.47)	1.35 (0.22,13.53)	0.01 (-0.04,0.05)	>0.999
All Infections [1]	82 (66%)	80 (58%)	0.71 (0.42,1.21)	0.88 (0.72,1.07)	-0.08 (-0.20,0.04)	0.206
Serious Infections	4 (3%)	1 (<1%)	0.22 (0.00,2.27)	0.22 (0.01,1.65)	-0.02 (-0.07,0.01)	0.193
Potential Opportunistic Infections [2]	2 (2%)	1 (<1%)	0.45 (0.01,8.68)	0.45 (0.02,4.99)	-0.01 (-0.05,0.03)	0.605
Neoplasms [1]	2 (2%)	2 (1%)	0.90 (0.06,12.56)	0.90 (0.06,13.43)	0.00 (-0.04,0.04)	>0.999
Malignancies [3]	1 (<1%)	0	0.00 (0.00,17.09)	0.00 (0.00,13.17)	-0.01 (-0.04,0.02)	0.473

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	1 (<1%)	1 (<1%)	0.90 (0.01,71.10)	0.90 (0.03,30.09)	0.00 (-0.04,0.03)	>0.999
Serious Cardiac Disorders	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.01 (-0.02,0.04)	>0.999
Serious CVT Events [4]	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.01 (-0.02,0.04)	>0.999
Serious Ischemic Events [5]	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.01 (-0.02,0.04)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	76	67				
Risks						
Serious Adverse Events	4 (5%)	1 (1%)	0.27 (0.01,2.87)	0.28 (0.01,2.05)	-0.04 (-0.12,0.04)	0.371
Systemic Reactions	0	0				
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	2 (3%)	Inf (0.33,Inf)	Inf (0.42,Inf)	0.03 (-0.02,0.11)	0.218
All Infections [1]	54 (71%)	42 (63%)	0.68 (0.32,1.46)	0.88 (0.69,1.12)	-0.08 (-0.24,0.08)	0.373
Serious Infections	0	0				
Potential Opportunistic Infections [2]	5 (7%)	2 (3%)	0.44 (0.04,2.80)	0.45 (0.05,2.23)	-0.04 (-0.12,0.05)	0.448
Neoplasms [1]	1 (1%)	3 (4%)	3.52 (0.27,186.97)	3.40 (0.35,87.37)	0.03 (-0.04,0.11)	0.341
Malignancies [3]	1 (1%)	0	0.00 (0.00,21.55)	0.00 (0.00,16.57)	-0.01 (-0.07,0.04)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	2 (3%)	0	0.00 (0.00,3.93)	0.00 (0.00,3.05)	-0.03 (-0.09,0.03)	0.498
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	2 (3%)	0	0.00 (0.00,3.93)	0.00 (0.00,3.05)	-0.03 (-0.09,0.03)	0.498
Serious Ischemic Events [5]	1 (1%)	0	0.00 (0.00,21.55)	0.00 (0.00,16.57)	-0.01 (-0.07,0.04)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	85	86				
Risks						
Serious Adverse Events	4 (5%)	8 (9%)	2.08 (0.53,9.77)	1.98 (0.62,13.13)	0.05 (-0.04,0.14)	0.370
Systemic Reactions	0	1 (1%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.01 (-0.03,0.06)	>0.999
Allergic (Type I Hypersensitivity)	0	1 (1%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.01 (-0.03,0.06)	>0.999
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (2%)	3 (3%)	1.50 (0.17,18.35)	1.48 (0.24,14.84)	0.01 (-0.05,0.08)	>0.999
All Infections [1]	65 (76%)	56 (65%)	0.57 (0.28,1.18)	0.85 (0.68,1.04)	-0.11 (-0.25,0.02)	0.130
Serious Infections	1 (1%)	1 (1%)	0.99 (0.01,78.49)	0.99 (0.03,33.02)	0.00 (-0.06,0.05)	>0.999
Potential Opportunistic Infections [2]	5 (6%)	0	0.00 (0.00,0.79)	0.00 (0.00,0.94)	-0.06 (-0.13,-0.01)	0.029
Neoplasms [1]	1 (1%)	4 (5%)	4.10 (0.39,204.15)	3.95 (0.54,99.75)	0.03 (-0.02,0.10)	0.368
Malignancies [3]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	3 (4%)	1 (1%)	0.32 (0.01,4.12)	0.33 (0.01,3.22)	-0.02 (-0.09,0.03)	0.368
Serious Cardiac Disorders	0	1 (1%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.01 (-0.03,0.06)	>0.999
Serious CVT Events [4]	1 (1%)	1 (1%)	0.99 (0.01,78.49)	0.99 (0.03,33.02)	0.00 (-0.06,0.05)	>0.999
Serious Ischemic Events [5]	1 (1%)	1 (1%)	0.99 (0.01,78.49)	0.99 (0.03,33.02)	0.00 (-0.06,0.05)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	28	28				
Risks						
Serious Adverse Events	2 (7%)	1 (4%)	0.48 (0.01,9.90)	0.50 (0.02,5.37)	-0.04 (-0.21,0.12)	>0.999
Systemic Reactions	0	1 (4%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.04 (-0.10,0.18)	>0.999
Allergic (Type I Hypersensitivity)	0	1 (4%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.04 (-0.10,0.18)	>0.999
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	1 (4%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.04 (-0.10,0.18)	>0.999
All Infections [1]	18 (64%)	18 (64%)	1.00 (0.29,3.43)	1.00 (0.66,1.52)	0.00 (-0.25,0.25)	>0.999
Serious Infections	1 (4%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.46)	-0.04 (-0.18,0.10)	>0.999
Potential Opportunistic Infections [2]	1 (4%)	1 (4%)	1.00 (0.01,81.37)	1.00 (0.03,33.16)	0.00 (-0.15,0.15)	>0.999
Neoplasms [1]	1 (4%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.46)	-0.04 (-0.18,0.10)	>0.999
Malignancies [3]	1 (4%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.46)	-0.04 (-0.18,0.10)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: United States

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	0	0				
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	0	0				
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	88	92				
Risks						
Serious Adverse Events	7 (8%)	3 (3%)	0.39 (0.06,1.79)	0.41 (0.07,1.51)	-0.05 (-0.13,0.02)	0.205
Systemic Reactions	1 (1%)	0	0.00 (0.00,18.17)	0.00 (0.00,14.00)	-0.01 (-0.06,0.03)	0.489
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	1 (1%)	0	0.00 (0.00,18.17)	0.00 (0.00,14.00)	-0.01 (-0.06,0.03)	0.489

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	1 (1%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.01 (-0.03,0.06)	>0.999
All Infections [1]	53 (60%)	48 (52%)	0.72 (0.38,1.36)	0.87 (0.65,1.14)	-0.08 (-0.23,0.07)	0.296
Serious Infections	2 (2%)	0	0.00 (0.00,3.31)	0.00 (0.00,2.58)	-0.02 (-0.08,0.02)	0.238
Potential Opportunistic Infections [2]	1 (1%)	2 (2%)	1.93 (0.10,115.35)	1.91 (0.17,52.01)	0.01 (-0.04,0.07)	>0.999
Neoplasms [1]	1 (1%)	1 (1%)	0.96 (0.01,75.90)	0.96 (0.03,31.97)	0.00 (-0.05,0.05)	>0.999
Malignancies [3]	1 (1%)	0	0.00 (0.00,18.17)	0.00 (0.00,14.00)	-0.01 (-0.06,0.03)	0.489

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	0	0				
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	1 (1%)	0	0.00 (0.00,18.17)	0.00 (0.00,14.00)	-0.01 (-0.06,0.03)	0.489
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Protocol: 205687
Population: Safety

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	63	45				
Risks						
Serious Adverse Events	7 (11%)	3 (7%)	0.57 (0.09,2.70)	0.60 (0.10,2.16)	-0.04 (-0.16,0.08)	0.517
Systemic Reactions	0	0				
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	1 (2%)	Inf (0.07,Inf)	Inf (0.10,Inf)	0.02 (-0.04,0.12)	0.417
All Infections [1]	46 (73%)	27 (60%)	0.55 (0.23,1.36)	0.82 (0.58,1.08)	-0.13 (-0.31,0.06)	0.211
Serious Infections	3 (5%)	0	0.00 (0.00,2.38)	0.00 (0.00,2.04)	-0.05 (-0.13,0.04)	0.264
Potential Opportunistic Infections [2]	2 (3%)	0	0.00 (0.00,4.86)	0.00 (0.00,3.73)	-0.03 (-0.11,0.06)	0.509
Neoplasms [1]	0	0				
Malignancies [3]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: Current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	0	0				
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	1 (2%)	0	0.00 (0.00,26.60)	0.00 (0.00,20.38)	-0.02 (-0.09,0.07)	>0.999
Serious Ischemic Events [5]	1 (2%)	0	0.00 (0.00,26.60)	0.00 (0.00,20.38)	-0.02 (-0.09,0.07)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	138	161				
Risks						
Serious Adverse Events	6 (4%)	9 (6%)	1.30 (0.40,4.57)	1.29 (0.47,3.80)	0.01 (-0.04,0.07)	0.792
Systemic Reactions	1 (<1%)	2 (1%)	1.72 (0.09,102.40)	1.71 (0.15,46.62)	0.01 (-0.03,0.04)	>0.999
Allergic (Type I Hypersensitivity)	0	2 (1%)	Inf (0.25,Inf)	Inf (0.32,Inf)	0.01 (-0.02,0.04)	0.501
Other Reactions	1 (<1%)	0	0.00 (0.00,16.29)	0.00 (0.00,12.56)	-0.01 (-0.04,0.02)	0.462

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (1%)	4 (2%)	1.73 (0.24,19.40)	1.71 (0.31,12.94)	0.01 (-0.03,0.05)	0.690
All Infections [1]	90 (65%)	95 (59%)	0.77 (0.47,1.26)	0.90 (0.75,1.09)	-0.06 (-0.17,0.05)	0.285
Serious Infections	1 (<1%)	1 (<1%)	0.86 (0.01,67.70)	0.86 (0.03,28.67)	0.00 (-0.04,0.03)	>0.999
Potential Opportunistic Infections [2]	5 (4%)	3 (2%)	0.51 (0.08,2.66)	0.51 (0.06,2.33)	-0.02 (-0.07,0.02)	0.478
Neoplasms [1]	3 (2%)	5 (3%)	1.44 (0.27,9.45)	1.43 (0.32,12.56)	0.01 (-0.04,0.05)	0.729
Malignancies [3]	2 (1%)	0	0.00 (0.00,2.97)	0.00 (0.00,2.32)	-0.01 (-0.05,0.01)	0.212

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.18
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by AERDS

AERDS: No current AERDS

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	3 (2%)	1 (<1%)	0.28 (0.01,3.56)	0.29 (0.01,2.81)	-0.02 (-0.06,0.02)	0.338
Serious Cardiac Disorders	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.01 (-0.02,0.04)	>0.999
Serious CVT Events [4]	1 (<1%)	1 (<1%)	0.86 (0.01,67.70)	0.86 (0.03,28.67)	0.00 (-0.04,0.03)	>0.999
Serious Ischemic Events [5]	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.01 (-0.02,0.04)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	81	108				
Risks						
Serious Adverse Events	3 (4%)	4 (4%)	1.00 (0.16,7.02)	1.00 (0.22,7.85)	0.00 (-0.07,0.06)	>0.999
Systemic Reactions	0	2 (2%)	Inf (0.22,Inf)	Inf (0.28,Inf)	0.02 (-0.03,0.07)	0.508
Allergic (Type I Hypersensitivity)	0	2 (2%)	Inf (0.22,Inf)	Inf (0.28,Inf)	0.02 (-0.03,0.07)	0.508
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	3 (3%)	Inf (0.44,Inf)	Inf (0.51,Inf)	0.03 (-0.02,0.08)	0.261
All Infections [1]	51 (63%)	64 (59%)	0.86 (0.45,1.61)	0.94 (0.75,1.21)	-0.04 (-0.18,0.11)	0.653
Serious Infections	1 (1%)	1 (<1%)	0.75 (0.01,59.41)	0.75 (0.02,25.07)	0.00 (-0.06,0.04)	>0.999
Potential Opportunistic Infections [2]	2 (2%)	1 (<1%)	0.37 (0.01,7.24)	0.38 (0.01,4.15)	-0.02 (-0.08,0.03)	0.577
Neoplasms [1]	1 (1%)	3 (3%)	2.29 (0.18,121.47)	2.25 (0.23,57.75)	0.02 (-0.04,0.07)	0.636
Malignancies [3]	1 (1%)	0	0.00 (0.00,14.25)	0.00 (0.00,10.98)	-0.01 (-0.07,0.02)	0.429

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 1

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	1 (1%)	0	0.00 (0.00,14.25)	0.00 (0.00,10.98)	-0.01 (-0.07,0.02)	0.429
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	1 (1%)	0	0.00 (0.00,14.25)	0.00 (0.00,10.98)	-0.01 (-0.07,0.02)	0.429
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	47	47				
Risks						
Serious Adverse Events	6 (13%)	1 (2%)	0.15 (0.00,1.33)	0.17 (0.01,1.06)	-0.11 (-0.24,0.00)	0.111
Systemic Reactions	1 (2%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.56)	-0.02 (-0.11,0.06)	>0.999
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	1 (2%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.56)	-0.02 (-0.11,0.06)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	1 (2%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.02 (-0.06,0.11)	>0.999
All Infections [1]	37 (79%)	26 (55%)	0.33 (0.12,0.90)	0.70 (0.50,0.95)	-0.23 (-0.41,-0.04)	0.027
Serious Infections	2 (4%)	0	0.00 (0.00,3.46)	0.00 (0.00,2.67)	-0.04 (-0.15,0.04)	0.495
Potential Opportunistic Infections [2]	2 (4%)	0	0.00 (0.00,3.46)	0.00 (0.00,2.67)	-0.04 (-0.15,0.04)	0.495
Neoplasms [1]	1 (2%)	0	0.00 (0.00,19.00)	0.00 (0.00,14.56)	-0.02 (-0.11,0.06)	>0.999
Malignancies [3]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: 2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	2 (4%)	0	0.00 (0.00,3.46)	0.00 (0.00,2.67)	-0.04 (-0.15,0.04)	0.495
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	0	0				
Serious Ischemic Events [5]	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	73	51				
Risks						
Serious Adverse Events	4 (5%)	7 (14%)	2.74 (0.65,13.44)	2.50 (0.77,12.77)	0.08 (-0.02,0.21)	0.197
Systemic Reactions	0	0				
Allergic (Type I Hypersensitivity)	0	0				
Other Reactions	0	0				

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (3%)	1 (2%)	0.71 (0.01,14.02)	0.72 (0.03,7.87)	-0.01 (-0.08,0.08)	>0.999
All Infections [1]	48 (66%)	32 (63%)	0.88 (0.39,1.99)	0.95 (0.70,1.25)	-0.03 (-0.21,0.14)	0.849
Serious Infections	1 (1%)	0	0.00 (0.00,27.20)	0.00 (0.00,20.87)	-0.01 (-0.08,0.06)	>0.999
Potential Opportunistic Infections [2]	3 (4%)	2 (4%)	0.95 (0.08,8.64)	0.95 (0.10,5.79)	0.00 (-0.08,0.10)	>0.999
Neoplasms [1]	1 (1%)	2 (4%)	2.94 (0.15,175.74)	2.86 (0.26,77.73)	0.03 (-0.04,0.12)	0.568
Malignancies [3]	1 (1%)	0	0.00 (0.00,27.20)	0.00 (0.00,20.87)	-0.01 (-0.08,0.06)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.19
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Number of Previous Surgeries

Number of Previous Surgeries: >2

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	0	1 (2%)	Inf (0.08,Inf)	Inf (0.10,Inf)	0.02 (-0.03,0.11)	0.411
Serious Cardiac Disorders	0	1 (2%)	Inf (0.08,Inf)	Inf (0.10,Inf)	0.02 (-0.03,0.11)	0.411
Serious CVT Events [4]	1 (1%)	1 (2%)	1.44 (0.02,114.58)	1.43 (0.04,47.70)	0.01 (-0.06,0.10)	>0.999
Serious Ischemic Events [5]	1 (1%)	1 (2%)	1.44 (0.02,114.58)	1.43 (0.04,47.70)	0.01 (-0.06,0.10)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher's Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)		Relative Risk (Exact 95% CI) [6]		Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	40	35						
Risks								
Serious Adverse Events	0	2 (6%)	Inf	(0.33,Inf)	Inf	(0.43,Inf)	0.06 (-0.04,0.19)	0.214
Systemic Reactions	0	1 (3%)	Inf	(0.06,Inf)	Inf	(0.08,Inf)	0.03 (-0.06,0.15)	0.467
Allergic (Type I Hypersensitivity)	0	1 (3%)	Inf	(0.06,Inf)	Inf	(0.08,Inf)	0.03 (-0.06,0.15)	0.467
Other Reactions	0	0						

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	0	1 (3%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.03 (-0.06,0.15)	0.467
All Infections [1]	28 (70%)	17 (49%)	0.40 (0.14,1.15)	0.69 (0.42,1.04)	-0.21 (-0.43,0.02)	0.097
Serious Infections	0	0				
Potential Opportunistic Infections [2]	2 (5%)	1 (3%)	0.56 (0.01,11.27)	0.57 (0.02,6.21)	-0.02 (-0.15,0.10)	>0.999
Neoplasms [1]	1 (3%)	1 (3%)	1.15 (0.01,92.32)	1.14 (0.03,37.98)	0.00 (-0.11,0.13)	>0.999
Malignancies [3]	1 (3%)	0	0.00 (0.00,21.71)	0.00 (0.00,16.59)	-0.03 (-0.13,0.08)	>0.999

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Population: Safety

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: <5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	1 (3%)	1 (3%)	1.15 (0.01,92.32)	1.14 (0.03,37.98)	0.00 (-0.11,0.13)	>0.999
Serious Cardiac Disorders	0	1 (3%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.03 (-0.06,0.15)	0.467
Serious CVT Events [4]	0	1 (3%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.03 (-0.06,0.15)	0.467
Serious Ischemic Events [5]	0	1 (3%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.03 (-0.06,0.15)	0.467

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Protocol: 205687
Population: Safety

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Number of Subjects in Subgroup	161	171				
Risks						
Serious Adverse Events	13 (8%)	10 (6%)	0.71 (0.27,1.81)	0.72 (0.29,1.61)	-0.02 (-0.08,0.04)	0.518
Systemic Reactions	1 (<1%)	1 (<1%)	0.94 (0.01,74.34)	0.94 (0.03,31.50)	0.00 (-0.03,0.03)	>0.999
Allergic (Type I Hypersensitivity)	0	1 (<1%)	Inf (0.05,Inf)	Inf (0.07,Inf)	0.01 (-0.02,0.03)	>0.999
Other Reactions	1 (<1%)	0	0.00 (0.00,17.89)	0.00 (0.00,13.82)	-0.01 (-0.04,0.02)	0.485

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Anaphylaxis	0	0				
Local Site Reactions	2 (1%)	4 (2%)	1.90 (0.27,21.28)	1.88 (0.34,14.21)	0.01 (-0.02,0.05)	0.686
All Infections [1]	108 (67%)	105 (61%)	0.78 (0.48,1.26)	0.92 (0.78,1.08)	-0.06 (-0.16,0.05)	0.304
Serious Infections	4 (2%)	1 (<1%)	0.23 (0.00,2.37)	0.24 (0.01,1.73)	-0.02 (-0.06,0.01)	0.203
Potential Opportunistic Infections [2]	5 (3%)	2 (1%)	0.37 (0.03,2.30)	0.38 (0.04,1.89)	-0.02 (-0.06,0.01)	0.271
Neoplasms [1]	2 (1%)	4 (2%)	1.90 (0.27,21.28)	1.88 (0.34,14.21)	0.01 (-0.02,0.05)	0.686
Malignancies [3]	1 (<1%)	0	0.00 (0.00,17.89)	0.00 (0.00,13.82)	-0.01 (-0.04,0.02)	0.485

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

Population: Safety

Table 37.20
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Total Endoscopic Nasal Polyps Score

Baseline Total Endoscopic Nasal Polyps Score: >=5

	Placebo (N=201)	Mepolizumab 100mg SC (N=206)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [6]	Risk Difference (Exact 95% CI) [6]	p-value [7]
Cardiac Disorders [1]	2 (1%)	0	0.00 (0.00,3.26)	0.00 (0.00,2.55)	-0.01 (-0.04,0.01)	0.234
Serious Cardiac Disorders	0	0				
Serious CVT Events [4]	2 (1%)	0	0.00 (0.00,3.26)	0.00 (0.00,2.55)	-0.01 (-0.04,0.01)	0.234
Serious Ischemic Events [5]	1 (<1%)	0	0.00 (0.00,17.89)	0.00 (0.00,13.82)	-0.01 (-0.04,0.02)	0.485

[1] Infections from Infections and infestations System Organ Class (SOC). Neoplasms from Neoplasms benign malignant and unspecified (including cysts and polyps) SOC. Cardiac disorders from Cardiac disorders SOC.
[2] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic infections in the setting of biologic therapy (Winthrop, 2015).
[3] Identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and standard MedDRA queries (SMQs). [4] Serious Cardiac Vascular & Thromboembolic (CVT) events identified from Cardiac disorders SOC, Vascular disorders SOC and SMQs. [5] Subset of Serious CVT events identified through SMQs. [6] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic. [7] 2-sided Fisher’s Exact p-value.

PPD